WO2006012374A1 - Substituted aryl-amine derivatives and methods of use - Google Patents

Substituted aryl-amine derivatives and methods of use Download PDF

Info

Publication number
WO2006012374A1
WO2006012374A1 PCT/US2005/025800 US2005025800W WO2006012374A1 WO 2006012374 A1 WO2006012374 A1 WO 2006012374A1 US 2005025800 W US2005025800 W US 2005025800W WO 2006012374 A1 WO2006012374 A1 WO 2006012374A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyridinecarboxamide
phenyl
methyl
dihydro
isoquinolinylamino
Prior art date
Application number
PCT/US2005/025800
Other languages
French (fr)
Inventor
Chester Chenguang Yuan
Kevin Yang
Simon Vanderplas
Babak Riahi
Michele Potashman
Vinod F. Patel
Rana Nomak
Aiwen Li
Qi Huang
Jean-Christophe Harmange
Jr. Benny C. Askew
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc. filed Critical Amgen Inc.
Priority to JP2007522715A priority Critical patent/JP2008507539A/en
Priority to MX2007000672A priority patent/MX2007000672A/en
Priority to EP05791799A priority patent/EP1773817B1/en
Priority to CA2571627A priority patent/CA2571627C/en
Priority to AT05791799T priority patent/ATE440834T1/en
Priority to AU2005267161A priority patent/AU2005267161B2/en
Priority to DE602005016261T priority patent/DE602005016261D1/en
Publication of WO2006012374A1 publication Critical patent/WO2006012374A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer and angiogenesis- related disorders.
  • Protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes, maintaining control over cellular function.
  • a partial list of such kinases includes abl, Akt, bcr-abl, BIk, Brk, Btk, c-kit, c-met, c-src, CDKl, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDKlO, cRafl, CSFlR, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFRl, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-lR, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC,
  • Certain diseases are known to be associated with deregulated angiogenesis, for example ocular neovascularisation, such as retinopathies (including diabetic retinopathy) , age-related macular degeneration, psoriasis, hemangioblastoma, hemangioma, arteriosclerosis, inflammatory disease, such as a rheumatoid or rheumatic inflammatory disease, especially arthritis (including rheumatoid arthritis) , or other chronic inflammatory disorders, such as chronic asthma, arterial or post- transplantational atherosclerosis, endometriosis, and neoplastic diseases, for example so-called solid tumors and liquid tumors (such as leukemias) .
  • retinopathies including diabetic retinopathy
  • age-related macular degeneration psoriasis
  • hemangioblastoma hemangioblastoma
  • hemangioma arteriosclerosis
  • inflammatory disease such as a
  • VEGF Vascular Endothelial Growth Factor
  • VPF Vascular Permeability Factor
  • VEGF is a dimeric, disulfide-linked 46-kDa glycoprotein related to "Platelet-Derived Growth Factor” (PDGF) ; it is produced by normal cell lines and tumor cell lines; is an endothelial cell-specific mitogen,- shows angiogenic activity in in vivo test systems (e.g. rabbit cornea) ; is chemotactic for endothelial cells and monocytes; and induces plasminogen activators in endothelial cells, which are involved in the proteolytic degradation of extracellular matrix during the formation of capillaries.
  • PDGF Platinum-Derived Growth Factor
  • a number of isoforms of VEGF are known, which show comparable biological activity, but differ in the type of cells that secrete them and in their heparin-binding capacity.
  • VEGF receptors are transmembranous receptor tyrosine kinases. They are characterized by an extracellular domain with seven immunoglobulin-like domains and an intracellular tyrosine kinase domain.
  • VEGFR-I also known as flt-1
  • VEGFR-2 also known as KDR
  • VEGFR-3 various types of VEGF receptor are known, e.g. VEGFR-I (also known as flt-1) , VEGFR-2 (also known as KDR), and VEGFR-3.
  • VEGF vascular endothelium
  • VEGF expression could explain the occurrence of cerebral edema in patients with glioma.
  • Direct evidence of the role of VEGF as a tumor angiogenesis factor in vivo is shown in studies in which VEGF expression or VEGF activity was inhibited. This was achieved with anti-VEGP antibodies, with dominant-negative VEGFR-2 mutants which inhibited signal transduction, and with antisense-VEGF RNA techniques. All approaches led to a reduction in the growth of glioma cell lines or other tumor cell lines in vivo as a result of inhibited tumor angiogenesis.
  • Angiogenesis is regarded as an absolute prerequisite for tumors which grow beyond a diameter of about 1-2 mm; up to this limit, oxygen and nutrients may be supplied to the tumor cells by diffusion. Every tumor, regardless of its origin and its cause, is thus dependent on angiogenesis for its growth after it has reached a certain size.
  • VEGF's are unique in that they are the only angiogenic growth factors known to contribute to vascular hyperpermeability and the formation of edema. Indeed, 00
  • vascular hyperpermeability and edema that is associated with the expression or administration of many other growth factors appears to be mediated via VEGF production.
  • VEGF-mediated hyperpermeability can significantly contribute to disorders with these etiologic features. As such, regulators of angiogenesis have become an important therapeutic target.
  • Japanese patent JP2000256358 describes pyrazole derivatives that block the calcium release-activated calcium channel.
  • WO01/29009 describes aminopyridines as KDR inhibitors.
  • WO01/30745 describes anthranilic acids as cGMP phosphodiesterase inhibitors.
  • WOOO/02851 published 20 Jan 2000 describes arylsulfonylamnoaryl amides as guanylate cyclase activators.
  • WO98/45268 describes nicotinamide derivatives as PDE4 inhibitors.
  • WO98/24771 describes benzamides as vasopressin antagonists.
  • PCT publication WO99/32477 published 1 July 1999, describes anthranilamides as anti-coagulants.
  • US patent 6,140,351 describes anthranilamides as anti-coagulants.
  • PCT publication WO99/62885 published 9 December 1999, describes 1- (4-aminophenyl)pyrazoles as antiinflammatories.
  • PCT publication WO00/39111 published 6 July 2000, describes amides as factor Xa inhibitors.
  • PCT publication WOOO/39117 published 6 July 2000, describes heteroaromatic amides as factor Xa inhibitors.
  • PCT publication WO00/27819 published 18 May 2000, describes anthranilic acid amides as VEGF inhibitors.
  • PCT publication WOOO/27820 published 18 May 2000 describes N-aryl anthranilic acid amides as VEGF inhibitors. 7-Chloroquinolinylamines are described in FR2168227 as antiinflammatories.
  • WO01/55114 published 2 Aug. 2001, describes nicotinamides for the treatment of cancer.
  • WO01/55115 published 2 Aug. 2001, describes nicotinamides for the treatment of apoptosis.
  • WO01/85715, published 15 November 2001 describes substituted pyridines and pyrimidines as anti-angiogenesis agents.
  • PCT publication WO01/85691 published 15 November 2001 describes anthranilic amides as VEGF inhibitors.
  • MPT microsomal triglyceride transfer protein
  • the compounds of the present invention have not been previously described as inhibitors of angiogenesis, and useful for treating angiogenesis- related diseases such as cancer.
  • the present invention provides classes of compounds, including their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer.
  • One class of compounds are defined by general Formula I
  • R is a 9- or 10-membered heterocyclyl ring containing at least one nitrogen or oxygen atom, the 00
  • ring selected from 7-isoquinolinyl, 2-methyl-3-oxo- 2,3-dihydroindazol-6-yl, [1, 6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, l-oxo-2, 3-dihydrobenzofuran-4- yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro- benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6- quinazolinyl, 3-oxo-3,4-dihydro-l,4-benzoxazin-6-yl, 2,2-difluoro-l,3-benzodioxol-5-yl and 2,2,3,3- tetrafluoro-2, 3-di
  • R 1 is selected from phenyl, 3-isoxazolyl, 3- pyrazolyl, 2-thiazolyl, 1,3,4-thiadiazol-2-yl, thienyl, 3- pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 2-oxo-1,2, 3,4-tetrahydroquinolyl, 2-oxo-l, 2,3, 4- tetrahydroquinolyl, 1-oxo-l,2,3 ,4-tetrahydro-isoquinolyl, 1' ,2'-dihydro-spiro[cyclopropane-1,3' -[3H]indol] -6'
  • 1,2,3,4-tetrahydroisoquinol-7-yl 2,3-dihydro-lH- indol-6-yl, 1,2,3, 4-tetrahydro-[1,8]naphthyridinyl, 1' ,2' -dihydro-spiro[cyclopropane-1, 3'-[3H]indol-6'- yl, tetrahydroquinolin-7-yl, 3-isoxazolyl, 3- pyrazolyl, 1,3,4-thiadiazol-2-yl, 3-pyridyl, 2-oxo- 1,2,3,4-tetrahydroquinol-7-yl, 2-oxo- tetrahydroquinolin-7-yl, 1-oxo-l,2,3,4-tetrahydro- isoquinol-7-yl, indol-6-yl, 3,4-dihydro-2H- benzo[l,4]oxazin-6-yl
  • R 1 is selected from 4,4-dimethyl-3,4-dihydro-2-oxo-lH-quinolinyl,
  • 3-dimethyl-2,3-dihydro-lH-indol-6-yl optionally substituted with one or more substituents selected from pyrrolidin-1-yl-carbonyl, pyrrolidin-1-yl-methyl, 1-methyl-4-piperidinyl, l-methyl-4-piperidinyl-methyl, 1-4-piperidinyl, tetrahydro-2-furanylcarbonyl, acetyl, N,N- dimethylglycyl, methylcarbonyl, and methylsulfonyl,
  • R 1 is substituted with one or more substituents, the substituents are selected from halo, optionally substituted Ci_ 6 -alkyl, optionally substituted C 3 _ 6 - cycloalkyl, optionally substituted phenyl, optionally substituted ph.enyl-C 1 _ 4 -alkylenyl, Ci- 2 -haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-Ci_ 6 -alkyl, optionally substituted 4-6 membered heterocyclyl-C 2 -C 4 -alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered
  • Ci- 3 - alkylamino-Ci_ 3 -alkyl Ci- 3 - alkylamino-Ci_ 3 -alkyl, C ⁇ _ 3 -alkylamino-Ci- 3 -alkoxy, Ci_ 3 - alkylamino-Ci_ 3 -alkoxy-Ci_ 3 -alkoxy, C 1 _ 4 -alkoxycarbonyl, Ci- 4 -alkoxycarbonylamino-Ci_ 4 -alkyl, Ci- 3 -alkylsulfonylamino- 00
  • the R 1 substituents are selected from bromo, chloro, fluoro, i ⁇ do, nitro, amino, cyano, Boc-aminoethyl, hydroxy, fluorosulfonyl, methylsulfonyl, aminosulfonyl, 4- methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, 4-pyridylmethyl, 4-morpholinylmethyl, l-methylpiperazin-4-ylmethyl, l-methylpiperazin-4- ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1- methylpiperidin-4-ylmethyl, 2-methyl-2- (1- methylpiperidin-4-yl)ethyl, 2-methyl-2- (4- pyrimidinyl
  • R is selected from 7-isoquinolinyl, 2-methyl-3-oxo- 2, 3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, oxo-2,3-dihydrobenzofuranyl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6- quinazolinyl, 4-methylamino-6-c[uinazolinyl, 2,4- diamino- ⁇ -quinazolinyl, 3-oxo-3,4-dihydro-l,4- benzoxazin-6-yl, 2, 2-difluoro-l,3-benzodioxol-5-yl and 2,2,3,3-tetrafluoro-2,3-dihydro-l, 4-benzodioxin- 6-yl, each of which is optionally substitute
  • Ci_ 4 - alkylcarbonyl Ci- 3 -alkylamino-Ci- 4 -alkylcarbonyl , Ci_ 3 - alkylamino-Ci_ 4 -alkylcarbonylamino , Ci_ 4 -alkoxycarbonyl-
  • Ci_ 4 -alkyl Cx-s-alkylamino-Ci-s-alkyl , Ci- 3 -alkylamino-C ! - 3 -alkoxy, Ci-s-alkylamino-Ci-s-alkoxy-Ci ⁇ -alkoxy, Ci_ 4 - alkoxycarbonyl , C 1 _ 4 -alkoxycarbonylamino-Ci- 4 -alkyl , C 1 - 3 -alkylsulf onylamino-Ci- 3 -alkoxy, C x _ 4 -hydroxyalkyl ,
  • the compounds of the present invention further include pharmaceutically acceptable derivatives, including salts, of the compounds defined by Formulas I and II.
  • An exemplary grouping of compounds of interest encompassed within Formulas I and II consist of compounds and pharmaceutically-acceptable derivatives thereof as follows: 2- ( (2-amino-6-quinazolinyl)amino) -N- (3-methyl-4- (1- methylethyl)phenyl) -3-pyridinecarboxamide; N- (4,4-dimethyl-l, 2,3,4-tetrahydro-7-quinolinyl) -2- (6- quinazolinylamino) -3-pyridinecarboxamide;
  • a second exemplary grouping of compounds of interest within Formulas I and II consist of compounds as follows: N- (4, 4-dimethyl-2-oxo-1,2,3,4-tetrahydro-7-quinolinyl)-2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (4, 4-dimethyl-l,2,3,4-tetrahydro-7-quinolinyl) -2- (7- isoquinolinylamino)benzamide; N- (5-(l,l-dimethylethyl)-3-isoxazolyl)-2-(7- isoquinolinylamino) -3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N-(3-methyl-4- (1- pyrrolidinyl)phenyl) -3-pyridinecarboxamide; N- (l-acetyl-3, 3-dimethyl-2,3-dihydro-lH-indol-6-yl
  • a third exemplary grouping of compounds of interest within Formulas I and II consist of pharmaceutically- acceptable hydrochloride, sulfate, sulfonate or phosphate salts of the follow compounds: N- (4,4-dimethyl-2-oxo-l,2,3,4-tetrahydro-7-quinolinyl)-2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl) -2- (7- isoquinolinylamino)benzamide; N- (5- (1, 1-dimethylethyl) -3-isoxazolyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide; 2- (7-isoquinolinylamino)-N- (3-methyl-4- (1- pyrrolidinyl)phenyl) -3-pyridinecarboxamide; N- (l-acetyl
  • Compounds of the present invention would be useful for, but not limited to, the prevention or treatment of angiogenesis related diseases and physiological conditions. Particularly, the compounds of the invention would inhibit the growth of blood vessels thereby reducing the blood flow to and from a given tumor site, resulting in no net growth to the tumor at that site and reduced or no migration of tumor cells to and from that site. Accordingly, these compounds are useful for an overall reduction in the size of the tumor.
  • the compounds of the present invention have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity, and are useful in therapy to minimize deleterious effects ,of VEGF. Accordingly, the compounds of the present invention would be useful, as antineoplasia agents, for the treatment of neoplasia including cancer and metastasis, including, but not limited to: carcinoma such as cancer of the bladder, breast, colon, kidney, liver, lung (including small cell lung cancer) , esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin (including squamous cell carcinoma) ; hematopoietic tumors of lymphoid lineage (including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell- lymphoma, Hodgkin's lymphoma, non-Hodgkin' s lymphoma, hairy cell lymph
  • the compounds are useful for the treatment of neoplasia selected from lung cancer, colon cancer and breast cancer.
  • the compounds of the present invention also would be useful for treatment of ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma; retinal ischemia; vitreous hemorrhage; ulcerative diseases such as gastric ulcer; pathological, but non-malignant, conditions such as hemangiomas, including infantile hemaginomas, angiofibroma of the nasopharynx and avascular necrosis of bone,- and disorders of the female reproductive system such as endometriosis.
  • the compounds are also useful for the treatment of edema, and conditions of vascular hyperpermeability.
  • the compounds of the present invention are useful in therapy of proliferative diseases. These compounds can be used for the treatment of an inflammatory rheumatoid or rheumatic disease, especially of manifestations at the locomotor apparatus, such as various inflammatory rheumatoid diseases, especially chronic polyarthritis including rheumatoid arthritis, juvenile arthritis or psoriasis arthropathy; paraneoplastic syndrome or tumor-induced inflammatory diseases, turbid effusions, collagenosis, such as systemic Lupus erythematosus, poly-myositis, dermato- myositis, systemic sclerodermia or mixed collagenosis; postinfectious arthritis (where no living pathogenic organism can be found at or in the affected part of the body), seronegative spondylarthritis, such as spondylitis ankylosans,- vasculitis, sarcoidosis, or arthrosis; or further any combinations thereof.
  • synovial inflammation for example, synovitis, including any of the particular forms of synovitis, in particular bursal synovitis and purulent synovitis, as far as it is not crystal-induced.
  • synovial inflammation may for example, be consequential to or associated with disease, e.g. arthritis, e.g. osteoarthritis, rheumatoid arthritis or arthritis deformans.
  • the present invention is further applicable to the systemic treatment of inflammation, e.g. inflammatory diseases or conditions, of the joints or locomotor apparatus in the region of the tendon insertions and tendon sheaths.
  • Such inflammation may be, for example, consequential to or associated with disease or further (in a broader sense of the invention) with surgical intervention, including, in particular conditions such as insertion endopathy, myofasciale syndrome and tendomyosis.
  • the present invention is further especially applicable to the treatment of inflammation, e.g. inflammatory disease or condition, of connective tissues including dermatomyositis and myositis.
  • the compounds of the present invention can be used as active agents against such disease states as arthritis, atherosclerosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, wound healing, peptic ulcer Helicobacter related diseases, fractures, cat scratch fever, rubeosis, neovascular glaucoma and retinopathies such as those associated with diabetic retinopathy or macular degeneration.
  • disease states as arthritis, atherosclerosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, wound healing, peptic ulcer Helicobacter related diseases, fractures, cat scratch fever, rubeosis, neovascular glaucoma and retinopathies such as those associated with diabetic retinopathy or macular degeneration.
  • some of these compounds can be used as active agents against solid tumors, malignant ascites, hematopoietic cancers and hyperproliferative disorders such as thyroid hyperplasia (especially Grave's disease) , and cysts (such as hypervascularity of ovarian stroma, characteristic of polycystic ovarian syndrome (Stein- Leventhal syndrome) ) since such diseases require a proliferation of blood vessel cells for growth and/or metastasis.
  • thyroid hyperplasia especially Grave's disease
  • cysts such as hypervascularity of ovarian stroma, characteristic of polycystic ovarian syndrome (Stein- Leventhal syndrome)
  • some of these compounds can be used as active agents against burns, chronic lung disease, stroke, polyps, anaphylaxis, chronic and allergic inflammation, ovarian hyperstimulation syndrome, brain tumor-associated cerebral edema, high-altitude, trauma or hypoxia induced cerebral or pulmonary edema, ocular and macular edema, ascites, and other diseases where vascular hyperpermeability, effusions, exudates, protein extravasation, or edema is a manifestation of the disease.
  • the compounds will also be useful in treating disorders in which protein extravasation leads to the deposition of fibrin and extracellular matrix, promoting stromal proliferation (e.g. fibrosis, cirrhosis and carpal tunnel syndrome) .
  • the compounds of the present invention are also useful in the treatment of ulcers including bacterial, fungal, Mooren ulcers and ulcerative colitis.
  • the compounds of the present invention are also useful in the treatment of conditions wherein undesired angiogenesis, edema, or stromal deposition occurs in viral infections such as Herpes simplex, Herpes Zoster, AIDS, Kaposi's sarcoma, protozoan infections and toxoplasmosis, following trauma, radiation, stroke, endometriosis, ovarian hyperstimulation syndrome, systemic lupus, sarcoidosis, synovitis, Crohn's disease, sickle cell anaemia, Lyme disease, pemphigoid, Paget 's disease, hyperviscosity syndrome, Osler-Weber-Rendu disease, chronic inflammation, chronic occlusive pulmonary disease, asthma, and inflammatory rheumatoid or rheumatic disease.
  • the compounds are also useful in the reduction of sub-cutaneous fat and for the treatment of obesity.
  • the compounds of the present invention are also useful in the treatment of ocular conditions such as ocular and 2005/025800
  • macular edema ocular neovascular disease, scleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser complications, glaucoma, conjunctivitis, Stargardt's disease and Eales disease in addition to retinopathy and macular degeneration.
  • the compounds of the present invention are also useful in the treatment of cardiovascular conditions such as atherosclerosis, restenosis, arteriosclerosis, vascular occlusion and carotid obstructive disease.
  • cardiovascular conditions such as atherosclerosis, restenosis, arteriosclerosis, vascular occlusion and carotid obstructive disease.
  • the compounds of the present invention are also useful in the treatment of cancer related indications such as solid tumors, sarcomas (especially Ewing's sarcoma and osteosarcoma) , retinoblastoma, rhabdomyosarcomas, neuroblastoma, hematopoietic malignancies, including leukemia and lymphoma, tumor- induced pleural or pericardial effusions, and malignant ascites.
  • cancer related indications such as solid tumors, sarcomas (especially Ewing's sarcoma and osteosarcoma) , retinoblastom
  • the compounds of the present invention are also useful in the treatment of diabetic conditions such as diabetic retinopathy and microangiopathy.
  • the compounds of the present invention may also act as inhibitors of other protein kinases, e.g. Src, Lck, AbI, GSK, Kit, p38, EGFR, CDK-2, CDK-5, IKK, JNK3, bFGFR, PDGFR, RAF and ZAP70.
  • these compounds may be effective in the treatment of diseases and conditions associated with the function and activity of various other protein kinases, such as those listed above.
  • these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like.
  • these compounds may be used to treat horses, dogs, and cats.
  • treatment includes therapeutic treatment as well as prophylactic treatment (either preventing the onset of disorders altogether or delaying the onset of a preclinically evident stage of disorders in individuals) .
  • derivative is broadly construed herein, and intended to encompass any salt of a compound of this invention, any ester of a compound of this invention, or any other compound, such as a prodrug, which upon administration to a patient is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to inhibit angiogenesis.
  • neoplastic therapeutic agents prolong the survivability of the patient, inhibit the rapidly-proliferating cell growth associated with the neoplasm, or effect a regression of the neoplasm.
  • carrier denotes any pharmaceutically acceptable additive, excipient, adjuvant, or other suitable ingredient, other than the active pharmaceutical ingredient (API) , which is typically included for formulation and/or administration purposes.
  • H denotes a single hydrogen atom. This radical may be attached, for example, to an oxygen atom to form a hydroxyl radical.
  • alkyl is used, either alone or within other terms such as “haloalkyl” and “alkylamino” , it embraces linear or branched radicals having one to about twelve carbon atoms. More preferred alkyl radicals are “lower alkyl” radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl and the like.
  • alkyl substitutions embraces, beyond its normal meaning, the instance where a single atom, such as carbon, has two of the same or different substituents attached to it.
  • a B gem-dimethyl group which the phrase above embraces, refers to a single carbon atom in a structural moeity having two methyl radicals attached to it.
  • w alkylenyl embraces bridging divalent alkyl radicals such as methylenyl and ethylenyl.
  • alkenyl embraces linear or branched radicals having at least one carbon-carbon double bond of two to about twelve carbon atoms.
  • alkenyl radicals are "lower alkenyl” radicals having two to about six carbon atoms.
  • alkenyl radicals include ethenyl, propenyl, allyl, propenyl, butenyl and 4- methylbutenyl.
  • alkenyl and lower alkenyl embrace radicals having "cis” and “trans” orientations, or alternatively, "E” and "Z” orientations.
  • alkynyl denotes linear or branched radicals having at least one carbon-carbon triple bond and having two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl” radicals having two to about six carbon atoms. Most preferred are lower alkynyl radicals having two to about four carbon atoms. Examples of such radicals include propargyl, butynyl, and the like.
  • halo means halogens such as fluorine, chlorine, bromine or iodine atoms.
  • haloalkyl embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals including perhaloalkyl.
  • a monohaloalkyl radical for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical.
  • Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals.
  • “Lower haloalkyl” embraces radicals having 1- 6 carbon atoms.
  • haloalkyl radicals having one to three carbon atoms.
  • haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
  • Perfluoroalkyl means alkyl radicals having all hydrogen atoms replaced with fluoro atoms . Examples include trifluoromethyl and pentafluoroethyl.
  • hydroxyalkyl embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl” radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. Even more preferred are lower hydroxyalkyl radicals having one to three carbon atoms.
  • alkoxy embrace linear or branched oxy- containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms.
  • radicals examples include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. Even more preferred are lower alkoxy radicals having one to three carbon atoms. Alkoxy radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" radicals. Even more preferred are lower haloalkoxy radicals having one to three carbon atoms. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.
  • aryl alone or in combination, means a carbocyclic aromatic system containing one or two rings wherein such rings may be attached together in a fused manner.
  • aryl embraces aromatic radicals such as phenyl, naphthyl, indenyl, tetrahydronaphthyl, and indanyl. More preferred aryl is phenyl.
  • Said "aryl” group may have 1 to 5 substituents such as lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy and lower alkylamino. Phenyl substituted with -0-CH 2 -O- forms the aryl benzodioxolyl substituent.
  • heterocyclyl embraces saturated, partially saturated and unsaturated heteroatom-containing ring radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. It does not include rings containing -0-0-, -0-S- or -S-S- portions. Said
  • heterocyclyl group may have 1 to 3 substituents such as oxo (also known as “carbonyl”), hydroxyl, Boc, halo, haloalkyl, cyano, lower alkyl, lower aralkyl, lower alkoxy, amino and lower alkylamino.
  • saturated heterocyclic radicals include saturated 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl] ; saturated 3 to 6- membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g.
  • morpholinyl saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl] .
  • partially saturated heterocyclyl radicals include dihydrothienyl, dihydropyranyl, dihydrofuryl and dihydrothiazolyl.
  • unsaturated heterocyclic radicals also termed "heteroaryl” radicals
  • unsaturated heterocyclic radicals include unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, imidazolyl, pyrazolyl, 2- pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-1, 2,4-triazolyl, IH-I,2,3- triazolyl, 2H-1,2,3-triazolyl] ; unsaturated 5- to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, 2-furyl, 3-furyl, etc.; unsaturated 5 to 6-membered heteromonocyclic group containing a sulfur atom, for example, 2-thienyl, 3-thienyl, etc
  • heterocyclic radicals are fused/condensed with aryl radicals: unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, guinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1, 5-b]pyridazinyl] ; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g.
  • benzoxazolyl, benzoxadiazolyl] unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., benzothiazolyl, benzothiadiazolyl] ; and saturated, partially unsaturated and unsaturated condensed heterocyclic group containing 1 to 2 oxygen or sulfur atoms [e.g. benzofuryl, benzothienyl, 2, 3-dihydro-benzo[l,4]dioxinyl, benxo[1,3]dioxyIy, dihydrobenzofury1 and dihydroisobenzofuryl] .
  • Preferred heterocyclic radicals include five to ten membered fused or unfused radicals. More preferred examples of heteroaryl radicals include quinolyl, isoquinolyl, imidazolyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, and pyrazinyl.
  • heteroaryl radicals are 5- or 6-membered heteroaryl, containing one or two heteroatoms selected from sulfur, nitrogen and oxygen, selected from thienyl, furyl, pyrrolyl, indazolyl, pyrazolyl, oxazolyl, triazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, piperidinyl and pyrazinyl.
  • non-nitrogen containing heteroaryl include pyranyl, 2-furyl, 3-furyl, 2-thienyl, 3- thienyl, benzofuryl, benzothienyl, and the like.
  • Particular examples of partially saturated and saturated heterocyclyl include pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, pyrazolidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, thiazolidinyl, dihydrothienyl, 2,3-dihydro-benzo[l,4]dioxanyl, indolinyl, isoindolinyl, dihydrobenzothienyl, dihydrobenzofuryl, isochromanyl, chromanyl, 1, 2-dihydroquinoIyI, 1,2,3,4- tetrahydro-isoquinolyl, 1,2,3, 4-tetrahydro-quinolyl,
  • sulfonyl whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals -SO 2 -.
  • aminonosulfonyl denotes a sulfonyl radical substituted with an amine radical, forming a sulfonamide (- SO 2 NH 2 ) .
  • alkylaminosulfonyl includes "N- alkylaminosulfonyl” where sulfamyl radicals are independently substituted with one or two alkyl radical(s). More preferred alkylaminosulfonyl radicals are “lower alkylaminosulfonyl” radicals having one to six carbon atoms. Even more preferred are lower alkylaminosulfonyl radicals having one to three carbon atoms. Examples of such lower alkylaminosulfonyl radicals include N-methylaminosulfonyl, and N-ethylaminosulfonyl.
  • carboxy whether used alone or with other terms, such as “carboxyalkyl” , denotes -CO 2 H.
  • N-alkylaminocarbonyl and N,N- dialkylaminocarbonyl denote aminocarbonyl radicals independently substituted with one or two alkyl radicals, respectively. More preferred are “lower alkylaminocarbonyl” having lower alkyl radicals as described above attached to an aminocarbonyl radical.
  • N-arylaminocarbonyl and N-alkyl-N- arylaminocarbonyl denote aminocarbonyl radicals substituted, respectively, with one aryl radical, or one alkyl and one aryl radical.
  • heterocyclylalkyl and “heterocyclylalkylenyl” embrace heterocyclic-substituted alkyl and alkylenyl radicals. More preferred heterocyclylalkylenyl radicals are "5- or 6-membered heteroarylalkylenyl” radicals having alkyl portions of one to six carbon atoms and a 5- or 6-membered heteroaryl radical. Even more preferred are lower heteroarylalkylenyl radicals having alkyl portions of one to three carbon atoms. Examples include such radicals as pyridylmethyl and thienylmethyl.
  • aralkyl and w aryl alkylenyl embrace aryl- substituted alkyl and alkylenyl radicals.
  • Preferable aralkyl radicals are "lower aralkyl” radicals having aryl radicals attached to alkyl radicals having one to six carbon atoms. Even more preferred are “phenylalkylenyl” attached to alkyl portions having one to three carbon atoms. Examples of such radicals include benzyl, diphenylmethyl and phenylethyl.
  • the aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.
  • alkylthio embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. Even more preferred are lower alkylthio radicals having one to three carbon atoms. An example of “alkylthio” is methylthio, (CH 3 S-) .
  • haloalkylthio embraces radicals containing a haloalkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. Even more preferred are lower haloalkylthio radicals having one to three carbon atoms. An example of "haloalkylthio" is trifluoromethylthio.
  • alkylamino embraces “N-alkylamino” and "N,N-dialkylamino” where amino groups are independently substituted with one alkyl radical and with two alkyl radicals, respectively. More preferred alkylamino radicals are “lower alkylamino” radicals having one or two alkyl radicals of one to six carbon atoms, attached to a nitrogen atom. Even more preferred are lower alkylamino radicals having one to three carbon atoms. Suitable alkylamino radicals may be mono or dialkylamino such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino and the like.
  • arylamino denotes amino groups, which have been substituted with one or two aryl radicals, such as N- phenylamino.
  • the arylamino radicals may be further substituted on the aryl ring portion of the radical.
  • heteroarylamino denotes amino groups, which have been substituted with one or two heteroaryl radicals, such as N-thienylamino.
  • heteroarylamino radicals may be further substituted on the heteroaryl ring portion of the radical.
  • aralkylamino denotes amino groups, which have been substituted with one or two aralkyl radicals. More preferred are phenyl-Ci-Ca-alkylamino radicals, such as N- benzylamino. The aralkylamino radicals may be further substituted on the aryl ring portion.
  • N-alkyl-N-arylamino and “N-aralkyl-N- alkylamino” denote amino groups, which have been independently substituted with one aralkyl and one alkyl radical, or one aryl and one alkyl radical, respectively, to an amino group.
  • aminoalkyl embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more amino radicals . More preferred aminoalkyl radicals are "lower aminoalkyl” radicals having one to six carbon atoms and one or more amino radicals. Examples of such radicals include aminomethyl, aminoethyl, aminopropyl, aminobutyl and aminohexyl. Even more preferred are lower aminoalkyl radicals having one to three carbon atoms.
  • alkylaminoalkyl embraces alkyl radicals substituted with alkylamino radicals. More preferred alkylaminoalkyl radicals are "lower alkylaminoalkyl” radicals having alkyl radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkyl radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkyl radicals may be mono or dialkyl substituted, such as N-methylaminomethyl, N,N-dimethyl-aminoethyl, N,N- diethylaminomethyl and the like.
  • alkylaminoalkoxy embraces alkoxy radicals substituted with alkylamino radicals. More preferred alkylaminoalkoxy radicals are "lower alkylaminoalkoxy” radicals having alkoxy radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkoxy radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkoxy radicals may be mono or dialkyl substituted, such as N-methylaminoethoxy, N,N- dimethylaminoethoxy, N,N-diethylaminoethoxy and the like.
  • alkylaminoalkoxyalkoxy embraces alkoxy radicals substituted with alkylaminoalkoxy radicals. More preferred alkylaminoalkoxyalkoxy radicals are "lower alkylaminoalkoxyalkoxy" radicals having alkoxy radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkoxyalkoxy radicals having alkyl radicals of one to three carbon atoms.
  • Suitable alkylaminoalkoxyalkoxy radicals may be mono or dialkyl substituted, such as N- methylaminomethoxyethoxy, N-methylaminoethoxyethoxy, N,N- dimethylaminoethoxyethoxy, N,N-diethylaminomethoxymethoxy and the like.
  • halosulfonyl embraces sulfonyl radicals substituted with a halogen radical. Examples of such halosulfonyl radicals include chlorosulfonyl and fluorosulfonyl.
  • arylthio embraces aryl radicals of six to ten carbon atoms, attached to a divalent sulfur atom. An example of “arylthio” is phenylthio.
  • aralkylthio embraces aralkyl radicals as described above, attached to a divalent sulfur atom. More preferred are phenyl-Ci-C 3 -alkylthio radicals. An example of “aralkylthio” is benzylthio.
  • aryloxy embraces optionally substituted aryl radicals, as defined above, attached to an oxygen atom. Examples of such radicals include phenoxy.
  • aralkoxy embraces oxy-containing aralkyl radicals attached through an oxygen atom to other radicals. More preferred aralkoxy radicals are "lower aralkoxy” radicals having optionally substituted phenyl radicals attached to lower alkoxy radical as described above.
  • heterocyclyloxy embraces optionally substituted heteroaryl radicals, as defined above, attached to an oxygen atom.
  • heterocyclylalkoxy embraces oxy-containing heteroarylalkyl radicals attached through an oxygen atom to other radicals. More preferred heteroarylalkoxy radicals are “lower heteroarylalkoxy” radicals having optionally substituted heteroaryl radicals attached to lower alkoxy radical as described above.
  • cycloalkyl includes saturated carbocyclic groups. Preferred cycloalkyl groups include C 3 -C 6 rings. More preferred compounds include, cyclopentyl, cyclopropyl, and cyclohexyl.
  • the present invention also comprises the use of a compound of the invention, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment either acutely or chronically of an angiogenesis mediated disease state, including those described previously.
  • the compounds of the present invention are useful in the manufacture of an anti-cancer medicament.
  • the compounds of the present invention are also useful in the manufacture of a medicament to attenuate or prevent disorders through inhibition of KDR.
  • the present invention comprises a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or Formula II in association with a least one pharmaceutically acceptable carrier, adjuvant or diluent.
  • the present invention also comprises a method of treating angiogenesis related disorders in a subject having or susceptible to such disorder, the method comprising treating the subject with a therapeutically effective amount of a compound of Formula I
  • R is a 9- or 10-membered heterocyclyl ring containing at least one nitrogen or oxygen atom, said ring selected from 7-isoquinolinyl, 2-methyl-3-oxo-2, 3- dihydroindazol-6-yl, [1, 6]-naphthydrin-3-yl, [1,7]- naphthydrin-2-yl, l-oxo-2, 3-dihydrobenzofuran-4-yl, 3-oxo- 2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6- quinazolinyl, 2-amino-6-quinazolinyl, 4-methy1amino-6- guinazolinyl, 2,4-diamino-6-quinazolinyl, 3-oxo-3,4-dihydro- 1,4-benzoxazin-6-yl, 2,2-diflu
  • R 1 is substituted with one or more substituents selected from halo, optionally substituted Ci_ 6 -alkyl, optionally substituted C 3 _ 6 - cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-Ci_C 4 -alkylenyl, C 1 _ 2 -haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-Ci_C 6 -alkyl, optionally substituted 4-6 membered heterocyclyl-C 2 -C 4 - alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-Ci- 4 -alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered
  • Ci- 4 -alkyl Ci.s-alkylainino-Ci- 3 -alkyl , Ci- 3 -alkylamino-Ci_ 3 -alkoxy, Ci- 3 -alkylamino-Ci_ 3 -alko:xy-Ci_ 3 -alkoxy, C ⁇ _ 4 - alkoxycarbonyl , Ci- 4 -alkoxycarbonylamino-Ci_ 4 -alkyl , Ci- 3 -alkylsulf onylamino-Ci- 3 -alkoxy # Ci_ 4 -hydroxyalkyl ,
  • R e and R f are independently selected from H and Ci_ 2 - haloalkyl; and wherein R 7 is selected from H, C ⁇ - 3 -alkyl, optionally substituted phenyl, optionally substituted phenyl-Ci- 3 - alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-Ci_C 3 -alkyl, Ci_ 3 - alkoxy-C ⁇ - 2 -alkyl and Ci-s-alkoxy-Ci-s-alkoxy-Ci-s-alkyl; and wherein R 2 is selected from H, halo, haloalkyl and C 1-6 alkyl.
  • the present invention further comprises a method of treating angiogenesis related disorders in a subject having or susceptible to such disorder, the method comprising treating the subject with a therapeutically effective amount of a compound of Formula II, as described herein.
  • the compounds of the present invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents.
  • the therapeutic agents can be formulated as separate compositions that are administered at the same time or sequentially at different times, or the therapeutic agents can be formulated and administered as a single composition.
  • co-therapy in defining use of a compound of the present invention and another pharmaceutical agent, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace co ⁇ administration of these agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of these active agents or in multiple, separate capsules or other formulations for each agent.
  • the combination therapy can include a compound, or composition, of the present invention with at least one anti-tumor agent or other conventional therapeutic agent.
  • the combination comprises a compound, or composition, of the present invention (e.g., an antibody or antigen binding region) in combination with at least one 25800
  • Agents are inclusive of, but not limited to, in vitro synthetically prepared chemical compositions, antibodies, antigen binding regions, radionuclides, and combinations and conjugates thereof.
  • An agent can be an agonist, antagonist, allosteric modulator, toxin or, more generally, may act to inhibit or stimulate its target (e.g., receptor or enzyme activation or inhibition) , and thereby promote cell death or arrest cell growth.
  • target e.g., receptor or enzyme activation or inhibition
  • standard treatment of primary tumors consists of surgical excision followed by either radiation or IV administered chemotherapy.
  • the typical chemotherapy regime consists of either DNA alkylating agents, DNA intercalating agents, CDK inhibitors, or microtubule poisons.
  • the chemotherapy doses used are just below the maximal tolerated dose and therefore dose limiting toxicities typically include, nausea, vomiting, diarrhea, hair loss, neutropenia and the like.
  • antineoplastic agents available in commercial use, in clinical evaluation and in pre-clinical development, which would be selected for treatment of neoplasia by combination drug chemotherapy.
  • Such antineoplastic agents fall into several major categories, namely, antibiotic-type agents, alkylating-type agents, antimetabolite-type agents, hormonal agents, immunological agents, interferon-type agents and a category of miscellaneous antineoplastic agents.
  • a first family of antineoplastic agents which may be used in combination with compounds of the present invention, consists of antimetabolite-type/thymidilate synthase inhibitor antineoplastic agents.
  • Suitable antimetabolite- type antineoplastic agents may be selected from, but not limited to, the group consisting of 5-FU-fibrinogen, acanthifolic acid, aminothiadiazole, brequinar sodium, carmofur, Ciba-Geigy CGP-30694, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck & Co.
  • a second family of antineoplastic agents which may be used in combination with compounds of the present invention, consists of alkylating-type antineoplastic agents.
  • Suitable alkylating-type antineoplastic agents may be selected from, but not limited to, the group consisting of Shionogi 254-S, aldo-phosphamide analogues, alkyl sulfonates such as busulfan, altretamine, anaxirone, Boehringer Mannheim BBR- 2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine (BCNU), Chinoin-139, Chinoin-153, chlorambucil, cisplatin, cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, Degussa D-19-384, Sumimoto
  • DACHP(Myr)2 diphenylspiromustine, diplatinum cytostatic, Erba distamycin derivatives, Chugai DWA-2114R, ITI E09, elmustine, Erbamont FCE-24517, estramustine, estramustine phosphate, estramustine phosphate sodium, fotemustine, Unimed G-6-M, Ctiinoin GYKI-17230, hepsul-fam, ifosfamide, iproplatin, lomustine (CCNU) , mafosfamide, mechlorethamine, melphalan, mitolactol, Nippon Kayaku NK-121, nitrogen mustards, NCI NSC-264395, NCI NSC-342215, oxaliplatin, Upjohn PCNU, prednimustine, Proter PTT-119, ranimustine, semustine (methyl-CCNU), SmithKline SK&F-101772, Yakult Honsha SN
  • a third family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antibiotic-type antineoplastic agents.
  • Suitable antibiotic-type antineoplastic agents may be selected from, but not limited to, the group consisting of Taiho 4181-A, aclarubicin, actinomycin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201- II, Ajinomoto AN-3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol- Myers BMY-25067, Bristol-Myers BMY-25551, Bristol-Myers BMY- 26605, Bristol-Myers BMY-27557, Bristol-Myers BMY-28438, bleomycins such as bleomycin sulfate, bryostatin-1, Taih
  • a fourth family of antineoplastic agents which may be used in combination with compounds of the present invention consists of a miscellaneous families of antineoplastic agents, including tubulin interacting agents, topoisomerase II inhibitors, topoisomerase I inhibitors and hormonal agents, selected from, but not limited to, the group consisting of ⁇ -carotene, ⁇ -difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti- neoplaston AlO, antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, Henkel APD, aphidicolin glycinate, asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen-Beaufour BIM-23015
  • the compounds of the present invention may also be used in co-therapies with other miscellaneous anti-neoplastic agents, such as acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, ancestim, ARGLABIN, arsenic trioxide, BAM 002 (Novelos) , bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocfosfate, DA 3030 (Dong-A) , daclizumab, denileukin diftitox, deslorelin, dexrazoxane, dilazep, do
  • the compounds of the present invention may also be used in co-therapy with anti-tumor and anti- angiogenic agents (both administered as cancer therapy agents) .
  • anti-tumor agents include HERCEPTINTM (trastuzumab) , which may be used to treat breast cancer and other forms of cancer, and RITUXANTM (rituximab) , ZEVALINTM (ibritumomab tiuxetan) , and LYMPHOCIDETM (epratuzumab) , which may be used to treat non-Hodgkin's lymphoma and other forms of cancer, GLEEVACTM which may be used to treat chronic myeloid leukemia and gastrointestinal stromal tumors, and BEXXARTM (iodine 131 tositumomab) which may be used for treatment of non-Hodgkins's lymphoma.
  • anti-angiogenic agents that may be used in combination with compounds of the present invention include ERBITUXTM (IMC-C225), KDR (kinase domain receptor) inhibitory agents (e.g., antibodies and antigen binding regions that specifically bind to the kinase domain receptor) , anti-VEGF agents (e.g., antibodies or antigen binding regions that specifically bind VEGF, or soluble VEGF receptors or a ligand binding region thereof) such as AVASTINTM or VEGF- TRAP IM , and anti-VEGF receptor agents (e.g., antibodies or antigen binding regions that specifically bind thereto) ,
  • KDR kinase domain receptor
  • anti-VEGF agents e.g., antibodies or antigen binding regions that specifically bind VEGF, or soluble VEGF receptors or a ligand binding region thereof
  • anti-VEGF receptor agents e.g., antibodies or antigen binding regions that specifically bind thereto
  • EGFR inhibitory agents e.g., antibodies or antigen binding regions that specifically bind thereto
  • ABX-EGF panitumumab
  • IRESSATM gefitinib
  • TARCEVATM erlotinib
  • anti-Angl and anti-Ang2 agents e.g., antibodies or antigen binding regions specifically binding thereto or to their receptors, e.g., Tie2/Tek
  • anti-Tie-2 kinase inhibitory agents e.g., antibodies or antigen binding regions that specifically bind thereto
  • compositions of the present invention can also include one or more agents (e.g., antibodies, antigen binding regions, or soluble receptors) that specifically bind and inhibit the activity of growth factors, such as antagonists of hepatocyte growth factor (HGF, also known as Scatter Factor) , and antibodies or antigen binding regions that specifically bind its receptor "c-met".
  • agents e.g., antibodies, antigen binding regions, or soluble receptors
  • HGF hepatocyte growth factor
  • c-met antibodies or antigen binding regions that specifically bind its receptor "c-met”.
  • anti-angiogenic agents include Campath, IL-8, B-FGF, Tek antagonists (Ceretti et al. , U.S. Publication No. 2003/0162712; U.S. Pat. No. 6,413,932), anti-TWEAK agents (e.g., specifically binding antibodies or antigen binding regions, or soluble TWEAK receptor antagonists; see, Wiley, U.S. Pat. No. 6,727,225), ADAM distintegrin domain to antagonize the binding of integrin to its ligands (Fanslow et al., U.S. Publication No.
  • anti-eph receptor and/or anti-ephrin antibodies or antigen binding regions U.S. Pat. Nos. 5,981,245; 5,728,813; 5,969,110; 6,596,852; 6,232,447; 6,057,124 and patent family members thereof
  • anti-PDGF- BB antagonists e.g., specifically binding antibodies or antigen binding regions
  • PDGFR kinase inhibitory agents e.g., antibodies or antigen binding regions that specifically bind thereto
  • Additional anti-angiogenic/anti-tumor agents that may be used in combination with compounds of the present invention include: SD-7784 (Pfizer, USA); cilengitide. (Merck KGaA, Germany, EPO 770622); pegaptanib octasodium, (Gilead Sciences, USA); Alphastatin, (BioActa, UK),- M-PGA, (Celgene, USA, US 5712291); ilomastat, (Arriva, USA, US 5892112); emaxanib, (Pfizer, USA, US 5792783); vatalanib, (Novartis, Switzerland) ; 2-methoxyestradiol, (EntreMed, USA) ; TLC ELL- 12, (Elan, Ireland); anecortave acetate, (Alcon, USA); alpha-Dl48 Mab, (Amgen, USA); CEP-7055, (Cephalon, USA); anti-Vn Mab, (C
  • cilengitide (plNN) , (Merck KGaA, German; Kunststoff Technical University, Germany, Scripps Clinic and Research Foundation, USA); cetuximab (INN), (Aventis, France); AVE 8062, (Ajinomoto, Japan); AS 1404, (Cancer Research Laboratory, New Zealand); SG 292, (Telios, USA); Endostatin, (Boston Childrens Hospital, USA); ATN 161, (Attenuon, USA); ANGIOSTATIN, (Boston Childrens Hospital, USA); 2- methoxyestradiol, (Boston Childrens Hospital, USA); ZD 6474, (AstraZeneca, UK); ZD 6126, (Angiogene Pharmaceuticals, UK); PPI 2458, (Praecis, USA); AZD 9935, (AstraZeneca, UK); AZD 2171, (AstraZeneca, UK); vatalanib (plNN) , (Novart
  • ABT 510 (Abbott, USA); AAL 993, (Novartis, Switzerland); VEGI, (ProteomTech, USA); tumor necrosis factor-alpha inhibitors, (National Institute on
  • KDR (imClone Systems, USA); MAb, alpha5 betal, (Protein Design, USA) ; KDR kinase inhibitor, (Celltech Group, UK, and
  • GFB 116 South Florida University, USA and Yale University, USA
  • CS 706, Septal, Japan
  • combretastatin A4 prodrug (Arizona State University, USA)
  • chondroitinase AC (IBEX, Canada)
  • BAY RES 2690 (Bayer, Germany)
  • AGM 1470 (Harvard University, USA, Takeda, Japan, and TAP, USA)
  • AG 13925 (Agouron, USA); Tetrathiomolybdate, (University of Michigan, USA)
  • GCS 100 (Wayne State University, USA) CV 247, (Ivy Medical, UK); CKD 732, (Chong Kun Dang, South Korea)
  • MAb vascular endothelium growth factor, (Xenova, UK)
  • irsogladine (INN) , (Nippon Shinyaku, Japan)
  • RG 13577 (Aventis, France)
  • WX 360 (Wilex,
  • Cancer therapy agents that may be used in combination with compounds of the present invention also include polypeptides (peptidal or peptide-like cancer therapy agents) , which selectively induce apoptosis in tumor cells, including, but not limited to, the TNF-related polypeptide TRAIL.
  • polypeptides peptidal or peptide-like cancer therapy agents
  • Certain cancer therapy agents include, but are not limited to: thalidomide and thalidomide analogues (N- (2,6- dioxo-3-piperidyl)phthalimide) ; tecogalan sodium (sulfated polysaccharide peptidoglycan) ; TAN 1120 (8-acetyl-7, 8, 9, 10- tetrahydro-6, 8, ll-trihydroxy-l-methoxy-10- [ [octahydro-5- hydroxy-2- (2-hydroxypropyl) -4, 10-dimethylpyrano[3,4-d]- 1, 3, 6-dioxazocin-8-yl]oxy] -5, 12-naphthacenedione) ; suradista (7,7 '- [carbonylbis[imino(l-methyl-lH-pyrrole-4, 2- diyl)carbonylimino(1-methyl-lH- pyrrole-4, 2- diyl)carbonylimino] ]bis-
  • ARRESTIN apomigren (1304-1388-type XV collagen (human gene COL15A1 alphal-chain precursor)),- angiopoietin 2,- angioinhibin; aaATIII,- A 36,- 9alpha- fluoromedroxyprogesterone acetate ( (6-alpha) -17- (acetyloxy) - 9-fluoro-6 ⁇ methyl-pregn-4-ene-3, 20-dione) ; 2-methyl-2- phthalimidino-glutaric acid (2- (1,3-dihydro-l-oxo-2H- isoindol-2-yl) -2-methylpentanedioic acid); Yttrium 90 labelled monoclonal antibody BC-I; Semaxanib (3- (4,5- Dimethylpyrrol-2-ylmethylene)indolin-2-one) (C15 H14 N2 O); PI 88 (phosphomannopentaose sulfate) ; Al
  • AGM 1470 (Carbamic acid, (chloroacetyl) -, 5- methoxy-4-[2-methyl-3-(3-methyl-2- butenyl) oxiranyl] -1- oxaspiro[2,5] oct-6-yl ester, [3R-[3alpha, 4alpha(2R, 3R), 5beta, 6beta] ] ) (C19 H28 Cl N 06); AZD 9935; BIBF 1000; AZD 2171; ABT 828; KS-interleukin-2,- TEK/Fc; Uteroglobin; A 6; NSC 639366 (1- [3- (Diethylamino) -2-hydroxypropylamino]-4- (oxyran-2- ylmethylamino)anthraquinone fumerate)
  • Exemplary cancers include, but are not limited to, breast cancer, colorectal cancer, gastric carcinoma, glioma, head and neck squamous cell carcinoma, hereditary and sporadic papillary renal carcinoma, leukemia, lymphoma, Li- Fraumeni syndrome, malignant pleural mesothelioma, melanoma, multiple myeloma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, small cell lung cancer, synovial sarcoma, thyroid carcinoma, and transitional cell carcinoma of urinary bladder.
  • the compounds of the present invention may also be used in co-therapies with other anti-neoplastic agents, such as other kinase inhibitors including p38 inhibitors and CDK inhibitors, TNP inhibitors, matrix metalloproteinase inhibitors (MMP) , COX-2 inhibitors including celecoxib, rofecoxib, parecoxib, valdecoxib, and etoricoxib, NSAID's, SOD mimics, C-met inhibitors or ⁇ v ⁇ 3 inhibitors.
  • other anti-neoplastic agents such as other kinase inhibitors including p38 inhibitors and CDK inhibitors, TNP inhibitors, matrix metalloproteinase inhibitors (MMP) , COX-2 inhibitors including celecoxib, rofecoxib, parecoxib, valdecoxib, and etoricoxib, NSAID's, SOD mimics, C-met inhibitors or ⁇ v ⁇ 3 inhibitors.
  • the invention includes administration of, in addition to a Tek antagonist, one or more chemotherapeutic agents in combination with the compound(s) or compositions of the invention.
  • Suitable chemotherapeutic agents include, without limitation, Fit3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-lBB ligand, anti- 4-lBB antibodies, TNF antagonists and TNF receptor antagonists including TNFR/Fc, TWEAK antagonists and TWEAK- R antagonists including TWEAK-R/Fc, TRAIL, VEGF antagonists including anti-VEGF antibodies, VEGF receptor (including VEGF-Rl and VEGF-R2, also known as Fltl and Flkl or KDR) antagonists, and CD148 (also referred to as DEP-I, ECRTP, and PTPRJ, see Takahashi et al. , J. Am. Soc. Nephrol. 10:2135-45, 1999) agonists
  • compounds or compositions of the invention may be combined with agents disclosed in the following patents and publications: U.S. Patent Nos. 5521184, 5747498, 5770599, 5990141, 6235764, 6258812, 6515004, 6630500, 6713485; U.S.
  • Patent Publication NO.US20030105091 Patent Publication No.US20030105091; and PCT application Nos: WO01/37820,WO01/32651, WO0268406, WO0266470, WO0255501, WO0405279, WO0407481, WO0407458, WO0409784, WO0259110, WO9945009, WO9835958, WO0059509, WO9961422, WO0012089 and WO0002871; as well as the following specific compounds: N- (4-chlorophenyl) -4- (4-pyridinylmethyl) -1- phthalazinamine; 4- [4- [ [ [ [4-chloro-3-
  • Specific binding agents to a cancer therapy agent may be administered with the cancer therapy agent, in conjunction with the compound, or composition, of the present invention. Binding agents may be administered prophylactically or therapeutically to prevent or mitigate the disease or condition in question.
  • Binding agents may be administered prophylactically or therapeutically to prevent or mitigate the disease or condition in question.
  • Included in the compounds of Formulas I and II are the pharmaceutically acceptable salts of the free-base compounds.
  • pharmaceutically-acceptable salts embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. As appreciated by those of ordinary skill in the art, salts may be formed from ionic associations, charge-charge interactions, covalent bonding, complexation, coordination, etc. The nature of the salt is not critical, provided that it is pharmaceutically acceptable.
  • a salt form of a compound of Formula I or of Formula II which has been approved for mammalian use, via ingestion or by other administrative routes, by a governing body or regulatory agency, such as the Food and Drug Administration (FDA) of the United States, is pharmaceutically acceptable.
  • Suitable pharmaceutically acceptable acid addition salts of compounds of Formulas I and II may be prepared from an inorganic acid or from an organic acid.
  • organic acids examples include hydrochloric, hydrobromic, hydroiodic, hydrofluoric, nitric, carbonic, sulfuric and phosphoric acid.
  • Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include, without limitation, formic, acetic, adipic, butyric, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic) , methanesulfonic, ethanesulfonic, ethanedisulfonic, benzenesulfonic, pantothenic
  • Suitable pharmaceutically-acceptable base addition salts of compounds of Formulas I and II include metallic salts, such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or salts made from organic bases including, without limitation, primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-ethyl piperidine, histidine, glucamine, isopropylamine, lysine, morpholine, N- ethyl morpholine, piperazine, piperidine, triethylamine, disopropylethylamine and trimethy1amine.
  • metallic salts such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc
  • organic bases including, without limitation, primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-e
  • salts may be prepared by conventional means from the corresponding compound of the invention by reacting, for example, the appropriate acid or base with the compound of Formulas I or II.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
  • Other examples include salts with alkali metals or alkaline earth metals such as sodium, potassium, calcium or magnesium, or with organic bases.
  • Preferred salts include hydrochloride, phosphate and edisylate.
  • the compound of Formulas I or II is in the form of a salt, such as a hemi-, mono-, or di-salt complex, wherein the salt is selected from a benzenesulfonate salt, an ethanesulfonate salt, an ethanedisulfonate salt, a methanesulfonate salt, a p- toluenesulfonate salt, a phosphate salt, a hydrobromide salt, a nitrate salt, a hydrochloride salt, a citrate salt, a medronate salt, a tosylate salt, a maleate salt, a fumarate salt, a napsylate salt, a pamoate salt, a salicylate salt and a stearate salt.
  • a salt such as a hemi-, mono-, or di-salt complex
  • the salt is selected from a benzenesulfonate salt, an ethane
  • a phosphate salt of a compound of the invention may be made by combining the desired compound free base in a desired solvent, or combination of solvents, with phosphoric acid in a desired stoichiometric amount, at a desired temperature, typically under mild heat between 40-80 2 C (depending upon the boiling point of the solvent) .
  • polar solvents such as alcohols (like EtOH) , DMF, DMSO, and the like are used to form salts, as is readily appreciated by those of ordinary skill in the art.
  • the salt can be precipitated upon cooling (slow or fast) and may crystallize (i.e., if crystalline in nature) , as appreciated by those of ordinary skill in the art. (See Example 75 for instance) Further, hemi-, mono-, di, tri- and poly-salt forms of the compounds of the present invention are also contemplated herein. Similarly, hemi-, mono-, di, tri- and poly-hydrated forms of the compounds, salts and derivatives thereof, are also contemplated herein.
  • the present invention further comprises procedures for the preparation of a compound of Formulas I and II.
  • schemes 1-33 illustrate procedures for preparing compounds of Formula I (amino-nicotinamides) , these schemes are also applicable as exemplary methods for the preparation of corresponding amino-benzamides of Formula II, which are described in more detail in the "Preparations" immediately following the General Synthetic Procedures.
  • Substituted nicotinamides 3 can be prepared from the corresponding halo analogs 1 by the process outlined in Scheme 1.
  • Substituted amino acids 2 are prepared from the corresponding chloro compounds 1 such as by reacting with an amine at a suitable temperature, such as about 80 0 C.
  • the acid 2 is coupled with an amine, preferably in the presence of a coupling agent such as EDC, to form the corresponding amide 3.
  • the amination process can be carried out as an Ullmann type reaction using a copper catalyst, such as copper[0] or a copper[I] compound such as copper[I]oxide, copper[I]bromide or copper[I]iodide in the presence of a suitable base (such as a metal carbonate, for example K 2 CO 3 to neutralize the acid generated in the reaction.
  • a copper catalyst such as copper[0] or a copper[I] compound such as copper[I]oxide, copper[I]bromide or copper[I]iodide
  • a suitable base such as a metal carbonate, for example K 2 CO 3 to neutralize the acid generated in the reaction.
  • the amount of catalyst is typically in the range of 1 to 20 mole percent.
  • the reaction is carried out in an inert, aprotic solvent such as an ether solvent (for example dimethoxyethane or dioxane) or an amide solvent (for example dimethylformamide or N- methylpyrrolidone) , under an inert atmosphere in the temperature range of 60-180 3 C.
  • aprotic solvent such as an ether solvent (for example dimethoxyethane or dioxane) or an amide solvent (for example dimethylformamide or N- methylpyrrolidone)
  • An alternative amination process involves using a Group VIII element, where the metal core of the catalyst should be a zero-valent transition metal, such as palladium or nickel, which has the ability to undergo oxidative addition to the aryl-halogen bond.
  • the zero valent state of the metal may be generated in situ from the M[II] state.
  • the catalyst complexes may include chelating ligands, such as alkyl, aryl or heteroaryl derivatives of phoshines or biphosphines, imines or arsines.
  • Preferred catalysts contain palladium or nickel.
  • Such catalysts include palladium[II] chloride, palladium[II]acetate, tetrakis (triphenyl- phosphine)palladium[0] and nickel[II]acetylacetonate.
  • the metal catalyst is typically in the range of 0.1 to 10 mole percent.
  • the chelating ligands may be either monodentate, as in the case for example of trialkyphosphines, such as tributylphosphine, triarylphosphines, such as tri- (ortho- tolyl)phosphine, and triheteroaryl phosphines, such as tri- 2-furylphosphine; or they may be bidentate such as in the case of 2, 2 ' -bis (diphenylphosphino) - 1, 1 'binaphthyl, 1,2- bis (diphenylphosphino)ethane, 1,1'-bis (diphenylphosphino) ferrocene and 1- (N,N-dimethyl-amino) -1 '- (dicyclohexylphosphino)biphenyl.
  • trialkyphosphines such as tributylphosphine
  • triarylphosphines such as tri- (ortho
  • the supporting ligand may be complexed to the metal center in the form of a metal complex prior to being added to the reaction mixture or may be added to the reaction mixture as a separate compound.
  • the supporting ligand is typically present in the range 0.01 to 20 mole percent. It is often necessary to add a suitable base to the reaction mixture, such as a trialkylamine (for example, DIEA or 1, 5-diazabicyclo[5,4,0]undec-5-ene) , a Group I alkali metal alkoxide (for example potassium tert- butoxide) or carbonate (for example cesium carbonate) or potassium phosphate.
  • a suitable base such as a trialkylamine (for example, DIEA or 1, 5-diazabicyclo[5,4,0]undec-5-ene) , a Group I alkali metal alkoxide (for example potassium tert- butoxide) or carbonate (for example cesium carbonate) or potassium phosphate.
  • the reaction is typically carried out in an inert aprotic solvent such as an ether solvent (for example dimethoxyethane or dioxane) or an amide solvent (for example, DMF or i ⁇ 7-methylpyrrolidone) , under an inert atmosphere in the temperature range of 60-180 ⁇ C.
  • aprotic solvent such as an ether solvent (for example dimethoxyethane or dioxane) or an amide solvent (for example, DMF or i ⁇ 7-methylpyrrolidone)
  • the amination is preferably carried out in an inert, aprotic, preferably anhydrous, solvent or solvent mixture, for example in a carboxylic acid amide, for example DMF or dimethylacetamide, a cyclic ether, for example THF or dioxane, or a nitrile, for example CH 3 CN, or in a mixture thereof, at an appropriate temperature, for example in a temperature range of from about 40 a C to about 180 a C, and if necessary under an inert gas atmosphere, for example a nitrogen or argon atmosphere.
  • an inert, aprotic preferably anhydrous, solvent or solvent mixture
  • a carboxylic acid amide for example DMF or dimethylacetamide
  • a cyclic ether for example THF or dioxane
  • a nitrile for example CH 3 CN
  • Substituted nicotinamides 3 can also be prepared from the corresponding halo analogs IA by the process outlined in Scheme 2.
  • the chloro acid 1 (LG is OH) is coupled with an amine, preferably in the presence of a coupling agent such as EDC, to form the corresponding chloro amide 4.
  • Substituted amino-nicotinamides 3 are prepared from the corresponding chloro compounds 4 such as by reacting with an amine at a suitable temperature, such as about 80 0 C.
  • the amination reaction can be run in the presence of an appropriate catalyst such as a palladium catalyst, in the presence of an aprotic base such as sodium t-butoxide or cesium carbonate, or a nickel catalyst, or a copper catalyst.
  • nicotinamides 3 can be prepared from 2- chloro-heterocyclyl acid chloride IA (LG is Cl) by coupling first with R X -NH 2 such as in the presence of base, e.g., NaHCO 3 , triethylamine (TEA) or other weak base, in a suitable solvent, such as CH 2 Cl 2 , to form the amide IB, then coupling with a primary or secondary amine in the presence of a base, such as LiHMDS or other strong base, to yield the substituted nicotinamide 3.
  • base e.g., NaHCO 3
  • TAA triethylamine
  • CH 2 Cl 2 a suitable solvent
  • a primary or secondary amine such as LiHMDS or other strong base
  • KF such as 40% KF on alumina in IpOH
  • a temperature over about 100 2 C, preferably about 160 2 C can be used in the formation of 3 from IB.
  • Substituted carboxamides 3 can also be prepared from the corresponding bromo/chloro analogs 5 by the process outlined in Scheme 3.
  • the bromo/chloro acid 5 is coupled with an amine, preferably in the presence of a coupling agent such as EDC, to form the corresponding bromo substituted amide 6.
  • Suzuki coupling with the bromo amide 6 and suitable boronic acids provides the substituted amide 4.
  • Substituted amino-amides 3 are prepared from the corresponding chloro compounds 4 as described in Scheme 2.
  • pyridines 12 can be prepared by the procedure described in Scheme 4.
  • a solution of sodium hypobromite is freshly prepared and added to a 2- hydroxynicotinic acid 7 and heated, such as at a temperature of about 50 0 C. Additional sodium hypobromide may be added to form the bromo compound 8 as needed.
  • the 5-bromo-2- hydroxynicotinic acid 8 is reacted with thionyl chloride, at suitable temperature, such as at a temperature >RT, and preferably at about 80 2 C, to form the 2-chloro-nicotinic acid analog 9.
  • the acid is coupled with an amine, preferably in the presence of a suitable coupling agent (s), such as EDC, HOBT, and DIEA, to form the corresponding substituted amide 10.
  • a suitable coupling agent such as EDC, HOBT, and DIEA
  • Suzuki coupling with the bromo nicotinamide 10 and suitable boronic acids provides the substituted nicotinamide 11.
  • 2-Amino-nicotinamides 12 are prepared from the corresponding chloro compounds 11 such as by reacting with substituted amines at a suitable temperature, such as about 80 3 C.
  • 2-Amino-nicotinamides can also be prepared by first functionalizing pyridine compounds, as shown by the procedure described in Scheme 5.
  • 2-Fluoropyridine 13 is lithiated by treatment with a lithium base, such as LDA or butyl lithium, at a temperature below about 0 0 C, and preferably at about -78 0 C, and quenched with a stream of dry CO 2 to form the nicotinic acid 14.
  • Solid CO 2 dry ice
  • the acid 14 is converted to the acid halide 15, such as by treatment with thionyl chloride and heating at a temperature above about 50 a C, and preferably at about reflux.
  • Chloro-substituted pyridines 18 are prepared such as by the procedure described in Scheme 6.
  • 2-Chloronicotinic acid 17 is activated with ethyl chloroformate, in the presence of base, such as TEA, at a temperature of about RT, to form the mixed anhydride (not shown) .
  • base such as TEA
  • Reaction of the mixed anhydride with an amine produces amide 18.
  • the amine can be coupled with the acid chloride 16, such as with polymer-supported DIEA. Excess acid chloride is removed by treating the reaction mixture with polymer-supported trisamine resin, to form amide 18.
  • Amino-isoquinoline-aryl-amides 21 can be prepared such as by the procedure described in Scheme 7. As shown, a halo- benzoic acid ester or nicotinic acid ester 19 can be coupled to an amino-isoquinoline under Buchwald-type palladium coupling conditions, such as with the use of Pd(OAc) 2 and BINAP in toluene with a mild base such as a carbonate base (see conditions a) . The resulting isoquinolin-7-ylamino-acid ester 20 can be saponified to the corresponding acid using a hydroxide base, such as LiOH, in a suitable solvent, such as in a mixed solvent of MeOH, water and THF, at mild temperature.
  • a hydroxide base such as LiOH
  • suitable solvent such as in a mixed solvent of MeOH, water and THF
  • the acid intermediate (not shown) can then be treated with known, conventional acid activating/coupling reagents, such as TBTU, HBTU, DCC, and the like, in the presence of a mild base, such as a tertiary amine base like DIEA (iV,i ⁇ J-diisopropylethyl amine) , and reacted with a desired amine such as an amino-tetrahydroisoquinoline 22 (below) , or suitable other nucleophile (not shown in scheme 7), to afford the amino-isoquinolines 21 as the product.
  • a mild base such as a tertiary amine base like DIEA (iV,i ⁇ J-diisopropylethyl amine)
  • a desired amine such as an amino-tetrahydroisoquinoline 22 (below) , or suitable other nucleophile (not shown in scheme 7)
  • This method is useful for installing the desired isoquinolines prior to modifying the
  • amino-isoquinoline (or quinazoline) - aryl-nicotinamid.es 25 can be prepared by the procedure described in Scheme 8, as follows: Amino- isoquinolines 23 can be coupled to benzoic esters or nicotinic esters 19 (scheme 7) after it has been converted to the desired amide 22 (see scheme 7 above) , under N 2 , by reacting compounds 22 and 23 in the presence of Pd 2 (dba) 3 , a catalytic amount of 2-dicyclohexylphosphino-2 '- (N,N- dimethylamino)biphenyl 24 (Cas# 213697-53-1, Strem Chemicals 15-1145,) and 1.0 M LiNTMS 2 THF solution, in a pressure- sealed reaction vessel. The reaction vessel is generally stirred at elevated temperatures, as at about 70 2 C for a prolonged period of time, such as about 17 hours. After cooling, the product 25 can be
  • amino-naphthydrin-aryl- nicotinamides 28 can be prepared by the procedure described in Scheme 9, as follows: 2-amino-N- (4-tert-butyl-phenyl)-benzamide 26 (where R 1 is 4-tert-butyl-phenyl) and 2-Chloro-[1,7]naphthyridine 27 can be coupled to form compound 28 using the reagents shown in scheme 8, i.e., Pd 2 (dba) 3 , (2 '-dicyclohexylphosphanyl- biphenyl-2-yl)-dimethyl-amine, and IM solution of LiN(TMS) 2 in THF, in a sealed reaction vessel at 70 2 C for about 24h.
  • Pd 2 (dba) 3 2- '-dicyclohexylphosphanyl- biphenyl-2-yl
  • IM solution of LiN(TMS) 2 in THF in a sealed reaction vessel at 70 2 C
  • a suitable solvent such as t-BuOH
  • Alkylated indazoles can be prepared by the procedure described in Scheme 11. To a solution of 6-nitroindazole 32 in a solvent such as THF is added strong base, such as NaH at a temperature below RT, preferably at about 0 2 C. Alkylhalides, such as where R" is methyl, are added and reacted at a temperature about RT to give l-alkyl-6-nitro- lH-indazole 33. The nitro indazole 33 is hydrogenated, such as with an H 2 atmosphere in the presence of a catalyst, such as Pd/C to give the l-substituted-6-amino-lH-indazole 34.
  • a catalyst such as Pd/C
  • Brominated indazoles can be prepared by the procedure described in Scheme 12. NBS is slowly added to an acidic solution, such as a mixture of TFA:H 2 SO 4 (5:1) and tert- butyl-4-nitrobenzene 35 at a temperature of about RT to yield the brominated compound 36.
  • an acidic solution such as a mixture of TFA:H 2 SO 4 (5:1) and tert- butyl-4-nitrobenzene 35 at a temperature of about RT to yield the brominated compound 36.
  • Indazolyl ethers 38 can be prepared by the procedure described in Scheme 13.
  • 6-Nitro-lH-2-hydroindazol-3-one 37 is protected such as with BoC 2 O and DMAP in CH 2 Cl 2 at a temperature of about RT, to give the protected 6-nitro-2- hydroindazol-3-one.
  • the protected ⁇ nitro-2-hydroindazol-3- one is reacted with an alcohol (where R x is an appropriate substituent selected from the possible substituents on R 1 ) and Ph 3 P in a solvent, such as THF, and DEAD, at a temperature of about RT, to give the protected 6- nitro(indazol-3-yl) ether.
  • the nitro intermediate is hydrogenated, such as with an H 2 atmosphere in the presence of a catalyst, such as Pd/C, to give the protected 6- amino ⁇ indazol-3- ⁇ l) ether 38.
  • the amine 38 is coupled with 2-chloronicotinic acid in a solvent, such as an alcohol, preferably pentanol, at a temperature above RT, preferably at a temperature above about 75 a C, and more preferably at a temperature at about 130 2 C to give the coupled and deprotected compound 39.
  • a solvent such as an alcohol, preferably pentanol
  • Indolinyl substituted carboxamides 45 can be prepared from the corresponding nitro indoline 40 by the procedure described in Scheme 14.
  • 3,3-dimethyl-6- nitroindoline 40 is alkylated, such as with N-protected-4- formylpiperidine in the presence of NaHB(OAc) 3 and acid, such as glacial AcOH, and solvent, such as dichloromethane, at a temperature of about RT, to afford the alkylated indane 41.
  • Hydrogenation of the alkylated indane 41 such as with an H 2 atmosphere in the presence of a catalyst, such as Pd/C, in the presence of a solvent, such as an alcohol, preferably MeOH, to give the amino intermediate 42.
  • amine 42 such as with 2-chloronicotinic acid and DIEA, HOBt and EDC, in a solvent such as CH 2 Cl 2 at a temperature of about RT provides the protected carboxamide 43, which upon deprotection and alkylation yields other compounds of the invention, 44 and 45, respectively.
  • amine 42 is reacted with 2-fluoronicotinoyl chloride to form a 2-fluoronicotinamide, which can be alkylated such as in Scheme 14.
  • Substituted indolines 51 are prepared such as by the procedures described in Scheme 15.
  • Substituted amino- indolines 48 are prepared from the nitroindoline 46 and a ketone in the presence of NaHB(OAc) 3 to form the 1- substituted indoline 47.
  • the nitroindoline 47 is hydrogenated, such as with H 2 in the presence of a catalyst, such as Pd/C, to yield the amino-indoline 48.
  • substituted amino-indolines 51 are prepared from the nitroindoline 46. Nitroindoline 46, is reacted with an acid chloride to form an amide.
  • Substituted indolines are prepared such as by the procedures described in Scheme 16.
  • Substituted acetamides 53 are prepared from the coupling of halo-5-nitroanilines 52 (where LG is bromo or chloro, preferably chloro) and an acylating agent, such as acetyl chloride or acetic anhydride, under standard coupling chemistry, such as with DIEA, and DMAP, at a temperature of about RT, in a suitable solvent, such as CH 2 Cl 2 , DMF and/or DMAC.
  • the N- (2-methylprop-2-enyl)acetamide 54 is prepared from the acetamide 53, such as by the treatment of base, such as NaH in a suitable solvent such as NMP or anhydrous DMF and a 3-halo-2-methylpropene such as 3-bromo-2- methylpropene or 3-chloro-2-methylpropene, at a temperature between about 0 2 C and RT, and preferably at about RT,- or with CsCO 3 at a temperature above RT, preferably above about 50 2 C and more preferably above about 60 a C.
  • base such as NaH
  • a suitable solvent such as NMP or anhydrous DMF
  • a 3-halo-2-methylpropene such as 3-bromo-2- methylpropene or 3-chloro-2-methylpropene
  • Deprotection such as with strong acid such as HCl or AcOH at a temperature above about 50 a C, and preferably at about 70-80 2 C, yields the 3,3-dimethyl-6-nitro-2,3-dihydro-indol- l-yl 56.
  • the protected dihydro-6-nitro indoline 55 can be reduced, such as with Pe, or with 10% Pd/C in the presence of an excess of NH 4 CO 2 H, or with H 2 in the presence of a catalyst to form the protected dihydro-6- amino indoline 55a.
  • 7-Amino-isoquinolines 61 can be prepared by the procedure described in Scheme 17.
  • 4-Nitrophenethylamine hydrochloride 57 can be treated with triflic anhydride in the presence of base, such as DIEA, in a suitable solvent, such as CH 2 Cl 2 , at reduced temperature and stirred at about RT to form the protected amino compound 58.
  • nitro group resulting nitro-tetrahydroisoquinoline 60 can then be reduced to the corresponding 7-amino-isoquinoline 61 with 10%Pd on carbon in diethylene glycol under radiation, such as in a Smith Synthesizer microwave at 220 2 C.
  • N 4 -Substituted-quinazoline-4, 6-diamines 63 can be prepared by the procedure described in Scheme 18.
  • the nitro group of substituted- (6-nitro-quinazolin-4-yl) -amines 62 can be reduced by conventional hydrogenation methods, such as with palladium on carbon (10 wt%) in suitable solubilizing solvent, such as methanol, under a suitable pressure of hydrogen gas.
  • [1, 6]naphthyridine-6 ⁇ carboxylic acid tert-butyl ester 66 can be prepared by reacting 1-methyl-3,5-dinitro-lH-pyridin-2- one 64 and 4-oxo-piperidine-l-carboxylic acid tert-butyl ester 65 with 2M solution of NH 3 in MeOH in a sealed vessel for 24h at 70 a C. Cooling and concentration of the reaction affords the crude compound 66, which may be recrystallized from one or more suitable solvents, such as from MeOH.
  • the Boc protecting group of 3-nitro-7, 8-dihydro-5H- [1, 6]naphthyridine-6-carboxylic acid tert-butyl ester 66 can be removed using standard deprotection chemistry, such as with TFA in solvent, to yield 3-nitro-5, 6,7, 8-tetrahydro- [1, 6]naphthyridine 67.
  • Compound 67 may be recrystallized from suitable solvents, such as CH 3 CN.
  • 1,2,3, 6-Tetrahydro-pyridyl substituted anilines 73 are prepared such as by the procedure described in Scheme 20.
  • Nitrobenzenes 69 are brominated, such as with bromine in the presence of acid, H 2 SO 4 for example, or with NBS to yield the 3-bromo derivative 70.
  • a series of substituted anilines are prepared such as by the procedure described in Scheme 21.
  • a nitrobenzyl bromide 74 is coupled with morpholine, such as at a temperature at about RT, to yield the heterocyclylmethyl nitrobenzene derivative (not shown) .
  • Reduction of the nitro compound (step 2) such as with iron powder, preferably above about 50 S C, and more preferably at about 80 2 C, yields the heterocyclylmethyl substituted aniline 75.
  • Protected alkylamine substituted anilines can be prepared from the nitro free amines 76, such as with standard protecting agents and chemistry known in the art, such as BOC chemistry.
  • Sulfonamide substituted anilines can be prepared from nitrobezenesulfonyl chlorides 78. Coupling of nitrobezenesulfonyl chlorides 78 with reactive heterocyclic compounds, such as substituted piperazines, piperidines, and the like, in a protic solvent such as EtOH, such as at a temperature about RT, yields the nitrobezenesulfonamides 78. Reduction of the nitro benzenesulfonamide, such as with iron powder, preferably above about 50 2 C, and more preferably at about 80 2 C, yields the aniline 79.
  • a series of perhaloalkyl-substituted anilines 82, where R y represents perhaloalkyl radicals, are prepared such as by the procedure described in Scheme 22.
  • l-Nitro-4- (perfluoroethyl)benzene can be synthesized by the method described in the reference [John N. Freskos, Synthetic Communications, 18(9), 965-972 (1988)].
  • 1- Nitro-4- (perfluoroalkyl)benzene can be synthesized from the nitro compound, where X a is a leaving group, such as bromo or iodo, by the method described by W. A. Gregory, et al. [J. Med. Chem., 1990, 33, 2569-2578].
  • Additional series of substituted anilines (85, 88 and 91) are prepared such as by the procedures described in Scheme 23 (where R x is a substituent selected those available for substituted R 1 , preferably haloalkyl and alkyl) .
  • 2-Alkoxy substituted anilines 85 are prepared from the corresponding phenol compounds 83 such as by the Mitsunobu reaction, including treatment with a N,N- dialkylethanolamine and PPh 3 and DEAD to give the corresponding nitro compound 84, followed by hydrogenation, such as with H 2 to give the aniline 85.
  • piperazinyl substituted anilines 88 can be prepared by the treatment of an aniline 86 with an N- substituted-bis (2-chloroethyl)amine, base, such as K 2 CO 3 and NaI, at a temperature above about 50 2 C, preferably above about 100 a C, and more preferably at about 170 2 C, to give the piperazinylbenzene compound 87. Nitration, such as with H 2 SO 4 and HNO 3 , at a temperature above 0 2 C, and preferably 5 025800
  • piperazinyl substituted anilines 91 can be prepared by the treatment of a fluoro-nitro-substituted aryl compounds 89.
  • the fluoro-nitro-substituted aryl compounds 89 and 1-substituted piperazines are heated, preferably neat, at a temperature above about 50 a C, and preferably at about 90 S C, to yield the piperazinyl- nitroaryl compounds 90.
  • Hydrogenation such as with H 2 atmosphere in the presence of a catalyst, such as 10% Pd/C, gives the substituted aniline 91.
  • Substituted anilines 98 are prepared such as by the procedures described in Scheme 24.
  • Nitrophenyl esters 93 are formed from the acid 92, such as by treatment with MeOH and acid.
  • Alkylation of the ester 93 such as by treatment with base, followed by alkyl halide, yields the branched alklyl compounds 94.
  • Reduction of the ester 94 such as with BH 3 , yields the alcohol 95.
  • the aldehyde 96 is prepared from the alcohol 95, such as by treatment with TPAP in the presence of N-methylmorpholine-N-oxide. Subsequent treatment with methoxymethyltriphenylphosphonium chloride and KHMDS yields 96.
  • Substituted aniline compounds 101 are prepared such as by the procedure described in Scheme 25 (where R x is a substituent selected those available for substituted R 1 , preferably haloalkyl and alkyl) .
  • Alkynyl-aniline 100 prepared similar to that described in Scheme 26 (below) , is hydrogenated such as with H 2 in the presence of a catalyst, such as Pd(OH) 2 , to yield the substituted alkyl 101.
  • bromophenyl compounds 103 are prepared such as by the procedure described in Scheme 26. Bromine is added to a optionally substituted nitrobenzene 102, silver(II) sulfate and acid, such as H 2 SO 4 , to provide the bromo derivative 103.
  • 4-(2,2,2-Trifluoro-l-methoxy-l-trifluoromethyl-ethyl)- phenylamine 105 can be prepared by the procedure decribed in scheme 27, as follows: the hydroxyl group of 2-(4-amino- phenyl) -1, 1, 1, 3,3,3-hexafluoro-propan-2-ol 104 can be activated for displacement by conventional methods, such as by treating 104 with diisopropyl azodicarboxylate in the presence of triphenylphosphine (polymer-bound, excess equivalents) then treated with MeOH and stirred at about reflux.
  • triphenylphosphine polymer-bound, excess equivalents
  • Substituted indoles 110 are prepared such as by the procedure described in Scheme 29.
  • a nitroindole 108 is coupled with a halo compound, in the presence of base, for example K 2 CO 3 .
  • Heating at a temperature above about 50 2 C, and preferably at about reflux yields the substituted-nitro- lH-indole 109.
  • Hydrogenation similar to conditions described above yield the amino derivative 110.
  • Amino-substituted indoles 113 are prepared such as by the procedure described in Scheme 30. Nitroindoline 111 is reacted with N-methyl-4-piperidone in the presence of NaOMe at a temperature above about 50 2 C, and preferably at about reflux, to form the 3-substituted indole 112. Hydrogenation as previously discussed yields the amino indole 113.
  • Substituted carboxamides 115 can be prepared from the corresponding phenols 114 of the invention, by the procedure described in Scheme 31.
  • a carboxamide 114 is coupled with an alcohol, such as 4-hydroxy-N-methylpiperidine, in the presence of DEAD and triphenylphosphine, in a solvent such as THF, at a temperature of about RT, provides the ether 115.
  • 2,3, 4,4a, 9, 9a-Hexahydro-lH-3-aza-fluoren-6- ⁇ lamine 121 can be prepared by the procedure described in Scheme 32.
  • Nitrobenzylpyridines 116 are alkylated, such as with MeI, in the presence of TBAI and base to form the pyridinium compound 117.
  • the pyridinium compounds 117 are halogenated, such as brominated with NBS, to form the brominated pyridinium compounds 118 which are reduced such as with NaBH 4 , dehalogenated and reduced to form the hexahydro- fluorenes 121.
  • Acylated amino-isoquinoline-tetrahydroisoquinoline- nicotinamides 124 can be prepared by the procedure described in scheme 33.
  • Tetrahydroisoquinoline-quinoline nicotinamides 122 can be treated with Boc-protected glycine 123 in the presence of known acid-activating coupling reagents and combinations of same reagents, such as EDAC and HOBt, with a mild base, such as DIEA, to effect the acylation of compound 122 and provide compound 124.
  • the glycyl amine can be deprotected or cleaved using dilute HCl to afford the free glycine amine 125, for subsequent coupling to desired chemical structures.
  • Amides (not shown) of compound 125 can be made by coupling compound 125 with activated carboxylic acid compounds (not shown) such as acid chlorides, or by displacing other suitable leaving groups of desired compounds.
  • the starting compounds defined in Schemes 1-33 may also be present with functional groups in protected form if necessary, such as BOC-protected glycine, and/or' in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible.
  • one compound of Formula I or II can be converted into another compound of Formula I or II, or a N-oxide thereof; a compound of Formula I or II can be converted into a salt; a salt of a compound of Formula I or II can be converted into the free compound or another salt; and/or a mixture of isomeric compounds of Formula I or II can be separated into the individual isomers.
  • N-Oxides are also contemplated to be included in the present invention.
  • N-oxides can be obtained in a known matter by reacting a compound of Formula I or II with hydrogen peroxide or a peracid, e.g. 3-chloroperoxy-benzoic acid, in an inert solvent, e.g. dichloromethane, at a temperature between about -10-35 3 C, such as about 0 2 C - RT.
  • one or more other functional groups for example carboxy, hydroxy, amino, or mercapto, are or need to be protected in a compound of Formula I or II or in the preparation of compounds of Formula I or II, because they should not take part in the reaction, these are such groups as are usually used in the synthesis of peptide compounds, and also of cephalosporins and penicillins, as well as nucleic acid derivatives and sugars.
  • the protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products.
  • the specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned above and hereinafter.
  • Salts of a compound of Formula I or II with a salt- forming group may be prepared in a manner known per se. Acid addition salts of compounds of Formula I or II may thus be obtained by treatment with an acid or with a suitable anion exchange reagent.
  • a salt with two acid molecules for example a dihalogenide of a compound of formula I
  • Acid salts can usually be converted to free-base compounds, e.g. by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide.
  • suitable basic agents for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide.
  • basic salts of compounds may be converted to the corresponding free-base compound by treatment with the desired number of equivalents of a suitable acidic agent, such as HCl, acetic acid, and the like.
  • a carbonyl group in a compound of Formula I or II may be converted into the respective thiocarbonyl, for example, by using an appropriate sulfur compound, e. g.
  • All process steps described here can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralizing agents, for example ion exchangers, typically cation exchangers, for example in the H+ form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from about - 100 0 C to about 190 0 C, preferably from about -80 0 C to about 150 0 C, for example at about -80 0 C to about 60 0 C, at room temperature, at about -20 0 C to about 40 0 C or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen.
  • solvents or diluents
  • Salts may be present in all starting compounds and transients, if these contain salt-forming groups. Salts may also be present during the reaction of such compounds, provided the reaction is not thereby disturbed. In certain cases, typically in hydrogenation processes, it is possible to achieve stereoselective reactions, allowing for example easier recovery of individual isomers.
  • Suitable solvents which may be selected to carry out the reactions in question, as appreciated by those of ordinary skill in the art.
  • Suitable aqueous, organic and inorganic solvents include, without limitation, water; esters, typically lower alkyl-lower alkanoates, e.g., ethyl acetate; ethers, typically aliphatic ethers, e.g., diethylether, or cyclic ethers, e.g., THF; liquid aromatic hydrocarbons, typically benzene or toluene,- alcohols, typically MeOH, EtOH or 1-propanol, IPOH, BuOH, t-BuOH,- nitriles, typically CH 3 CN; halogenated hydrocarbons, typically CH 2 Cl 2 , CHCl 3 ; acid amides, typically DMF; bases, typically heterocyclic nitrogen bases, e.g.
  • carboxylic acids typically lower alkanecarboxylic acids, e.g., AcOH
  • carboxylic acid anhydrides typically lower alkane acid anhydrides, e.g., acetic anhydride
  • cyclic, linear, or branched hydrocarbons typically cyclohexane, hexane, pentane, cyclopentane, or isopentane
  • solvents e.g., aqueous solutions and solvent combinations, unless otherwise stated in the description of the process.
  • solvent mixtures may also be used in processing, for example in chromatography, extraction and recystallization.
  • the invention relates also to those methods of the process in which one starts from a compound obtainable at any stage as a transient and carries out the missing steps, or breaks off the process at any stage, or forms a starting material under the reaction conditions, or uses said starting material in the form of a reactive derivative or salt, or produces a compound obtainable by means of the process according to the invention and processes the said compound in situ.
  • the compounds of Formula I or II, including their derivatives, are also obtainable in the form of salts, hydrates or crystals.
  • a crystalline form for example, can include the solvent, or solvents, used for crystallization (generally present as solvates) .
  • New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention.
  • such starting materials are used and reaction conditions so selected as to enable the preferred compounds to be obtained.
  • amine compounds represented in Schemes 11, 18, 20 and 22, can be prepared by reduction of the corresponding nitro precurser.
  • the reduction preferably takes place in the presence of a suitable reducing agent, such as tin(II) chloride or hydrogen in the presence of an appropriate catalyst, such as Raney nickel (then preferably the hydrogen is used under pressure, e.g. between 2 and 20 bar) , Pd or PtO 2 , in an appropriate solvent, e.g. an alcohol, such as MeOH.
  • a suitable reducing agent such as tin(II) chloride or hydrogen
  • an appropriate catalyst such as Raney nickel
  • an appropriate solvent e.g. an alcohol, such as MeOH.
  • the reaction temperature is preferably between about 0 2 C and about 80 2 C, especially about 15 2 C to about 30 9 C.
  • optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base.
  • appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts.
  • a different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers.
  • Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate.
  • the synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound.
  • the optically active compounds of the invention can likewise be obtained by using optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.
  • the compounds of the present invention may contain one or more asymmetric centers and, therefore, occur as racemates and racemic mixtures, scalemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.
  • the compounds of this invention may also be represented in multiple tautomeric forms, for example, as illustrated below:
  • the invention expressly includes all tautomeric forms of the compounds described herein.
  • the compounds of this invention may also occur in cis- or trans- or E- or Z- double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the invention. All crystal forms of the compounds described herein are expressly included in the invention.
  • Substituents on ring moieties may be attached to specific atoms, whereby they are intended to be fixed to that atom, or they may be drawn unattached to a specific atom, whereby they are intended to be attached at any available atom that is not already substituted by an atom other than H (hydrogen) .
  • the compounds of this invention may contain heterocyclic ring systems attached to another ring system. Such heterocyclic ring systems may be attached through a carbon atom or a heteroatom in the ring system.
  • a compound of Formula I or II herein may be synthesized according to any of the procedures described herein.
  • the steps may be performed in an alternate order and may be preceded, or followed, by additional protection/deprotection steps as necessary.
  • the procedures may further comprise use of appropriate reaction conditions, including inert solvents, additional reagents, such as bases (e.g., LDA, DIEA, pyridine, K 2 CO 3 , and the like) , catalysts, and salt forms of the above.
  • bases e.g., LDA, DIEA, pyridine, K 2 CO 3 , and the like
  • catalysts e.g., pyridine, K 2 CO 3 , and the like
  • Purification methods include, for example, crystallization, chromatography (liquid and gas phase, simulated moving bed (“SMB”)), extraction, distillation, trituration, reverse phase HPLC and the like.
  • Reactions conditions such as temperature, duration, pressure, and atmosphere (inert gas, ambient) are known in the art and may be adjusted as appropriate for the reaction.
  • the compounds of the present invention may be modified by appending appropriate functionalities to enhance selective biological properties.
  • modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system) , increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
  • Preparative HPLC was conducted on a Beckman or Waters HPLC system with 0.1% TFA/H 2 O and 0.1% TFA/CH 3 CN as mobile phase. The flow rate was at 20 ml/min. and gradient method was used. 1 H NMR spectra were determined with super conducting FT MMR spectrometers operating at 400 MHz or a Varian 300 MHz instrument. Chemical shifts are expressed in ppm downfield from internal standard tetramethylsilane. All compounds showed NMR spectra consistent with their assigned structures.
  • Mass spectra were determined on a Perkin Elmer - SCIEX API 165 electrospray mass spectrometer (positive and, or negative) or an HP 1100 MSD LC-MS with eletrospray ionization and quadrupole detection. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated.
  • N- [3- (1-Methyl-piperidin-4-yl) -5-trifluoromethyl-phenyl]- 2-fluoro-nicotinamide was prepared with K 2 CO 3 instead of NaHCO 3 .
  • PD(dppf)Cl 2 /CH 2 Cl 2 was added to a degassed mixture of N- (3- bromo-5-trifluoromethyl-phenyl)-acetamide, K 2 CO 3 (9.8 g) DMF (32.1 ml and H 2 O (3 ml) .
  • the allyl piperidine solution was added heated to 60 2 C for 3 h. After cooling to RT and reheating at 60 3 C for 6 h, the mixture was cooled to RT and poured into H 2 O. The mixture was extracted with EtOAc (2x) , and the EtOAc portion was washed with 2 N HCl (2x) and brine.
  • N-[3- (3-Morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]- acetamide was prepared from allyl morpholine and N-(3-bromo- 5-trifluoromethyl-phenyl)-acetamide similar to that described in the preparation of N-[3-(3-piperidin-1-yl- propyl)-5-trifluoromethyl-phenyl]-acetamide.
  • 3- (3-Morpholin-4-yl-propyl)-5-trifluoromethyl-phenylamine was prepared from N- [3- (3-morpholin-4-yl-propyl) -5- trifluoromethyl-phenyl]-acetamide similar to that described in the preparation of 3- (3-piperidin-1-yl-propyl) -5- trifluoromethyl-phenylamine.
  • the pH of the acid washings was adjusted to -11 with 6 N NaOH, then they were extracted with CH 2 Cl 2 (4x) .
  • the CH 2 Cl 2 washings were dried over Na 2 SO 4 and concentrated cold in vacuo to provide 1- methyl-4-methylene-piperidine, which was used as is.
  • 3- (l-Methylpiperidin-4-yl) -5-trifluoromethyl-phenylamine was prepared from N- [3- (l-methylpiperidin-4-yl) -5- trifluoromethyl-phenyl]-acetamide similar to the procedure described in the preparation of 3- (3-piperidin-l-yl-propyl)- 5-trifluoromethyl-phenylamine.
  • 2- (2-Morpholin-4- ⁇ l-propox ⁇ ) -4-pyridylcarbonitrile was prepared from 2-chloro-4-cyanopyridine and 2-morpholin-4-yl- propanol by a procedure similar to that described in the preparation of 2- (l-methylpiperidin-4-yloxy) -4- pyridylcarbonitrile.
  • the black mix was diluted with H 2 O and extracted with EtOAc.
  • the aqueous layer was basified with solid NaOH slowly then extracted with EtOAc (2x) .
  • the combined organic layers were washed with 6N NaOH and then with a mix of 6N NaOH and brine, dried over Na 2 SO 4 , filtered and concentrated in vacuo to obtain crude 2-tert-butyl-5-nitro-aniline as a dark red- black oil which solidified when standing at RT.
  • the crude material was triturated with about 130 mL hexanes. After decanting the hexanes, the material was dried to obtain a dark-red black solid.
  • Piperidine-4-carboxylic acid ethyl ester (78 g) was dissolved in MeOH (1.2 L) at RT then formaldehyde (37%, 90 ml) and acetic acid (42 ml) were added and stirred for 2 h. The mixture was cooled to 0 2 C, NaCNBH 3 (70 g) was added, and the mix was stirred for 20 min at 0 a C, then overnight at RT. The mixture was cooled to 0 3 C then quenched with 6N NaOH.
  • N- [4-tert-Butyl-3- (l-methyl-piperidin-4-ylmethoxy) -phenyl] - 2-chloro-nicotinamide was prepared from 4-tert-butyl-3- (1- methyl-piperidin-4-ylmethoxy)-phenylamine by a procedure similar to that described in the preparation of l-Boc-4- ⁇ 3- [ (2-chloro-pyridine-3-carbon ⁇ l) -amino] -5-trifluoromethyl- phenoxy ⁇ -piperidine.
  • the acidic aqueous layer was basified to pH>12 with 6 N NaOH, extracted with Et 2 O, brine- washed, dried over Na 2 SO 4 , filtered, and concentrated in vacuo to provide 1-[4- (2-tert-butyl-5-nitro-phenyl) -but-3- enyl]-pyrrolidine as a orange-brown oil.
  • N- (2-Bromo-5-nitrophenyl)-N-(2-methylprop-2-enyl)acetamide (4.5 g) was dissolved in anhydrous DMF (50 mL) , tetraethyl- ammonium chloride (2.5 g) , sodium formate (1.2 g) , NaOAc (3 g) were added, and the resulting mixture was bubbled with N 2 gas for 10 min.
  • Pd(OAc) 2 350 mg was added and the mixture was heated at 80 0 C under N 2 atmosphere overnight. After the mixture was concentrated in vacuo, it was partitioned between saturated NaHCO 3 solution and EtOAc, the resulting organic layer was, dried over MgSO 4 , filtered and concentrated in vacuo.
  • 3,3-Dimethyl-6-nitroindoline (450 mg) was dissolved in 20 ⁇ iL of dichloroethane, N-boc-4-formylpiperidine (750 mg) was added to the mixture, followed by 2 g NaHB(OAc) 3 and 1 mL of glacial AcOH. The mixture was stirred at RT overnight. Saturated NaHCO 3 solution (20 mL) was added to the reaction mixture and stirred for 1 h. The resulting mixture was separated by separation funnel, the organic layer was extracted once with saturated NaHCO 3 solution and once with brine. The resulting organic layer was dried over MgSO 4 , filtered and concentrated in vacuo.
  • 6-Nitroindoline (5 g) was dissolved in 200 mL of dichloroethane. N-Methyl-4-piperidone (5 g) was added to the mixture, followed by NaHB(OAc) 3 (12 g) and 1 mL of glacial AcOH. The mixture was stirred at RT overnight. A saturated NaHCO 3 (200 mL) solution was added to the reaction mixture and stirred for 1 h. The resulting mixture was separated by separation funnel. The organic layer was extracted once with saturated NaHCO 3 solution and once with brine. The resulting organic layer was dried over MgSO 4 , filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 2:1 EtOAc:MeOH to afford orange oil. MS: 262 (M+l) . Calc'd. for C 14 H 19 N 3 O 2 - 261.3.
  • N- (2-Bromo-5-nitrophenyl) -N- (2-methylprop-2-enyl)acetamide (4.5 g) was dissolved in 50 mL anhydrous DMF, 2.5 g tetraethyl-ammonium chloride, 1.2 g sodium formate, 3 g sodium acetate were added, the resulting mixture was bubbled with N 2 gas for 10 min. Pd(OAc) 2 (350 mg) was added and the mixture was heated at 80 0 C under N 2 overnight. After the mixture was concentrated in vacuo, it was extracted between saturated NaHCO 3 solution and EtOAc, the resulting organic layer was dried over MgSO 4 , filtered and concentrated in vacuo.
  • the reaction was quenched by diluting it with H 2 O and extracting it 3x with EtOAc.
  • the EtOAc extracts were washed multiple times with saturated NaHCO 3 (aq) , until gas evolution ceased, then with brine.
  • the EtOAc extracts were combined, dried over anhydrous Na 2 SO 4 , filtered and concentrated under reduced pressure giving a black oil.
  • the oil was eluted through a 36 x 7 cm column of silica gel with a 5%; 10%; 15%; 25%; and 50% EtOAc:Hexanes step gradient (2 L each step) giving 2- tert-butyl-5-nitro-phenylamine as a red solid.
  • pyrolidino and morpholino analogs are prepared by substituting the dimethylamine with respectively pyrolidine or morpholine and using the same chemistry as described, a) N- (2-tert-Butyl-5-nitro-phenyl)-2-pyrrolidin-l-yl- acetamide. b) N- (2-tert-Butyl-5-nitro-phenyl) -2-morpholin-4-yl- acetamide.
  • N- (2-tert-But ⁇ l-5-nitro-phen ⁇ l) -2-dimeth ⁇ lamino-acetamide (25.8 g, 92 mmol) was dissolved in EtOH (1.4 L) and 1,4- dioxane (200 mL) . The solution was degassed under vacuum with stirring. 10% Pd/C (2.5 g) was added (as a slurry in EtOH) . The mixture was degassed again, then the reaction vessel was charged with H 2 gas (balloon) and stirred overnight at RT. The reaction was filtered through Celite ® with MeOH and the filtrate was concentrated under reduced pressure.
  • the recovered material was eluted through a 36 x 7 cm column of silica gel with a 97.5:2.5:0.25 and 95:5:0.5 CH 2 Cl 2 :MeOH:NH 4 OH( SCj ) step gradient giving N- (5-amino-2-tert- butyl-phenyl) -2-dimethylamino-acetamide as a brown solid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)

Abstract

The present invention provides classes of compounds, including-their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. Formula I and II wherein R is a 9- or 10-membered heterocyclyl ring selected from 7-isoquinolinyl,..2-methyl-3-oxo-2,3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, 1-oxo-2,3-dihydrobenzofuran-4-yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6 quinazolinyl, 3-oxo-3,4-dihydro-1,4-benzoxazin-6-yl, 2,2-difluoro-l;3-benzodioxol-5-yl and 2,2,3,3 tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, N-dimethylamino-C1-6-alkyl, N-dimethylamino-C1-6-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl,4 morpholinyl, carboxyl, cyano, and acetyl; wherein R1 in formula I is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, and R1 in formula II is selected from specific bicyclic heterocycles.

Description

SUBSTITUTED ARYL-AMINE DERIVATIVES AND METHODS OF USE
This application claims the benefit of U.S. Provisional Application No. 60/590,544 filed July 22, 2004, which is incorporated by reference herein.
FIELD OF THE INVENTION
This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer and angiogenesis- related disorders.
BACKGROUND OF THE INVENTION
Protein kinases represent a large family of proteins which play a central role in the regulation of a wide variety of cellular processes, maintaining control over cellular function. A partial list of such kinases includes abl, Akt, bcr-abl, BIk, Brk, Btk, c-kit, c-met, c-src, CDKl, CDK2, CDK3, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDKlO, cRafl, CSFlR, CSK, EGFR, ErbB2, ErbB3, ErbB4, Erk, Fak, fes, FGFRl, FGFR2, FGFR3, FGFR4, FGFR5, Fgr, flt-1, Fps, Frk, Fyn, Hck, IGF-lR, INS-R, Jak, KDR, Lck, Lyn, MEK, p38, PDGFR, PIK, PKC, PYK2, ros, tie, tie2, TRK, Yes, and Zap70. Inhibition of such kinases has become an important therapeutic target.
Certain diseases are known to be associated with deregulated angiogenesis, for example ocular neovascularisation, such as retinopathies (including diabetic retinopathy) , age-related macular degeneration, psoriasis, hemangioblastoma, hemangioma, arteriosclerosis, inflammatory disease, such as a rheumatoid or rheumatic inflammatory disease, especially arthritis (including rheumatoid arthritis) , or other chronic inflammatory disorders, such as chronic asthma, arterial or post- transplantational atherosclerosis, endometriosis, and neoplastic diseases, for example so-called solid tumors and liquid tumors (such as leukemias) .
At the center of the network regulating the growth and differentiation of the vascular system and its components, both during embryonic development and normal growth, and in a wide number of pathological anomalies and diseases, lies the angiogenic factor known as Vascular Endothelial Growth Factor" (VEGF; originally termed 'Vascular Permeability Factor", VPF), along with its cellular receptors (see G. Breier et al., Trends in Cell Biology, 6, 454-6 (1996)) .
VEGF is a dimeric, disulfide-linked 46-kDa glycoprotein related to "Platelet-Derived Growth Factor" (PDGF) ; it is produced by normal cell lines and tumor cell lines; is an endothelial cell-specific mitogen,- shows angiogenic activity in in vivo test systems (e.g. rabbit cornea) ; is chemotactic for endothelial cells and monocytes; and induces plasminogen activators in endothelial cells, which are involved in the proteolytic degradation of extracellular matrix during the formation of capillaries. A number of isoforms of VEGF are known, which show comparable biological activity, but differ in the type of cells that secrete them and in their heparin-binding capacity. In addition, there are other members of the VEGF family, such as "Placenta Growth Factor" (PlGF) and VEGF-C. VEGF receptors (VEGFR) are transmembranous receptor tyrosine kinases. They are characterized by an extracellular domain with seven immunoglobulin-like domains and an intracellular tyrosine kinase domain. Various types of VEGF receptor are known, e.g. VEGFR-I (also known as flt-1) , VEGFR-2 (also known as KDR), and VEGFR-3.
A large number of human tumors, especially gliomas and carcinomas, express high levels of VEGF and its receptors. This has led to the hypothesis that the VEGF released by tumor cells stimulates the growth of blood capillaries and the proliferation of tumor endothelium in a paracrine manner and through the improved blood supply, accelerate tumor growth. Increased VEGF expression could explain the occurrence of cerebral edema in patients with glioma. Direct evidence of the role of VEGF as a tumor angiogenesis factor in vivo is shown in studies in which VEGF expression or VEGF activity was inhibited. This was achieved with anti-VEGP antibodies, with dominant-negative VEGFR-2 mutants which inhibited signal transduction, and with antisense-VEGF RNA techniques. All approaches led to a reduction in the growth of glioma cell lines or other tumor cell lines in vivo as a result of inhibited tumor angiogenesis.
Angiogenesis is regarded as an absolute prerequisite for tumors which grow beyond a diameter of about 1-2 mm; up to this limit, oxygen and nutrients may be supplied to the tumor cells by diffusion. Every tumor, regardless of its origin and its cause, is thus dependent on angiogenesis for its growth after it has reached a certain size.
Three principal mechanisms play an important part in the activity of angiogenesis inhibitors against tumors: 1) Inhibition of the growth of vessels, especially capillaries, into avascular resting tumors, with the result that there is no net tumor growth owing to the balance that is achieved between cell death and proliferation; 2) Prevention of the migration of tumor cells owing to the absence of blood flow to and from tumors,- and 3) Inhibition of endothelial cell proliferation, thus avoiding the paracrine growth-stimulating effect exerted on the surrounding tissue by the endothelial cells which normally line the vessels. See R. Connell and J. Beebe, Exp. Opin. Ther. Patents, 11, 77-114 (2001) .
VEGF's are unique in that they are the only angiogenic growth factors known to contribute to vascular hyperpermeability and the formation of edema. Indeed, 00
A-917 - 4 -
vascular hyperpermeability and edema that is associated with the expression or administration of many other growth factors appears to be mediated via VEGF production.
Inflammatory cytokines stimulate VEGF production. Hypoxia results in a marked upregulation of VEGF in numerous tissues, hence situations involving infarct, occlusion, ischemia, anemia, or circulatory impairment typically invoke VEGF/VPF-mediated responses. Vascular hyperpermeability, associated edema, altered transendothelial exchange and macromolecular extravasation, which is often accompanied by diapedesis, can result in excessive matrix deposition, aberrant stromal proliferation, fibrosis, etc. Hence, VEGF- mediated hyperpermeability can significantly contribute to disorders with these etiologic features. As such, regulators of angiogenesis have become an important therapeutic target.
Schipper US patent 3,226,394, issued Dec. 28, 1965, describes anthranilamides as CNS depressants. Japanese patent JP2000256358 describes pyrazole derivatives that block the calcium release-activated calcium channel. EP application 9475000, published 6 October 1999, describes compounds as PGE2 antagonists. PCT publication WO96/41795, published 27 December 1996, describes benzamides as vasopressin antagonists. WO01/29009 describes aminopyridines as KDR inhibitors. WO01/30745 describes anthranilic acids as cGMP phosphodiesterase inhibitors. WOOO/02851, published 20 Jan 2000 describes arylsulfonylamnoaryl amides as guanylate cyclase activators. WO98/45268 describes nicotinamide derivatives as PDE4 inhibitors. WO98/24771 describes benzamides as vasopressin antagonists.
US Patent No. 5,532,358, issued July 2, 1996, describes the preparation of 2- (cyclopropylamino) -N- (2- methoxy-4-methyl-3- pyridinyl) -3-pyridinecarboxamide as an intermediate for HIV inhibitors. Triazine-substituted amines are described for their aggregating ability (J. Amer. Chem. Soc, 115, 905-16 (1993). Substituted imidazolines were tested for their antidepressant activity in Ind. J. Het. Chem., 2, 129-32 (1992) . N- (4-Pyridyl)anthranilic amides were described in Chem Abstr. 97:109837 (1981). PCT publication WO99/32477, published 1 July 1999, describes anthranilamides as anti-coagulants. US patent 6,140,351 describes anthranilamides as anti-coagulants. PCT publication WO99/62885, published 9 December 1999, describes 1- (4-aminophenyl)pyrazoles as antiinflammatories. PCT publication WO00/39111, published 6 July 2000, describes amides as factor Xa inhibitors. PCT publication WOOO/39117, published 6 July 2000, describes heteroaromatic amides as factor Xa inhibitors. PCT publication WO00/27819, published 18 May 2000, describes anthranilic acid amides as VEGF inhibitors. PCT publication WOOO/27820 published 18 May 2000, describes N-aryl anthranilic acid amides as VEGF inhibitors. 7-Chloroquinolinylamines are described in FR2168227 as antiinflammatories. WO01/55114, published 2 Aug. 2001, describes nicotinamides for the treatment of cancer. WO01/55115, published 2 Aug. 2001, describes nicotinamides for the treatment of apoptosis. WO01/85715, published 15 November 2001, describes substituted pyridines and pyrimidines as anti-angiogenesis agents. PCT publication WO01/85691 published 15 November 2001, describes anthranilic amides as VEGF inhibitors. PCT publication WO01/85671 published 15 November 2001, describes anthranyl amides as VEGF inhibitors. PCT publication WO01/81311 published 1 November 2001, describes anthranilic amides as VEGF inhibitors. U.S. Patent No. 6,462,075, issued
October 8, 2002, describes chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states. U.S. Patent No., issued August 19, 2003, describes the preparation of 6-methyl nicotinamides as anti- US2005/025800
A-917 - 6 -
viral agents. U.S. Patent Publication No. 2002111495, published August 15, 2002, describes the preparation of nicotinamides as PDE4 D isozyme inhibitors. U.S. Patent Publication No. 2003073836, published April 17, 2003, describes the preparation of biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein (MPT). U.S. Patent Publication No. 20040053908, published March 18, 2004, describes nitrogen containing aromatic derivatives as VEGF inhibitors. U.S. Patent Publication No. 20040067985, published April 8, 2004, describes nicotinamides as inhibitors of angiogensis, and useful for treating cancer. However, the compounds of the present invention have not been previously described as inhibitors of angiogenesis, and useful for treating angiogenesis- related diseases such as cancer.
DESCRIPTION OF THE INVENTION
The present invention provides classes of compounds, including their pharmaceutically acceptable derivatives, useful for treating angiogenesis and related diseases such as cancer. One class of compounds are defined by general Formula I
Figure imgf000007_0001
wherein R is a 9- or 10-membered heterocyclyl ring containing at least one nitrogen or oxygen atom, the 00
A-917 - 7 -
ring selected from 7-isoquinolinyl, 2-methyl-3-oxo- 2,3-dihydroindazol-6-yl, [1, 6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, l-oxo-2, 3-dihydrobenzofuran-4- yl, 3-oxo-2,3-dihydrobenzofuran-5-yl, dihydro- benzodioxinyl, 6-quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4-diamino-6- quinazolinyl, 3-oxo-3,4-dihydro-l,4-benzoxazin-6-yl, 2,2-difluoro-l,3-benzodioxol-5-yl and 2,2,3,3- tetrafluoro-2, 3-dihydro-l, 4-benzodioxin-6-yl, each of which is optionally substituted with one or more substituents selected from halo, haloakyl, C1-6 alkyl, C2.8 alkenyl, C2.8 alkynyl, N-dimethylamino-C^-alkyl, N- dimethylamino-C^g-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl, morpholinyl, carboxyl, cyano, and acetyl; wherein R1 is selected from unsubstituted or substituted phenyl,
5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, advantageously, R1 is selected from phenyl, 3-isoxazolyl, 3- pyrazolyl, 2-thiazolyl, 1,3,4-thiadiazol-2-yl, thienyl, 3- pyridyl, pyrimidinyl, pyridazinyl, 1,2-dihydroquinolyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 2-oxo-1,2, 3,4-tetrahydroquinolyl, 2-oxo-l, 2,3, 4- tetrahydroquinolyl, 1-oxo-l,2,3 ,4-tetrahydro-isoquinolyl, 1' ,2'-dihydro-spiro[cyclopropane-1,3' -[3H]indol] -6'-yl, isoquinolyl, quinolyl, indol-6-yl, 6-isoindolyl, 3,4- dihydro-2H-benzo[1,4]oxazin-6-yl, 3-oxo-3,4-dihydro-2H- benzo[l,4]oxazin-6-yl, 2,3-dihydro-IH-indol-6-yl, naphthyridinyl, 2-oxo-3,4-dihydro-lH-[1, 8]naphthyridin-7-yl, 3,4-dihydro- [1,8]naphthyridinyl, 1,2,3, 4-tetrahydro- [1, 8]naphthyridinyl, quinozalinyl, 2-oxo-chromen-7-yl, benzo[d]isothiazolyl, 3,4-dihydro-quinazolinyl, 2,3,4,4a, 9,9a-hexahydro-lH-3-aza-fluorenyl, 5,6, 7-trihydro- 1,2,4-triazolo[3,4-a]isoquinolyl, 5, 6-dihydro- [1,2,4]triazolo[3,4-a]isoquinolin-9-yl, indazol-6-yl, 2,1,3- benzothiadiazolyl, benzodioxanyl, benzothienyl, 2,3-dihydro- benzofuran-6-yl, benzofuranyl, benzimidazolyl, dihydro- benzimidazolyl, benzoxazolyl and 5-benzthiazol-5-yl, more advantageously, R1 is selected from phenyl,
1,2,3,4-tetrahydroisoquinol-7-yl, 2,3-dihydro-lH- indol-6-yl, 1,2,3, 4-tetrahydro-[1,8]naphthyridinyl, 1' ,2' -dihydro-spiro[cyclopropane-1, 3'-[3H]indol-6'- yl, tetrahydroquinolin-7-yl, 3-isoxazolyl, 3- pyrazolyl, 1,3,4-thiadiazol-2-yl, 3-pyridyl, 2-oxo- 1,2,3,4-tetrahydroquinol-7-yl, 2-oxo- tetrahydroquinolin-7-yl, 1-oxo-l,2,3,4-tetrahydro- isoquinol-7-yl, indol-6-yl, 3,4-dihydro-2H- benzo[l,4]oxazin-6-yl, 3-oxo-3, 4-dihydro-2H- benzo[1,4]oxazin-6-yl, 2-oxo-3,4-dihydro-lH- [1, 8]naphthyridin-7-yl, 2-oxo-chromen-7-yl, 5,6- dihydro- [1,2,4]triazolo[3, 4-a]isoquinolin-9-yl, indazol-6-yl, 2, 1, 3-benzothiadiazolyl, 2,3-dihydro- benzofur-6-yl, and 5-benzthiazol-5-yl, and even more advantageously, R1 is phenyl substituted with one or more substituents selected from methyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, hydroxyl, phenyl, chloro, ethyl-2-propanoyl, 2-methyl-2- (1-methylpiperidin- 4-yl)ethyl, methylsulfonylamino, dimethylaminomethylcarbonylamino, piperazine- methyl, 4-methylsulfonyl-l-piperazine-methyl, 1- pyrrolidinyl-CH2-C(=O)-NH-, 1-methyl- pyrrolidinyl-CH2-0-, l-isopropyl-pyrrolidinyl- CH2-O-, l-acetyl-pyrrolidinyl-CHz-O-,2-hydroxy-3- pyrrolidinyl-propoxy, 4-morpholinyl-CH2-C(=0) -NH- , 1-pyrrolidinyl-CH2CH2O-, pyrrolidinyl-propyl, piperidinyl-propyl, 1-rtιethγl-l,2,3, 6-tetrahydro- 4-pyridinyl, 1-pyrrolidinyl-l-butenyl, 3,3- dimethylamino-1-propynyl, 4-methyl-l-piperazinyl, piperazinyl, 4-methyl-l-piperazinyl-methyl, morpholino-propyl, l-N-methyl-piperidinyl-CHa-,
1-piperidinyl-propyl, hydroxyethylamino, 3- tetrahydrofuryl-O-C(=0) -NH-, 3-tetrahydrofuryl- CH2O-, trifluoromethyl, pentafluoroethyl, tetrafluoroethoxyl, 1,1-di (trifluoromethyl) -1- hydroxymethyl, 1, 1-di (trifluoromethyl) -1-
(pyrrolidin-2-ylmethoxy)methyl, 3- tetrahydrofuryloxy, 1-methylcarbonyl-pyrrolidin- 2-ylmethoxy, l-methyl-pyrrolindin-2-ylmethoxy, piperidinyl-amino, N,N-dimethyl-glycyl-amino, isopropyl-piperidinyl-methoxyl, isopropyl- piperazinyl, benzoxyl, 4-N-methyl-piperazinyl- propyl, 4-N-propyl-piperazinyl, methylsulfonyl, and methylsulfonylaminoethoxy, yet even more advantageously, R1 is selected from 4,4-dimethyl-3,4-dihydro-2-oxo-lH-quinolinyl,
4,4-dimethyl-l,2,3,4-tetrahydro-lH-quinolinyl, 4,4-dimethyl-3,4-dihydro-2-oxo-lH- [1,8]naphthyridinyl,
3, 3-dimethyl-2,3-dihydro-lH-indol-6-yl optionally substituted with one or more substituents selected from pyrrolidin-1-yl-carbonyl, pyrrolidin-1-yl-methyl, 1-methyl-4-piperidinyl, l-methyl-4-piperidinyl-methyl, 1-4-piperidinyl, tetrahydro-2-furanylcarbonyl, acetyl, N,N- dimethylglycyl, methylcarbonyl, and methylsulfonyl,
4, 4-dimethyl-l,2,3, 4-tetrahydro-lH-isoquinolin-7- yl, and 4,4-dimethyl-l,2,3,4-tetrahydro-2-oxo-lH- isoquinolin-7-yl; where R1 is substituted with one or more substituents, the substituents are selected from halo, optionally substituted Ci_6-alkyl, optionally substituted C3_6- cycloalkyl, optionally substituted phenyl, optionally substituted ph.enyl-C1_4-alkylenyl, Ci-2-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-Ci_6-alkyl, optionally substituted 4-6 membered heterocyclyl-C2-C4-alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-Ci_4- alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4- 6 membered heterocyclyl-Ci_4-alkylcarbonyl, optionally substituted 4-6 membered heterocyclylcarbonyl-Ci_4-alkyl, optionally substituted 4-6 membered heterocyclyl-Ci_4- alkylcarbonylamino, optionally substituted 4-6 membered heterocyclyl-oxycarbonylamino, Ci_2-haloalkyl, Cχ_4- aminoalkyl, optionally substituted Ci-4- aminoalkylcarbonyl, nitro, amino, C1^- alkylsulfonylamino, hydroxy, cyano, alkylthio, haloalkylthio, arylthio, aralkylthio, aminosulfonyl, C1. 2-alkylsulfonyl, Ci_2-alkylsulfonylamino, Ci_2- alkylsulfonylamino-Ci-4-alkoxy, halosulfonyl, Ci-4- alkylcarbonyl, amino-Ci_4-alkylcarbonyl, Ci-3-alkylamino- Ci-4-alkylcarbonyl, C1_3-alkylamino-Ci_4- alkylcarbonylamino, C1_4-alkoxycarbonyl-Ci-.4-alkyl, Ci-3- alkylamino-Ci_3-alkyl, Cχ_3-alkylamino-Ci-3-alkoxy, Ci_3- alkylamino-Ci_3-alkoxy-Ci_3-alkoxy, C1_4-alkoxycarbonyl, Ci- 4-alkoxycarbonylamino-Ci_4-alkyl, Ci-3-alkylsulfonylamino- 00
17 - 11 -
Ci-3-alkoxγ, Ci-4-hydroxγalkyl,
Figure imgf000012_0001
ana d-4- alkoxy; advantageously, the R1 substituents are selected from bromo, chloro, fluoro, iόdo, nitro, amino, cyano, Boc-aminoethyl, hydroxy, fluorosulfonyl, methylsulfonyl, aminosulfonyl, 4- methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, 4-pyridylmethyl, 4-morpholinylmethyl, l-methylpiperazin-4-ylmethyl, l-methylpiperazin-4- ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, 1- methylpiperidin-4-ylmethyl, 2-methyl-2- (1- methylpiperidin-4-yl)ethyl, 2-methyl-2- (4- pyrimidinyl) ethyl, 2-methyl-2- (5-methyloxadiazol-2- yl)ethyl, 2-methyl-2- (pyrazol-5-yl)ethyl, 2-methyl-2- (1-ethoxycarbonyl-l,2,3, 6-tetrahydropyridin-4- yDethyl, morpholinylethyl, 1- (4-morpholinyl) -2,2- dimethylpropyl, 1- (4-morpholinyl)-2, 2-dimethylethyl, piperidin-4-ylethyl, l-Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, l-Boc-piperidin-4-ylethyl, piperidin-4-ylmethyl, l-Boc-piperidin-4-ylmethyl, piperidin-4-ylpropyl, l-Boc-piperidin-4-ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, 1-Boc-pyrrolidin-2-ylpropyl, 1- (pyrrolidin-1-yl) -2-inethylpropyl, pyrrolidin-1- ylmethyl, pyrrolidin-2-ylmethyl, l-Boc-pyrrolidin-2- ylmethyl, pyrrolidinylpropenyl, pyrrolidinylbutenyl, methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, pyrrolidin-1-yl-carbonyl, 4-pyridylcarbonyl, 4- methylpiperazin-1-ylcarbonylethyl, CH3O-C (=0) -CH2-, methoxycarbonyl, aminomethylcarbonyl, dimethylaminomethylcarbonyl, methylsulfonylamino, dimethylaminomethylcarbonylamino, l-pyrrolidinyl-CH2- C(=O)-NH-, 4-morpholinyl-CH2-C(=0)-NH-, 3- tetrahydrofuryl-O-C(=O)-NH-, cyclohexyl-N(CH3) -, (4- pyrimidinyl)amino, (2-methylthio-4-pyrimidinyl)amino, 3-ethoxycarbonyl-2-methyl-fur-5-yl, 4- methylpiperazin-1-yl, 4-methyl-l-piperidyl, l-Boc-4- piperidyl, piperidin-4-yl, l-methylpiperidin-4-yl, 1- methyl- (1,2,3, 6-tetrahydropyridyl) , imidazolyl, morpholinyl, 4-trifluoromethyl-1-piperidinyl, hydroxybutyl, methyl, gem-dimethyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec-butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1,1-di(trifluoromethyl) -1- hydroxymethyl, 1, 1-di(trifluoromethyl) -1- (piperidinylethoxy)methyl, 1, 1-di(trifluoromethyl) -1- (pyrrolidin-2-ylmethoxy)methyl, 1,1- di (trifluoromethyl) -1- (methoxyethoxyethoxy)methyl, 1- hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1- aminoethyl, 2-aminoethyl, 1- (N-isopropylamino)ethyl, 2- (N-isopropylamino)ethyl, 3-tetrahydrofuryloxy, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, l-Boc-azetidin-3-ylmethoxy, 3- tetrahydrofurylmethoxy, pyrrolidin-2-ylmethoxy, 1- methylcarbonyl-pyrrolidin-2-ylmethoxy, 1-Boc- pyrrolidin-2-ylmethoxy, pyrrolidin-1-ylmethoxy, 1- methyl-pyrrolidin-2-ylmethoxy, 1-isopropyl- pyrrolidin-2-ylmethoxy, l-Boc-piperdin-4-ylmethoxy, (1-pyrrolidinyl)ethoxy, piperdin-4-ylmethoxy, piperdin-3-ylmethoxy, 1-methylpiperdin-4-yloxy, methylsulfonylaminoethoxy, isopropoxy, methoxy and ethoxy; even more advantageously, the R1 substituents are selected from chloro, fluoro, acetyl, oxo, inethylsulfonyl, 2-methyl-2-(l-methylpiperidin-4- yl)ethyl, piperidine-ethoxy-ditrifluoromethyl- methyl-, l-methylpiperidin-4-yl, 1- methylpiperidin-4-yl-methyl, l-methylpiperidin-4- yl-propyl, pyrrolidin-1-yl-carbonyl, methylsulfonylamino, dimethylaminomethylcarbonylamino, 1-pyrrolidinyl- CH2-C(=0)- NH-, N-methyl-pyrrolidinyl-CHz-O-, N- isopropyl-pyrrolidinyl-CH2-0-, N-pyrrolidinyl- CH2CH2O-, pyrrolidinyl-propyl, morpholine-propyl, N-methyl-piperazine, piperazine-methyl, 4N- methylsulfonyl-piperazine-methyl, tetrafluoroethyl-O-, 4-morpholinyl-CH2-C (=0) -NH-,
N-Boc-methyl C(O)-, amino-CH2-C(0) -, 3- tetrahydrofuryl-C(=0)-, 3-tetrahydrofuryl-O-C (=0) • NH-, 3-tetrahydrofuryl-CH2-0-, N,N-dimethylamino- CH2-C(O)-, N,N-dimethylamino-CH2-C(0)NH~, N,N- dimethylamino-CH2CH2CH2-, hydroxyethylamino, methylcyclopropyl, methyl, gem-dimethyl, ethyl, tert-butyl, t-butoxycarbonyl, propyl, isopropyl, methoxy, piperidinemethyl, 1, 1-dimethyl-propyl, azetidinyl, trifluoromethyl, pentafluoroethyl, 1,1-di (trifluoromethyl) -1-hydroxymethyl, 1- hydroxy-1, 1-di(trifluoromethyl) methyl, 1,1- di(trifluoromethyl) -1- (pyrrolidin-2- ylmethoxy)methyl, 3-tetrahydrofuryloxy, 1- methylcarbonyl-pyrrolidin-2-ylmethoxy, 1-methyl- pyrrolidin-2-ylmethoxy, 2-hydroxy-3-pyrrolidin- propoxy, 1, 1-dimethylethylacetyl, 1,1- dimethylacetic acid, and methylsulfonylaminoethoxy, and yet even more advantageously, the R1 substituents are selected from methyl, ethyl, isopropyl, t- butyl, 2-methyl-2- (1-ethoxycarbonyl-l, 2,3,6- tetrahydropyridin-4-yl)ethyl, 1- (4- morpholinyl)~2,2-dimethylethyl, pyrrolidin-1- yl-carbonyl, CH3O-C(=0) -CH2-, methylsulfonylamino, dimethylaminomethylcarbonylamino; 1- pyrrolidinyl-CH2-C(=0) -NH-, 4-morpholinyl-CH2- C(=O)-NH-, 3-tetrahydrofuryl-0-C(=0)-NH-, 1,1- di(trifluoromethyl) -1- (pyrrolidin-2- ylmethoxy)methyl, 3-tetrahydrofuryloxy, 1- methylcarbonyl-pyrrolidin-2-ylmethoxy, and methylsulfonylaminoethoxy; wherein Re and Rf are independently selected from H and Ci_2- haloalkyl; advantageously -CF3; wherein R7 is selected from H, Ci_3-alkyl, optionally substituted phenyl, optionally substituted phenyl-Ci_3- alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-Ci_C3-alkyl, Ci_3- alkoxy-Ci_2-alkyl and Cx-s-alkoxy-Ci-s-alkoxy-Ci^-alkyl; and wherein R2 is selected from H, halo, haloalkyl and C1-6 alkyl, and advantageously, H, fluoro, chloro, bromo, trifluoromethyl, methyl, ethyl, isopropyl and t-butyl. In another embodiment, the invention provides a second class of compounds as defined below by Formula II:
Figure imgf000015_0001
II
wherein R is selected from 7-isoquinolinyl, 2-methyl-3-oxo- 2, 3-dihydroindazol-6-yl, [1,6]-naphthydrin-3-yl, [1,7]-naphthydrin-2-yl, oxo-2,3-dihydrobenzofuranyl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6- quinazolinyl, 4-methylamino-6-c[uinazolinyl, 2,4- diamino-δ-quinazolinyl, 3-oxo-3,4-dihydro-l,4- benzoxazin-6-yl, 2, 2-difluoro-l,3-benzodioxol-5-yl and 2,2,3,3-tetrafluoro-2,3-dihydro-l, 4-benzodioxin- 6-yl, each of which is optionally substituted with one or more substitutions selected from halo, haloakyl, C1-6 alkyl, C2.8 alkenyl, C2.8 alkynyl, N- dimethylamino-C1_6-alkyl, N-dimethylamino-C1_6-alkoxy, amino, carbonylamino, morpholino-sulfonyl, amino- sulfonyl, oxazolyl, pyrrolyl, morpholinyl, carboxyl, cyano, and acetyl; wherein R1 is selected from unsubstituted or substituted
1, 2-dihydroquinolyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 2-oxo-l,2,3,4- tetrahydroquinolyl, 2-oxo-l,2, 3,4-tetrahydroquinolyl, 1-oxo- 1,2,3,4-tetrahydro-isoquinolyl, isoquinolyl, quinolyl, indol-6-yl, 6-isoindolyl, 3,4-dihydro-2H-benzo[l, 4]oxazin-6- yl, 3-OXO-3,4-dihydro-2H-benzo[l,4]oxazin-6-yl, 2,3-dihydro- IH-indol-6-yl, naphthyridinyl, 2-oxo-3,4-dihydro-lH- [l,8]naphthyridin-7-yl, 3, 4-dihydro- [1, 8]naphthyridinyl, 1,2,3,4-tetrahydro- [1,8]naphthyridinyl, quinozalinyl, wherein substituted R1 is substituted with one or more substituents selected from halo, optionally substituted Ci_6-alkyl, optionally substituted C3-6- cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-C1.C4-alkylenyl, d-2-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-Ci-C6-alkyl, optionally substituted 4-6 membered heterocyclyl-C2-C4- alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-Ci-4-alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino , optionally substituted 4-6 membered heterocyclylcarbonyl , optionally substituted 4-6 membered heterocyclyl-Ci-4- alkylcarbonyl , optionally substituted 4-6 membered heterocyclylcarbonyl-Ci-4-alkyl , optionally substituted
4-6 membered heterocyclyl-Ci_4-alkylcarbonylamino, optionally substituted 4-6 membered heterocyclyl- oxycarbonylamino , Ci-2-haloalkyl , Ci-4-aminoalkyl , optionally substituted Ci-4-aminoalkylcarbonyl , nitro , amino , Ci-3-alkylsulfonylamino, hydroxy, cyano , aminosulfonyl , Ci-2-alkylsulfonyl , CV2- alkylsulfonylamino , Ci-2-alkylsulfonylamino-Ci_4-alkoxy, halosulfonyl , Ci_4-alkylcarbonyl , amino-C!_4- alkylcarbonyl , Ci-3-alkylamino-Ci-4-alkylcarbonyl , Ci_3- alkylamino-Ci_4-alkylcarbonylamino , Ci_4-alkoxycarbonyl-
Ci_4-alkyl , Cx-s-alkylamino-Ci-s-alkyl , Ci-3-alkylamino-C!- 3-alkoxy, Ci-s-alkylamino-Ci-s-alkoxy-Ci^-alkoxy, Ci_4- alkoxycarbonyl , C1_4-alkoxycarbonylamino-Ci-4-alkyl , C1- 3-alkylsulf onylamino-Ci-3-alkoxy, Cx_4-hydroxyalkyl ,
R\^ Rf 7 /\ /R O and Ci_4-alkoxy; and wherein Re and Rf are independently selected from H and Ci_2- haloalkyl,- wherein R7 is selected from H, d-3-alkyl, optionally substituted phenyl, optionally substituted phenyl-Ci-3- alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-C;i_C3-alkyl, Ci_3- alkoxy-Ci-2-alkyl and C1-3-alkoxy-C1-3-alkoxy-C1-3-alkyl; and wherein R2 is selected from H, halo, haloalkyl and C1-6 alkyl.
The compounds of the present invention further include pharmaceutically acceptable derivatives, including salts, of the compounds defined by Formulas I and II. An exemplary grouping of compounds of interest encompassed within Formulas I and II consist of compounds and pharmaceutically-acceptable derivatives thereof as follows: 2- ( (2-amino-6-quinazolinyl)amino) -N- (3-methyl-4- (1- methylethyl)phenyl) -3-pyridinecarboxamide; N- (4,4-dimethyl-l, 2,3,4-tetrahydro-7-quinolinyl) -2- (6- quinazolinylamino) -3-pyridinecarboxamide;
N- (4, 4-dimethyl-2-oxo-1,2,3,4-tetrahydro-7-quinolinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide;
N- (5- (1, 1-dimethylethyl) -3-isoxazolyl) -2- ( (l-oxo-2,3- dihydro-lH-isoindol-4-yl)amino) -3-pyridinecarboxamide; N- (5- (1,1-dimethylethyl) -3-isoxazolyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N-(I- (N,N-dimethylglycyl) -4, 4-dimethyl-l,2,3 ,4-tetrahydro-7- guinolinyl)-2- (lH-indazol-6-ylamino) -3- pyridinecarboxamide; N- (l-acetyl-3,3-dimethyl-2,3-dihydro-lH-indol-6-yl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (4, 4-dimethyl-l,2,3,4-tetrahydro-7-isoquinolinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; 5-fluoro-2- (7-isoquinolinylamino) -N- (3-methyl-4- (1- methylethyl)phenyl) -3-pyridinecarboxamide; N- (4, 4-dimethyl-l,2,3,4-tetrahydro-7-quinolinyl) -2- (IH- indazol-6-ylamino) -3-pyridinecarboxamide;
N- (4, 4-dimethyl-l, 2,3, 4-tetrahydro-7-quinolinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (3 ,3-dimethyl-2,3-dihydro-lH-indol-6-yl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (6- (1, 1-dimethylethyl) -3-pyridinyl) -2- ( (l-oxo-2, 3-dihydro- lH-isoindol-4-yl)amino) -3-pyridinecarboxamide; N- (2-glycyl-4,4-dimethyl-l, 2,3, 4-tetrahydro-7- isoquinolinyl)-2- (7-isoquinolinylamino) -3- pyridinecarboxamide; 25800
A-917 - 18 -
2- (7-isoquinolinγlamino) -N- (3-methyl-4- (1- methylethyl)phenyl)-3-pyridinecarboxamide; N- (3- ( ( ( (2S) -l-methyl-2-pyrrolidinyl)methyl) oxy) -5-
(trifluoromethyl)phenyl) -2- ( (l-oxo-2,3-dihydro-IH- isoindol-4-yl)amino)-3-pyridinecarboxamide;
N- (3,3-dimethyl-1- ( (2S) -tetrahydro-2-furanylcarbonyl) -2,3- dihydro-lH-indol-6-yl)-2-(7-isoquinolinylamino)-3- pyridinecarboxamide;
N- (4- (1,1-dimethylethyl)phenyl)-2- (6-quinazolinylamino) -3- pyridinecarboxamide;
N- (4,4-dimethyl-1,2,3, 4-tetrahydro-7-isoquinolinyl) -2- (6-
(juinazolinylamino) -3-pyridinecarboxamide; N- (5,5-dimethyl-7-oxo-5, 6, 7, 8-tetrahydro-l, 8-naphthyridin-2- yl) -2- (7-isoquinolinylamino) -3-pyridinecarboxamide; N-(l-acetyl-4,4-dimethyl-l,2,3,4-tetrahydro-7-cfuinolinyl) -2-
(lH-indazol-6-ylamino)-3-pyridinecarboxamide; 2- (7-isoguinolinylamino) -N- (4- (2,2,2-trifluoro-l-hydroxy-l-
(trifluoromethyl)ethyl)phenyl) -3-pyridinecarboxamide; N- (l-acetyl-4, 4-dimethyl-l,2,3,4-tetrahydro-7-φiinolinyl)-2- ( (l-oxo-2,3-dihydro-lH-isoindol-4-yl)amino) -3- pyridinecarboxamide; N- (4,4-dimethyl-2- ( (2R) -tetrahydro-2-furanylcarbonyl)- l,2,3,4-tetrahydro-7-isoquinolinyl)-2-(7- isoquinolinylamino)-3-pyridinecarboxamide; N- (5- (1, 1-dimethylethyl) -3-isoxazolyl) -2- (6- quinazolinylamino) -3-pyridinecarboxamide; N- (5, 5-dimethyl-7-oxo-5,6,7, 8-tetrahydro-l, 8-naphthyridin-2- yl) -2- (6-quinazolinylamino) -3-pyridinecarboxamide; N- (4- (1,1-dimethylethyl)phenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide;
N- (4,4-dimethyl-l,2, 3,4-tetrahydro-7-isoguinolinyl) -2- (5- isoquinolinylamino) -3-pyridinecarboxamide; N- (2-acetyl-4, 4-dimethyl-l, 2,3,4-tetrahydro-7- isoquinolinyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3-methyl-4-
(pentafluoroethyl)phenyl) -3-pyridinecarboxamide; N-(5- (1, 1-dimethylethyl) -3-isoxazolyl) -2- (5- isoguinolinylamino) -3-pyridinecarboxamide;
N- (4- (1,1-dimethylpropyl)phenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3- (methyloxy) -5-
(trifluoromethyl)phenyl)-3-pyridinecarboxamide; N- (4,4-dimethyl-l,2,3,4-tetrahydro-7-isoquinolinyl)-2- (1,6- naphthyridin-3-ylamino)-3-pyridinecarboxamide; N- (6- (1, 1-dimethylethyl)-3-pyridinyl)-2- (7- isoguinolinylamino)-3-pyridinecarboxamide;
N- (1- (N,N-dimethylglycyl)-4,4-dimethyl-l, 2,3,4-tetrahydro-7- quinolinyl)-2-( (l-oxo-2, 3-dihydro-lH-isoindol-4- yl)amino) -3-pyridinecarboxamide; N- (4- (1, 1-dimethylethyl)phenyl) -2- (5-isoquinolinylamino) -3- pyridinecarboxamide; 2~ ( (l-oxo-2,3-dihydro-lH-isoindol-4-yl)amino) -N- (4- (2,2,2- trifluoro-1- (methyloxy) -1-
(trifluoromethyl) ethyl)phenyl) -3-pyridinecarboxamide; N- (6- (1-methylcyclopropyl) -3-pyridinyl) -2- ( (l-oxo-2,3- dihydro-lH-isoindol-4-yl)amino) -3-pyridinecarboxamide; 2- (IH-I, 2, 3-benzotriazol-5-ylamino) -N- (5- (1, 1- dimethylethyl) -3-isoxazolyl) -3-pyridinecarboxamide; 2- ( (l-oxo-2,3-dihydro-lH-isoindol-4-yl)amino) -N- (4-
(pentafluoroethyl) -3- (1-piperazinylmethyl)phenyl) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (pentafluoroethyl)phenyl) -3- pyridinecarboxamide;
2- (7-isoquinolinylamino)-N- (4- (2,2,2-trifluoro-l-
(methyloxy)-1- (trifluoromethyl)ethyl)phenyl)-3- pyridinecarboxamide; 2- (IH-indazol-6-ylamino)-N- (6- (1-methylcyclopropyl)-3- pyridinyl) -3-pyridinecarboxamide; N- (4- (1,1-dimethylethyl)phenyl) -2-(1, 6-naphthyridin-3- ylamino)-3-pyridinecarboxamide;
2- (7-isoquinolinylamino)-N- (2-methyl-l,3-benzothiazol-5-yl) 3-pyridinecarboxamide;
N- (4-chloro-3- (trifluoromethyl)phenyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (trifluoromethyl)phenyl) -3- pyridinecarboxamide; 2-(l,6-naphthyridin-3-ylamino)-N-(4- (2, 2,2-trifluoro-l- hydroxy-1- (trifluoromethyl)ethyl)phenyl) -3- pyridinecarboxamide; 1,1-dimethylethyl 4,4-dimethyl-7- ( ( (2- (1, 6-naphthyridin-3- ylamino)-3-pyridinyl)carbonyl)amino)-3, 4-dihydro- 2 (IH)-isoquinolinecarboxylate;
N- (3- ( (4- (methylsulfonyl)-l-piperazinyl)methyl)-4-
(pentafluoroethyl)phenyl) -2- ( (l-oxo-2,3-dihydro-lH- isoindol-4-yl)amino) -3-pyridinecarboxamide; N- (4,4-dimethyl-l,2,3,4-tetrahydro-7-isoquinolinyl)-2- ( (1- oxo-1,3-dihydro-2-benzofuran-4-yl)amino)-3- pyridinecarboxamide; N- (3- (1,1-dimethylethyl)phenyl) -2- ( (l-oxo-2,3-dihydro-IH- isoindol-4-yl)amino) -3-pyridinecarboxamide; N- (7-isoquinolinyl)-2- ( (l-oxo-2,3-dihydro-lH-isoindol-4- yl)amino) -3-pyridinecarboxamide;
N- (4- (1, 1-dimethylethyl)phenyl)-2- ( (2-methyl-3-oxo-2, 3- dihydro-lH-indazol-6-yl)amino) -3-pyridinecarboxamide 2- ( (2,2-difluoro-l,3-benzodioxol-5-yl)amino)-N- (4,4- dimethyl-1,2,3, 4-tetrahydro-7-isoquinolinyl) -3- pyridinecarboxamide,-
2- ( (2,4-diamino-6-guinazolinyl)amino)-N- (4- (1, 1- dimethylethyl)phenyl) -3-pyridinecarboxamide; 2- ( (l-oxo-2,3-dihydro-lH-isoindol-4-yl)amino)-N- (6-
(trifluoromethyl) -3-pyridinyl) -3-pyridinecarboxamide N- (6-chloro-3-pyridinyl) -2- ( (l-oxo-2, 3-dihydro-lH-isoindol-
4-γl)amino) -3-pyridinecarboxamide; N- (2-acetγl-4,4-dimethyl-1,2,3,4-tetrahydro-7- isoquinolinyl) -2- ( (4- (methylamino) -6- quinazolinyl)amino) -3-pyridinecarboxamide;
2- (4-(1, 1-dimethylethyl)phenyl) -4-(lH-indazol-6-ylamino) -
1,2-dihγdro-3H-pyrrolo[3,4-c]pyridin-3-one; 2- (5-isoquinolinylamino) -N- (3- ( ( ( (2S) -1-methyl-2- pyrrolidinyl)methyl)oxy) -5- (trifluoromethyl)phenyl) -3- pyridinecarboxamide;
N-(l-acetyl-3,3-dimethyl-2,3-dihydro-lH-indol-6-yl)-2-( (1- oxo-1,3-dihydro-2-benzofuran-4-yl)amino)-3- pyridinecarboxamide; N- (4- (phenyloxy)phenyl)-2- ( (4- (trifluoromethyl)phenyl)amino)-3-pyridinecarboxamide; N-(3,3-dimethyl-2,3-dihydro-lH-indol-6-yl)-2-( (1-oxo-l, 3- dihydro-2-benzofuran-4-yl)amino) -3- pyridinecarboxamide;
2- ( (1-oxo-l,3-dihydro-2-benzofuran-5-yl)amino) -N- (4- (pentafluoroethyl)phenyl) -3-pyridinecarboxamide;
N- (4- (1, 1-dimethylethyl)phenyl) -2- ( (1-oxo-l, 3-dihydro-2- benzofuran-4-yl)amino) -3-pyridinecarboxamide; 2- ( (l-oxo-l,3-dihydro-2-benzofuran-4-yl)amino)-N- (4- (2,2,2- trifluoro-l-hydroxy-1- (trifluoromethyl) ethyl)phenyl) - 3-pyridinecarboxamide;
N- (3,3-dimethyl-2,3-dihydro-lH-indol-6-yl) -2- (5- isoquinolinylamino) -3-pyridinecarboxamide; 2- ( (3-oxo-l,3-dihydro-2-benzofuran-5-yl)amino) -N- (4-
(pentafluoroethyl)phenyl)-3-pyridinecarboxamide; N- (6- (1-azetidinyl) -3-pyridinyl) -2- (7-isoguinolinylamino) -3- pyridinecarboxamide; N- (5- (1-azetidinyl) -2-pyridinyl)-2- (7-isoquinolinylamino)-3- pyridinecarboxamide; N- (5- (1, 1-dimethylethyl) -3-isoxazolyl)-2- ((2,2,3,3- 2005/025800
A-917 - 22 -
tetrafluoro-2,3-dihydro-l,4-benzodioxin-6-yl)amino) -3- pyridinecarboxamide; N- (4- (1, 1-dimethylethyl)phenyl) -2- ((2,2,3,3-tetrafluoro-2,3- dihydro-1,4-benzodioxin-6-yl)amino)-3- pyridinecarboxamide;
N-(4,4-dimethyl-2-oxo-l,2,3,4-tetrahydro-7-quinolinyl) -2-
((2,2,3,3-tetrafluoro-2,3-dihydro-l,4-benzodioxin-6- yl)amino) -3-pyridinecarboxamide;
2- (lH-l,2,3-benzotriazol-5-ylamino)-N- (2-methyl-1, 3- benzothiazol-5-yl) -3-pyridinecarboxamide;
2- (IH-I, 2, 3-benzotriazol-5-ylamino) -N- (4, 4-dimethyl-2-oxo-
1,2,3,4-tetrahydro-7-quinolinyl) -3- pyridinecarboxamide;
2-(7-isoquinolinylamino) -N- (3- ( ( (2R) -tetrahydro-2- furanylmethyl)oxy)-5- (trifluoromethyl)phenyl)-3- pyridinecarboxamide; N- (5, 5-dimethyl-7-oxo-5, 6,7, 8-tetrahydro-l, 8-naphthyridin-2- yl) -2- ( (3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl)amino) -3-pyridinecarboxamide; N- (5- (1, 1-dimethylethyl)-3-isoxazolyl)-2- ( (3-oxo-3,4- dihydro-2H-l,4-benzoxazin-6-yl)amino)-3- pyridinecarboxamide; 2- (lH-indazol-6-ylamino)-N- (2-methyl-1, 3-benzothiazol-5-yl)-
3-pyridinecarboxamide; ethyl (2S)-2- (4- ( ( (2- (7-isoφαinolinylamino)-3- pyridinyl)carbonyl)amino)phenyl)propanoate; (2S)-2- (4- ( ( (2-(7-isoquinolinylamino) -3- pyridinyl) carbonyl)amino)phenyl)propanoic acid; 2- (7-isoqαiinolinylamino)-N-(3-oxo-3,4-dihydro-2H-l,4- benzothiazin-6-yl)-3-pyridinecarboxamide; and
N-(4-(1,1-dimethylethyl)phenyl) -2- (5-quinolinylamino) -3- pyridinecarboxamide.
A second exemplary grouping of compounds of interest within Formulas I and II consist of compounds as follows: N- (4, 4-dimethyl-2-oxo-1,2,3,4-tetrahydro-7-quinolinyl)-2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (4, 4-dimethyl-l,2,3,4-tetrahydro-7-quinolinyl) -2- (7- isoquinolinylamino)benzamide; N- (5-(l,l-dimethylethyl)-3-isoxazolyl)-2-(7- isoquinolinylamino) -3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N-(3-methyl-4- (1- pyrrolidinyl)phenyl) -3-pyridinecarboxamide; N- (l-acetyl-3, 3-dimethyl-2,3-dihydro-lH-indol-6-yl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide;
N- (4,4-dimethyl-l,2, 3, 4-tetrahydro-7-isoquinolinyl)-2- (7- isoquinolinylamino)-3-pyridinecarboxamide; 5-fluoro-2- (7-isoquinolinylamino) -N- (3-methyl-4- (1- methylethyl)phenyl) -3-pyridinecarboxamide; N- (4,4-dimethyl-l,2,3,4-tetrahydro-7-quinolinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (3,3-dimethyl-2, 3-dihydro-lH-indol-6-yl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (2-glycyl-4,4-dimethyl-l,2,3,4-tetrahydro-7- isoquinolinyl) -2- (7-isoquinolinylamino)-3- pyridinecarboxamide; N- (3,3-dimethyl-l- ( (2S)-tetrahydro-2-furanylcarbonyl)-2,3- dihydro-lH-indol-6-yl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N-(5, 5-dimethyl-7-oxo-5, 6,7, 8-tetrahydro-l,8-naphthyridin-2- yl)-2- (7-isoquinolinylamino)-3- pyridinecarboxamide; N- (4- (1, 1-dimethylethyl)phenyl) -2- (7- isoquinolinylamino)benzamide;
2- (7-isoquinolinylamino)-N- (4- (2, 2,2-trifluoro-l-hydroxy-1- (trifluoromethyl)ethyl)phenyl) -3- pyridinecarboxamide; N- (4,4-dimethyl-2-( (2R) -tetrahydro-2-furanylcarbonyl) -
1,2,3,4-tetrahydro-7-isoquinolinyl)-2- (7- isoquinolinylamino) -3-pyridinecarboxamide; 005/025800
A-917 - 24 -
N- (4- (1,1-dimethylethyl)phenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-7- isoquinolinyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide;
2- (7-isoqμinolinylamino) -N- (3-methyl-4-
(pentafluoroethyl)phenyl)-3-pyridinecarboxamide,- N- (4- (1, 1-dimethylethyl)phenyl) -3-fluoro-2- (7- isoquinolinylamino)benzamide; 2- (7-isoquinolinylamino) -N- (4- (1-methylethyl)phenyl)-3- pyridinecarboxamide,- N- (4- (1, 1-dimethylpropyl)phenyl)-2- (7-isoquinolinylamino)-3- pyridinecarboxamide;
2- (7-isoquinolinylamino)-N- (3- (methyloxy) -5- (trifluoromethyl)phenyl) -3-pyridinecarboxamide;
N- (3-chloro-4-methylphenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (6- (1,1-dimethylethyl) -3-pyridinyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (pentafluoroethyl)phenyl) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (2,2,2-trifluoro-l-
(methyloxy) -1- (trifluoromethyl)ethyl)phenyl) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (2-methyl-l,3-benzothiazol-5-yl) -
3-pyridinecarboxamide; N- (4-chloro-3- (trifluoromethyl)phenyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (trifluoromethyl)phenyl) -3- pyridinecarboxamide;
N- (6- (1-azetidinyl) -3-pyridinyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (5- (1-azetidinyl)-2-pyridinyl)-2- (7-isoquinolinylamino)-3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3- ( ( (2R) -tetrahydro-2- furanylmethyl)oxy) -5- (trifluoromethyl)phenyl) -3- pyridinecarboxamide; ethyl (2S)-2- (4- ( ( (2-
Figure imgf000026_0001
pyridinyl)carbonyl)amino)phenyl)propanoate; (2S) -2- (4- ( ( (2- (7-isoquinolinylamino) -3- pyridinyl)carbonyl)amino)phenyl)propanoic acid; (2R)-2- (4- ( ( (2- (7-isoquinolinylamino)-3- pyridinyl)carbonyl)amino)phenyl)propanoic acid; 2- (7-isoquinolinylamino) -N- (3-oxo-3,4-dihydro-2H-l,4- benzothiazin-6-yl)-3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- ( (trifluoromethyl)oxy)phenyl) -
3-pyridinecarboxamide; and
N- (3-chloro-4- (trifluoromethyl)phenyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide.
A third exemplary grouping of compounds of interest within Formulas I and II consist of pharmaceutically- acceptable hydrochloride, sulfate, sulfonate or phosphate salts of the follow compounds: N- (4,4-dimethyl-2-oxo-l,2,3,4-tetrahydro-7-quinolinyl)-2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl) -2- (7- isoquinolinylamino)benzamide; N- (5- (1, 1-dimethylethyl) -3-isoxazolyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide; 2- (7-isoquinolinylamino)-N- (3-methyl-4- (1- pyrrolidinyl)phenyl) -3-pyridinecarboxamide; N- (l-acetyl-3,3-dimethyl-2,3-dihydro-lH-indol-6-yl) -2-(7- isoquinolinylamino)-3-pyridinecarboxamide; N- (4, 4-dimethyl-1,2,3,4-tetrahydro-7-isoquinolinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; 5-fluoro-2- (7-isoquinolinylamino)-N- (3-methyl-4- (1- methylethyl)phenyl)-3-pyridinecarboxamide; N- (4,4-dimethyl-1,2,3,4-tetrahydro-7-quinolinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (3,3-dimethyl-2,3-dihγdro-lH-indol-6-γl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (2-glycyl-4,4-dimethyl-1,2,3,4-tetrahydro-7- isoquinolinyl)-2- (7-isoguinolinylamino)-3- pyridinecarboxamide;
N- (3,3-dimethyl-1- ( (2S) -tetrahydro-2-furanylcarbonyl)-2, 3- dihydro-lH-indol-6-yl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (5,5-dimethyl-7-oxo-5, 6,7, 8-tetrahydro-l, 8-naphthyridin-2- yl)-2- (7-isoquinolinylamino)-3- pyridinecarboxamide; N- (4- (1, 1-dimethylethyl)phenyl)-2- (7- isoquinolinylamino)benzamide;
2- (7-isoquinolinylamino) -N- (4- (2, 2, 2-trifluoro-1-hydroxy-1- (trifluoromethyl)ethyl)phenyl) -3- pyridinecarboxamide;
N- (4,4-dimethyl-2-( (2R)-tetrahydro-2-furanylcarbonyl)- l,2,3,4-tetrahydro-7-isoquinolinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (4- (1, 1-dimethylethyl)phenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide;
N- (2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-7- isoquinolinyl)-2- (7-isoquinolinylamino)-3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3-methyl-4-
(pentafluoroethyl)phenyl) -3-pyridinecarboxamide; N- (4- (1,1-dimethylethyl)phenyl) -3-fluoro-2- (7- isoquinolinylamino)benzamide;
2- (7-isoquinolinylamino)-N- (4- (1-methylethyl)phenyl)-3- pyridinecarboxamide;
N- (4- (1,1-dimethylpropyl)phenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3- (methyloxy) -5-
(trifluoromethyl)phenyl) -3-pyridinecarboxamide; N- (3-chloro-4-methylphenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (6- (1, 1-dimethylethyl)-3-pyridinyl)-2- (7- isoquinolinylamino) -3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (pentafluoroethyl)phenyl) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (2,2,2-trifluoro-1-
(methyloxy)-1- (trifluoromethyl)ethyl)phenyl) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (2-methyl-1,3-benzothiazol-5-yl) -
3-pyridinecarboxamide; N- (4-chloro-3- (trifluoromethyl)phenyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (trifluoromethyl)phenyl)-3- pyridinecarboxamide;
N- (6-(1-azetidinyl) -3-pyridinyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (5- (1-azetidinyl) -2-pyridinyl)-2- (7-isoquinolinylamino)-3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3- ( ( (2R) -tetrahydro-2- furanylmethyl) oxy) -5- (trifluoromethyl)phenyl) -3- pyridinecarboxamide; ethyl (2S)-2-(4-( ( (2- (7-isoquinolinylamino)-3- pyridinyl)carbonyl)amino)phenyl)propanoate; (2S) -2- (4- ( ( (2- (7-isoquinolinylamino) -3- pyridinyl)carbonyl) amino)phenyl)propanoic acid; (2R)-2-(4- ( ( (2- (7-isoquinolinylamino) -3- pyridinyl)carbonyl)amino)phenyl)propanoic acid; 2- (7-isoquinolinylamino) -N- (3-oxo-3,4-dihydro-2H-l, 4- benzothiazin-6-yl) -3-pyridinecarboxamide;
2- (7-isoquinolinylamino) -N-(4- ( (trifluoromethyl)oxy)phenyl) ■
3-pyridinecarboxamide; and N- (3-chloro-4- (trifluoromethyl)phenyl)-2- (7- isoquinolinylamino) -3-pyridinecarboxamide. US2005/025800
A-917 - 28 -
INDICATIONS
Compounds of the present invention would be useful for, but not limited to, the prevention or treatment of angiogenesis related diseases and physiological conditions. Particularly, the compounds of the invention would inhibit the growth of blood vessels thereby reducing the blood flow to and from a given tumor site, resulting in no net growth to the tumor at that site and reduced or no migration of tumor cells to and from that site. Accordingly, these compounds are useful for an overall reduction in the size of the tumor.
The compounds of the present invention have kinase inhibitory activity, such as VEGFR/KDR inhibitory activity, and are useful in therapy to minimize deleterious effects ,of VEGF. Accordingly, the compounds of the present invention would be useful, as antineoplasia agents, for the treatment of neoplasia including cancer and metastasis, including, but not limited to: carcinoma such as cancer of the bladder, breast, colon, kidney, liver, lung (including small cell lung cancer) , esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin (including squamous cell carcinoma) ; hematopoietic tumors of lymphoid lineage (including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell- lymphoma, Hodgkin's lymphoma, non-Hodgkin' s lymphoma, hairy cell lymphoma and Burkett's lymphoma); hematopoietic tumors of myeloid lineage (including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia) ; tumors of mesenchymal origin (including fibrosarcoma and rhabdomyosarcoma, and other sarcomas, e.g. soft tissue and bone) ; tumors of the central and peripheral nervous system (including astrocytoma, neuroblastoma, glioma and schwannomas) ; and other tumors (including melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma) . Preferably, the compounds are useful for the treatment of neoplasia selected from lung cancer, colon cancer and breast cancer.
The compounds of the present invention also would be useful for treatment of ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, retrolental fibroplasia and neovascular glaucoma; retinal ischemia; vitreous hemorrhage; ulcerative diseases such as gastric ulcer; pathological, but non-malignant, conditions such as hemangiomas, including infantile hemaginomas, angiofibroma of the nasopharynx and avascular necrosis of bone,- and disorders of the female reproductive system such as endometriosis. The compounds are also useful for the treatment of edema, and conditions of vascular hyperpermeability.
The compounds of the present invention are useful in therapy of proliferative diseases. These compounds can be used for the treatment of an inflammatory rheumatoid or rheumatic disease, especially of manifestations at the locomotor apparatus, such as various inflammatory rheumatoid diseases, especially chronic polyarthritis including rheumatoid arthritis, juvenile arthritis or psoriasis arthropathy; paraneoplastic syndrome or tumor-induced inflammatory diseases, turbid effusions, collagenosis, such as systemic Lupus erythematosus, poly-myositis, dermato- myositis, systemic sclerodermia or mixed collagenosis; postinfectious arthritis (where no living pathogenic organism can be found at or in the affected part of the body), seronegative spondylarthritis, such as spondylitis ankylosans,- vasculitis, sarcoidosis, or arthrosis; or further any combinations thereof. An example of an inflammation related disorder is (a) synovial inflammation, for example, synovitis, including any of the particular forms of synovitis, in particular bursal synovitis and purulent synovitis, as far as it is not crystal-induced. Such synovial inflammation may for example, be consequential to or associated with disease, e.g. arthritis, e.g. osteoarthritis, rheumatoid arthritis or arthritis deformans. The present invention is further applicable to the systemic treatment of inflammation, e.g. inflammatory diseases or conditions, of the joints or locomotor apparatus in the region of the tendon insertions and tendon sheaths. Such inflammation may be, for example, consequential to or associated with disease or further (in a broader sense of the invention) with surgical intervention, including, in particular conditions such as insertion endopathy, myofasciale syndrome and tendomyosis. The present invention is further especially applicable to the treatment of inflammation, e.g. inflammatory disease or condition, of connective tissues including dermatomyositis and myositis. The compounds of the present invention can be used as active agents against such disease states as arthritis, atherosclerosis, psoriasis, hemangiomas, myocardial angiogenesis, coronary and cerebral collaterals, ischemic limb angiogenesis, wound healing, peptic ulcer Helicobacter related diseases, fractures, cat scratch fever, rubeosis, neovascular glaucoma and retinopathies such as those associated with diabetic retinopathy or macular degeneration. In addition, some of these compounds can be used as active agents against solid tumors, malignant ascites, hematopoietic cancers and hyperproliferative disorders such as thyroid hyperplasia (especially Grave's disease) , and cysts (such as hypervascularity of ovarian stroma, characteristic of polycystic ovarian syndrome (Stein- Leventhal syndrome) ) since such diseases require a proliferation of blood vessel cells for growth and/or metastasis.
Further, some of these compounds can be used as active agents against burns, chronic lung disease, stroke, polyps, anaphylaxis, chronic and allergic inflammation, ovarian hyperstimulation syndrome, brain tumor-associated cerebral edema, high-altitude, trauma or hypoxia induced cerebral or pulmonary edema, ocular and macular edema, ascites, and other diseases where vascular hyperpermeability, effusions, exudates, protein extravasation, or edema is a manifestation of the disease. The compounds will also be useful in treating disorders in which protein extravasation leads to the deposition of fibrin and extracellular matrix, promoting stromal proliferation (e.g. fibrosis, cirrhosis and carpal tunnel syndrome) .
The compounds of the present invention are also useful in the treatment of ulcers including bacterial, fungal, Mooren ulcers and ulcerative colitis.
The compounds of the present invention are also useful in the treatment of conditions wherein undesired angiogenesis, edema, or stromal deposition occurs in viral infections such as Herpes simplex, Herpes Zoster, AIDS, Kaposi's sarcoma, protozoan infections and toxoplasmosis, following trauma, radiation, stroke, endometriosis, ovarian hyperstimulation syndrome, systemic lupus, sarcoidosis, synovitis, Crohn's disease, sickle cell anaemia, Lyme disease, pemphigoid, Paget 's disease, hyperviscosity syndrome, Osler-Weber-Rendu disease, chronic inflammation, chronic occlusive pulmonary disease, asthma, and inflammatory rheumatoid or rheumatic disease. The compounds are also useful in the reduction of sub-cutaneous fat and for the treatment of obesity.
The compounds of the present invention are also useful in the treatment of ocular conditions such as ocular and 2005/025800
A-917 - 32 -
macular edema, ocular neovascular disease, scleritis, radial keratotomy, uveitis, vitritis, myopia, optic pits, chronic retinal detachment, post-laser complications, glaucoma, conjunctivitis, Stargardt's disease and Eales disease in addition to retinopathy and macular degeneration.
The compounds of the present invention are also useful in the treatment of cardiovascular conditions such as atherosclerosis, restenosis, arteriosclerosis, vascular occlusion and carotid obstructive disease. The compounds of the present invention are also useful in the treatment of cancer related indications such as solid tumors, sarcomas (especially Ewing's sarcoma and osteosarcoma) , retinoblastoma, rhabdomyosarcomas, neuroblastoma, hematopoietic malignancies, including leukemia and lymphoma, tumor- induced pleural or pericardial effusions, and malignant ascites.
The compounds of the present invention are also useful in the treatment of diabetic conditions such as diabetic retinopathy and microangiopathy. The compounds of the present invention may also act as inhibitors of other protein kinases, e.g. Src, Lck, AbI, GSK, Kit, p38, EGFR, CDK-2, CDK-5, IKK, JNK3, bFGFR, PDGFR, RAF and ZAP70. Thus, these compounds may be effective in the treatment of diseases and conditions associated with the function and activity of various other protein kinases, such as those listed above.
Besides being useful for human treatment, these compounds are also useful for veterinary treatment of companion animals, exotic animals and farm animals, including mammals, rodents, and the like. By way of example, these compounds may be used to treat horses, dogs, and cats.
DEFINITIONS The term "treatment" includes therapeutic treatment as well as prophylactic treatment (either preventing the onset of disorders altogether or delaying the onset of a preclinically evident stage of disorders in individuals) . The term "derivative" is broadly construed herein, and intended to encompass any salt of a compound of this invention, any ester of a compound of this invention, or any other compound, such as a prodrug, which upon administration to a patient is capable of providing (directly or indirectly) a compound of this invention, or a metabolite or residue thereof, characterized by the ability to inhibit angiogenesis.
The term and "pharmaceutically-acceptable derivative" as used herein, denotes a derivative which is pharmaceutically acceptable.
The phrase "therapeutically-effective" is intended to qualify the amount of each agent, which will achieve the goal of improvement in disorder severity and the frequency of incidence over treatment of each agent by itself, while avoiding adverse side effects typically associated with alternative therapies. For example, effective neoplastic therapeutic agents prolong the survivability of the patient, inhibit the rapidly-proliferating cell growth associated with the neoplasm, or effect a regression of the neoplasm. The term "carrier", as used herein, denotes any pharmaceutically acceptable additive, excipient, adjuvant, or other suitable ingredient, other than the active pharmaceutical ingredient (API) , which is typically included for formulation and/or administration purposes. The term "H" denotes a single hydrogen atom. This radical may be attached, for example, to an oxygen atom to form a hydroxyl radical.
Where the term "alkyl" is used, either alone or within other terms such as "haloalkyl" and "alkylamino" , it embraces linear or branched radicals having one to about twelve carbon atoms. More preferred alkyl radicals are "lower alkyl" radicals having one to about six carbon atoms. Examples of such radicals include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isoamyl, hexyl and the like. The phrase "one or more alkyl substitutions" embraces, beyond its normal meaning, the instance where a single atom, such as carbon, has two of the same or different substituents attached to it. For example, a Bgem-dimethyl" group, which the phrase above embraces, refers to a single carbon atom in a structural moeity having two methyl radicals attached to it. The term walkylenyl" embraces bridging divalent alkyl radicals such as methylenyl and ethylenyl. The term "alkenyl" embraces linear or branched radicals having at least one carbon-carbon double bond of two to about twelve carbon atoms. More preferred alkenyl radicals are "lower alkenyl" radicals having two to about six carbon atoms. Examples of alkenyl radicals include ethenyl, propenyl, allyl, propenyl, butenyl and 4- methylbutenyl. The terms "alkenyl" and "lower alkenyl", embrace radicals having "cis" and "trans" orientations, or alternatively, "E" and "Z" orientations.
The term "alkynyl" denotes linear or branched radicals having at least one carbon-carbon triple bond and having two to about twelve carbon atoms. More preferred alkynyl radicals are "lower alkynyl" radicals having two to about six carbon atoms. Most preferred are lower alkynyl radicals having two to about four carbon atoms. Examples of such radicals include propargyl, butynyl, and the like.
The term "halo" means halogens such as fluorine, chlorine, bromine or iodine atoms.
The term "haloalkyl" embraces radicals wherein any one or more of the alkyl carbon atoms is substituted with halo as defined above. Specifically embraced are monohaloalkyl, dihaloalkyl and polyhaloalkyl radicals including perhaloalkyl. A monohaloalkyl radical, for one example, may have either an iodo, bromo, chloro or fluoro atom within the radical. Dihalo and polyhaloalkyl radicals may have two or more of the same halo atoms or a combination of different halo radicals. "Lower haloalkyl" embraces radicals having 1- 6 carbon atoms. Even more preferred are lower haloalkyl radicals having one to three carbon atoms. Examples of haloalkyl radicals include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl. "Perfluoroalkyl" means alkyl radicals having all hydrogen atoms replaced with fluoro atoms . Examples include trifluoromethyl and pentafluoroethyl.
The term "hydroxyalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more hydroxyl radicals. More preferred hydroxyalkyl radicals are "lower hydroxyalkyl" radicals having one to six carbon atoms and one or more hydroxyl radicals. Examples of such radicals include hydroxymethyl, hydroxyethyl, hydroxypropyl, hydroxybutyl and hydroxyhexyl. Even more preferred are lower hydroxyalkyl radicals having one to three carbon atoms. The term "alkoxy" embrace linear or branched oxy- containing radicals each having alkyl portions of one to about ten carbon atoms. More preferred alkoxy radicals are "lower alkoxy" radicals having one to six carbon atoms.
Examples of such radicals include methoxy, ethoxy, propoxy, butoxy and tert-butoxy. Even more preferred are lower alkoxy radicals having one to three carbon atoms. Alkoxy radicals may be further substituted with one or more halo atoms, such as fluoro, chloro or bromo, to provide "haloalkoxy" radicals. Even more preferred are lower haloalkoxy radicals having one to three carbon atoms. Examples of such radicals include fluoromethoxy, chloromethoxy, trifluoromethoxy, trifluoroethoxy, fluoroethoxy and fluoropropoxy.
The term "aryl", alone or in combination, means a carbocyclic aromatic system containing one or two rings wherein such rings may be attached together in a fused manner. The term "aryl" embraces aromatic radicals such as phenyl, naphthyl, indenyl, tetrahydronaphthyl, and indanyl. More preferred aryl is phenyl. Said "aryl" group may have 1 to 5 substituents such as lower alkyl, hydroxyl, halo, haloalkyl, nitro, cyano, alkoxy and lower alkylamino. Phenyl substituted with -0-CH2-O- forms the aryl benzodioxolyl substituent.
The term " heterocyclyl" embraces saturated, partially saturated and unsaturated heteroatom-containing ring radicals, where the heteroatoms may be selected from nitrogen, sulfur and oxygen. It does not include rings containing -0-0-, -0-S- or -S-S- portions. Said
"heterocyclyl" group may have 1 to 3 substituents such as oxo (also known as "carbonyl"), hydroxyl, Boc, halo, haloalkyl, cyano, lower alkyl, lower aralkyl, lower alkoxy, amino and lower alkylamino. Examples of saturated heterocyclic radicals include saturated 3 to 6-membered heteromonocyclic groups containing 1 to 4 nitrogen atoms [e.g. pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, piperazinyl] ; saturated 3 to 6- membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. morpholinyl] ; saturated 3 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., thiazolidinyl] . Examples of partially saturated heterocyclyl radicals include dihydrothienyl, dihydropyranyl, dihydrofuryl and dihydrothiazolyl.
Examples of unsaturated heterocyclic radicals, also termed "heteroaryl" radicals, include unsaturated 5 to 6 membered heteromonocyclyl group containing 1 to 4 nitrogen atoms, for example, pyrrolyl, imidazolyl, pyrazolyl, 2- pyridyl, 3-pyridyl, 4-pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, triazolyl [e.g., 4H-1, 2,4-triazolyl, IH-I,2,3- triazolyl, 2H-1,2,3-triazolyl] ; unsaturated 5- to 6-membered heteromonocyclic group containing an oxygen atom, for example, pyranyl, 2-furyl, 3-furyl, etc.; unsaturated 5 to 6-membered heteromonocyclic group containing a sulfur atom, for example, 2-thienyl, 3-thienyl, etc.; unsaturated 5- to 6-membered heteromonocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms, for example, oxazolyl, isoxazolyl, oxadiazolyl [e.g., 1,2,4-oxadiazolyl, 1,3,4- oxadiazolyl, 1,2,5-oxadiazolyl] ; unsaturated 5 to 6-membered heteromonocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms, for example, thiazolyl, thiadiazolyl [e.g., 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,5- thiadiazolyl] .
The term also embraces radicals where heterocyclic radicals are fused/condensed with aryl radicals: unsaturated condensed heterocyclic group containing 1 to 5 nitrogen atoms, for example, indolyl, isoindolyl, indolizinyl, benzimidazolyl, guinolyl, isoquinolyl, indazolyl, benzotriazolyl, tetrazolopyridazinyl [e.g., tetrazolo [1, 5-b]pyridazinyl] ; unsaturated condensed heterocyclic group containing 1 to 2 oxygen atoms and 1 to 3 nitrogen atoms [e.g. benzoxazolyl, benzoxadiazolyl] ; unsaturated condensed heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3 nitrogen atoms [e.g., benzothiazolyl, benzothiadiazolyl] ; and saturated, partially unsaturated and unsaturated condensed heterocyclic group containing 1 to 2 oxygen or sulfur atoms [e.g. benzofuryl, benzothienyl, 2, 3-dihydro-benzo[l,4]dioxinyl, benxo[1,3]dioxyIy, dihydrobenzofury1 and dihydroisobenzofuryl] . Preferred heterocyclic radicals include five to ten membered fused or unfused radicals. More preferred examples of heteroaryl radicals include quinolyl, isoquinolyl, imidazolyl, pyridyl, thienyl, thiazolyl, oxazolyl, furyl, and pyrazinyl. Other preferred heteroaryl radicals are 5- or 6-membered heteroaryl, containing one or two heteroatoms selected from sulfur, nitrogen and oxygen, selected from thienyl, furyl, pyrrolyl, indazolyl, pyrazolyl, oxazolyl, triazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, pyridyl, piperidinyl and pyrazinyl. Particular examples of non-nitrogen containing heteroaryl include pyranyl, 2-furyl, 3-furyl, 2-thienyl, 3- thienyl, benzofuryl, benzothienyl, and the like.
Particular examples of partially saturated and saturated heterocyclyl include pyrrolidinyl, imidazolidinyl, piperidinyl, pyrrolinyl, pyrazolidinyl, piperazinyl, morpholinyl, tetrahydropyranyl, thiazolidinyl, dihydrothienyl, 2,3-dihydro-benzo[l,4]dioxanyl, indolinyl, isoindolinyl, dihydrobenzothienyl, dihydrobenzofuryl, isochromanyl, chromanyl, 1, 2-dihydroquinoIyI, 1,2,3,4- tetrahydro-isoquinolyl, 1,2,3, 4-tetrahydro-quinolyl,
2,3,4,4a,9,9a-hexahydro-lH-3-aza-fluorenyl, 5,6,7-trihydro- 1,2,4-triazolo[3,4-a]isoquinolyl, 3,4-dihydro-2H- benzo[l,4]oxazinyl, benzo[l, 4]dioxanyl, 2,3-dihydro-lH-lλ' - benzo[d]isothiazol-6-yl, dihydropyranyl, dihydrofuryl and dihydrothiazolyl, and the like.
The term "sulfonyl", whether used alone or linked to other terms such as alkylsulfonyl, denotes respectively divalent radicals -SO2-. The term "aminosulfonyl" denotes a sulfonyl radical substituted with an amine radical, forming a sulfonamide (- SO2NH2) .
The term "alkylaminosulfonyl" includes "N- alkylaminosulfonyl" where sulfamyl radicals are independently substituted with one or two alkyl radical(s). More preferred alkylaminosulfonyl radicals are "lower alkylaminosulfonyl" radicals having one to six carbon atoms. Even more preferred are lower alkylaminosulfonyl radicals having one to three carbon atoms. Examples of such lower alkylaminosulfonyl radicals include N-methylaminosulfonyl, and N-ethylaminosulfonyl.
The term "carboxy", whether used alone or with other terms, such as "carboxyalkyl" , denotes -CO2H. The term "carbonyl", whether used alone or with other terms, such as "aminocarbonyl" , denotes -(C=O)-.
The term "aminocarbonyl" denotes an amide group of the formula -C(=0)NH2.
The terms "N-alkylaminocarbonyl" and "N,N- dialkylaminocarbonyl" denote aminocarbonyl radicals independently substituted with one or two alkyl radicals, respectively. More preferred are "lower alkylaminocarbonyl" having lower alkyl radicals as described above attached to an aminocarbonyl radical. The terms "N-arylaminocarbonyl" and "N-alkyl-N- arylaminocarbonyl" denote aminocarbonyl radicals substituted, respectively, with one aryl radical, or one alkyl and one aryl radical.
The terms "heterocyclylalkyl" and "heterocyclylalkylenyl" embrace heterocyclic-substituted alkyl and alkylenyl radicals. More preferred heterocyclylalkylenyl radicals are "5- or 6-membered heteroarylalkylenyl" radicals having alkyl portions of one to six carbon atoms and a 5- or 6-membered heteroaryl radical. Even more preferred are lower heteroarylalkylenyl radicals having alkyl portions of one to three carbon atoms. Examples include such radicals as pyridylmethyl and thienylmethyl. The terms "aralkyl" and waryl alkylenyl" embrace aryl- substituted alkyl and alkylenyl radicals. Preferable aralkyl radicals are "lower aralkyl" radicals having aryl radicals attached to alkyl radicals having one to six carbon atoms. Even more preferred are "phenylalkylenyl" attached to alkyl portions having one to three carbon atoms. Examples of such radicals include benzyl, diphenylmethyl and phenylethyl. The aryl in said aralkyl may be additionally substituted with halo, alkyl, alkoxy, halkoalkyl and haloalkoxy.
The term "alkylthio" embraces radicals containing a linear or branched alkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. Even more preferred are lower alkylthio radicals having one to three carbon atoms. An example of "alkylthio" is methylthio, (CH3S-) . The term "haloalkylthio" embraces radicals containing a haloalkyl radical, of one to ten carbon atoms, attached to a divalent sulfur atom. Even more preferred are lower haloalkylthio radicals having one to three carbon atoms. An example of "haloalkylthio" is trifluoromethylthio. The term "alkylamino" embraces "N-alkylamino" and "N,N-dialkylamino" where amino groups are independently substituted with one alkyl radical and with two alkyl radicals, respectively. More preferred alkylamino radicals are "lower alkylamino" radicals having one or two alkyl radicals of one to six carbon atoms, attached to a nitrogen atom. Even more preferred are lower alkylamino radicals having one to three carbon atoms. Suitable alkylamino radicals may be mono or dialkylamino such as N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino and the like.
The term "arylamino" denotes amino groups, which have been substituted with one or two aryl radicals, such as N- phenylamino. The arylamino radicals may be further substituted on the aryl ring portion of the radical.
The term "heteroarylamino" denotes amino groups, which have been substituted with one or two heteroaryl radicals, such as N-thienylamino. The "heteroarylamino" radicals may be further substituted on the heteroaryl ring portion of the radical.
The term "aralkylamino" denotes amino groups, which have been substituted with one or two aralkyl radicals. More preferred are phenyl-Ci-Ca-alkylamino radicals, such as N- benzylamino. The aralkylamino radicals may be further substituted on the aryl ring portion.
The terms "N-alkyl-N-arylamino" and "N-aralkyl-N- alkylamino" denote amino groups, which have been independently substituted with one aralkyl and one alkyl radical, or one aryl and one alkyl radical, respectively, to an amino group.
The term "aminoalkyl" embraces linear or branched alkyl radicals having one to about ten carbon atoms any one of which may be substituted with one or more amino radicals . More preferred aminoalkyl radicals are "lower aminoalkyl" radicals having one to six carbon atoms and one or more amino radicals. Examples of such radicals include aminomethyl, aminoethyl, aminopropyl, aminobutyl and aminohexyl. Even more preferred are lower aminoalkyl radicals having one to three carbon atoms.
The term "alkylaminoalkyl" embraces alkyl radicals substituted with alkylamino radicals. More preferred alkylaminoalkyl radicals are "lower alkylaminoalkyl" radicals having alkyl radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkyl radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkyl radicals may be mono or dialkyl substituted, such as N-methylaminomethyl, N,N-dimethyl-aminoethyl, N,N- diethylaminomethyl and the like.
The term "alkylaminoalkoxy" embraces alkoxy radicals substituted with alkylamino radicals. More preferred alkylaminoalkoxy radicals are "lower alkylaminoalkoxy" radicals having alkoxy radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkoxy radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkoxy radicals may be mono or dialkyl substituted, such as N-methylaminoethoxy, N,N- dimethylaminoethoxy, N,N-diethylaminoethoxy and the like. The term "alkylaminoalkoxyalkoxy" embraces alkoxy radicals substituted with alkylaminoalkoxy radicals. More preferred alkylaminoalkoxyalkoxy radicals are "lower alkylaminoalkoxyalkoxy" radicals having alkoxy radicals of one to six carbon atoms. Even more preferred are lower alkylaminoalkoxyalkoxy radicals having alkyl radicals of one to three carbon atoms. Suitable alkylaminoalkoxyalkoxy radicals may be mono or dialkyl substituted, such as N- methylaminomethoxyethoxy, N-methylaminoethoxyethoxy, N,N- dimethylaminoethoxyethoxy, N,N-diethylaminomethoxymethoxy and the like.
The term "halosulfonyl" embraces sulfonyl radicals substituted with a halogen radical. Examples of such halosulfonyl radicals include chlorosulfonyl and fluorosulfonyl. The term "arylthio" embraces aryl radicals of six to ten carbon atoms, attached to a divalent sulfur atom. An example of "arylthio" is phenylthio.
The term "aralkylthio" embraces aralkyl radicals as described above, attached to a divalent sulfur atom. More preferred are phenyl-Ci-C3-alkylthio radicals. An example of "aralkylthio" is benzylthio.
The term "aryloxy" embraces optionally substituted aryl radicals, as defined above, attached to an oxygen atom. Examples of such radicals include phenoxy.
The term "aralkoxy" embraces oxy-containing aralkyl radicals attached through an oxygen atom to other radicals. More preferred aralkoxy radicals are "lower aralkoxy" radicals having optionally substituted phenyl radicals attached to lower alkoxy radical as described above.
The term "heterocyclyloxy" embraces optionally substituted heteroaryl radicals, as defined above, attached to an oxygen atom.
The term "heterocyclylalkoxy" embraces oxy-containing heteroarylalkyl radicals attached through an oxygen atom to other radicals. More preferred heteroarylalkoxy radicals are "lower heteroarylalkoxy" radicals having optionally substituted heteroaryl radicals attached to lower alkoxy radical as described above. The term "cycloalkyl" includes saturated carbocyclic groups. Preferred cycloalkyl groups include C3-C6 rings. More preferred compounds include, cyclopentyl, cyclopropyl, and cyclohexyl.
The term "comprising" or "comprises" is meant to be open ended, i.e., including the indicated component but not excluding other elements.
The terms "Formula I and Formula II" include any sub formulas.
The present invention also comprises the use of a compound of the invention, or pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment either acutely or chronically of an angiogenesis mediated disease state, including those described previously. The compounds of the present invention are useful in the manufacture of an anti-cancer medicament. The compounds of the present invention are also useful in the manufacture of a medicament to attenuate or prevent disorders through inhibition of KDR. The present invention comprises a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I or Formula II in association with a least one pharmaceutically acceptable carrier, adjuvant or diluent. The present invention also comprises a method of treating angiogenesis related disorders in a subject having or susceptible to such disorder, the method comprising treating the subject with a therapeutically effective amount of a compound of Formula I
Figure imgf000045_0001
I or a pharmaceutically acceptable derivative thereof, wherein R is a 9- or 10-membered heterocyclyl ring containing at least one nitrogen or oxygen atom, said ring selected from 7-isoquinolinyl, 2-methyl-3-oxo-2, 3- dihydroindazol-6-yl, [1, 6]-naphthydrin-3-yl, [1,7]- naphthydrin-2-yl, l-oxo-2, 3-dihydrobenzofuran-4-yl, 3-oxo- 2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6- quinazolinyl, 2-amino-6-quinazolinyl, 4-methy1amino-6- guinazolinyl, 2,4-diamino-6-quinazolinyl, 3-oxo-3,4-dihydro- 1,4-benzoxazin-6-yl, 2,2-difluoro-l,3-benzodioxol-5-yl and 2,2,3,3-tetrafluoro-2, 3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substitutions selected from halo, haloalkyl, C1-6 alkyl, C2_8 alkenyl, C2_8 alkynyl, N-dimethylamino-C^g-alkyl, N- dimethylamino-C^j-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl, morpholinyl, carboxyl, cyano, and acetyl; wherein R1 is selected from unsubstituted or substituted phenyl,
5-6 membered heteroaryl, 9-10 membered bicyclic heterocyclyl and
11-14 membered tricyclic heterocyclyl, wherein substituted R1 is substituted with one or more substituents selected from halo, optionally substituted Ci_6-alkyl, optionally substituted C3_6- cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-Ci_C4-alkylenyl, C1_2-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-Ci_C6-alkyl, optionally substituted 4-6 membered heterocyclyl-C2-C4- alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-Ci-4-alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl-Ci_4- alkylcarbonyl, optionally substituted 4-6 membered heterocyclylcarbonyl-Ci-4-alkyl, optionally substituted 4-6 membered heterocyclyl-Ci-4-alkylcarbonylamino, optionally substituted 4-6 membered heterocyclyl- oxycarbonylamino, Ci_2-haloalkyl, Cα-4-aminoalkyl, optionally substituted Ci_4-aminoalkylcarbonyl, nitro, amino, Cn.-3-alkylsulfonylamino, hydroxy, cyano, aminosulfonyl , Ci-2-alkγlsulfonyl , Ci_2- alkylsulfonylamino , Ci-.2-alkylsulfonylamino-C1_4-alkoxy, halosulfonyl , Ci_4-alkylcarbonyl , amino-Ci-4- alkylcarbonyl , Ci-3-alkylamino-C1.4-alkylcarbonyl , Ci_3- alkylamino-Ci_4-alkylcarbonylamino , Ci_4-alkoxycarbonyl-
Ci-4-alkyl , Ci.s-alkylainino-Ci-3-alkyl , Ci-3-alkylamino-Ci_ 3-alkoxy, Ci-3-alkylamino-Ci_3-alko:xy-Ci_3-alkoxy, Cχ_4- alkoxycarbonyl , Ci-4-alkoxycarbonylamino-Ci_4-alkyl , Ci- 3-alkylsulf onylamino-Ci-3-alkoxy# Ci_4-hydroxyalkyl ,
Figure imgf000047_0001
and Ci_4-alkoxy; and wherein Re and Rf are independently selected from H and Ci_2- haloalkyl; and wherein R7 is selected from H, Cχ-3-alkyl, optionally substituted phenyl, optionally substituted phenyl-Ci-3- alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-Ci_C3-alkyl, Ci_3- alkoxy-Cχ-2-alkyl and Ci-s-alkoxy-Ci-s-alkoxy-Ci-s-alkyl; and wherein R2 is selected from H, halo, haloalkyl and C1-6 alkyl.
Similarly, the present invention further comprises a method of treating angiogenesis related disorders in a subject having or susceptible to such disorder, the method comprising treating the subject with a therapeutically effective amount of a compound of Formula II, as described herein.
COMBINATIONS
While the compounds of the present invention can be administered as the sole active pharmaceutical agent, they can also be used in combination with one or more compounds of the invention or other agents. When administered as a combination, the therapeutic agents can be formulated as separate compositions that are administered at the same time or sequentially at different times, or the therapeutic agents can be formulated and administered as a single composition.
The phrase "co-therapy" (or "combination-therapy"), in defining use of a compound of the present invention and another pharmaceutical agent, is intended to embrace administration of each agent in a sequential manner in a regimen that will provide beneficial effects of the drug combination, and is intended as well to embrace co¬ administration of these agents in a substantially simultaneous manner, such as in a single capsule having a fixed ratio of these active agents or in multiple, separate capsules or other formulations for each agent.
If formulated as a fixed dose, such combination products employ the compounds of this invention within the accepted dosage ranges. Compounds of Formulas I and II may also be administered sequentially with known anticancer or cytotoxic agents when a combination formulation is inappropriate. The invention is not limited in the sequence of administration; compounds of the invention may be administered either prior to, simultaneous with or after administration of the known anticancer or cytotoxic agent. The administration of compounds, or compositions, of the present invention may be in conjunction with additional therapies known to those skilled in the art in the prevention or treatment of neoplasia, such as with radiation therapy or with cytostatic or cytotoxic agents. In some embodiments, the combination therapy can include a compound, or composition, of the present invention with at least one anti-tumor agent or other conventional therapeutic agent. In some embodiments, the combination comprises a compound, or composition, of the present invention (e.g., an antibody or antigen binding region) in combination with at least one 25800
A-917 - 48 - anti-angiogenic agent. Agents are inclusive of, but not limited to, in vitro synthetically prepared chemical compositions, antibodies, antigen binding regions, radionuclides, and combinations and conjugates thereof. An agent can be an agonist, antagonist, allosteric modulator, toxin or, more generally, may act to inhibit or stimulate its target (e.g., receptor or enzyme activation or inhibition) , and thereby promote cell death or arrest cell growth. Currently, standard treatment of primary tumors consists of surgical excision followed by either radiation or IV administered chemotherapy. The typical chemotherapy regime consists of either DNA alkylating agents, DNA intercalating agents, CDK inhibitors, or microtubule poisons. The chemotherapy doses used are just below the maximal tolerated dose and therefore dose limiting toxicities typically include, nausea, vomiting, diarrhea, hair loss, neutropenia and the like.
There are large numbers of antineoplastic agents available in commercial use, in clinical evaluation and in pre-clinical development, which would be selected for treatment of neoplasia by combination drug chemotherapy. Such antineoplastic agents fall into several major categories, namely, antibiotic-type agents, alkylating-type agents, antimetabolite-type agents, hormonal agents, immunological agents, interferon-type agents and a category of miscellaneous antineoplastic agents.
A first family of antineoplastic agents, which may be used in combination with compounds of the present invention, consists of antimetabolite-type/thymidilate synthase inhibitor antineoplastic agents. Suitable antimetabolite- type antineoplastic agents may be selected from, but not limited to, the group consisting of 5-FU-fibrinogen, acanthifolic acid, aminothiadiazole, brequinar sodium, carmofur, Ciba-Geigy CGP-30694, cyclopentyl cytosine, cytarabine phosphate stearate, cytarabine conjugates, Lilly DATHF, Merrel Dow DDFC, dezaguanine, dideoxycytidine, dideoxyguanosine, didox, Yoshitomi DMDC, doxifluridine, Wellcome EHNA, Merck & Co. EX-015, fazarabine, Daiichi Seiyaku FO-152, isopropyl pyrrolizine, Lilly LY-188011, Lilly LY-264618, methobenzaprim, Wellcome MZPES, norspermidine, NCI NSC-127716, NCI NSC-264880, NCI NSC- 39661, NCI NSC-612567, Warner-Lambert PALA, pentostatin, piritrexim, plicamycin, Asahi Chemical PL-AC, Takeda TAC- 788, thioguanine, tiazofurin, Erbamont TIF, tyrosine kinase inhibitors, Taiho UFT, uricytin, folic acid analogs such as methotrexate and trimetrexate, pyrimidine analogs such as 5- fluorouracil, N- (2 ' -furanidyl) -5-fluorouracil, floxuridine, fluorodeoxyuridine, gemcitabine, cytosine arabinoside (AraC, cytarabine), 5-azacytidine, 2,2 '-difluorodeoxycytidine and purine analogs such as 6-mercaptopurine, 6-thioguanine, azathioprine, 2'-deoxycoformycin (pentostatin), erythrohydroxynonyladenine (EHNA) , fludarabine phosphate, and 2-chlorodeoxyadenosine (cladribine, 2-CdA) . A second family of antineoplastic agents, which may be used in combination with compounds of the present invention, consists of alkylating-type antineoplastic agents. Suitable alkylating-type antineoplastic agents may be selected from, but not limited to, the group consisting of Shionogi 254-S, aldo-phosphamide analogues, alkyl sulfonates such as busulfan, altretamine, anaxirone, Boehringer Mannheim BBR- 2207, bestrabucil, budotitane, Wakunaga CA-102, carboplatin, carmustine (BCNU), Chinoin-139, Chinoin-153, chlorambucil, cisplatin, cyclophosphamide, American Cyanamid CL-286558, Sanofi CY-233, cyplatate, Degussa D-19-384, Sumimoto
DACHP(Myr)2, diphenylspiromustine, diplatinum cytostatic, Erba distamycin derivatives, Chugai DWA-2114R, ITI E09, elmustine, Erbamont FCE-24517, estramustine, estramustine phosphate, estramustine phosphate sodium, fotemustine, Unimed G-6-M, Ctiinoin GYKI-17230, hepsul-fam, ifosfamide, iproplatin, lomustine (CCNU) , mafosfamide, mechlorethamine, melphalan, mitolactol, Nippon Kayaku NK-121, nitrogen mustards, NCI NSC-264395, NCI NSC-342215, oxaliplatin, Upjohn PCNU, prednimustine, Proter PTT-119, ranimustine, semustine (methyl-CCNU), SmithKline SK&F-101772, Yakult Honsha SN-22, spiromus-tine, Tanabe Seiyaku TA-077, tauromustine, temozolomide, teroxirone, tetraplatin and trimelamol, ethylenimines/methylmelamine such as thriethylenemelamine (TEM) , triethylene, thiophosphoramide (thiotepa) , hexamethylmelamine (HMM, altretamine) and triazines such as dacarbazine (DTIC) .
A third family of antineoplastic agents which may be used in combination with compounds of the present invention consists of antibiotic-type antineoplastic agents. Suitable antibiotic-type antineoplastic agents may be selected from, but not limited to, the group consisting of Taiho 4181-A, aclarubicin, actinomycin, actinomycin D, actinoplanone, Erbamont ADR-456, aeroplysinin derivative, Ajinomoto AN-201- II, Ajinomoto AN-3, Nippon Soda anisomycins, anthracycline, azino-mycin-A, bisucaberin, Bristol-Myers BL-6859, Bristol- Myers BMY-25067, Bristol-Myers BMY-25551, Bristol-Myers BMY- 26605, Bristol-Myers BMY-27557, Bristol-Myers BMY-28438, bleomycins such as bleomycin sulfate, bryostatin-1, Taiho C- 1027, calichemycin, chromoximycin, dactinomycin, daunorubicin, daunomycin (rubidomycin) , mitoxantrone Kyowa Hakko DC-102, Kyowa Hakko DC-79, Kyowa Hakko DC-88A, Kyowa Hakko DC89-A1, Kyowa Hakko DC92-B, ditrisarubicin B, Shionogi DOB-41, doxorubicin, doxorubicin-fibrinogen, elsamicin-A, epirubicin, erbstatin, esorubicin, esperamicin- Al, esperamicin-Alb, Erbamont FCE-21954, Fujisawa FK-973, fostriecin, Fujisawa FR-900482, glidobactin, gregatin-A, grincamycin, herbimycin, idarubicin, illudins, kazusamycin, kesarirhodins, Kyowa Hakko KM-5539, Kirin Brewery KRN-8602, Kyowa Hakko KT-5432, Kyowa Hakko KT-5594, Kyowa Hakko KT- 6149, American Cyanamid LL-D49194, Meiji Seika ME 2303, menogaril, mitomycin, mitomycinC, mitoxantrone, SmithKline M-TAG, neoenactin, Nippon Kayaku NK-313, Nippon Kayaku NKT- 01, SRI International NSC-357704, oxalysine, oxaunomycin, peplomycin, pilatin, pirarubicin, plicamycin (mithramycin) , porothramycin, pyrindanycin A, Tobishi RA-I, rapamycin, rhizoxin, rodorubicin, sibanomicin, siwenmycin, Sumitomo SM- 5887, Snow Brand SN-706, Snow Brand SN-07, sorangicin-A, sparsomycin, SS Pharmaceutical SS-21020, SS Pharmaceutical SS-7313B, SS Pharmaceutical SS-9816B, steffimycin B, Taiho 4181-2, talisomycin, Takeda TAN-868A, terpentecin, thrazine, tricrozarin A, Upjohn U-73975, Kyowa Hakko UCN-10028A, Fujisawa WF-3405, Yoshitomi Y-25024 and zorubicin. A fourth family of antineoplastic agents which may be used in combination with compounds of the present invention consists of a miscellaneous families of antineoplastic agents, including tubulin interacting agents, topoisomerase II inhibitors, topoisomerase I inhibitors and hormonal agents, selected from, but not limited to, the group consisting of α-carotene, α-difluoromethyl-arginine, acitretin, Biotec AD-5, Kyorin AHC-52, alstonine, amonafide, amphethinile, amsacrine, Angiostat, ankinomycin, anti- neoplaston AlO, antineoplaston A2, antineoplaston A3, antineoplaston A5, antineoplaston AS2-1, Henkel APD, aphidicolin glycinate, asparaginase, Avarol, baccharin, batracylin, benfluron, benzotript, Ipsen-Beaufour BIM-23015, bisantrene, Bristol-Myers BMY-40481, Vestar boron-10, bromofosfamide, Wellcome BW-502, Wellcome BW-773, caracemide, carmethizole hydrochloride, Ajinomoto CDAF, chlorsulfaquinoxalone, Chemes CHX-2053, Chemex CHX-100, Warner-Lambert CI-921, Warner-Lambert CI-937, Warner-Lambert CI-941, Warner-Lambert CI-958, clanfenur, claviridenone, ICN compound 1259, ICN compound 4711, Contracan, Yakult Honsha CPT-Il, crisnatol, curaderm, cytochalasin B, cytarabine, cytocytin, Merz D-609, DABIS maleate, dacarbazine, datelliptinium, didemnin-B, dihaematoporphyrin ether, dihydrolenperone, dinaline, distamycin, Toyo Pharmar DM-341, Toyo Pharmar DM-75, Daiichi Seiyaku DN-9693, docetaxel elliprabin, elliptinium acetate, Tsumura EPMTC, the epothilones, ergotamine, etoposide, etretinate, fenretinide, Fujisawa FR-57704, gallium nitrate, genkwadaphnin, Chugai GLA-43, Glaxo GR-63178, grifolan NMF-5N, hexadecylphosphocholine, Green Cross HO-221, homoharringtonine, hydroxyurea, BTG ICRF-187, ilmofosine, isoglutamine, isotretinoin, Otsuka JI-36, Ramot K-477, Otsuak K-76COONa, Kureha Chemical K-AM, MECT Corp KI-8110, American Cyanamid L-623, leukoregulin, lonidamine, Lundbeck LU-23-112, Lilly LY-186641, NCI (US) MAP, marycin, Merrel Dow MDL-27048, Medco MEDR-340, merbarone, merocyanlne derivatives, methylanilinoacridine, Molecular Genetics MGI- 136, minactivin, mitonafide, mitoquidone mopidamol, motretinide, Zenyaku Kogyo MST-I6, N- (retinoyl)amino acids, Nisshin Flour Milling N-021, N-acylated-dehydroalanines, nafazatrom, Taisho NCU-190, nocodazole derivative, Normosang, NCI NSC-145813, NCI NSC-361456, NCI NSC-604782, NCI NSC-95580, ocreotide, Ono ONO-112, oquizanocine, Akzo Org-10172, natural antimitotic drugs such as paclitaxel, pancratistatin, pazelliptine, Warner-Lambert PD-111707,
Warner-Lambert PD-115934, Warner-Lambert PD-131141, Pierre Fabre PE-1001, ICRT peptide D, piroxantrone, polyhaematoporphyrin, polypreic acid, Efamol porphyrin, ppipodophylotoxins such as etoposide and teniposide, probimane, procarbazine, proglumide, Invitron protease nexin I, Tobishi RA-700, razoxane, Sapporo Breweries RBS, restrictin-P, retelliptine, retinoic acid, Rhone-Poulenc RP- 49532, Rhone-Poulenc RP-56976, SmithKline SK&F-104864, Sumitomo SM-108, Kuraray SMANCS, SeaPharm SP-I0094, spatol, spirocyclopropane derivatives, spirogermanium, Unimed, SS Pharmaceutical SS-554, strypoldinone, Stypoldione, Suntory SUN 0237, Suntory SUN 2071, superoxide dismutase, taxotere, Toyama T-506, Toyama T-680, taxol, Teijin TEI-0303, teniposide, thaliblastine, Eastman Kodak TJB-29, tocotrienol, topotecan, Topostin, Teijin TT-82, Kyowa Hakko UCN-01, Kyowa Hakko UCN-1028, ukrain, Eastman Kodak USB-006, vinca alkaloids including vinblastine (VLB) , vinblastine sulfate, vincristine, vindesine, vinestramide, vinorelbine, vintriptol and vinzolidine, withanolides, Yamanouchi YM-534, enzymes such as L-asparaginase, biological response modifiers such as G-CSF and GM-CSF, miscellaneous agents including platinium coordination complexes such as cisplatin and carboplatin, anthracenediones such as mitoxantrone, substituted urea such as hydroxyurea, methylhydrazine derivatives including N-methylhydrazine (MIH) and procarbazine, adrenocortical suppressants such as mitotane (o,p'-DDD) and aminoglutethimide, hormones and antagonists including adrenocorticosteroid antagonists such as prednisone and equivalents, dexamethasone and aminoglutethimide, progestin such as hydroxyprogesterone caproate, medroxyprogesterone acetate and megestrol acetate, estrogen such as diethylstilbestrol and ethinyl estradiol equivalents, antiestrogen such as tamoxifen, androgens including testosterone propionate and fluoxymesterone/equivalents, antiandrogens such as flutamide, gonadotropin-releasing hormone analogs and leuprolide, and non-steroidal antiandrogens such as flutamide. Alternatively, the compounds of the present invention may also be used in co-therapies with other miscellaneous anti-neoplastic agents, such as acemannan, aclarubicin, aldesleukin, alemtuzumab, alitretinoin, altretamine, amifostine, aminolevulinic acid, amrubicin, amsacrine, anagrelide, anastrozole, ANCER, ancestim, ARGLABIN, arsenic trioxide, BAM 002 (Novelos) , bexarotene, bicalutamide, broxuridine, capecitabine, celmoleukin, cetrorelix, cladribine, clotrimazole, cytarabine ocfosfate, DA 3030 (Dong-A) , daclizumab, denileukin diftitox, deslorelin, dexrazoxane, dilazep, docetaxel, docosanol, doxercalciferol, doxifluridine, doxorubicin, bromocriptine, carmustine, cytarabine, fluorouracil, HIT diclofenac, interferon alfa, daunorubicin, tretinoin, edelfosine, edrecolomab, eflornithine, emitefur, epirubicin, epoetin beta, etoposide phosphate, exemestane, exisulind, fadrozole, filgrastim, finasteride, fludarabine phosphate, formestane, fotemustine, gallium nitrate, gemcitabine, gemtuzumab zogamicin, gimeracil/oteracil/tegafur combination, glycopine, goserelin, heptaplatin, human chorionic gonadotropin, human fetal alpha fetoprotein, ibandronic acid, idarubicin, (imiquimod, interferon alfa, interferon alfa, natural, interferon alfa-2, interferon alfa-2a, interferon alfa-2b, interferon alfa-Nl, interferon alfa-n3, interferon alfacon-1, interferon alpha, natural, interferon beta, interferon beta-la, interferon beta-lb, interferon gamma, natural interferon gamma-Ia, interferon gamma-Ib, interleukin-1 beta, iobenguane, irinotecan, irsogladine, lanreotide, LC 9018 (Yakult) , leflunomide, lenograstim, lentinan sulfate, letrozole, leukocyte alpha interferon, leuprorelin, levamisole + fluorouracil, liarozole, lobaplatin, lonidamine, lovastatin, masoprocol, melarsoprol, metoclopramide, mifepristone, miltefosine, mirimostim, mismatched double stranded RNA, mitoguazone, mitolactol, mitoxantrone, molgramostim, nafarelin, naloxone + pentazocine, nartograstim, nedaplatin, nilutamide, noscapine, novel erythropoiesis stimulating protein, NSC 631570 octreotide, oprelvekin, osaterone, oxaliplatin, paclitaxel, pamidronic acid, pegaspargase, peginterferon alfa-2b, pentosan polysulfate sodium, pentostatin, picibanil, pirarubicin, rabbit antithymocyte polyclonal antibody, polyethylene glycol interferon alfa-2a, porfimer sodium, raloxifene, raltitrexed, rasburicase, rhenium Re 186 etidronate, RII retinamide, rituximab, ritromurtide, samarium (153 Sm) lexidronam, sargramostim, sizofiran, sobuzoxane, sonermin, strontium-89 chloride, suramin, tasonermin, tazarotene, tegafur, temoporfin, temozolomide, teniposide, tetrachlorodecaoxide, thalidomide, thymalfasin, thyrotropin alfa, topotecan, toremifene, tositumomab-iodine 131, altreptin, trastuzumab, treosulfan, tretinoin, trilostane, trimetrexate, triptorelin, tumor necrosis factor alpha, natural, ubenimex, bladder cancer vaccine, Maruyama vaccine, melanoma lysate vaccine, valrubicin, verteporfin, vinorelbine, VIRULIZIN, zinostatin stimalamer, or zoledronic acid; abarelix,- AE 941 (Aeterna) , ambamustine, antisense oligonucleotide, bcl-2 (Genta) , APC 8015 (Dendreon) , cetuximab, decitabine, dexaminoglutethimide, diaziguone, EL 532 (Elan) , EM 800 (Endorecherche) , eniluracil, etanidazole, fenretinide, filgrastim SDOl (Amgen) , fulvestrant, galocitabine, gastrin 17 immunogen, HLA-B7 gene therapy (Vical) , granulocyte macrophage colony stimulating factor, histamine dihydrochloride, ibritumomab tiuxetan, ilomastat, IM 862 (Cytran) , interleukin-2, iproxifene, LDI 200 (Milkhaus) , leridistim, lintuzumab, CA 125 MAb (Biomira) , cancer MAb (Japan Pharmaceutical Development) , HER-2 and Fc MAb (Medarex) , idiotypic 105AD7 MAb (CRC Technology) , idiotypic CEA MAb (Trilex) , LYM-1-iodine 131 MAb (Techniclone) , polymorphic epithelial mucin-yttrium 90 MAb (Antisoma) , marimastat, menogaril, mitumomab, motexafin gadolinium, MX 6 (Galderma) , nelarabine, nolatrexed, P 30 protein, pegvisomant, pemetrexed, porfiromycin, prinomastat, RL 0903 (Shire) , rubitecan, satraplatin, sodium phenylacetate, sparfosic acid, SRL 172 (SR Pharma) , SU 5416 (SUGEN), TA 077 (Tanabe) , tetrathiomolybdate, thaliblastine, thrombopoietin, tin ethyl etiopurpurin, tirapazamine, cancer vaccine (Biomira) , melanoma vaccine (New York University) , melanoma vaccine (Sloan Kettering Institute) , melanoma oncolysate vaccine (New York Medical College) , viral melanoma cell lysates vaccine (Royal Newcastle Hospital) , or valspodar.
Alternatively, the compounds of the present invention may also be used in co-therapy with anti-tumor and anti- angiogenic agents (both administered as cancer therapy agents) . Exemplary anti-tumor agents include HERCEPTIN™ (trastuzumab) , which may be used to treat breast cancer and other forms of cancer, and RITUXAN™ (rituximab) , ZEVALIN™ (ibritumomab tiuxetan) , and LYMPHOCIDE™ (epratuzumab) , which may be used to treat non-Hodgkin's lymphoma and other forms of cancer, GLEEVAC™ which may be used to treat chronic myeloid leukemia and gastrointestinal stromal tumors, and BEXXAR™ (iodine 131 tositumomab) which may be used for treatment of non-Hodgkins's lymphoma.
Exemplary anti-angiogenic agents that may be used in combination with compounds of the present invention include ERBITUX™ (IMC-C225), KDR (kinase domain receptor) inhibitory agents (e.g., antibodies and antigen binding regions that specifically bind to the kinase domain receptor) , anti-VEGF agents (e.g., antibodies or antigen binding regions that specifically bind VEGF, or soluble VEGF receptors or a ligand binding region thereof) such as AVASTIN™ or VEGF- TRAPIM, and anti-VEGF receptor agents (e.g., antibodies or antigen binding regions that specifically bind thereto) ,
EGFR inhibitory agents (e.g., antibodies or antigen binding regions that specifically bind thereto) such as ABX-EGF (panitumumab) , IRESSA™ (gefitinib) , TARCEVA™ (erlotinib) , anti-Angl and anti-Ang2 agents (e.g., antibodies or antigen binding regions specifically binding thereto or to their receptors, e.g., Tie2/Tek) , and anti-Tie-2 kinase inhibitory agents (e.g., antibodies or antigen binding regions that specifically bind thereto) . The pharmaceutical compositions of the present invention can also include one or more agents (e.g., antibodies, antigen binding regions, or soluble receptors) that specifically bind and inhibit the activity of growth factors, such as antagonists of hepatocyte growth factor (HGF, also known as Scatter Factor) , and antibodies or antigen binding regions that specifically bind its receptor "c-met".
Other anti-angiogenic agents that may be used in combination with compounds of the present invention include Campath, IL-8, B-FGF, Tek antagonists (Ceretti et al. , U.S. Publication No. 2003/0162712; U.S. Pat. No. 6,413,932), anti-TWEAK agents (e.g., specifically binding antibodies or antigen binding regions, or soluble TWEAK receptor antagonists; see, Wiley, U.S. Pat. No. 6,727,225), ADAM distintegrin domain to antagonize the binding of integrin to its ligands (Fanslow et al., U.S. Publication No. 2002/0042368) , specifically binding anti-eph receptor and/or anti-ephrin antibodies or antigen binding regions (U.S. Pat. Nos. 5,981,245; 5,728,813; 5,969,110; 6,596,852; 6,232,447; 6,057,124 and patent family members thereof), and anti-PDGF- BB antagonists (e.g., specifically binding antibodies or antigen binding regions) as well as antibodies or antigen binding regions specifically binding to PDGF-BB ligands, and PDGFR kinase inhibitory agents (e.g., antibodies or antigen binding regions that specifically bind thereto) .
Additional anti-angiogenic/anti-tumor agents that may be used in combination with compounds of the present invention include: SD-7784 (Pfizer, USA); cilengitide. (Merck KGaA, Germany, EPO 770622); pegaptanib octasodium, (Gilead Sciences, USA); Alphastatin, (BioActa, UK),- M-PGA, (Celgene, USA, US 5712291); ilomastat, (Arriva, USA, US 5892112); emaxanib, (Pfizer, USA, US 5792783); vatalanib, (Novartis, Switzerland) ; 2-methoxyestradiol, (EntreMed, USA) ; TLC ELL- 12, (Elan, Ireland); anecortave acetate, (Alcon, USA); alpha-Dl48 Mab, (Amgen, USA); CEP-7055, (Cephalon, USA); anti-Vn Mab, (Crucell, Netherlands) DAC:antiangiogenic, (ConjuChem, Canada) ; Angiocidin, (InKine Pharmaceutical, US2005/025800
A-917 - 58 -
USA); KM-2550, (Kyowa Hakko, Japan); SU-0879, (Pfizer, USA); CGP-79787, (Novartis, Switzerland, EP 970070); ARGENT technology, (Ariad, USA) ; YIGSR-Stealth, (Johnson & Johnson, USA) ; fibrinogen-E fragment, (BioActa, UK) ; angiogenesis inhibitor, (Trigen, UK); TBC-1635, (Encysive
Pharmaceuticals, USA); SC-236, (Pfizer, USA); ABT-567, (Abbott, USA) ; Metastatin, (EntreMed, USA) ; angiogenesis inhibitor, (Tripep, Sweden) ,• maspin, (Sosei, Japan) ; 2- methoxyestradiol, (Oncology Sciences Corporation, USA) ; ER- 68203-00, (IVAX, USA); Benefin, (Lane Labs, USA); Tz-93, (Tsumura, Japan); TAN-1120, (Takeda, Japan); FR-111142, (Fujisawa, Japan, JP 02233610); platelet factor 4, (RepliGen, USA, EP 407122) ; vascular endothelial growth factor antagonist, (Borean, Denmark); cancer therapy, (University of South Carolina, USA) ; bevacizumab (plNN) ,
(Genentech, USA) ; angiogenesis inhibitors, (SUGEN, USA) ; XL 784, (Exelixis, USA); XL 647, (Exelixis, USA); MAb, alpha5beta3 integrin, second generation, (Applied Molecular Evolution, USA and Medlmmune, USA) ; gene therapy, retinopathy, (Oxford BioMedica, UK) ; enzastaurin hydrochloride (USAN), (Lilly, USA); CEP 7055, (Cephalon, USA and Sanofi-Synthelabo, France); BC 1, (Genoa Institute of Cancer Research, Italy) ; angiogenesis inhibitor, (Alchemia, Australia); VEGF antagonist, (Regeneron, USA); rBPI 21 and BPl-derived antiangiogenic, (XOMA, USA); PI 88, (Progen,
Australia) ; cilengitide (plNN) , (Merck KGaA, German; Munich Technical University, Germany, Scripps Clinic and Research Foundation, USA); cetuximab (INN), (Aventis, France); AVE 8062, (Ajinomoto, Japan); AS 1404, (Cancer Research Laboratory, New Zealand); SG 292, (Telios, USA); Endostatin, (Boston Childrens Hospital, USA); ATN 161, (Attenuon, USA); ANGIOSTATIN, (Boston Childrens Hospital, USA); 2- methoxyestradiol, (Boston Childrens Hospital, USA); ZD 6474, (AstraZeneca, UK); ZD 6126, (Angiogene Pharmaceuticals, UK); PPI 2458, (Praecis, USA); AZD 9935, (AstraZeneca, UK); AZD 2171, (AstraZeneca, UK); vatalanib (plNN) , (Novartis, Switzerland and Schering AG, Germany) ; tissue factor pathway inhibitors, (EntreMed, USA) ; pegaptanib (Pinn) , (Gilead Sciences, USA); xanthorrhizol, (Yonsei University, South Korea); vaccine, gene-based, VEGF-2, (Scripps Clinic and Research Foundation, USA); SPV5.2, (Supratek, Canada); SDX 103, (University of California at San Diego, USA); PX 478, (ProlX, USA); METASTATIN, (EntreMed, USA); troponin I, (Harvard University, USA); SU 6668, (SUGEN, USA); OXI 4503, (OXiGENE, USA); o-guanidines, ( Dimensional Pharmaceuticals, USA) ; motuporamine C, (British Columbia University, Canada) ,- CDP 791, (Celltech Group, UK); atiprimod (pINN) , (GlaxoSmithKline, UK),- E 7820, (Eisai, Japan); CYC 381, (Harvard University, USA); AE 941, (Aeterna, Canada); vaccine, angiogenesis, (EntreMed, USA); urokinase plasminogen activator inhibitor, (Dendreon, USA) ; oglufanide (pINN) , (Melmotte, USA); HIF-lalfa inhibitors, (Xenova, UK),- CEP 5214, (Cephalon, USA); BAY RES 2622, (Bayer, Germany); Angiocidin, (InKine, USA); A6, (Angstrom, USA); KR 31372, (Korea Research Institute of Chemical Technology, South Korea); GW 2286, (GlaxoSmithKline, UK); EHT 0101, (ExonHit, France); CP 868596, (Pfizer, USA); CP 564959, (OSI, USA); CP 547632, (Pfizer, USA); 786034, (GlaxoSmithKline, UK); KRN 633, (Kirin Brewery, Japan); drug delivery system, intraocular, 2-methoxyestradiol, (EntreMed, USA) ; anginex, (Maastricht University, Netherlands, and Minnesota
University, USA); ABT 510, (Abbott, USA); AAL 993, (Novartis, Switzerland); VEGI, (ProteomTech, USA); tumor necrosis factor-alpha inhibitors, (National Institute on
Aging, USA); SU 11248, (Pfizer, USA and SUGEN USA); ABT 518, (Abbott, USA); YH16, (Yantai Rongchang, China); S-3APG , (Boston Childrens Hospital, USA and EntreMed, USA); MAb,
KDR, (imClone Systems, USA); MAb, alpha5 betal, (Protein Design, USA) ; KDR kinase inhibitor, (Celltech Group, UK, and
Johnson & Johnson, USA); GFB 116, (South Florida University, USA and Yale University, USA); CS 706, (Sankyo, Japan); combretastatin A4 prodrug, (Arizona State University, USA) ; chondroitinase AC, (IBEX, Canada); BAY RES 2690, (Bayer, Germany); AGM 1470, (Harvard University, USA, Takeda, Japan, and TAP, USA); AG 13925, (Agouron, USA); Tetrathiomolybdate, (University of Michigan, USA); GCS 100, (Wayne State University, USA) CV 247, (Ivy Medical, UK); CKD 732, (Chong Kun Dang, South Korea) ; MAb, vascular endothelium growth factor, (Xenova, UK) ; irsogladine (INN) , (Nippon Shinyaku, Japan); RG 13577, (Aventis, France); WX 360, (Wilex, Germany); squalamine (pINN) , (Genaera, USA); RPI 4610, (Sirna, USA) ; cancer therapy, (Marinova, Australia) ; heparanase inhibitors, (InSight, Israel); KL 3106, (Kolon, South Korea); Honokiol, (Emory University, USA); ZK CDK, (Schering AG, Germany) ; ZK Angio, (Schering AG, Germany) ; ZK 229561, (Novartis, Switzerland, and Schering AG, Germany) ; XMP 300, (XOMA, USA); VGA 1102, (Taisho, Japan); VEGF receptor modulators, (Pharmacopeia, USA) ; VE-cadherin-2 antagonists , (ImClone Systems, USA) ; Vasostatin, (National Institutes of Health, USA) ;vaccine, Flk-1, (ImClone Systems, USA); TZ 93, (Tsumura, Japan); TumStatin, (Beth Israel Hospital, USA) ; truncated soluble FLT 1 (vascular endothelial growth factor receptor 1) , (Merck & Co, USA) ; Tie-2 ligands, (Regeneron, USA); and, thrombospondin 1 inhibitor, (Allegheny Health, Education and Research Foundation, USA) .
Cancer therapy agents that may be used in combination with compounds of the present invention also include polypeptides (peptidal or peptide-like cancer therapy agents) , which selectively induce apoptosis in tumor cells, including, but not limited to, the TNF-related polypeptide TRAIL. Certain cancer therapy agents include, but are not limited to: thalidomide and thalidomide analogues (N- (2,6- dioxo-3-piperidyl)phthalimide) ; tecogalan sodium (sulfated polysaccharide peptidoglycan) ; TAN 1120 (8-acetyl-7, 8, 9, 10- tetrahydro-6, 8, ll-trihydroxy-l-methoxy-10- [ [octahydro-5- hydroxy-2- (2-hydroxypropyl) -4, 10-dimethylpyrano[3,4-d]- 1, 3, 6-dioxazocin-8-yl]oxy] -5, 12-naphthacenedione) ; suradista (7,7 '- [carbonylbis[imino(l-methyl-lH-pyrrole-4, 2- diyl)carbonylimino(1-methyl-lH- pyrrole-4, 2- diyl)carbonylimino] ]bis-l,3-naphthalenedisulfonic acid tetrasodium salt); SU 302; SU 301; SU 1498 ( (E) -2-cyano-3- [4-hydroxy-3,5-bis (1-methylethyl)phenyl] -N- (3-phenylpropyl) - 2-pro penamide) ; SU 1433 (4- (6,7-dimethyl-2-quinoxalinyl)- 1,2-benzenediol) ; ST 1514; SR 25989,-soluble Tie-2; SERM derivatives, Pharmos; semaxanib (pINN) (3-[ (3,5-dimethyl-lH- pyrrol-2-yl)methylene]-l,3-dihydro-2H-indol-2-one) ; S 836; RG 8803; RESTIN; R 440 (3- (l-methyl-lH-indol-3-yl)-4- (1- methyl-6-nitro-lH-indol-3-yl) -lH-pyrrole-2,5-dione) ; R
123942 (1- [6- (1, 2,4-thiadiazol-5-yl) -3-pyridazinyl]-N- [3- (trifluoromethyl)phenyl]-4-piperidinamine) ; prolyl hydroxylase inhibitor; progression elevated genes; prinomastat (INN) ( (S)-2, 2-dimethyl-4-[ [p- (4- pyridyloxy)phenyl]sulphonyl]-3-thiomorpholinecarbohyd roxamic acid); NV 1030; NM 3 (8-hydroxy-6-methoxy-alpha- methyl-l-oxo-lH-2-benzopyran-3-acetic acid); NF 681; NF 050; MIG; METH 2; METH 1; manassantin B (alpha- [1- [4- [5- [4- [2- (3,4-dimethoxyphenyl) -2-hydroxy-l-methylethoxy]-3- methoxyphenyl]tetrahydro-3,4-dimethyl-2-furanyl]-2- methoxyphenoxy]ethyl] -1,3-benzodioxole-5-methanol) ; KDR monoclonal antibody; alpha5beta3 integrin monoclonal antibody; LY 290293 (2-amino-4- (3-pyridinyl) -4H-naphtho[l,2- b]pyran-3-carbonitrile) ; KP 0201448; KM 2550; integrin- specific peptides; INGN 401; GYKI 66475; GYKI 66462; greenstatin (101-354-plasminogen (human) ) ; gene therapy for rheumatoid arthritis, prostate cancer, ovarian cancer, glioma, endostatin, colorectal cancer, ATF BTPI, antiangiogenesis genes, angiogenesis inhibitor, or angiogenesis; gelatinase inhibitor, FR 111142 (4,5- dihydroxy-2-hexenoic acid 5-methoxy-4- [2-methyl-3- (3-methyl- 2-butenyl)oxiranyl]-l-oxaspiro[2.5]oct-6-yl ester) ; forfenimex (pINN) (S) -alpha-amino-3-hydroxy-4- (hydroxymethyl)benzeneacetic acid) ; fibronectin antagonist (1-acetyl-L-prolyl-L-histidyl-L-seryl-L-cysteinyl-L- aspartamide) ; fibroblast growth factor receptor inhibitor; fibroblast growth factor antagonist; FCE 27164 [I1I'- [carbonylbis[imino(l-methyl-lH-pyrrole-4,2- diyl)carbonylimino(1-methyl-IH- pyrrole-4,2- diyl)carbonylimino] ]bis-l,3, 5-naphthalenetrisulfonic acid hexasodium salt); FCE 26752 (8, 8 ' -[carbonylbis[imino(1- methyl-lH-pyrrole-4,2-diyl)carbonylimino(1-methyl-IH- pyrrole-4, 2-diyl)carbonylimino] ]bis-l,3,6- naphthalenetrisulfonic acid) ; endothelial monocyte activating polypeptide II; VEGFR antisense oligonucleotide; anti-angiogenic and trophic factors; ANCHOR angiostatic agent; endostatin; DeI-I angiogenic protein,- CT 3577; contortrostatin,- CM 101,- chondroitinase AC; CDP 845,- CanStatin,- BST 2002; BST 2001; BLS 0597; BIBF 1000;
ARRESTIN; apomigren (1304-1388-type XV collagen (human gene COL15A1 alphal-chain precursor)),- angiopoietin 2,- angioinhibin; aaATIII,- A 36,- 9alpha- fluoromedroxyprogesterone acetate ( (6-alpha) -17- (acetyloxy) - 9-fluoro-6~methyl-pregn-4-ene-3, 20-dione) ; 2-methyl-2- phthalimidino-glutaric acid (2- (1,3-dihydro-l-oxo-2H- isoindol-2-yl) -2-methylpentanedioic acid); Yttrium 90 labelled monoclonal antibody BC-I; Semaxanib (3- (4,5- Dimethylpyrrol-2-ylmethylene)indolin-2-one) (C15 H14 N2 O); PI 88 (phosphomannopentaose sulfate) ; Alvocidib (4H-1-
Benzopyran-4-one, 2- (2-chlorophenyl) -5,7-dihydroxy-8- (3- hydroxy-1- methyl-4-piperidinyl) - cis-(-)-) (C21 H20 Cl N 05); E 7820,- SU 11248 (5- [3-Fluoro-2-oxo-l, 2-dihydroindol- (3Z) -ylidenemethyl]-2,4-dimethyl-lH- pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide) (C22 H27 F N4 02); Sgualamine (Cholestane-7,24-diol, 3-[[3-[(4- aminobutyl)aminopropyl]amino]-, 24- (hydrogen sulfate), (3.beta. ,5.alpha. ,7.alpha.)-) (C34 H65 N3 05 S),- Eriochrome Black T; AGM 1470 (Carbamic acid, (chloroacetyl) -, 5- methoxy-4-[2-methyl-3-(3-methyl-2- butenyl) oxiranyl] -1- oxaspiro[2,5] oct-6-yl ester, [3R-[3alpha, 4alpha(2R, 3R), 5beta, 6beta] ] ) (C19 H28 Cl N 06); AZD 9935; BIBF 1000; AZD 2171; ABT 828; KS-interleukin-2,- TEK/Fc; Uteroglobin; A 6; NSC 639366 (1- [3- (Diethylamino) -2-hydroxypropylamino]-4- (oxyran-2- ylmethylamino)anthraquinone fumerate) (C24 H29 N3 04 . C4 H4 04); ISV 616; anti-ED-B fusion proteins; HUI 77; Troponin I; BC-I monoclonal antibody; SPV 5.2; ER 68203; CKD 731 (3- (3,4,5-Trimethoxyphenyl)-2 (E) -propenoic acid (3R,4S,5S,6R)-4-[2(R)- methyl-3 (R) -3 (R) - (3-methyl-2- butenyl)oxiran-2-yl]-5-methoxy-l- oxaspiro[2.5]oct-6-yl ester) (C28 H38 08); IMC-IClI; aaATIII; SC 7; CM 101; Angiocol; Kringle 5; CKD 732 (3- [4- [2- (Dimethylamino)ethoxy]phenyl]-2 (E) -propenoic acid) (C29 H41 N 06); U 995; Canstatin,- SQ 885; CT 2584 (1-[11-
(Dodecylamino) -10-hydroxyundecyl]-3, 7-dimethylxanthine) (C30 H55 N5 03); Salmosin,- EMAP II; TX 1920 (l-(4- Methylpiperazino) -2- (2-nitro-lH-l-imidazoyl) -1-ethanone) (ClO H15 N5 03); Alpha-v Beta-x inhibitor,- CHIR 11509 (N-(I- Propynyl)glycyl- [N- (2-naphthyl) ]glycyl- [N- (carbamoylmethyl) ]glycine bis (4- methoxyphenyDmethylamide) (C36 H37 N5 06); BST 2002; BST 2001; B 0829; FR 111142; and 4,5-Dihydroxy-2 (E) -hexenoic acid (3R,4S, 5S, 6R) -4- [1 (R) ,2 (R) -epoxy-1,5- dimethyl-4- hexenyl]-5-methoxy-l-oxaspiro[2.5]octan-6-yl ester (C22 H34 07) .
Exemplary cancers include, but are not limited to, breast cancer, colorectal cancer, gastric carcinoma, glioma, head and neck squamous cell carcinoma, hereditary and sporadic papillary renal carcinoma, leukemia, lymphoma, Li- Fraumeni syndrome, malignant pleural mesothelioma, melanoma, multiple myeloma, non-small cell lung carcinoma, osteosarcoma, ovarian cancer, pancreatic cancer, prostate cancer, small cell lung cancer, synovial sarcoma, thyroid carcinoma, and transitional cell carcinoma of urinary bladder.
Alternatively, the compounds of the present invention may also be used in co-therapies with other anti-neoplastic agents, such as other kinase inhibitors including p38 inhibitors and CDK inhibitors, TNP inhibitors, matrix metalloproteinase inhibitors (MMP) , COX-2 inhibitors including celecoxib, rofecoxib, parecoxib, valdecoxib, and etoricoxib, NSAID's, SOD mimics, C-met inhibitors or αvβ3 inhibitors.
In some embodiments, the invention includes administration of, in addition to a Tek antagonist, one or more chemotherapeutic agents in combination with the compound(s) or compositions of the invention. Suitable chemotherapeutic agents, including various soluble forms thereof, include, without limitation, Fit3 ligand, CD40 ligand, interleukin-2, interleukin-12, 4-lBB ligand, anti- 4-lBB antibodies, TNF antagonists and TNF receptor antagonists including TNFR/Fc, TWEAK antagonists and TWEAK- R antagonists including TWEAK-R/Fc, TRAIL, VEGF antagonists including anti-VEGF antibodies, VEGF receptor (including VEGF-Rl and VEGF-R2, also known as Fltl and Flkl or KDR) antagonists, and CD148 (also referred to as DEP-I, ECRTP, and PTPRJ, see Takahashi et al. , J. Am. Soc. Nephrol. 10:2135-45, 1999) agonists.
In other embodiments, compounds or compositions of the invention may be combined with agents disclosed in the following patents and publications: U.S. Patent Nos. 5521184, 5747498, 5770599, 5990141, 6235764, 6258812, 6515004, 6630500, 6713485; U.S. Patent Publication NO.US20030105091; and PCT application Nos: WO01/37820,WO01/32651, WO0268406, WO0266470, WO0255501, WO0405279, WO0407481, WO0407458, WO0409784, WO0259110, WO9945009, WO9835958, WO0059509, WO9961422, WO0012089 and WO0002871; as well as the following specific compounds: N- (4-chlorophenyl) -4- (4-pyridinylmethyl) -1- phthalazinamine; 4- [4- [ [ [ [4-chloro-3-
(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N- methyl-2-pyridinecarboxamide;
N-[2- (diethylamino)ethyl]-5- [ (5-fluoro-1, 2-dihydro-2-oxo-3H- indol-3-ylidene)methyl]-2,4-dimethyl-lH-pyrrole-3- carboxamide;
3-[ (4-bromo-2, 6-difluorophenyl)methoxy] -5-[ [ [ [4- (1- pyrrolidinyl)butyl]amino]carbonyl]amino] -4- isothiazolecarboxamide; N-(4-bromo-2-fluorophenyl) -6-methoxy-7-[ (l-methyl-4- piperidinyl)methoxy]-4-quinazolinamine;
3-[5,6,7,13-tetrahydro-9-[ (1-methylethoxy)methyl]-5-oxo-12H- indeno[2, l-a]pyrrolo[3,4-c]carbazol-12-yl]propyl ester N,N- dimethyl-glycine; N- [5- [ [[5-(l,l-dimethylethyl)-2-oxazolyl]methyl]thio]-2- thiazolyl]-4-piperidinecarboxamide;
N- [3-chloro-4- [ (3-fluorophenyl)methoxy]phenyl]-6- [5- [ [ [2-
(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4- quinazo1inamine; 4- [ (4-Methyl-l-piperazinyl)methyl]-N- [4-methyl-3- [ [4- (3- pyridinyl) -2-pyrimidinyl]amino]-phenyl]benzamide;
JW- (3-chloro-4-fluorophenyl) -7-methoxy-6- [3- (4- morpholinyl)propoxy]-4-quinazolinamine;
N- (3-ethynylphenyl) -6,7-bis (2-methoxyethoxy) -4- quinazolinamine,-
N- (3- ( ( ( (2R) -l-methyl-2-pyrrolidinyl)methyl) oxy) -5-
(trifluoromethyl)phenyl) -2- ( (3- (1, 3-oxazol-5- yl)phenyl)amino) -3-pyridinecarboxamide;
2-( ( (4-fluorophenyl)methyl)amino) -N- (3-( ( ( (2R) -l-methyl-2- pyrrolidinyl)methyl)oxy) -5- (trifluoromethyl)phenyl) -3- pyridinecarboxamide;
N- [3- (Azetidin-3-ylmethoxy)-5-trifluoromethyl-phenyl]-2- (4- fluoro-benzylamino)-nicotinamide; 6-fluoro-N- (4- (1-methylethyl)phenyl) -2- ( (4- pyridinylmethyl)amino) -3-pyridinecarboxamide;
2-( (4-pyridinylmethyl)amino)-N- (3-( ( (2S)-2- pyrrolidinylmethyl)oxy) -5- (trifluoromethyl)phenyl) -3- pyridinecarboxamide;
N- (3- (1, 1-dimethylethyl)-lH-pyrazol-5-yl) -2- ( (4- pyridinylmethyl)amino) -3-pyridinecarboxamide;
N- (3,3-dimethyl-2,3-dihydro-l-benzofuran-6-yl) -2- ( (4- pyridinylmethyl)amino) -3-pyridinecarboxamide; N- (3- ( ( ( (2S) -l-methyl-2-pyrrolidinyl)methyl) oxy) -5-
(trifluoromethyl)phenyl) -2- ( (4-pyridinylmethyl)amino) -3- pyridinecarboxamide;
2-( (4-pyridinylmethyl)amino) -N- (3- ( (2-(l- pyrrolidinyl)ethyl)oxy)-4- (trifluoromethyl)phenyl)-3- pyridinecarboxamide;
N- (3,3-dimethyl-2,3-dihydro-lH-indol-6-yl) -2- ( (4- pyridinylmethyl)amino) -3-pyridinecarboxamide;
N- (4- (pentafluoroethyl)-3- ( ( (2S)-2- pyrrolidinylmethyl)oxy)phenyl)-2- ( (4-pyridinylmethyl)amino) - 3-pyridinecarboxamide;
N- (3- ( (3-azetidinylmethyl)oxy)-5- (trifluoromethyl)phenyl) -2-
( (4-pyridinylmethyl)amino) -3-pyridinecarboxamide;
N- (3- (4-piperidinyloxy) -5- (trifluoromethyl)phenyl) -2- ( (2- (3- pyridinyl)ethyl)amino) -3-pyridinecarboxamide; N- (4,4-dimethyl-l,2,3 ,4-tetrahydro-isoquinolin-7-yl) -2- (IH- indazol-6-ylamino) -nicotinamide;
2- (lH-indazol-6-ylamino)-N- [3- (l-methylpyrrolidin-2- ylmethoxy) -5-trifluoromethyl-phenyl]-nicotinamide;
N-[I- (2-dimethylamino-acetyl) -3,3-dimethyl-2,3-dihydro-lH- indol-6-yl] -2- (lH-indazol-6-ylamino) -nicotinamide;
2- (lH-indazol-6-ylamino) -N- [3- (pyrrolidin-2-ylmethoxy) -5- trifluoromethyl-phenyl]-nicotinamide;
N- (l-acetyl-3,3-dimethyl-2,3-dihydro-lH-indol-6-yl)-2- (IH- indazol-6-ylamino) -nicotinamide; N- (4, 4-dimethyl-l-oxo-l,2,3,4-tetrahγdro-isoquinolin-7-yl)- 2- (lH-indazol-6-γlamino) -nicotinamide; N- [4- (tert-butyl) -3- (3-piperidylpropyl)phenyl] [2- (IH- indazol-6-ylamino) (3-pyridyl) ]carboxamide; N- [5- (tert-butyl) isoxazol-3-yl] [2- (lH-indazol-6-ylamino) (3- pyridyl) ]carboxamide; and
N- [4- (tert-butyl)phenyl] [2- (lH-indazol-6-ylamino) (3- pyridyl) ]carboxamide.
Specific binding agents to a cancer therapy agent (s) may be administered with the cancer therapy agent, in conjunction with the compound, or composition, of the present invention. Binding agents may be administered prophylactically or therapeutically to prevent or mitigate the disease or condition in question. Included in the compounds of Formulas I and II are the pharmaceutically acceptable salts of the free-base compounds. The term "pharmaceutically-acceptable salts" embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases. As appreciated by those of ordinary skill in the art, salts may be formed from ionic associations, charge-charge interactions, covalent bonding, complexation, coordination, etc. The nature of the salt is not critical, provided that it is pharmaceutically acceptable. The term pharmaceutically-acceptable" when used with reference to a compound, including a salt or derivative, a carrier, excipient, adjuvant, and other ingredients used for formulation, is intended to refer to a form of the ingredient that is safe for administration. For example, a salt form of a compound of Formula I or of Formula II, which has been approved for mammalian use, via ingestion or by other administrative routes, by a governing body or regulatory agency, such as the Food and Drug Administration (FDA) of the United States, is pharmaceutically acceptable. Suitable pharmaceutically acceptable acid addition salts of compounds of Formulas I and II may be prepared from an inorganic acid or from an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, hydrofluoric, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include, without limitation, formic, acetic, adipic, butyric, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, mesylic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic) , methanesulfonic, ethanesulfonic, ethanedisulfonic, benzenesulfonic, pantothenic, 2-hydroxyethanesulfonic, toluenesulfonic, sulfanilic, cyclohexylaminosulfonic, camphoric, camphorsulfonic, digluconic, cyclopentanepropionic, dodecylsulfonic, glucoheptanoic, glycerophosphonic, heptanoic, hexanoic, 2-hydroxy-ethanesulfonic, nicotinic, 2- naphthalenesulfonic, oxalic, palmoic, pectinic, persulfuric, 2-phenylpropionic, picric, pivalic propionic, succinic, thiocyanic, undecanoic, stearic, algenic, β-hydroxybutyric, salicylic, galactaric and galacturonic acid. Suitable pharmaceutically-acceptable base addition salts of compounds of Formulas I and II include metallic salts, such as salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc, or salts made from organic bases including, without limitation, primary, secondary and tertiary amines, substituted amines including cyclic amines, such as caffeine, arginine, diethylamine, N-ethyl piperidine, histidine, glucamine, isopropylamine, lysine, morpholine, N- ethyl morpholine, piperazine, piperidine, triethylamine, disopropylethylamine and trimethy1amine. All of these salts may be prepared by conventional means from the corresponding compound of the invention by reacting, for example, the appropriate acid or base with the compound of Formulas I or II. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.
Examples of acids that may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, citric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, stearic and, salicylic acid, pamoic acid, gluconic acid, ethanesulfonic acid, methanesulfonic acid, toluenesulfonic acid, tartaric acid, fumaric acid, medronic acid, napsylic acid, maleic acid, succinic acid and citric acid. Other examples include salts with alkali metals or alkaline earth metals such as sodium, potassium, calcium or magnesium, or with organic bases. Preferred salts include hydrochloride, phosphate and edisylate.
In one embodiment of the invention, the compound of Formulas I or II is in the form of a salt, such as a hemi-, mono-, or di-salt complex, wherein the salt is selected from a benzenesulfonate salt, an ethanesulfonate salt, an ethanedisulfonate salt, a methanesulfonate salt, a p- toluenesulfonate salt, a phosphate salt, a hydrobromide salt, a nitrate salt, a hydrochloride salt, a citrate salt, a medronate salt, a tosylate salt, a maleate salt, a fumarate salt, a napsylate salt, a pamoate salt, a salicylate salt and a stearate salt.
Additional examples of such salts can be found in Berge et al., J. Pharm. Sci. , 66, 1 (1977) . Conventional methods may be used to form the salts. For example, a phosphate salt of a compound of the invention may be made by combining the desired compound free base in a desired solvent, or combination of solvents, with phosphoric acid in a desired stoichiometric amount, at a desired temperature, typically under mild heat between 40-80 2C (depending upon the boiling point of the solvent) . Generally, polar solvents such as alcohols (like EtOH) , DMF, DMSO, and the like are used to form salts, as is readily appreciated by those of ordinary skill in the art. The salt can be precipitated upon cooling (slow or fast) and may crystallize (i.e., if crystalline in nature) , as appreciated by those of ordinary skill in the art. (See Example 75 for instance) Further, hemi-, mono-, di, tri- and poly-salt forms of the compounds of the present invention are also contemplated herein. Similarly, hemi-, mono-, di, tri- and poly-hydrated forms of the compounds, salts and derivatives thereof, are also contemplated herein.
The present invention further comprises procedures for the preparation of a compound of Formulas I and II.
GENERAL SYNTHETIC PROCEDURES
The compounds of the invention can be synthesized according to the following procedures of Schemes 1-33, wherein the substituents are as defined for Formulas I and
II, above, except where further noted. Although schemes 1-33 illustrate procedures for preparing compounds of Formula I (amino-nicotinamides) , these schemes are also applicable as exemplary methods for the preparation of corresponding amino-benzamides of Formula II, which are described in more detail in the "Preparations" immediately following the General Synthetic Procedures.
Scheme 1
Figure imgf000072_0001
H2N R1
EDC
Figure imgf000072_0002
Substituted nicotinamides 3 can be prepared from the corresponding halo analogs 1 by the process outlined in Scheme 1. Substituted amino acids 2 are prepared from the corresponding chloro compounds 1 such as by reacting with an amine at a suitable temperature, such as about 800C. The acid 2 is coupled with an amine, preferably in the presence of a coupling agent such as EDC, to form the corresponding amide 3.
The amination process can be carried out as an Ullmann type reaction using a copper catalyst, such as copper[0] or a copper[I] compound such as copper[I]oxide, copper[I]bromide or copper[I]iodide in the presence of a suitable base (such as a metal carbonate, for example K2CO3 to neutralize the acid generated in the reaction.
This reaction is reviewed in Houben-Weyl "Methoden der Organischen Chemie", Band 11/1, page 32 -33, 1958, in Organic Reactions, 14, page 19-24, 1965 and by J. Lindley (1984) in Tetrahedron, 40, page 1433-1456. The amount of catalyst is typically in the range of 1 to 20 mole percent. The reaction is carried out in an inert, aprotic solvent such as an ether solvent (for example dimethoxyethane or dioxane) or an amide solvent (for example dimethylformamide or N- methylpyrrolidone) , under an inert atmosphere in the temperature range of 60-180 3C.
An alternative amination process involves using a Group VIII element, where the metal core of the catalyst should be a zero-valent transition metal, such as palladium or nickel, which has the ability to undergo oxidative addition to the aryl-halogen bond. The zero valent state of the metal may be generated in situ from the M[II] state. The catalyst complexes may include chelating ligands, such as alkyl, aryl or heteroaryl derivatives of phoshines or biphosphines, imines or arsines. Preferred catalysts contain palladium or nickel.
Examples of such catalysts include palladium[II] chloride, palladium[II]acetate, tetrakis (triphenyl- phosphine)palladium[0] and nickel[II]acetylacetonate. The metal catalyst is typically in the range of 0.1 to 10 mole percent. The chelating ligands may be either monodentate, as in the case for example of trialkyphosphines, such as tributylphosphine, triarylphosphines, such as tri- (ortho- tolyl)phosphine, and triheteroaryl phosphines, such as tri- 2-furylphosphine; or they may be bidentate such as in the case of 2, 2 ' -bis (diphenylphosphino) - 1, 1 'binaphthyl, 1,2- bis (diphenylphosphino)ethane, 1,1'-bis (diphenylphosphino) ferrocene and 1- (N,N-dimethyl-amino) -1 '- (dicyclohexylphosphino)biphenyl. The supporting ligand may be complexed to the metal center in the form of a metal complex prior to being added to the reaction mixture or may be added to the reaction mixture as a separate compound. The supporting ligand is typically present in the range 0.01 to 20 mole percent. It is often necessary to add a suitable base to the reaction mixture, such as a trialkylamine (for example, DIEA or 1, 5-diazabicyclo[5,4,0]undec-5-ene) , a Group I alkali metal alkoxide (for example potassium tert- butoxide) or carbonate (for example cesium carbonate) or potassium phosphate. The reaction is typically carried out in an inert aprotic solvent such as an ether solvent (for example dimethoxyethane or dioxane) or an amide solvent (for example, DMF or i\7-methylpyrrolidone) , under an inert atmosphere in the temperature range of 60-180 ΞC.
The amination is preferably carried out in an inert, aprotic, preferably anhydrous, solvent or solvent mixture, for example in a carboxylic acid amide, for example DMF or dimethylacetamide, a cyclic ether, for example THF or dioxane, or a nitrile, for example CH3CN, or in a mixture thereof, at an appropriate temperature, for example in a temperature range of from about 40 aC to about 180 aC, and if necessary under an inert gas atmosphere, for example a nitrogen or argon atmosphere.
Scheme 2
Figure imgf000074_0001
Substituted nicotinamides 3 can also be prepared from the corresponding halo analogs IA by the process outlined in Scheme 2. The chloro acid 1 (LG is OH) is coupled with an amine, preferably in the presence of a coupling agent such as EDC, to form the corresponding chloro amide 4.
Substituted amino-nicotinamides 3 are prepared from the corresponding chloro compounds 4 such as by reacting with an amine at a suitable temperature, such as about 80 0C. The amination reaction can be run in the presence of an appropriate catalyst such as a palladium catalyst, in the presence of an aprotic base such as sodium t-butoxide or cesium carbonate, or a nickel catalyst, or a copper catalyst.
Alternatively, nicotinamides 3 can be prepared from 2- chloro-heterocyclyl acid chloride IA (LG is Cl) by coupling first with RX-NH2 such as in the presence of base, e.g., NaHCO3, triethylamine (TEA) or other weak base, in a suitable solvent, such as CH2Cl2, to form the amide IB, then coupling with a primary or secondary amine in the presence of a base, such as LiHMDS or other strong base, to yield the substituted nicotinamide 3.
Additionally, where A is a pi-electron rich heterocycle, the addition of KF, such as 40% KF on alumina in IpOH, at a temperature over about 100 2C, preferably about 160 2C, can be used in the formation of 3 from IB.
Scheme 3
Figure imgf000076_0001
Substituted carboxamides 3 can also be prepared from the corresponding bromo/chloro analogs 5 by the process outlined in Scheme 3. The bromo/chloro acid 5 is coupled with an amine, preferably in the presence of a coupling agent such as EDC, to form the corresponding bromo substituted amide 6. Suzuki coupling with the bromo amide 6 and suitable boronic acids provides the substituted amide 4. Substituted amino-amides 3 are prepared from the corresponding chloro compounds 4 as described in Scheme 2. Scheme 4
Figure imgf000077_0001
Figure imgf000077_0002
Neat
11 12
Substituted, pyridines 12 can be prepared by the procedure described in Scheme 4. A solution of sodium hypobromite is freshly prepared and added to a 2- hydroxynicotinic acid 7 and heated, such as at a temperature of about 50 0C. Additional sodium hypobromide may be added to form the bromo compound 8 as needed. The 5-bromo-2- hydroxynicotinic acid 8 is reacted with thionyl chloride, at suitable temperature, such as at a temperature >RT, and preferably at about 80 2C, to form the 2-chloro-nicotinic acid analog 9. The acid is coupled with an amine, preferably in the presence of a suitable coupling agent (s), such as EDC, HOBT, and DIEA, to form the corresponding substituted amide 10. Suzuki coupling with the bromo nicotinamide 10 and suitable boronic acids, provides the substituted nicotinamide 11. 2-Amino-nicotinamides 12 are prepared from the corresponding chloro compounds 11 such as by reacting with substituted amines at a suitable temperature, such as about 80 3C.
Scheme 5
Figure imgf000078_0001
13 14 1 5
2-Amino-nicotinamides can also be prepared by first functionalizing pyridine compounds, as shown by the procedure described in Scheme 5. 2-Fluoropyridine 13 is lithiated by treatment with a lithium base, such as LDA or butyl lithium, at a temperature below about 0 0C, and preferably at about -78 0C, and quenched with a stream of dry CO2 to form the nicotinic acid 14. Solid CO2 (dry ice) can be used, preferably dried with N2, instead of gaseous CO2. The acid 14 is converted to the acid halide 15, such as by treatment with thionyl chloride and heating at a temperature above about 50 aC, and preferably at about reflux. Scheme 6
Figure imgf000079_0001
2.Polymer trisamine resin 16
Chloro-substituted pyridines 18 are prepared such as by the procedure described in Scheme 6. 2-Chloronicotinic acid 17 is activated with ethyl chloroformate, in the presence of base, such as TEA, at a temperature of about RT, to form the mixed anhydride (not shown) . Reaction of the mixed anhydride with an amine produces amide 18. Alternatively, the amine can be coupled with the acid chloride 16, such as with polymer-supported DIEA. Excess acid chloride is removed by treating the reaction mixture with polymer- supported trisamine resin, to form amide 18.
Scheme 7
Figure imgf000079_0002
a : 7-Aminoisoquinoline, Pd (OAc ) 2 , BINAP, Toluene , K2CO3 b: (i) LiOH, MeOH, H2O, THF. (U)R1"]^, TBTU, N,N- diisopropylethylamine, Methylene chloride.
Amino-isoquinoline-aryl-amides 21 can be prepared such as by the procedure described in Scheme 7. As shown, a halo- benzoic acid ester or nicotinic acid ester 19 can be coupled to an amino-isoquinoline under Buchwald-type palladium coupling conditions, such as with the use of Pd(OAc)2 and BINAP in toluene with a mild base such as a carbonate base (see conditions a) . The resulting isoquinolin-7-ylamino-acid ester 20 can be saponified to the corresponding acid using a hydroxide base, such as LiOH, in a suitable solvent, such as in a mixed solvent of MeOH, water and THF, at mild temperature. The acid intermediate (not shown) can then be treated with known, conventional acid activating/coupling reagents, such as TBTU, HBTU, DCC, and the like, in the presence of a mild base, such as a tertiary amine base like DIEA (iV,i\J-diisopropylethyl amine) , and reacted with a desired amine such as an amino-tetrahydroisoquinoline 22 (below) , or suitable other nucleophile (not shown in scheme 7), to afford the amino-isoquinolines 21 as the product. This method is useful for installing the desired isoquinolines prior to modifying the amide moieties of compound 21.
Scheme 8
Figure imgf000081_0001
Alternatively, amino-isoquinoline (or quinazoline) - aryl-nicotinamid.es 25 (where R1 is aryl) can be prepared by the procedure described in Scheme 8, as follows: Amino- isoquinolines 23 can be coupled to benzoic esters or nicotinic esters 19 (scheme 7) after it has been converted to the desired amide 22 (see scheme 7 above) , under N2, by reacting compounds 22 and 23 in the presence of Pd2(dba)3, a catalytic amount of 2-dicyclohexylphosphino-2 '- (N,N- dimethylamino)biphenyl 24 (Cas# 213697-53-1, Strem Chemicals 15-1145,) and 1.0 M LiNTMS2 THF solution, in a pressure- sealed reaction vessel. The reaction vessel is generally stirred at elevated temperatures, as at about 70 2C for a prolonged period of time, such as about 17 hours. After cooling, the product 25 can be recovered by conventional extraction and/or purification methods.
Scheme 9
Figure imgf000082_0001
As an alternative to Scheme 8, amino-naphthydrin-aryl- nicotinamides 28 (see also similar compounds 22, 25) can be prepared by the procedure described in Scheme 9, as follows: 2-amino-N- (4-tert-butyl-phenyl)-benzamide 26 ( where R1 is 4-tert-butyl-phenyl) and 2-Chloro-[1,7]naphthyridine 27 can be coupled to form compound 28 using the reagents shown in scheme 8, i.e., Pd2(dba)3, (2 '-dicyclohexylphosphanyl- biphenyl-2-yl)-dimethyl-amine, and IM solution of LiN(TMS)2 in THF, in a sealed reaction vessel at 70 2C for about 24h. Such a method is useful especially where desired amino- napththydrins, for use in the procedure described in Scheme 8, are not commercially available and/or are difficult to synthesize.
Scheme 10
Figure imgf000082_0002
Nicotinamides 31 can be made under various coupling conditions. For example, and as shown in Scheme 10, nicotinamides 31 can be made by treating a desired fluoro- nicotinamide 29 and a desired 7-aminoisoquinoline (or quinazoline where Z=N) 30 with TFA in a suitable solvent, such as t-BuOH, and stirring the resulting mixture for 24 hours at elevated temperature, such as at 90 2C.
Various aryl R and R1 groups of the compounds of the present invention can be prepared as described in the following Schemes 11-25, 27-30 and 32-33.
Scheme 11
Figure imgf000083_0001
32 33 34
Alkylated indazoles can be prepared by the procedure described in Scheme 11. To a solution of 6-nitroindazole 32 in a solvent such as THF is added strong base, such as NaH at a temperature below RT, preferably at about 0 2C. Alkylhalides, such as where R" is methyl, are added and reacted at a temperature about RT to give l-alkyl-6-nitro- lH-indazole 33. The nitro indazole 33 is hydrogenated, such as with an H2 atmosphere in the presence of a catalyst, such as Pd/C to give the l-substituted-6-amino-lH-indazole 34.
Scheme 12
Figure imgf000083_0002
35 36 Brominated indazoles can be prepared by the procedure described in Scheme 12. NBS is slowly added to an acidic solution, such as a mixture of TFA:H2SO4 (5:1) and tert- butyl-4-nitrobenzene 35 at a temperature of about RT to yield the brominated compound 36.
Scheme 13
Figure imgf000084_0001
pentanol
Figure imgf000084_0002
Figure imgf000084_0003
Indazolyl ethers 38 can be prepared by the procedure described in Scheme 13. 6-Nitro-lH-2-hydroindazol-3-one 37 is protected such as with BoC2O and DMAP in CH2Cl2 at a temperature of about RT, to give the protected 6-nitro-2- hydroindazol-3-one. The protected β~nitro-2-hydroindazol-3- one is reacted with an alcohol (where Rx is an appropriate substituent selected from the possible substituents on R1) and Ph3P in a solvent, such as THF, and DEAD, at a temperature of about RT, to give the protected 6- nitro(indazol-3-yl) ether. The nitro intermediate is hydrogenated, such as with an H2 atmosphere in the presence of a catalyst, such as Pd/C, to give the protected 6- amino{indazol-3-γl) ether 38. The amine 38 is coupled with 2-chloronicotinic acid in a solvent, such as an alcohol, preferably pentanol, at a temperature above RT, preferably at a temperature above about 75 aC, and more preferably at a temperature at about 130 2C to give the coupled and deprotected compound 39.
Scheme 14
Figure imgf000085_0001
40 41
Figure imgf000085_0002
Deprotection
Figure imgf000085_0003
Figure imgf000085_0004
44 Indolinyl substituted carboxamides 45 can be prepared from the corresponding nitro indoline 40 by the procedure described in Scheme 14. For example, 3,3-dimethyl-6- nitroindoline 40 is alkylated, such as with N-protected-4- formylpiperidine in the presence of NaHB(OAc)3 and acid, such as glacial AcOH, and solvent, such as dichloromethane, at a temperature of about RT, to afford the alkylated indane 41. Hydrogenation of the alkylated indane 41, such as with an H2 atmosphere in the presence of a catalyst, such as Pd/C, in the presence of a solvent, such as an alcohol, preferably MeOH, to give the amino intermediate 42. Alternatively, other hydrogenation methods can be used, such as Fe powder with NH4Cl. Coupling of the amine 42, such as with 2-chloronicotinic acid and DIEA, HOBt and EDC, in a solvent such as CH2Cl2 at a temperature of about RT provides the protected carboxamide 43, which upon deprotection and alkylation yields other compounds of the invention, 44 and 45, respectively. Alternatively, amine 42 is reacted with 2-fluoronicotinoyl chloride to form a 2-fluoronicotinamide, which can be alkylated such as in Scheme 14.
Figure imgf000087_0001
Figure imgf000087_0002
Figure imgf000087_0003
Substituted indolines 51 are prepared such as by the procedures described in Scheme 15. Substituted amino- indolines 48 are prepared from the nitroindoline 46 and a ketone in the presence of NaHB(OAc)3 to form the 1- substituted indoline 47. The nitroindoline 47 is hydrogenated, such as with H2 in the presence of a catalyst, such as Pd/C, to yield the amino-indoline 48. Alternatively, substituted amino-indolines 51 are prepared from the nitroindoline 46. Nitroindoline 46, is reacted with an acid chloride to form an amide. Further treatment with a primary or secondary amine, preferably a secondary amine, such as in the presence of NaI, at a temperature above about 50 2C, and preferably at about 70 2C yields the nitroindoline 49. The nitro compound 49 is hydrogenated, such as with H2 in the presence of a catalyst, such as Pd/C, to yield the amino-indoline) 50. The carbonyl is reduced, such as with BH3-THF yields 1-aminoalkyl- indolines 51. Scheme 16
Figure imgf000088_0001
56 55
Figure imgf000088_0002
55a
Substituted indolines (55, 55a, and 56) are prepared such as by the procedures described in Scheme 16. Substituted acetamides 53 are prepared from the coupling of halo-5-nitroanilines 52 (where LG is bromo or chloro, preferably chloro) and an acylating agent, such as acetyl chloride or acetic anhydride, under standard coupling chemistry, such as with DIEA, and DMAP, at a temperature of about RT, in a suitable solvent, such as CH2Cl2, DMF and/or DMAC. The N- (2-methylprop-2-enyl)acetamide 54 is prepared from the acetamide 53, such as by the treatment of base, such as NaH in a suitable solvent such as NMP or anhydrous DMF and a 3-halo-2-methylpropene such as 3-bromo-2- methylpropene or 3-chloro-2-methylpropene, at a temperature between about 0 2C and RT, and preferably at about RT,- or with CsCO3 at a temperature above RT, preferably above about 50 2C and more preferably above about 60 aC. Cyclization of the N- (2-methylprop-2-enyl)acetamide 54, such as by the Heck-type reaction (treatment with Pd(OAc)2 in the presence of base, for example tetraethyl-ammonium chloride, sodium formate, and NaOAc) at a temperature above about 50 2C, and preferably at about 80 8C, yields the protected (3,3- dimethyl-6-nitro-2,3-dihydro-indol-l-yl)ethanone 55. Deprotection, such as with strong acid such as HCl or AcOH at a temperature above about 50 aC, and preferably at about 70-80 2C, yields the 3,3-dimethyl-6-nitro-2,3-dihydro-indol- l-yl 56. Alternatively, the protected dihydro-6-nitro indoline 55 can be reduced, such as with Pe, or with 10% Pd/C in the presence of an excess of NH4CO2H, or with H2 in the presence of a catalyst to form the protected dihydro-6- amino indoline 55a.
Scheme 17
Figure imgf000089_0001
7-Amino-isoquinolines 61 can be prepared by the procedure described in Scheme 17. 4-Nitrophenethylamine hydrochloride 57 can be treated with triflic anhydride in the presence of base, such as DIEA, in a suitable solvent, such as CH2Cl2, at reduced temperature and stirred at about RT to form the protected amino compound 58. Treatment of the resulting yellow 2,2,2-trifluoro-N- [2- (4-nitro-phenyl) - ethyl] -acetamide 58 with paraformaldehyde and acid, such as HOAc or a mixture of HOAc with H2SO4, slowly under controlled reaction conditions affords the N-acetyl protected 7-nitro-l,2,3,4-tetrahydroisoquinoline 59. Isoquinoline-acetamide 59 can then be reduced to 7-nitro- 1,2,3,4-tetrahγdro-isoquinoline 60 with a hydroxide base, such as LiOH, for example, in solvent such as MeOH, CH2Cl2 and H2O, to cleave the acetamide. The nitro group resulting nitro-tetrahydroisoquinoline 60 can then be reduced to the corresponding 7-amino-isoquinoline 61 with 10%Pd on carbon in diethylene glycol under radiation, such as in a Smith Synthesizer microwave at 220 2C.
Scheme 18
Figure imgf000090_0001
N4-Substituted-quinazoline-4, 6-diamines 63 can be prepared by the procedure described in Scheme 18. The nitro group of substituted- (6-nitro-quinazolin-4-yl) -amines 62 can be reduced by conventional hydrogenation methods, such as with palladium on carbon (10 wt%) in suitable solubilizing solvent, such as methanol, under a suitable pressure of hydrogen gas.
2005/025800
A-917 - 90 -
Scheme 19
Figure imgf000091_0001
[1, 6]Naphthyridin-3-ylamines 68 can be prepared by the procedure described in Scheme 19. 3-Nitro-7, 8-dihydro-5H-
[1, 6]naphthyridine-6~carboxylic acid tert-butyl ester 66 can be prepared by reacting 1-methyl-3,5-dinitro-lH-pyridin-2- one 64 and 4-oxo-piperidine-l-carboxylic acid tert-butyl ester 65 with 2M solution of NH3 in MeOH in a sealed vessel for 24h at 70 aC. Cooling and concentration of the reaction affords the crude compound 66, which may be recrystallized from one or more suitable solvents, such as from MeOH. The Boc protecting group of 3-nitro-7, 8-dihydro-5H- [1, 6]naphthyridine-6-carboxylic acid tert-butyl ester 66 can be removed using standard deprotection chemistry, such as with TFA in solvent, to yield 3-nitro-5, 6,7, 8-tetrahydro- [1, 6]naphthyridine 67. Compound 67 may be recrystallized from suitable solvents, such as CH3CN. Hydrogenation of 3- nitro-5, 6,7, 8-tetrahydro- [1, 6]naphthyridine 67 with Pd/C, with simultaneous oxidation under known conditions, such as in a microwave reaction vessel, affords the corresponding amino-naphthydrins 68. Scheme 20
Figure imgf000092_0001
1,2,3, 6-Tetrahydro-pyridyl substituted anilines 73 are prepared such as by the procedure described in Scheme 20. Nitrobenzenes 69 are brominated, such as with bromine in the presence of acid, H2SO4 for example, or with NBS to yield the 3-bromo derivative 70. Suzuki coupling of the bromo- derivative 70 and a substituted pyridylboronic acid, such as at a temperature above RT, preferably above about 50 °C, and more preferably at about 80 0C, yields the pyridyl derivative 71. Alkylation of the nitrophenyl-pyridine 71, such as by treatment with iodomethane, preferably above about 50 2C, and more preferably at about 80 eC, yields the pyridinium compound 72, which upon reduction, such as by NaBH4, yields the tetrahydyropyridine substituted aniline 73. Scheme 21
Figure imgf000093_0001
Figure imgf000093_0002
Figure imgf000093_0003
A series of substituted anilines are prepared such as by the procedure described in Scheme 21. A nitrobenzyl bromide 74 is coupled with morpholine, such as at a temperature at about RT, to yield the heterocyclylmethyl nitrobenzene derivative (not shown) . Reduction of the nitro compound (step 2) , such as with iron powder, preferably above about 50 SC, and more preferably at about 80 2C, yields the heterocyclylmethyl substituted aniline 75. Protected alkylamine substituted anilines can be prepared from the nitro free amines 76, such as with standard protecting agents and chemistry known in the art, such as BOC chemistry. Reduction of the protected nitro compound, such as with iron powder, preferably above about 50 2C, and more preferably at about 80 2C, yields the aniline 77. Sulfonamide substituted anilines can be prepared from nitrobezenesulfonyl chlorides 78. Coupling of nitrobezenesulfonyl chlorides 78 with reactive heterocyclic compounds, such as substituted piperazines, piperidines, and the like, in a protic solvent such as EtOH, such as at a temperature about RT, yields the nitrobezenesulfonamides 78. Reduction of the nitro benzenesulfonamide, such as with iron powder, preferably above about 50 2C, and more preferably at about 80 2C, yields the aniline 79.
Scheme 22
Figure imgf000094_0001
A series of perhaloalkyl-substituted anilines 82, where Ry represents perhaloalkyl radicals, are prepared such as by the procedure described in Scheme 22. l-Nitro-4- (perfluoroethyl)benzene can be synthesized by the method described in the reference [John N. Freskos, Synthetic Communications, 18(9), 965-972 (1988)]. Alternatively, 1- Nitro-4- (perfluoroalkyl)benzene can be synthesized from the nitro compound, where Xa is a leaving group, such as bromo or iodo, by the method described by W. A. Gregory, et al. [J. Med. Chem., 1990, 33, 2569-2578].
Reduction of the nitrobenzenes 81, with a metal such as iron powder, at a temperature above about 50 2C, and preferably at about 80 2C, yields the aniline 82. Hydrogenation, such as with H2 atmosphere in the presence of a catalyst, such as 10% Pd/C, is also possible. Scheme 23
Figure imgf000095_0001
83 84 85
Figure imgf000095_0002
Additional series of substituted anilines (85, 88 and 91) are prepared such as by the procedures described in Scheme 23 (where Rx is a substituent selected those available for substituted R1, preferably haloalkyl and alkyl) . 2-Alkoxy substituted anilines 85 are prepared from the corresponding phenol compounds 83 such as by the Mitsunobu reaction, including treatment with a N,N- dialkylethanolamine and PPh3 and DEAD to give the corresponding nitro compound 84, followed by hydrogenation, such as with H2 to give the aniline 85. Alternatively, piperazinyl substituted anilines 88 can be prepared by the treatment of an aniline 86 with an N- substituted-bis (2-chloroethyl)amine, base, such as K2CO3 and NaI, at a temperature above about 50 2C, preferably above about 100 aC, and more preferably at about 170 2C, to give the piperazinylbenzene compound 87. Nitration, such as with H2SO4 and HNO3, at a temperature above 0 2C, and preferably 5 025800
A-917 - 95 - at about RT, followed by hydrogenation, such as with H2 atmosphere gives the substituted aniline 88.
Alternatively, piperazinyl substituted anilines 91 can be prepared by the treatment of a fluoro-nitro-substituted aryl compounds 89. The fluoro-nitro-substituted aryl compounds 89 and 1-substituted piperazines are heated, preferably neat, at a temperature above about 50 aC, and preferably at about 90 SC, to yield the piperazinyl- nitroaryl compounds 90. Hydrogenation, such as with H2 atmosphere in the presence of a catalyst, such as 10% Pd/C, gives the substituted aniline 91.
Scheme 24
Figure imgf000096_0001
Substituted anilines 98 are prepared such as by the procedures described in Scheme 24. Nitrophenyl esters 93 are formed from the acid 92, such as by treatment with MeOH and acid. Alkylation of the ester 93, such as by treatment with base, followed by alkyl halide, yields the branched alklyl compounds 94. Reduction of the ester 94, such as with BH3, yields the alcohol 95. The aldehyde 96 is prepared from the alcohol 95, such as by treatment with TPAP in the presence of N-methylmorpholine-N-oxide. Subsequent treatment with methoxymethyltriphenylphosphonium chloride and KHMDS yields 96. Coupling of the aldehyde 96 and morpholine, such as with NaBH(OAc)3 yields the tertiary amine 97. Reduction of the nitro group on compound 97, such as with acid, for example AcOH, and zinc yields the aniline 98.
Scheme 25
Figure imgf000097_0001
99
Substituted aniline compounds 101 are prepared such as by the procedure described in Scheme 25 (where Rx is a substituent selected those available for substituted R1, preferably haloalkyl and alkyl) . Alkynyl-aniline 100, prepared similar to that described in Scheme 26 (below) , is hydrogenated such as with H2 in the presence of a catalyst, such as Pd(OH)2, to yield the substituted alkyl 101.
Scheme 26
Figure imgf000097_0002
102 103 Substituted bromophenyl compounds 103 are prepared such as by the procedure described in Scheme 26. Bromine is added to a optionally substituted nitrobenzene 102, silver(II) sulfate and acid, such as H2SO4, to provide the bromo derivative 103.
Scheme 27
Figure imgf000098_0001
4-(2,2,2-Trifluoro-l-methoxy-l-trifluoromethyl-ethyl)- phenylamine 105 can be prepared by the procedure decribed in scheme 27, as follows: the hydroxyl group of 2-(4-amino- phenyl) -1, 1, 1, 3,3,3-hexafluoro-propan-2-ol 104 can be activated for displacement by conventional methods, such as by treating 104 with diisopropyl azodicarboxylate in the presence of triphenylphosphine (polymer-bound, excess equivalents) then treated with MeOH and stirred at about reflux.
Scheme 28
Figure imgf000098_0002
Figure imgf000098_0003
DEAD, PPh3, THF
Figure imgf000098_0004
Substituted anilines (106 and 107) are prepared such as by the procedure described in Scheme 28. Treatment with the haloalkyl alcohol 104 with an alcohol, under Mitsunobu conditions such as in the presence of DEAD and PPh3 yields the corresponding ether adducts 106 or 107.
Scheme 29
Figure imgf000099_0001
Substituted indoles 110 are prepared such as by the procedure described in Scheme 29. A nitroindole 108 is coupled with a halo compound, in the presence of base, for example K2CO3. Heating at a temperature above about 50 2C, and preferably at about reflux yields the substituted-nitro- lH-indole 109. Hydrogenation similar to conditions described above yield the amino derivative 110.
Scheme 30
Figure imgf000099_0002
111 112 113
Amino-substituted indoles 113 are prepared such as by the procedure described in Scheme 30. Nitroindoline 111 is reacted with N-methyl-4-piperidone in the presence of NaOMe at a temperature above about 50 2C, and preferably at about reflux, to form the 3-substituted indole 112. Hydrogenation as previously discussed yields the amino indole 113.
Scheme 31
Figure imgf000100_0001
Substituted carboxamides 115 can be prepared from the corresponding phenols 114 of the invention, by the procedure described in Scheme 31. A carboxamide 114 is coupled with an alcohol, such as 4-hydroxy-N-methylpiperidine, in the presence of DEAD and triphenylphosphine, in a solvent such as THF, at a temperature of about RT, provides the ether 115.
Scheme 32
Figure imgf000101_0001
Reduction
Figure imgf000101_0003
Figure imgf000101_0002
Figure imgf000101_0004
2,3, 4,4a, 9, 9a-Hexahydro-lH-3-aza-fluoren-6-γlamine 121 can be prepared by the procedure described in Scheme 32. Nitrobenzylpyridines 116 are alkylated, such as with MeI, in the presence of TBAI and base to form the pyridinium compound 117. The pyridinium compounds 117 are halogenated, such as brominated with NBS, to form the brominated pyridinium compounds 118 which are reduced such as with NaBH4, dehalogenated and reduced to form the hexahydro- fluorenes 121.
Scheme 33
Figure imgf000102_0001
122 124 125
Acylated amino-isoquinoline-tetrahydroisoquinoline- nicotinamides 124 can be prepared by the procedure described in scheme 33. Tetrahydroisoquinoline-quinoline nicotinamides 122 can be treated with Boc-protected glycine 123 in the presence of known acid-activating coupling reagents and combinations of same reagents, such as EDAC and HOBt, with a mild base, such as DIEA, to effect the acylation of compound 122 and provide compound 124. The glycyl amine can be deprotected or cleaved using dilute HCl to afford the free glycine amine 125, for subsequent coupling to desired chemical structures. Amides (not shown) of compound 125 can be made by coupling compound 125 with activated carboxylic acid compounds (not shown) such as acid chlorides, or by displacing other suitable leaving groups of desired compounds. The starting compounds defined in Schemes 1-33 may also be present with functional groups in protected form if necessary, such as BOC-protected glycine, and/or' in the form of salts, provided a salt-forming group is present and the reaction in salt form is possible. If so desired, one compound of Formula I or II can be converted into another compound of Formula I or II, or a N-oxide thereof; a compound of Formula I or II can be converted into a salt; a salt of a compound of Formula I or II can be converted into the free compound or another salt; and/or a mixture of isomeric compounds of Formula I or II can be separated into the individual isomers.
N-Oxides are also contemplated to be included in the present invention. N-oxides can be obtained in a known matter by reacting a compound of Formula I or II with hydrogen peroxide or a peracid, e.g. 3-chloroperoxy-benzoic acid, in an inert solvent, e.g. dichloromethane, at a temperature between about -10-35 3C, such as about 0 2C - RT. If one or more other functional groups, for example carboxy, hydroxy, amino, or mercapto, are or need to be protected in a compound of Formula I or II or in the preparation of compounds of Formula I or II, because they should not take part in the reaction, these are such groups as are usually used in the synthesis of peptide compounds, and also of cephalosporins and penicillins, as well as nucleic acid derivatives and sugars.
The protecting groups may already be present in precursors and should protect the functional groups concerned against unwanted secondary reactions, such as acylations, etherifications, esterifications, oxidations, solvolysis, and similar reactions. It is a characteristic of protecting groups that they lend themselves readily, i.e. without undesired secondary reactions, to removal, typically by solvolysis, reduction, photolysis or also by enzyme activity, for example under conditions analogous to physiological conditions, and that they are not present in the end-products. The specialist knows, or can easily establish, which protecting groups are suitable with the reactions mentioned above and hereinafter.
The protection of such functional groups by such protecting groups, the protecting groups themselves, and their removal reactions are described for example in standard reference works, such as J. F. W. McOrαie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973, in T. W. Greene, "Protective Groups in Organic Synthesis", Wiley, New York 1981, in "The Peptides"; Volume 3 (editors: E. Gross and J. Meienhofer) , Academic Press, London and New York 1981, in "Methoden der organischen Chemie" (Methods of organic chemistry) , Houben Weyl, 4th edition, Volume 15/1, Georg Thieme Verlag, Stuttgart 1974, in H.-D. Jakubke and H. Jescheit, "Aminosauren, Peptide, Proteine" (Amino acids, peptides, proteins) , Verlag Chemie, Weinheim, Deerfield Beach, and Basel 1982, and in Jochen Lehmann, "Chemie der Kohlenhydrate: Monosaccharide und Derivate" (Chemistry of carbohydrates: monosaccharides and derivatives), Georg Thieme Verlag, Stuttgart 1974. In the additional process steps, carried out as desired, functional groups of the starting compounds which should not take part in the reaction may be present in unprotected form or may be protected for example by one or more of the protecting groups mentioned above under "protecting groups". The protecting groups are then wholly or partly removed according to one of the methods described there.
Salts of a compound of Formula I or II with a salt- forming group may be prepared in a manner known per se. Acid addition salts of compounds of Formula I or II may thus be obtained by treatment with an acid or with a suitable anion exchange reagent. A salt with two acid molecules (for example a dihalogenide of a compound of formula I) may also be converted into a salt with one acid molecule per compound (for example a monohalogenide) ; this may be done by heating to a melt, or for example by heating as a solid under a high vacuum at elevated temperature, for example from 130 0C to 170 0C, one molecule of the acid being expelled per molecule of a compound of Formula I or II. Acid salts can usually be converted to free-base compounds, e.g. by treating with suitable basic agents, for example with alkali metal carbonates, alkali metal hydrogen carbonates, or alkali metal hydroxides, typically potassium carbonate or sodium hydroxide. Similarly, basic salts of compounds may be converted to the corresponding free-base compound by treatment with the desired number of equivalents of a suitable acidic agent, such as HCl, acetic acid, and the like. A carbonyl group in a compound of Formula I or II may be converted into the respective thiocarbonyl, for example, by using an appropriate sulfur compound, e. g. using reaction with Lawesson's reagent (2,4-bis-(4- methoxyphenyl) 2,4-dithioxo-l,2,3, 4-dithiaphosphetan) in a halogenated hydrocarbon, such as CH2Cl2, or an aprotic solvent, such as toluene or xylene, at temperatures from about 30 0C to reflux.
All process steps described here can be carried out under known reaction conditions, preferably under those specifically mentioned, in the absence of or usually in the presence of solvents or diluents, preferably such as are inert to the reagents used and able to dissolve these, in the absence or presence of catalysts, condensing agents or neutralizing agents, for example ion exchangers, typically cation exchangers, for example in the H+ form, depending on the type of reaction and/or reactants at reduced, normal, or elevated temperature, for example in the range from about - 100 0C to about 190 0C, preferably from about -80 0C to about 1500C, for example at about -800C to about 600C, at room temperature, at about -20 0C to about 40 0C or at the boiling point of the solvent used, under atmospheric pressure or in a closed vessel, where appropriate under pressure, and/or in an inert atmosphere, for example under argon or nitrogen. Salts may be present in all starting compounds and transients, if these contain salt-forming groups. Salts may also be present during the reaction of such compounds, provided the reaction is not thereby disturbed. In certain cases, typically in hydrogenation processes, it is possible to achieve stereoselective reactions, allowing for example easier recovery of individual isomers.
Suitable solvents, which may be selected to carry out the reactions in question, as appreciated by those of ordinary skill in the art. Suitable aqueous, organic and inorganic solvents include, without limitation, water; esters, typically lower alkyl-lower alkanoates, e.g., ethyl acetate; ethers, typically aliphatic ethers, e.g., diethylether, or cyclic ethers, e.g., THF; liquid aromatic hydrocarbons, typically benzene or toluene,- alcohols, typically MeOH, EtOH or 1-propanol, IPOH, BuOH, t-BuOH,- nitriles, typically CH3CN; halogenated hydrocarbons, typically CH2Cl2, CHCl3; acid amides, typically DMF; bases, typically heterocyclic nitrogen bases, e.g. pyridine; carboxylic acids, typically lower alkanecarboxylic acids, e.g., AcOH; carboxylic acid anhydrides, typically lower alkane acid anhydrides, e.g., acetic anhydride; cyclic, linear, or branched hydrocarbons, typically cyclohexane, hexane, pentane, cyclopentane, or isopentane; and mixtures of such solvents, e.g., aqueous solutions and solvent combinations, unless otherwise stated in the description of the process. Such solvent mixtures may also be used in processing, for example in chromatography, extraction and recystallization.
The invention relates also to those methods of the process in which one starts from a compound obtainable at any stage as a transient and carries out the missing steps, or breaks off the process at any stage, or forms a starting material under the reaction conditions, or uses said starting material in the form of a reactive derivative or salt, or produces a compound obtainable by means of the process according to the invention and processes the said compound in situ. In the preferred embodiment, one starts from those starting materials, which lead to the compounds described above as preferred.
The compounds of Formula I or II, including their derivatives, are also obtainable in the form of salts, hydrates or crystals. A crystalline form, for example, can include the solvent, or solvents, used for crystallization (generally present as solvates) .
New starting materials and/or intermediates, as well as processes for the preparation thereof, are likewise the subject of this invention. In the preferred embodiment, such starting materials are used and reaction conditions so selected as to enable the preferred compounds to be obtained.
Starting materials of the invention, are known, are commercially available, or can be synthesized in analogy to or according to methods that are known in the art.
For example, amine compounds, represented in Schemes 11, 18, 20 and 22, can be prepared by reduction of the corresponding nitro precurser. The reduction preferably takes place in the presence of a suitable reducing agent, such as tin(II) chloride or hydrogen in the presence of an appropriate catalyst, such as Raney nickel (then preferably the hydrogen is used under pressure, e.g. between 2 and 20 bar) , Pd or PtO2, in an appropriate solvent, e.g. an alcohol, such as MeOH. The reaction temperature is preferably between about 0 2C and about 80 2C, especially about 15 2C to about 30 9C.
It would also be possible to reduce the nitro compound after forming the other amide linkages, under reaction conditions analogous to those for the reduction of nitro compounds described above. This would eliminate the need to protect the free amino group as described in various of the schemes above. In the preparation of starting materials, existing functional groups, which do not participate in the reaction should, if necessary, be protected. Preferred protecting groups, their introduction and their removal are described above or in the examples . All remaining starting materials are known, capable of being prepared according to known processes, or commercially obtainable; in particular, they can be prepared using processes as described in the examples .
Compounds of the present invention can possess, in general, one or more asymmetric carbon atoms and, therefore, are capable of existing in the form of optical isomers as well as in the form of racemic or non-racemic mixtures thereof. The optical isomers can be obtained by resolution of the racemic mixtures according to conventional processes, e.g., by formation of diastereoisomeric salts, by treatment with an optically active acid or base. Examples of appropriate acids are tartaric, diacetyltartaric, dibenzoyltartaric, ditoluoyltartaric, and camphorsulfonic acid and then separation of the mixture of diastereoisomers by crystallization followed by liberation of the optically active bases from these salts. A different process for separation of optical isomers involves the use of a chiral chromatography column optimally chosen to maximize the separation of the enantiomers. Still another available method involves synthesis of covalent diastereoisomeric molecules by reacting compounds of the invention with an optically pure acid in an activated form or an optically pure isocyanate. The synthesized diastereoisomers can be separated by conventional means such as chromatography, distillation, crystallization or sublimation, and then hydrolyzed to deliver the enantiomerically pure compound. The optically active compounds of the invention can likewise be obtained by using optically active starting materials. These isomers may be in the form of a free acid, a free base, an ester or a salt.
The compounds of the present invention may contain one or more asymmetric centers and, therefore, occur as racemates and racemic mixtures, scalemic mixtures, single enantiomers, individual diastereomers and diastereomeric mixtures. All such isomeric forms of these compounds are expressly included in the present invention.
The compounds of this invention may also be represented in multiple tautomeric forms, for example, as illustrated below:
Figure imgf000109_0001
The invention expressly includes all tautomeric forms of the compounds described herein.
The compounds of this invention may also occur in cis- or trans- or E- or Z- double bond isomeric forms. All such isomeric forms of such compounds are expressly included in the invention. All crystal forms of the compounds described herein are expressly included in the invention.
Substituents on ring moieties (e.g., phenyl, thienyl, etc.) may be attached to specific atoms, whereby they are intended to be fixed to that atom, or they may be drawn unattached to a specific atom, whereby they are intended to be attached at any available atom that is not already substituted by an atom other than H (hydrogen) . The compounds of this invention may contain heterocyclic ring systems attached to another ring system. Such heterocyclic ring systems may be attached through a carbon atom or a heteroatom in the ring system. Alternatively, a compound of Formula I or II herein may be synthesized according to any of the procedures described herein. In the procedures described herein, the steps may be performed in an alternate order and may be preceded, or followed, by additional protection/deprotection steps as necessary. The procedures may further comprise use of appropriate reaction conditions, including inert solvents, additional reagents, such as bases (e.g., LDA, DIEA, pyridine, K2CO3, and the like) , catalysts, and salt forms of the above. The intermediates may be isolated or carried on in situ, with or without purification.
Purification methods are known in the art and include, for example, crystallization, chromatography (liquid and gas phase, simulated moving bed ("SMB")), extraction, distillation, trituration, reverse phase HPLC and the like. Reactions conditions such as temperature, duration, pressure, and atmosphere (inert gas, ambient) are known in the art and may be adjusted as appropriate for the reaction.
As can be appreciated by the skilled artisan, the above synthetic schemes are not intended to comprise a comprehensive list of all means by which the compounds described and claimed in this application may be synthesized. Further methods will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps described above may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the inhibitor compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989) ; T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3rd. Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994) ; A. Katritzky and A. Pozharski, Handbook of Heterocyclic Chemistry, 2nd Ed. (2001); M. Bodanszky, A. Bodanszky: The practice of Peptide Synthesis Springer-Verlag, Berlin Heidelberg 1984; J. Seyden-Penne: Reductions by the Alumino- and Borohydrides in Organic
Synthesis, 2nd Ed., Wiley-VCH, 1997; and L. Paguette, ed. , Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) .
The compounds of the present invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are known in the art and include those which increase biological penetration into a given biological compartment (e.g., blood, lymphatic system, central nervous system) , increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
The following examples contain detailed descriptions of the methods for the preparation of exemplary compounds of Formula I or II. These detailed descriptions fall within the scope, and serve to exemplify, the above-described General Synthetic Procedures, which form part of the invention. These detailed descriptions are presented for illustrative purposes only and are not intended as a restriction on the scope of the invention.
Unless otherwise noted, all materials were obtained from commercial suppliers and used without further purification. Anhydrous solvents such as DMF, THF, CH2Cl2 and toluene were obtained from the Aldrich Chemical Company, typically available as nitrogen blanketed, sure-sealed bottles. All reactions involving air- or moisture-sensitive compounds were performed under a nitrogen atmosphere. Flash chromatography was performed using Aldrich Chemical Company silica gel (200-400 mesh, 60A) or Biotage pre-packed column. Thin-layer chromatography (TLC) was performed with Analtech gel TLC plates (250 μ) . Preparative TLC was performed with Analtech silica gel plates (1000-2000 μ) . Preparative HPLC was conducted on a Beckman or Waters HPLC system with 0.1% TFA/H2O and 0.1% TFA/CH3CN as mobile phase. The flow rate was at 20 ml/min. and gradient method was used. 1H NMR spectra were determined with super conducting FT MMR spectrometers operating at 400 MHz or a Varian 300 MHz instrument. Chemical shifts are expressed in ppm downfield from internal standard tetramethylsilane. All compounds showed NMR spectra consistent with their assigned structures. Mass spectra (MS) were determined on a Perkin Elmer - SCIEX API 165 electrospray mass spectrometer (positive and, or negative) or an HP 1100 MSD LC-MS with eletrospray ionization and quadrupole detection. All parts are by weight and temperatures are in Degrees centigrade unless otherwise indicated.
The following abbreviations, which are used in the description of the invention, mean the following: AcOH - acetic acid
Ac2O - acetic anhydride
AIBN - 2,2'-azobisisobutyronitrile
Ar - argon
AgSO4 - silver sulfate AlCl3 - aluminum tricloride
ATP - adenosine triphosphate
BH3 - borane
Boc - tert-butyloxycarbony1
BoC2O - Boc anhydride BOP-Cl - bis (2-oxo-3-oxazolidinyl)phosphinic chloride
Br2 - bromine BSA - bovine serum albumin t-BuOH - tert-butanol CAN - ammonium cerium(IV) nitrate
CH3CN, AcCN acetonitrile CH2Cl2 - dichloromethane CH3I , MeI - iodomethane, methyl iodide CCl4 - carbon tetrachloride CCl3 - chloroform CO2 - carbon dioxide Cs2CO3 - cesium carbonate DIEA - diisopropylethylamine CuI - copper iodide CuCN - copper cyanide DCE - 1,2-dichloroethane DEAD - diethyl azodicarboxylate DIEA - diisopropylethylamine DIPAD - disopropyl azodicarboxylate dppf - 1,1-diphenylphosphinoferrocene DMAP - 4- (dimethylamino)pyridine DMAC - N,N-dimethylacetamide DMF - dimethylformamide DMSO - dimethylsulfoxide DTT - dithiothreitol EDC , EDAC- 1- (3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride
EGTA - ethylene glycol-bis (β-aminoethyl ether)
N,N,N' ,N'-tetraacetic acid
EtOAC - ethyl acetate EtOH - ethanol Et2O - diethyl ether Fe - iron g - gram h - hour
HATU - 0-(7-azabenzotriazol-l-yl)-N,N,N' ,N'- tetramethyluronium hexafluorophosphate
H2 - hydrogen
H2O - water
HCl - hydrochloric acid
H2SO4 - sulfuric acid
H2NNH2 - hydrazine
HC(OEt)3 ~ triethylorthoformate
HCHO, H2CO - formaldehyde
HCO2Na - sodium formate
HOAc, AcOH - acetic acid
HOAt - l-hydroxy-7-azabenzotriazole
HOBt - hydroxybenzotriazole
IpOH - isopropanol
KF - potassium fluoride
K2CO3 - potassium carbonate
KHMDS - potassium hexamethylsilazane
KNO3 - potassium nitrate
KOAc - potassium acetate
KOH - potassium hydroxide
LAH, LiAlH4 - lithium aluminum hydride
LDA - lithium diisopropylamide
LiCl - lithium chloride
LiHMDS - lithium hexamethyldisilazide
MeOH - methanol
MgCl2 - magnesium chloride
MgSO4 - magnesium sulfate mg - milligram ml - milliliter
MnCl2 - manganese chloride
NBS - N-bromosuccinimide
NMO - 4-methylmorpholine, N-oxide NMP - N-methylpyrrolidone
Na2SO4 - sodium sulfate
Na2S2O5 - sodium metabisulfite
NaHSO3 - sodium bisulfite
NaHCO3 - sodium bicarbonate
Na2CO3 - sodium carbonate
NaCl - sodium chloride
NaH - sodium hydride
NaI - sodium iodide
NaOH - sodium hydroxide
NaOMe - sodium methoxide
NaOEt - sodium ethoxide
NaCNBH3 - sodium cyanoborohydride
NaBH4 - sodium borohydride
NaNO2 - sodium nitrate
NaBH(OAc)3 - sodium triacetoxyborohydride
NH4Cl - ammonium chloride
N2 - nitrogen
Pd/C - palladium on carbon
PdCl2 (PPh3)2 - palladium chloride bis (triphenylphosphine)
PdCl2 (dppf) - 1,1-bis (diphenylphosphino) ferrocene palladium chloride
Pd(PPh3J4 - palladium tetrakis triphenylphosphine
Pd(OH)2 - palladium hydroxide
Pd(OAc)2 - palladium acetate
PMB - para methoxybenzyl
POCl3 - phosphorus oxychloride
PPh3 - triphenylphosphine
PtO2 - platinum oxide
RT - room temperature
SiO2 - silica
SOCl2 - thionyl chloride
TBAI - tetrabutylammonium iodide TBTU - 0-(lH-benzotriazol-l-yl)-N,N,N' ,N'- tetramethyluronium tetrafluoroborate TEA - triethylamine
Tf2NPh - N-phenyltrifluoromethanesulfonimide TFA - trifluoroacetic acid
THF - tetrahydrofur'an
TPAP - tetrapropylammoniumperruthenate Tris-HCl - Tris(hydroxymethyl)aminomethane hydrochloride salt Zn - zinc
PREPARATIONS
The preparation of the following exemplary compounds, intermediates and starting materials should assist in the understanding and appreciation of the invention.
Preparation I - 3-nitro-5-trifluoromethyl-phenol: l-Methoxy-3-nitro-5-trifluoromethyl-benzene (1Og, Aldrich) and pyridine-HCl (41.8g, Aldrich) were mixed together and heated neat at 210 2C in an open flask. After 2.5 h the mixture was cooled to RT and partitioned between IN HCl and EtOAc. The EtOAc fraction was washed with IN HCl (4x) , brine (Ix) , dried with Na2SO4, filtered and concentrated in vacuo to form 3-nitro-5-trifluoromethyl-phenol as an off-white solid.
Preparation II - l~Boc-4-(3-nitro-5-trifluoromethyl- phenoxy)-piperidine: 3-Nitro-5-trifluoromethyl-phenol (8.8Ig) was dissolved in THF (76 ml) . l-Boc-4-hydroxy-piperidine (8.81 g, Aldrich) and Ph3P (11.15 g) were added and the solution was cooled to -20 eC. A solution of DEAD (6.8 ml, Aldrich) in THF (36 ml) was added dropwise, maintaining the temperature between -20 and -10 2C. The reaction was warmed to RT and stirred overnight. The reaction was concentrated in vacuo and triturated with hexane. The yellow solid was removed by- filtration and washed with Et2O (25 ml), and hexane. The white filtrate was washed with IN NaOH (2x) , brine (Ix) and the hexane layer was dried over Na2SO4, filtered and concentrated in vacuo. The crude material was purified with flash chromatography (SiO2, 5-10% EtOAc/hexane) to obtain 1- Boc-4- (3-nitro-5-trifluoromethyl-phenoxy) -piperidine.
The following compounds were prepared similarly to the procedure outlined above:
a) (S)-1-Boc-[2- (5-nitro-2-trifluoromethylphenoxymethyl]- pyrrolidine b) (R) -1-Boc-[2- (5-nitro-2-trifluoromethylphenoxymethyl]- pyrrolidine. c) (R) l-Boc-2- (3-Nitro-5-trifluoromethyl-phenoxymethyl)- pyrrolidine d) 4- (2-tert-Butyl-5-nitro-phenoxymethyl)-1-methyl- piperidine. e) (S) l-Boc-2-(3-Nitro-5-trifluoromethyl-phenoxymethyl) - pyrrolidine f) l-Boc-3- (5-nitro-2-pentafluoroethyl-phenoxymethyl)- azetidine. g) N-Boc- [2- (5-nitro-2-pentafluoroethyl-phenoxy)- ethyl]amine. h) (R) 3- (2-tert-Butyl-5-nitro-phenoxymethyl)-1-Boc- pyrrolidine. i) 3- (2-tert-Butyl-5-nitro-phenoxymethyl) -1-Boc-azetidine. j) (S)-l-Boc-[2-(5-nitro-2-tert-butylphenoxymethyl]- pyrrolidine k) (S) 3-(2-tert-Butyl-5-nitro-phenoxymethyl)-l-Boc- pyrrolidine. 1) (R)-l-Boc-[2- (5-nitro-2-tert-butylphenoxymethyl]- pyrrolidine
Preparation III - l-Boc-4-(3-amino-5-trifluoromethyl- phenoxy)-piperidine: l-Boc-4- (3-nitro-5-trifluoromethy1-phenoxy)-piperidine (470 mg) was dissolved in MeOH (12 ml) and Pd/C (10 mg) was added. After sparging briefly with H2, the mixture was stirred under H2 for 6 H. The catalyst was removed by filtration and the MeOH solution was concentrated in vacuo to yield l-Boc-4- (3-amino-5-trifluoromethy1-phenoxy)- piperidine as an off-white foam.
The following compounds were prepared similarly to the procedure outlined above:
a) l-Boc-2-(3-Amino-5-trifluoromethyl-phenoxymethyl) - pyrrolidine. b) 2- (3-Amino-5-trifluoromethyl-phenoxymethyl) -1-methyl- pyrrolidine. c) [2- (l-Methylpiperidin-4-yloxy) -pyridin-4-yl]methylamine.
ESI (M+H)=222. d) [2- (2-Morpholin-4-yl-ethoxy) -pyridin-4-yl]methylamine. e) [2- (2-Morpholin-4-yl-propoxy)-pyridin-4-yl]methylamine. f) [2-(l-Methyl-pyrrolidin-2-ylmethoxy)-pyridin-4- yl]methylamine. ESI MS: (M+'H)=222. g) (4-Aminomethyl-pyridin-2-yl) - (3-morpholin-4-yl-propyl) - amine. ESI MS: (M+H)=251. h) 4-tert-Butyl-3- (1-methyl-piperidin-4-ylmethoxy) - phenylamine. i) 4-tert-Butyl-3- (2-piperidin-l-yl-ethoxy) -phenylamine. j ) 3- (l-Methyl-piperidin-4-ylmethoxy) -4-pentafluoroethyl- phenylamine. k) 3- (l-Isopropγl-piperidin-4-γlmetlioxγ) -4-pentaf luoroethyl- phenylamine.
1) (S) 3-Oxiranylmeth.oxγ-4-pentafluoroethyl-phenγlamine. m) 3- (2-Pyrrolidin-l-yl-ethoxy)-4-trifluoromethyl- phenylamine. n) 3- (2-Piperidin-l-yl-ethoxy) -4-trifluoromethyl- phenylamine. o) (S) 3- (l-Boc-pyrrolidin-2-ylmethoxy) -4-pentafluoroethyl- phenylamine. p) (R) 3- (l-Boc-pyrrolidin-2-ylmethoxy) -4-pentafluoroethyl- phenylamine. q) (R) 3- (1-Methyl-pyrrolidin-2-ylmethoxy)-5- trifluoromethyl-phenylamine. r) (S) 3-(l-Methyl-pyrrolidin-2-ylmethoxy)-5- trifluoromethyl-phenylamine s) (R) 3-Oxiranylmethoxy-4-pentafluoroethyl-phenylamine. t) (R) 2- (5-Amino-2-pentafluoroethyl-phenoxy)-1-pyrrolidin-
1-yl-ethanol. u) 3- (l-Boc-azetidin-3-ylmethoxy)-4-pentafluoroethyl- phenylamine. v) 3-(2- (Boc-amino)ethoxy) -4-pentafluoroethyl-phenylamine. w) 6-Amino-2,2-dimethyl-4H-benzo[1,4]oxazin-3-one. M+H
193.2. Calc'd 192.1. x) 2,2, 4-Trimethyl-3, 4-dihydro-2H-benzo[l, 4]oxazin-6- ylamine. y) 1- (6~Amino-2, 2-dimethyl-2,3-dihydro-benzo[l,4]oxazin-4- yl)-ethanone. M+H 221.4. CaIc'd 220.3. z) [2- (l-Benzhydryl-azetidin-3-yloxy) -pyridin-4-yl]- methylamine. aa) [2- (l-Methyl-piperidin-4-ylmethoxy) -pyridin-4-yl] - methylamine. M+H 236.3. CaIc'd 235.2. ab) 3- (4-Boc-piperazin-l-ylmethyl) -5-trifluoromethyl- phenylamine. M+H 360.3. ac) 2-BOC-4,4-dimethyl-1,2,3,4-tetrahydro-isoquinolin-7- ylamine. ad) 3-Morpholin-4-ylmethyl-4-pentafluoroethyl-phenylamine. ae) 3- (4-Methyl-piperazin-l-ylmethyl) -4-pentafluoroethyl- phenylamine. M+H 410.3. CaIc'd 409.4. af) 7-Amino-2- (4-methoxy-benzyl) -4,4-dimethyl-3,4-dihydro- 2H-isoquinolin-l-one. M+H 311.1. ag) 7-Amino-4,4-dimethyl-3,4-dihydro-2H-isoguinolin-l-one. ah) (3-Amino-5-trifluoromethyl-phenyl)- (4-Boc-piperazin-l- yl)-methanone. M+H 374.3; CaIc'd 373. ai) 3- (4-Boc-Piperazin-l-ylmethyl) -5-trifluoromethyl- phenylamine. aj) 1- (7-Amino-4,4-dimethyl-3,4-dihydro-lH-isoquinolin-2- yl)-ethanone. M+H 219.2. ak) {2- [2- (l-Methylpiperidin-4-yl) ethoxy]-pyridin-4-yl}- methylamine. al) {2- [2- (1-Pyrrolidinyl)ethoxy] -pyridin-4-yl}-methylamine. am) {2- [2- (l-Methylpyrrolin-2-yl)ethoxy]-pyridin-4-yl}- methylamine. an) (2-Chloro-pyrimidin-4-yl) -methy1amine. ao) 3- (l-Boc-azetidin-3-ylmethoxy)-5-trifluoromethyl- phenylamine. ap) 4-tert-Butyl-3- (l-Boc-pyrrolidin-3-ylmethoxy) - phenylamine. M+H 385. aq) 4-tert-Butyl-3- (l-Boc-azetidin-3-ylmethoxy) -phenylamine.
M+Na 357. ar) (S) 4-tert-Butyl-3- (l-Boc-pyrrolidin-2-ylmethoxy) - phenylamine. M+Na 371. as) 3-tert-Butyl-4- (4-Boc-piperazin-l-yl) -phenylamine at) 3-(l-Methyl-piperidin-4-yl)-5-trifluoromethyl- phenylamine. au) 3, 3-Dimethyl-2,3-dihydro-benzofuran-6-ylamine. av) 3,9, 9-Trimethyl-2,3, 4,4a,9,9a-hexahydro-lH-3-aza- fluoren-6-ylamine. aw) 4-[1-Methyl-l-(l-methγl-piperidin-4-γl)-ethyl]- phenylamine was prepared using EtOH as the solvent. ax) 4-tert-Butyl-3-(4-pyrrolidin-l-yl-but-l-enyl)- phenylamine. ay) (R) 3- (l-Boc-pyrrolidin-2-ylmethoxy) -5-trifluoromethyl- phenylamine. az) (S) 3-(l-Boc-pyrrolidin-2-ylmethoxy)-5-trifluoromethyl- phenylamine.
Preparation IV - l-Boc-4-{3-[(2-fluoro-pyridine-3-carbonyl)- amino]-5-trifluorαmethyl-phenoxy}-piperidine: l-Boc-4- (3-amino-5-trifluoromethyl-phenoxy)-piperidine (4.37 g) was dissolved in CH2Cl2 (100 ml) and NaHCO3 (2.4 g, Baker) was added. 2-Fluoropyridine-3-carbonyl chloride (2.12 g) was added an the reaction was stirred at RT for 2.5 h. The reaction was filtered and concentrated in vacuo to yield a yellow foam. (30%) EtOAc/Hexane was added and l-Boc-4-{3- [ (2-fluoro-pyridine-3-carbonyl)-amino]-5-trifluoromethyl- phenoxy}-piperidine precipitated as an off white solid.
The following compounds were prepared similarly to the procedure outlined above:
a) 2-Fluoro-N-[3- (3-piperidin-1-yl-propyl)-5- trifluoromethyl-phenyl]-nicotinamide. b) N-[4-tert-Butyl-3- (2-piperidin-l-yl-ethoxy)-phenyl]-2- fluoro-nicotinamide. c) N-[3,3-Dimethyl-l- (l-methyl-piperidin-4-ylmethyl)-2,3- dihydro-lH-indol-6-yl]-2-fluoro-nicotinamide. d) N-[l-(2-Dimethylamino-acetyl)-3,3-dimethyl-2,3-dihydro-
IH-indol-6-yl]-2-fluoro-nicotinamide e) N-[3,3-Dimethyl-l- (2- (Boc-amino)acetyl)-2,3-dihydro-lH- indol-6-yl]-2-fluoro-nicotinamide. f) N- (4-Acetyl-2,2-dimethyl-3,4-dihydro-2H-benzo[1,4]oxazin-
6-yl)-2-fluoro-nicotinamide. M+H 344.5. Calc'd 343.4. g) 2-Fluoro-N-(2,2,4-trimethyl-3,4-dihydro-2H- benzo.l,4]oxazin-6-yl)-nicotinamide. M+H 316.2. Calc'd 315.1. h) N- (2,2-Dimethyl-3-oxo-3,4-dihydro-2H-benzo[1,4]oxazin-6- yl)-2-fluoro-nicotinamide. M+H 316.1. Calc'd 315.10. i) 2-Fluoro-N-[3- (4-methyl-piperazin-l-ylmethyl)-5- trifluoromethyl-phenyl]-nicotinamide. M+H 481. Calc'd 480. j) 2-Fluoro-N-(2-BOC-4,4-dimethyl-1,2,3,4-tetrahydro- isoquinolin-7-yl)-nicotinamide. M+H 400. k) 2-Fluoro-N-[3- (4-methyl-piperazin-l-ylmethyl) -4- pentafluoroethyl-phenyl]-nicotinamide. M+H 447.0. Calc'd 446.
1) 2-Fluoro-N-(3-morpholin-4-ylmethyl-4-pentafluoroethyl- phenyl)-nicotinamide. m) 2-Fluoro-N-[4-iodophenyl]-nicotinamide, n) 2-Fluoro-N-(4,4-dimethyl-l-oxo-l,2,3,4-tetrahydro- isoquinolin-7-yl) -nicotinamide. M+H 314.0, Calc'd 311. o) 2-Fluoro-N- [3- (4-Boc-piperazine-l-carbonyl)-5- trifluoromethyl-phenyl]-nicotinamide. M+H 495. p) 2-Fluoro-N-[3- (4-Boc-piperazin-l-ylmethyl)-5- trifluoromethyl-phenyl]-nicotinamide. M+H 483.3; Calc'd 482. q) N- (2-Acetyl-4,4-dimethyl-l,2,3,4-tetrahydro-isoquinolin-
7-yl)-2-fluoro-nicotinamide. M+H 430.0. r) N-[3,3-Dimethyl-l- (1-methyl-piperidin-4-yl)-2,3-dihydro- lH-indol-6-yl]-2-fluoro-nicotinamide. M+H 383.2; Calc'd 382.5. s) N- (4-tert-Butylphenyl)-2-fluoronicotinamide. t) N-(4-Trifluoromethylphenyl) -2-fluoronicotinamide. u) 2-Fluoro-N- [3- (l-Boc-azetidin-3-ylmethoxy) -5- trifluoromethyl-phenyl] -nicotinamide. M-H 468.2; Calc'd 469.16. v) 2-Fluoro-N- [3- (l-Boc-azetidin-3-ylmethoxy) -4-tert-butyl- phenyl] -nicotinamide. w) (S) N- [4-tert-Butyl-3- (l-Boc-pyrrolidin-2-ylmethoxy) - phenyl]-2-fluoro-nicotinamide. M+Na = 494. x) N- [3- (1-Methyl-piperidin-4-yl) -5-trifluoromethyl-phenyl]- 2-fluoro-nicotinamide was prepared with K2CO3 instead of NaHCO3. y) N- (3-Bromo-5-trifluoromethyl-phenyl) -2-fluoro- nicotinamide. z) 2-Fluoro-N- (3,9, 9-trimethyl-2,3,4,4a, 9, 9a-hexahydro-lH-3- aza-fluoren-6-yl) -nicotinamide. aa) 2-Fluoro-N-{4- [1-methyl-1- (l-methyl-piperidin-4-yl) - ethyl]-phenyl}-nicotinamide ab) N- [3,3-Dimethyl-l- (l-Boc-piperidin-4-ylmethyl) -2,3- dihydro-lH-indol-6-yl]-2-fluoro-nicotinamide.
Preparation V - l-Boc-4~{3-[(2-chloro-pyridine-3-carbonyl)- amino] -5-trifluorαmethyl-phenoxy}-piperidine: l-Boc-4-{3- [ (2-chloro-pyridine-3-carbonyl) -amino] -5- trifluoromethyl-phenoxy}-piperidine was prepared from 1-Boc- 4- (3-amino-5-trifluoromethyl-phenoxy) -piperidine and 2- chloropyridine-3-carbonyl chloride by a procedure similar to that described in the preparation of l-Boc-4-{3- [ (2-fluoro- pyridine-3-carbonyl) -amino]-5-trifluoromethyl-phenoxy}- piperidine.
The following compounds were prepared similarly to the procedure outlined above:
a) N- (4-tert-Butyl-3-nitro-phenyl) -2-chloro-nicotinamide. b) 2-Chloro-N-[3-(3-piperidin-l-yl-propyl)-5- trifluoromethyl-phenyl]-nicotinamide. c) 2-Chloro-N-[3-(3-morpholin-4-yl-propyl) -5- trifluoromethy1-phenyl]-nicotinamide. d) 2-Chloro-N-[3-(l-methylpiperidin-4-yl)-5-trifluoromethyl- phenyl]-nicotinamide. e) 2-Chloro-N-[3-(1-methyl-piperidin-4-ylmethoxy)-4- pentafluoroethyl-phenyl]-nicotinamide. f) 2-Chloro-N-[3-(l-isopropyl-piperidin-4-ylmethoxy)-4- pentafluoroethyl-phenyl]-nicotinamide. g) (S) 2-Chloro-N-[4-(oxiranylmethoxy)-3-pentafluoroethyl- phenyl]-nicotinamide. h) 2-Chloro-N-[3-(2-pyrrolidin-l-yl-ethoxy)-4- trifluoromethyl-phenyl]-nicotinamide. i) 2-Chloro-N-[3-(2-piperidin-l-yl-ethoxy)-4- pentafluoroethyl-phenyl]-nicotinamide. j) (R) 2-Chloro-N-[3- (l-Boc-pyrrolidin-2-ylmethoxy)-4- pentafluoroethyl-phenyl]-nicotinamide. k) (S) 2-Chloro-N- [3-(l-Boc-pyrrolidin-2-ylmethoxy)-4- pentafluoroethyl-phenyl]-nicotinamide.
1) (R) 2-Chloro-N- [3-(l-methyl-pyrrolidin-2-ylmethoxy)-5- trifluoromethyl-phenyl]-nicotinamide. m) (S) 2-Chloro-N-[3-(l-methyl-pyrrolidin-2-ylmethoxy)-5- trifluoromethyl-phenyl]-nicotinamide. n) (R) 2-Chloro-N-[4- (oxiranylmethoxy)-3-pentafluoroethyl- phenyl]-nicotinamide. o) (R) Acetic acid 2-{5-[ (2-chloro-pyridine-3-carbonyl)- amino]-2-pentafluoroethyl-phenoxy}-l-pyrrolidin-l-yl- ethyl ester. p) 2-Chloro-N-[3- (4-methyl-piperazin-l-ylmethyl)-5- trifluoromethyl-phenyl]-nicotinamide. q) 2-Chloro-N-[2- (4-methoxy-benzyl)-4,4-dimethyl-1-oxo-
1,2,3,4-tetrahydro-isoquinolin-7-yl]-nicotinamide. M+H 450.2. Calc'd 449. r) 2-Chloro-N- (4, 4-dimethyl-1-oxo-1, 2,3,4-tetrahydro- isoqτιinolin-7-yl) -nicotinamide. M+H 330.1, CaIc'd 329. s) 2-Chloro-N- [3- (4-Boc-piperazin-l-ylmethyl) -5- trifluoromethy1-phenyl]-nicotinamide. t) 2-{3-[ (2-Chloro-pyridine-3-carbonyl) -amino]-phenyl}-2- methyl-propionic acid methyl ester. M+H 405 u) N-{4-tert-Butyl-3-[2-(l-Boc-piperidin-4-yl) -ethyl] - phenyl}-2-chloro-nicotinamide. M+Na 524. CaIc'd 501.1. v) N- [3,3-Dimethyl-1, l-dioxo-2, 3-dihydro-lH- benzo[d]isothiazol-6-yl] -2-chloro-nicotinamide. w) N-[1,1,4, 4-Tetramethyl-l,2,3,4-tetrahydro-naphth-6-yl]-2- chloro-nicotinamide. x) 2-Chloro-N-[3,3-dimethyl-2,3-dihydro-benzofuran-6-yl]-2- chloro-nicotinamide. y) 2-Chloro-N- [3- (l-Boc-piperidin-4-yloxy) -5- trifluoromethyl-phenyl] -nicotinamide. z) 2-Chloro-N- [3- (1-methyl-piperidin-4-ylmethyl) -5- trifluoromethyl-phenyl] -nicotinamide. aa) 2-Chloro-N-[3- (3-piperidin-l-yl-propyl) -5- trifluoromethyl-phenyl]-nicotinamide. ab) N- [4-tert-Butyl-3- (4-pyrrolidin-l-yl-but-l-enyl)- phenyl]-2-chloro-nicotinamide. ac) (R) 2-Chloro-N- [3- (l-Boc-pyrrolidin-2-ylmethoxy) -5- trifluoromethyl-phenyl] -nicotinamide. ad) (S) 2-Chloro-N- [3- (l-Boc-pyrrolidin-2-ylmethoxy) -5- trifluoromethyl-phenyl] -nicotinamide.
Preparation VI - l-Boc-2-{3-[ (2-fluoro-pyridine-3-carbonyl)- amino]-5-trifluoromethyl-phenoxymβthyl}-pyrrolidine: l-Boc-2-{3-[ (2-Fluoro-pyridine-3-carbonyl) -amino]-5- trifluoromethyl-phenoxymethyl}-pyrrolidine was prepared from l-Boc-2- (3-amino-5-trifluoromethyl-phenoxymethyl) - pyrrolidine by a procedure similar to that described in the preparation of l-Boc-4-{3-[ (2-fluoro-pγridine-3-carbonyl) - amino]-5-trifluoromethyl-phenoxy}-piperidine.
Preparation VII - 2-(3-nitro-5-trifluoromethyl- phenoxymethyl)-pyrrolidine: l-Boc-2- (3-nitro-5-trifluoromethyl-phenoxymethyl) - pyrrolidine (2.35 g) was dissolved in CH2Cl2 (60 ml) and TFA (20 ml) was added. After stirring for 1 h at RT, the mixture was concentrated in vacuo to yield 2- (3-nitro-5- trifluoromethyl-phenoxymethyl)-pyrrolidine as an oil that solidified upon standing. The material was used as is without further purification.
The following compounds were prepared similarly to the procedure outlined above:
a) (4-Aminomethyl-pyrimidin-2-yl)- (3-morpholin-4-yl-propyl) - amine. b) (4-Aminomethyl-pyrimidin-2-yl)-[2- (l-methyl-pyrrolidin-2- yl)-ethyl]-amine.
Preparation VIII - l-methyl-2-(3-nitro-5-trifluoromethyl- phenoxymethyl)-pyrrolidine:
2- (3-Nitro-5-trifluoromethyl-phenoxymethyl)-pyrrolidine (6 mmol) was dissolved in CH3CN (20 ml) and formaldehyde (2.4 ml, 37% aqueous) was added. NaBH3CN (607 mg) was added, an exotherm was observed. The pH is monitored every 15 min and adjusted to ~7 with AcOH. After 45 min, the mixture was concentrated in vacuo and the residue is dissolved in EtOAc, washed with 6N NaOH, IN NaOH, and 2N HCl (3x) . The acid washings were combined, adjusted to ~pH 10 with solid Na2CO3 and extracted with EtOAc (2x) . The EtOAc fractions were combined, dried with Na2SO4, and purified with flash chromatography (SiO2, 95:5:0.5 CH2Cl2:MeOH:NH4OH) to afford 1-methyl-2- (3-nitro-5-trifluoromethyl-phenoxymethyl) - pyrrolidine.
The following compounds were prepared similarly to the procedure outlined above:
a) 2- (l-Methylpiperidin-4-yl) -ethanol. b) 2-{3-[ (2-Fluoro-pyridine-3-carbonyl) -amino]-5- trifluoromethyl-phenoxymethyl}-1-methylpyrrolidine.
Preparation IX - 4-tert-butyl-3-nitro-phenylamine: A mixture of 1,3-dinitro-4-tert-butylbenzene (10.0 g) in H2O (56 ml) was heated to reflux. A mixture of Na2S (21.42 g) and sulfur (2.85 g) in H2O (34 ml) was added over 1 h via an addition funnel. The reaction maintained at reflux for 1.5 h then cooled to RT and extracted with EtOAc. The organic extracts were combined and washed with H2O, brine, dried over MgSO4 and concentrated in vacuo to afford 4-tert-butyl- 3-nitro-phenylamine, which was used as is without further purification.
Preparation X - N-(3-brαmo-5-tri£luoroπιeth,γl-phenyl)- acetamide:
3-Bromo-5- (trifluoromethyl)phenylamine (5 g, Alfa-Aesar) was dissolved in AcOH (140 ml) and Ac2O (5.9 ml, Aldrich) was added. The reaction was stirred at RT overnight. The mixture was added slowly to H2O (-700 ml) forming a white precipitate. The solid was isolated by filtration, washed with H2O and dried under vacuum to yield N- (3-bromo-5- trifluoromethyl-phenyl)-acetamide. Preparation XI - N-[3-(3-piperidin-l-yl-propyl)-5- trifluorαmethyl-phenyl]-acetamide:
Allylpiperidine (1.96 g, Lancaster) was degassed under vacuum, dissolved in 0.5 M 9-BBN in THF (31.2 ml, Aldrich) , and heated to reflux for 1 h, then cooled to RT.
PD(dppf)Cl2/CH2Cl2 was added to a degassed mixture of N- (3- bromo-5-trifluoromethyl-phenyl)-acetamide, K2CO3 (9.8 g) DMF (32.1 ml and H2O (3 ml) . The allyl piperidine solution was added heated to 60 2C for 3 h. After cooling to RT and reheating at 60 3C for 6 h, the mixture was cooled to RT and poured into H2O. The mixture was extracted with EtOAc (2x) , and the EtOAc portion was washed with 2 N HCl (2x) and brine. The aqueous phases were combined and the pH was adjusted to -11 with NaOH (15%) forming a cloudy suspension. The cloudy suspension was extracted with EtOAc (2x) and the EtOAc portion was dried with Na2SO4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography (SiO2, 95:5:0.5 CH2Cl2:MeOH:NH4OH) to afford N-[3- (3-piperidin-1-yl-propyl)-5-trifluoromethyl- phenyl]-acetamide as a brown oil that solidified under vacuum.
The following compounds were prepared similarly to the procedure outlined above:
a) N-(3-Morpholin-4-ylpropyl-5-trifluoromethyl-phenyl) - acetamide from 4-allyl-morpholine. b) N- (3- (l-methylpiperdin-4-ylmethyl-5-trifluoromethyl- phenyl)-acetamide from l-Methyl-4-methylene-piperidine.
Preparation XII - 3-(3-piperidin-l-yl-propyl)-5- trifluoromethyl-phenylamine:
N-[3- (3-Piperidin-l-yl-propyl)-5-trifluoromethyl-phenyl]- acetamide (1.33 g) was dissolved in EtOH (40 ml) and 12 N HCl (40 ml) was added. After stirring overnight at 70 aC and RT, the mixture was concentrated in vacuo, affording 3- (3-piperidin-1-yl-propyl)-5-trifluoromethyl-phenylamine as a brown oil.
The following compounds were prepared similarly to the procedure outlined above:
a) 3,3-Dimethyl-6-nitro-2,3-dihydro-lH-indole. M+H 193.1; Calc'd 192.2. b) 3- (1-Methyl-piperidin-4-ylmethyl)-5-trifluoromethyl- phenylamine. c) 3-Morpholin-4-ylmethyl-5-trifluoromethyl-phenylamine.
Preparation XIII - 3,3-Dimethyl-6-nitro-l-piperidin-4- ylmethyl-2,3-dih.ydro-lH-indole:
3,3-Dimethyl-1-(1-Boc-piperidin-4-ylmethyl)-6-nitro-2,3- dihydro-IH-indole was dissolved in HCl/EtOAc and stirred for 2 h. The mixture was concentrated in vacuo and partitioned between 1,2-dichloroethane and IN NaOH. The organic layer was removed, washed with brine, dried (Na2SO4) and filtered. The material was used without further purification.
Preparation XIV - N-[3-(3-morpholin-4-yl-propyl)-5- trifluoromethyl-phenyl]-acetamide:
N-[3- (3-Morpholin-4-yl-propyl)-5-trifluoromethyl-phenyl]- acetamide was prepared from allyl morpholine and N-(3-bromo- 5-trifluoromethyl-phenyl)-acetamide similar to that described in the preparation of N-[3-(3-piperidin-1-yl- propyl)-5-trifluoromethyl-phenyl]-acetamide. Preparation XV - 3-(3-morpholin-4-yl-propyl)-5- trifluoromethyl-phenylamine:
3- (3-Morpholin-4-yl-propyl)-5-trifluoromethyl-phenylamine was prepared from N- [3- (3-morpholin-4-yl-propyl) -5- trifluoromethyl-phenyl]-acetamide similar to that described in the preparation of 3- (3-piperidin-1-yl-propyl) -5- trifluoromethyl-phenylamine.
Preparation 2CVI - l-methyl-4-methylene-piperidine: Ph3PCH3I (50 g, Aldrich) was suspended in Et2O (20 ml) and butyllithium (77.3 ml, 1.6 M in hexanes, Aldrich) was added dropwise. The reaction was stirred for 2 h at RT then 1- methylpiperidone (12.3 ml, Aldrich) was added slowly. The mixture was stirred at RT overnight. The solid was removed by filtration, the volume was reduced to ~400 ml and additional solid was removed by filtration. The Et2O was washed with H2O (2x) and 2N HCl (4x) . The pH of the acid washings was adjusted to -11 with 6 N NaOH, then they were extracted with CH2Cl2 (4x) . The CH2Cl2 washings were dried over Na2SO4 and concentrated cold in vacuo to provide 1- methyl-4-methylene-piperidine, which was used as is.
Preparation XVII - N- [3-(l-methylpiperidin-4-yl)-5- trifluoromethyl-phenyl]-acetamide: N-[3- (l-Methylpiperidin-4-yl)-5-trifluoromethyl-phenyl]- acetamide was prepared from l-methyl-4-methylene-piperidine and N- (3-bromo-5-trifluoromethyl-phenyl) -acetamide similar to that described in the preparation of N- [3- (3-piperidin-l- yl-propyl) -5-trifluoromethyl-phenyl]-acetamide.
Preparation XVIII - 3-(l-methylpiperidin-4-yl)-5- trifluoromethyl-phenylamine:
3- (l-Methylpiperidin-4-yl) -5-trifluoromethyl-phenylamine was prepared from N- [3- (l-methylpiperidin-4-yl) -5- trifluoromethyl-phenyl]-acetamide similar to the procedure described in the preparation of 3- (3-piperidin-l-yl-propyl)- 5-trifluoromethyl-phenylamine.
Preparation XIX - 2-(l-methylpiperidin-4-yloxy)-4- pyridylcarbonitrile:
4-Hydroxy-1-methylpiperidine (25.4 g) was dissolved in THF (50 ml) in a 100 mL r.b. flask. NaH/mineral oil mixture (9.58 g) was slowly added to the flask and stirred for 20 min. 2-Chloro-4-cyanopyridine was added to the mixture and stirred at RT until completion. Diluted mixture with EtOAc and added H2O to quench mixture, then transferred contents to a sep. funnel. The organic phase was collected while the aqueous phase was washed two times with EtOAc. The combined organics were dried over Na2SO4, filtered, then concentrated in vacuo. Then redissolved mixture in CH2Cl2, 10% HCl (300 ml) was added and the mixture was transferred to sep. funnel. The org. was extracted, while EtOAc along with 300 mL 5N NaOH was added to the sep. funnel. The organic phases were collected, dried over Na2SO4, filtered and concentrated in vacuo affording 2- (l-methylpiperidin-4-yloxy)-4- pyridylcarbonitrile as a brown solid. ESI (M+H) = 218.
The following compounds were prepared similarly to the procedure outlined above:
a) 2- (l-methylpiperidin-4-ylmethoxy)-4-pyridylcarbonitrile.
M+H 232.1. CaIc"d 231.1. b) 2- (l-Benzhydryl-azetidin-3-yloxy)-4-pyridylcarbonitrile. M+H 342.2. CaIc'd 341.2. c) 2- (l-methylpiperidin-4-ylethoxy)-4-pyridylcarbonitrile. d) 2- (1-pyrrolidinylethoxy)-4-pyridylcarbonitrile. e) 2- (l-methylpyrrolin-2-ylethoxy)-4-pyridylcarbonitrile. f) 2- [2-(l-Boc-azetidin-3-yl)-ethoxy]-4-pyridylcarbonitrile. Preparation XX - [2-(l-methylpiperidin-4-yloxy)-pyridin-4- yl]methylamine bis hydrochloride:
[2- (l-Methylpiperidin-4-yloxy) -pyridin-4-yl]methylamine was diluted with Et2O (50 ml) and IM HCl/Et2O (47 ml) was added. The vessel was swirled until precipitate formed.
Preparation XXI - 2-(2-morpholin-4-yl-ethoxy)-4- pyridylcarbonitrile: 2- (2-Morpholin-4-yl-ethoxy) -4-pyridylcarbonitrile was prepared from 2-chloro-4-cyanopyridine and 2-morpholin-4-yl- ethanol by a procedure similar to that described in the preparation of 2- (l-methylpiperidin-4-yloxy) -4- pyridylcarbonitrile. The HCl salt was prepared similar to that described for [2- (l-methylpiperidin-4-yloxy) -pyridin-4- yl]methylamine bis hydrochloride.
Preparation XXII - 2-morpholin-4-yl-propanol:
LAH powder (1.6 g) was added to a flask while under N2 atmosphere, immediately followed by THF (50 ml) . The mixture was chilled to 00C, methyl 2-morpholin-4-yl- propionate (5 g) was added dropwise to the reaction mixture and stirred at 00C. After 1 h, the mixture was worked up by adding H2O (44 iriL) , 2N NaOH (44 mL) , then H2O (44 mL, 3x) . After 30 min of stirring, the mixture was filtered through Celite® and the organic portion was concentrated in vacuo providing 2-morpholin-4-yl-propanol as a colorless oil.
The following compounds were prepared similarly to the procedure outlined above:
a) (l-Methyl-piperidin-4-yl) -methanol. M+H 130.2. CaIc'd 129.1. Preparation XXIII - 2-(2-morpholin~4-yl-propoxy)~4- pyridylcarbonitrile:
2- (2-Morpholin-4-γl-propoxγ) -4-pyridylcarbonitrile was prepared from 2-chloro-4-cyanopyridine and 2-morpholin-4-yl- propanol by a procedure similar to that described in the preparation of 2- (l-methylpiperidin-4-yloxy) -4- pyridylcarbonitrile.
Preparation XXIV - 2-(l-Methyl-pyrrolidin-2-ylmethoxy)-4- pyridylcarbonitrile:
2- (l-Methyl-pyrrolidin-2-ylmethoxy) -4-pyridylcarbonitrile was prepared from 2-chloro-4-cyanopyridine and 1-methyl- pyrrolidin-2-ylmethanol by a procedure similar to that described in the preparation of 2- (l-methylpiperidin-4- yloxy) -4-pyridylcarbonitrile. ESI MS: (M+H)=218.
Preparation XXV - 2~(3-morpholin-4-yl-propylamino)-4- pyridylcarbonitrile:
To a flask charged with 2-chloro-4-cyanopyridine (2.0 g) , was added the aminopropyl morpholine (2.11 ml). The mixture was heated to 79 2C for 5 h and stirred. After 5 h the reaction was incomplete. The mixture was then heated at 60 2C overnight. The crude compound was purified on silica gel (1-5% MeOH/CH2Cl2 gradient) . ESI MS: (M+H)=247, (M-H)=245.
Preparation XXVI - 5-Nitro-2-pentafluoroethylphenol: Combined 2-methoxy-4-nitro-l-pentafluoroethylbenzene (9.35 g) and pyridine HCl in a round bottom flask and heated at 210 2C for 1 h then cooled to RT. The mixture was diluted with EtOAc and 2N HCl (>500 ml) until all residue dissolved.
The organic layer was removed, washed with 2N HCl (2x) and concentrated in vacuo. The residue was dissolved in hexanes and Et2O, washed with 2N HCl, then brine. Dried organic layer over Na2SO4, filtered, concentrated in vacuo and dried under high vacuum to provide 5-nitro-2- pentafluoromethylphenol.
Preparation XXVII - 2-tert-Butyl-5-nitro-aniline: To H2SO4 (98%, 389 mL) in a 500 mL 3-neck flask was added 2- tert-butyl aniline (40.6 mL) . The reaction was cooled to - 10 aC and KNO3 in 3.89 g aliquots was added every 6 min for a total of 10 aliquots. Tried to maintain temperature at -5 2C to -10 2C. After final addition of KNO3, stirred the reaction for five min then it was poured onto ice (50 g) .
The black mix was diluted with H2O and extracted with EtOAc. The aqueous layer was basified with solid NaOH slowly then extracted with EtOAc (2x) . The combined organic layers were washed with 6N NaOH and then with a mix of 6N NaOH and brine, dried over Na2SO4, filtered and concentrated in vacuo to obtain crude 2-tert-butyl-5-nitro-aniline as a dark red- black oil which solidified when standing at RT. The crude material was triturated with about 130 mL hexanes. After decanting the hexanes, the material was dried to obtain a dark-red black solid.
Preparation XXVIII - 2-tert-Butyl-5-nitrophenol:
In a 250 ml round bottom flask, 20 mL concentrated H2SO4 was added to 2-tert-butyl-5-nitro-aniline (7.15 g) by adding 5 mL aliquots of acid and sonicating with occasional heating until all of the starting aniline went into solution. H2O (84 ml) was added with stirring, then the reaction was cooled to 0 2C forming a yellow-orange suspension. A solution of NaNO2 (2.792 g) in H2O (11.2 mL) was added dropwise to the suspension and stirred for 5 min. Excess NaNO2 was neutralized with urea, then the cloudy solution was transferred to 500 ml 3-necked round bottom flask then added 17 mL of 1:2 H2SO4:H20 solution, and heated at reflux. Two additional 5 mL aliquots of 1:2 H2SO4:H20 solution, a 7 mL aliquot of 1:2 H2SO4:H2O solution and another 10 mL of 1:2 H2SO4: H2O were added while heating at reflux. The mixture was cooled to RT forming a black layer floating on top of the aqueous layer. The black layer was diluted with EtOAc (300 mL) and separated. The organic layer was washed with H2O then brine, dried over Na2SO4 and concentrated in vacuo. Crude oil was purified on silica gel column with 8% EtOAc/Hexanes. Upon drying under vacuum, the 2-tert-butyl- 5-nitrophenol was isolated as a brown solid.
Preparation XXIX - l-methylpiperidine-4-carboxylic acid ethyl ester:
Piperidine-4-carboxylic acid ethyl ester (78 g) was dissolved in MeOH (1.2 L) at RT then formaldehyde (37%, 90 ml) and acetic acid (42 ml) were added and stirred for 2 h. The mixture was cooled to 0 2C, NaCNBH3 (70 g) was added, and the mix was stirred for 20 min at 0 aC, then overnight at RT. The mixture was cooled to 0 3C then quenched with 6N NaOH. The mixture was concentrated in vacuo to an aqueous layer, which was extracted with EtOAc (4x) , brine-washed, dried over Na2SO4, and concentrated in vacuo to provide 1- methylpiperidine-4-carboxylic acid ethyl ester.
The following compounds were prepared similarly to the procedure outlined above:
a) (1-Methyl-piperidin-4-yl)-methanol. M+H 130.2. CaIc'd 129.1.
Preparation XXX - N- [4-tert-Butyl-3-(l-methyl-piperidin-4- ylmethoxy)-phenyl] -2-chloro-nicotinamide:
N- [4-tert-Butyl-3- (l-methyl-piperidin-4-ylmethoxy) -phenyl] - 2-chloro-nicotinamide was prepared from 4-tert-butyl-3- (1- methyl-piperidin-4-ylmethoxy)-phenylamine by a procedure similar to that described in the preparation of l-Boc-4-{3- [ (2-chloro-pyridine-3-carbonγl) -amino] -5-trifluoromethyl- phenoxy}-piperidine.
Preparation XXXI - 1-[2-(2-tert-Butyl-5-nitro-phenoxy)- ethyl]-piperidine:
To 2-tert-butyl-5-nitrophenol (1.01 g) and K2CO3 (1.72 g) was added acetone (35 ml) and H2O (10.5 mL) , then l-(2- chloroethyl)piperidine HCl (1.909 g) and TBAI (153 mg) . The mixture was stirred at reflux overnight. Additional K2CO3
(850 mg) and 1- (2-chloroethyl) -piperidine HCl (950 mg) were added and the mixture was heated at reflux for 6 h. The mixture was concentrated in vacuo to an aqueous layer which was acidified with 2N HCl and extracted with EtOAc. The aqueous layer was basified with 6N NaOH and washed with
CH2Cl2 (3x) . The combined organic layers were washed with brine/IN NaOH and dried over Na2SO4. Washed the EtOAc layer with 2N NaOH/brine and dried over Na2SO4. The crude material was purified by silica gel column chromatography with 15% EtOAc/Hexanes to yield 1- [2- (2-tert-butyl-5-nitro- phenoxy)-ethyl]-piperidine as a light tan solid. (M+l)=307.3.
Preparation XXXII - l-Boc-Piperidine-4-carboxylic acid ethyl ester:
To a stirred solution of piperidine-4-carboxylic acid ethyl ester (23.5 g) in EtOAc (118 ml) at 0sC was added dropwise BoC2O in EtOAc (60 ml) . The reaction was warmed to RT and stirred overnight. The reaction was washed with H2O, 0.1N HCl, H2O, NaHCO3 and brine. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The liquid was dried under vacuum to provide l-Boc-piperidine-4-carboxylic acid ethyl ester. The following compounds were prepared similarly to the procedure outlined above:
a) N-Boc- (2-chloropyrimidin-4-yl)-methy1amine. b) 1- (2-tert-Butyl-4-nitrophenyl)-4-Boc-piperazine. c) l-Boc-azetidine-3-carboxylic acid d) l-Boc-4-Hydroxymethyl-piperidine using TEA.
Preparation XXXIII - l-Boc-4-hydroxymeth.yl-piperidine: l-Boc-4-Hydroxymethyl-piperidine was prepared from 1-Boc- piperidine-4-carboxylic acid ethyl ester by a procedure similar to that described in the preparation of 2-morpholin- 4-yl-propanol.
Preparation XXXIV - l-Boc-4-Methylsulfonyloxymeth.yl- piperidine:
Dissolved l-Boc-4-hydroxymethyl-piperidine in anhydrous CH2Cl2 (50 ml) and TEA (4.5 ml) and cooled to 0 0C. Mesyl chloride (840 μl) was added and the mixture was stirred for 15 min then at RT for 45 min. The mixture was washed with brine/IN HCl and then brine, dried over Na2SO4, concentrated in vacuo and dried under high vacuum to provide l-Boc-4- methylsulfonyloxymethyl-piperidine as a yellow orange thick oil.
The following compounds were prepared similarly to the procedure outlined above:
a) l-Boc-3-methylsulfonyloxymethyl-azetidine.
Preparation XXXV - l-Boc-4-(3-nitro-6-penta£luoroethyl- phenoxymethyl)-piperidine:
To a slurry of 60% NaH suspension in DMF (30 πiL) at RT added a solution of 5-nitro-2-pentafluoroethyl-phenol (3.6 g) in 5 mL DMF. The dark red mixture was stirred at RT for 10 min then added a solution of l-Boc-4-methylsulfonyloxymethyl- piperidine (3.1 g) in 5 mL DMF. The reaction was stirred at 60 aC and 95 2C. After 1 h, added 2.94 g K2CO3 and stirred overnight at 105 2C. After cooling to RT, the reaction was diluted with hexanes and IN NaOH. Separated layers, and washed organic layer with IN NaOH and with brine, dried over Na2SO4, filtered and concentrated in vacuo. Purification with silica gel column chromatography with 8% EtOAc/Hexanes yielded l-Boc-4- (3-nitro-6-pentafluoroethyl-phenoxymethyl) - piperidine as a light yellow thick oil.
Preparation XXXVI - 4-(3-nitro-6-penta£luoroethyl- phenoxymethyl)-piperidine: 4- (3-Nitro-6-pentafluoroethyl-phenoxymethyl) -piperidine was prepared from l-Boc-4-(3-nitro-6-pentafluoroethyl- phenoxymethyl) -piperidine by a procedure similar to that described in the preparation of 2- (3-nitro-5- trifluoromethyl-phenoxymethyl) -pyrrolidine.
Preparation XXXVII - l-methyl-4-(3-nitro-6-pentafluoroethyl- phenoxymethyl)-piperidine:
4- (3-Nitro-6-pentafluoroethyl-phenoxymethyl) -piperidine (316.5 mg) was dissolved in 2.7 mL CH3CN, then added 37% formaldehyde/H20 (360 ul) and then NaBH3CN (90 mg) . Upon addition of NaCNBH3 the reaction was found to be slightly exothermic. The reaction was stirred at RT and pH was maintained at ~7 by addition of drops of glacial AcOH. After about 1 h, the mixture was concentrated in vacuo, treated with 8 mL 2N KOH and extracted two times with 10 mL Et2O. The organic layers were washed with 0.5N KOH and then the combined organic layers were extracted two times with IN HCl. The aqueous layer was basified with solid KOH and extracted two times with Et2O. This organic layer was then washed with brine/lN NaOH, dried over Na2SO4, filtered, concentrated in vacuo and dried under high vacuum to give pure compound.
Preparation XXXVIlI - l-Isopropyl-4-(5-nitro-2- pentafluoroethyl-phenoxymethyl)-piperidine:
Dissolved 4- (5-nitro-2-pentafluoroethyl-phenoxymethyl) - piperidine (646 mg) in 1, 2-dichloroethane (6.4 ml), then added acetone (136 ul) , NaBH(OAc)3 (541 mg) and finally AcOH (105 ul) . Stirred the cloudy yellow solution under N2 at RT overnight. Added another 130 uL acetone and stirred at RT over weekend. Quenched the reaction with 30 mL N NaOH/H2O and stirred 10 min. Extracted with Et2O and the organic layer was brine-washed, dried over Na2SO4, filtered and concentrated in vacuo. Dried under high vacuum for several h to obtain l-isopropyl-4- (5-nitro-2-pentafluoroethyl- phenoxymethyl) -piperidine as a yellow orange solid.
The following compounds were prepared similarly to the procedure outlined above:
a) 3,3-Dimethyl-l-(l-methyl-piperidin-4-yl)-6-nitro-2,3- dihydro-IH-indole was prepared using 1-methyl-piperidin- 4-one. M+H 290; CaIc'd 289.4. b) 3,3-Dimethyl-l-(l-Boc-piperidin-4-ylmethyl)-6-nitro-2,3- dihydro-lH-indole using l-Boc-4-formyl-piperidine.
Preparation XXXIX - 3,3-Dimethy1-1-(l-methyl-piperidin-4- ylmethyl)-6-nitro-2,3-dihydro-IH-indole: 3,3-Dimethyl-l-piperidin-4-ylmethyl-6-nitro-2,3-dihydro-lH- indole was treated with an excess of formaldehyde and NaBH(OAc)3 and stirred overnight at RT. The reaction was quenched with MeOH and concentrated in vacuo. The residue was partitioned between EtOAc and IN NaOH. The organic layer was removed, washed with, brine, dried (Na2SO4) , filtered and concentrated to provide the compound.
Preparation XL - (S) 2-(5-Nitro-2-penta£luoroethyl- phenoxymethy1)-oxirane:
Combined 5-nitro-2-pentafluoromethylphenol (2.69 g) , DMF (25 ml) K2CO3 (3.03 g) and (S) toluene-4-sulfonic acid oxiranyl- methyl ester (2.27 g) and stirred the mixture at 9O0C.
After about 4 h, the mix was cooled, diluted with EtOAc, washed with H2O, IN NaOH (2x) , IN HCl and then with brine.
Dried over Na2SO4, filtered and concentrated in vacuo.
Purified the crude on silica gel column with 5% EtOAc/hexane and drying under high vacuum provided the (S) -2- (5-nitro-2- pentafluoroethyl-phenoxymethyl) -oxirane.
The following compounds were prepared similarly to the procedure outlined above:
a) (R) -2- (5-Nitro-2-pentafluoroethyl-phenoxymethyl) -oxirane.
Preparation XLl - (S) 2-Chloro-N- [3-(2-hydroxy-3-pyrrolidin- 1-yl-propoxy)-4-pentafluoroethyl-phenyl]-nicotinamide:
(S) 2-Chloro-N- [4- (2-oxiranylmethoxy-) -3-pentafluoroethyl- phenyl]-nicotinamide (1.11 g) in a sealed tube and added pyrrolidine (285 μl) . Stirred after sealing tube at 60 2C. After 12 h, the mixture was concentrated in vacuo and purified on a silica gel column (5:95:0.5 MeOH:CH2Cl2:NH4OH - 8:92:1, MeOH:CH2Cl2:NH4OH) . The product fractions were concentrated in vacuo and dried under high vacuum to obtain pure compound.
The following compounds were prepared similarly to the procedure outlined above: a) (R) 1- (5-Nitro-2-pentafluoroethyl-phenoxy) -3-pyrrolidin- l-γl-propan-2-ol.
Preparation XLII - 5-nitro-2-trifluoromethylanisole: Cooled 140 mL pyridine in a large sealable vessel to -40 2C. Bubbled in trifluoromethyl iodide from a gas cylinder, which had been kept in freezer overnight. After adding ICF3 for 20 min, added 2-iodo-5-nitroanisole (24.63 g) and copper powder (67.25 g) . Sealed vessel and stirred vigorously for 22 h at 140 2C After cooling to -50 aC, carefully unsealed reaction vessel and poured onto ice and Et2O. Repeatedly washed with Et2O and H2O. Allowed the ice - Et2O mixture to warm to RT. Separated layers, washed organic layer with IN HCl (3x) , then brine, dried over Na2SO4, filtered and concentrated in vacuo. Eluted material through silica gel plug (4.5:1 Hex:CH2Cl2) to provide 5-nitro-2- trifluoromethylanisole.
Preparation XLIII - l-[2-(5-nitro-2- trifluorαmethylphenoxy)ethyl]pyrrolidine:
1- [2- (5-Nitro-2-trifluoromethylphenoxy)ethyl] -pyrrolidine was prepared from 5-nitro-2-trifluoromethyl-phenol and l-(2- chloroethyl)pyrrolidine by a procedure similar to that described for 1- [2- (2-tert-butyl-5-nitro-phenoxy) -ethyl] - piperidine.
Preparation XLIV - 1-[2-(5-Nitro-2-pentafluoroethyl- phenoxy)-ethyl] -piperidine:
1- [2- (5-Nitro-2-pentafluoroethyl-phenoxy) -ethyl]-piperidine was prepared from 5-nitro-2-pentafru.oroethylph.enol and l-(2- chloroethyl)piperidine by a procedure similar to that described in the preparation of 1- [2- (2-tert-butyl-5-nitro- phenoxy) -ethyl]-piperidine.
Preparation XLV - 3-(l-Boc-pyrrolidin-2-ylmethoxy)-4- pentafluoroethyl-phenylamine:
3- (2-Pyrrolidin-l-yl-methoxy)-4-trifluoromethyl-phenylamine was prepared from 1- [2- (5-nitro-2- trifluoromethylphenoxy)methyl]-pyrrolidine by a procedure similar to that described in the preparation of l-Boc-4-(3- amino-5-trifluoromethyl-phenoxy) -piperidine.
Preparation XLVI - 2-Chloro-N-[3-(2-pyrrolidin-l-yl-ethoxy)- 4-trifluoromethyl-phenyl]-nicotinamide:
2-Chloro-N- [3- (2-pyrrolidin-l-yl-ethoxy)-4-trifluoromethyl- phenyl]-nicotinamide was prepared from 3- (2-pyrrolidin-l-yl- ethoxy) -4-trifluoromethyl-phenylamine and 2-chloropyridine- 3-carbonyl chloride by a procedure similar to that described in the preparation of l-Boc-4-{3- [ (2-chloro-pyridine-3- carbonyl) -amino]-5-trifluoromethyl-phenoxy}-piperidine. Preparation XLVII - (R) Acetic acid 2-(5-nitro-2- pentafluoroethyl-phenoxy)-l-pyrrolidin-l-ylmethyl-ethyl ester:
Dissolved 1-(5-nitro-2-pentafluoroethyl-phenoxγ) -3- pγrrolidin-l-γl-propan-2-ol (3.5 g) in CH2Cl2 (15 ml) , added TEA (2.55 ml) and cooled to 0 2C. Acetyl chloride (781.3 μl) was added dropwise, forming a suspension. The mixture was warmed to RT and stirred for 1.5 h. Additional acetyl chloride (200 μl) was added and the mix was stirred for another h. The mixture was diluted with CH2Cl2 and washed with sat. NaHCO3. The organic layer was removed, washed with brine and back extracted with CH2Cl2. Dried the combined organic layers over Na2SO4, filtered and concentrated in vacuo. The residue was purified over silica gel column (5:94.5:0.5 MeOH: CH2Cl2:NH40H) to provide acetic acid 2-(5-nitro-2-pentafluoroethyl-phenoxy)-1-pyrrolidin-l- ylmethyl-ethyl ester as a yellow brown oil.
The following compounds were prepared similarly to the procedure outlined above:
a) (R) Acetic acid 2-(5-amino-2-pentafluoroethyl-phenoxy)-1- pyrrolidin-1-yl-methyl-ethyl ester. b) 1- (2,2-Dimethyl-6-nitro-2,3-dihydro-benzo[l,4]oxazin-4- yl)~ethanone. M-NO2 206.4; Calc'd 250.1.
Preparation XLVIII - (R) 2-Chloro-N-[3-(2-hydroxy-2- pyrrolidin-1-yl-propoxy)-4-pentafluoroethyl-phenyl]- nicotinamide: (R) Acetic acid 2-{5-[ (2-chloro-pyridine-3-carbonyl)-amino]- 2-pentafluoroethyl-phenoxy}-1-pyrrolidin-l-yl-ethyl ester (408 mg) was dissolved in MeOH (15 ml) and NH4OH (6 ml) was added and the mixture was stirred at RT for 6 h. The reaction was concentrated in vacuo and dried under high vacuum. The residue was purified over silica gel column (8:92:0.6 MeOH: CH2Cl2:NH4OH) . The purified fractions were concentrated in vacuo and dried again to provide (R) -2- chloro-N- [3- (2-hydroxy-2-pyrrolidin-l-yl-ethoxy) -4- pentafluoroethyl-phenyl]-nicotinamide as a white foam.
Preparation XLIX - 2-Dimethylamino-l-(3#3-dimethyl~6-nitro- 2,3-dihydro-indol-l-yl)-ethanone
3,3-Dimethyl-6-nitro-2,3-dihydro-lH-indole (5 g) was dissolved in DMF (100 ml) and HOAt (3.89 g) dimethylamino- acetic acid (5.83 g) and EDC (3.89 g) were added. The reaction was stirred overnight. The mixture was diluted with CH2Cl2 (IL) and washed with sat'd NaHCO3 (3x200 ml). The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (SiO2, EtOAc to 5%MeOH/EtOAc) to afford the title compound.
The following compounds were prepared similarly to the procedure outlined above:
a) 1- (3 , 3-Dimethyl-6-nitro-2,3-dihydro-indol-l-yl) -2- (N-Boc- amino)-ethanone.
Preparation L - 1-(6-Amino-3,3-dimethy1-2,3-dihydro-indol-l- yl)-2-(N-Boc-amino)-ethanone:
1- (3, 3-Dimethyl-6-nitro-2,3-dihydro-indol-l-yl)-2- (N-Boc- amino) -ethanone (3.9 g) was dissolved in EtOH (30 ml) and Fe powder (3.1 g) NH4Cl (299 mg) and H2O (5 ml) were added. The reaction was stirred at 80 0C overnight. The reaction was filtered through Celite® and evaporated off the MeOH. The residue was partitioned between CH2Cl2 and sat'd NaHCO3. The organic layer was removed, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash chromatography (SiO2, 25% EtOAc/hexane) . The purified fractions were concentrated in vacuo to afford the compound as a white powder.
The following compounds were prepared similarly to the procedure outlined above:
a) 1- (6-Amino-3,3-dimethyl-2,3-dihydro-indol-l-yl)-2- dimethylamino-ethanone. b) 3,3-Dimethyl-l-(l-methyl-piperidin-4-ylmethyl)-2,3- dihydro-lH-indol-6-ylamine. c) 3- (4-Methyl-piperazin-l-ylmethyl)-4-pentafluoroethyl- phenylamine. M+H 324.2. CaIc'd 323. d) 3,3-Dimethyl-l-(1-methyl-piperidin-4-yl) -2,3-dihydro-lH- indol-6-ylamine. M+H 259.6; CaIc'd 259.3. e) 3,3-Dimethyl-l,l-dioxo-2,3-dihydro-lH-116- benzo[d]isothiazol-6-ylamine f) 1,1,4,4-Tetramethyl-l,2,3,4-tetrahydro-naphth-6-ylamine. g) 3,3-Dimethyl-l- (l-Boc-piperidin-4-ylmethyl)-2,3-dihydro- lH-indol-6-ylamine.
Preparation LI - 2-Boc-4,4-dimethyl-7-nitro-l/2#3,4- tetrahydro-isoquinoline:
4,4-Dimethyl-7-nitro-l,2,3,4-tetrahydro-isoquinoline (150 mg) was dissolved with CH2Cl2 (3 ml) DIEA (100 ul) DMAP (208 mg and BoC2O (204 mg) and the mixture was stirred for 6 h at RT. The reaction was diluted with CH2Cl2, washed with sat'd NaHCO3 and dried over MgSO4, filtered and concentrated to provide the compound which was used without further purification.
The following compounds were prepared similarly to the procedure outlined above substituting Ac2O: a) 1- (4,4-Dimethyl-7-nitro-3,4-dihydro-lH-isoquinolin-2-yl) - ethanone. M+H 249.3.
Preparation LII - 2-Brαmo-N-(4-methoxy-benzyl)-5-nitro- benzamide:
PMB-amine (5.35 ml) in CH2Cl2 (130 ml) was slowly added to 2-bromo-5-nitro-benzoyl chloride (10.55 g) and NaHCO3 (9.6 g) and the mixture was stirred at RT for 1 h. The mixture was diluted with CH2Cl2 (1 L) , filtered, washed with diluted HCl, dried, filtered again, concentrated and dried under vacuum to provide the compound as a white solid. M+H 367. Calc'd 366.
Preparation LIII - 2-Bromo-N-(4-methoxy-benzyl)-N-(2-methyl- allyl)-5-nitro-benzamide:
To a suspension of NaH (1.22 g) in DMF (130 ml) was added 2- bromo-N- (4-methoxy-benzyl) -5-nitro-benzamide (6.2 g) in DMF (60 ml) at -78 2C. The mixture was warmed to 0 2C, 3-bromo- 2-methyl-propene (4.57 g) was added and the mixture was stirred for 2 h at 0 SC. The reaction was poured into ice H2O, extracted with EtOAc (2x400 ml), dried over MgSO4, filtered and concentrated to a DMF solution which was used without further purification.
Preparation LIV - of 2-(4-Methoxy-benzyl)-4,4-dimethyl-7- nitro-3,4-dihydro-2H-isoquinolin-l-one:
2-Bromo-N- (4-methoxy-benzyl) -N- (2-methyl-allyl)-5-nitro- benzamide (23.4 mmol) was dissolved in DMF ( 150 ml) and Et4NCl (4.25 g) , HCO2Na (1.75 g) and NaOAc (4.99 g) were added. N2 was bubbled through the solution for 10 min, then
Pd(OAc)2 (490 mg) was added and the mixture was stirred overnight at 70 2C. The mixture was extracted with EtOAc, washed with sat'd NH4Cl, dried over MgSO4, filtered and concentrated until the compound precipitated as a white solid.
The following compounds were prepared similarly to the procedure outlined above:
a) 3, 3-Dimethyl-6-nitro-2, 3-dihydro-benzofuran was prepared from l-bromo-2- (2-methyl-allyloxy) -4-nitro-benzene. b) 3, 9, 9-Trimethyl-6-nitro-4, 9-dihydro-3H-3-aza-fluorene was prepared from 4- [1- (2-bromo-4-nitro-phenyl) -1-methyl- ethyl] -1-methyl-l, 2,3, 6-tetrahydro-pyridine.
Preparation LV - 4#4-Diπιeth.yl-7-nitro-3#4-dihydro-2H- isoquinolin-1-one: 2-(4-Methoxy-benzyl)-4,4-dimethyl-7-nitro-3,4-dihydro-2H- isoguinolin-1-one (2.0 g) was dissolved in CH3CN (100 ml) and H2O (50 ml) and cooled to 0 aC. CAN (9.64 g) was added and the reaction was stirred at 0 ΞC for 30 min, then warmed to RT and stirred for 6 h. The mixture was extracted with CH2Cl2 (2x300 ml) washed with sat'd NH4Cl, dried over MgSO4, filtered and concentrated. The crude material was recrystallized in CH2Cl2/Et0Ac (1:1) to give 4,4-dimethyl-7- nitro-3,4-dihydro-2H-isoguinolin-l-one as a white solid.
Preparation LVI - 4/4-Dimethyl-7-nitro-l,2f3,4-tetrahydro- isoquinoline:
4,4-Dimethyl-7-nitro-3,4-dihydro-2H-isoguinolin-l-one (230 mg) was dissolved in THF (10 ml) and BH3Me2S (400 ul) was added and the reaction was stirred overnight at RT. The reaction was quenched with MeOH (10 ml) and NaOH (200 mg) and heating at reflux for 20 min. The mixture was extracted with EtOAc, washed with sat'd NH4Cl, extracted with 10% HCl (20 ml) . The acidic solution was treated with 5N NaOH (15 ml) , extracted with EtOAc (30 ml) dried, filtered and evaporated to give the compound as a yellow solid. M+H 207.2, Calc'd 206.
The following compounds were prepared similarly to the procedure outlined above:
a) 4-BOC-2,2-dimethyl-6-nitro-3,4-dihydro-2H- benzo[1,4]oxazine.
Preparation LVII - 2-Brαmomethyl-4-nitro-l-penta£luoroethyl- benzene:
2-Methyl-4-nitro-l-pentafluoroethyl-benzene (2.55 g) was dissolved in CCl4 (30 ml) and AIBN (164 mg) and NBS (1.96 g) were added. The reaction was heated to reflux and stirred for 24 h. The mix was diluted with CH2Cl2, washed with sat'd NaHCO3, dried over MgSO4 and concentrated to give the compound as an oil which was used without further purification.
Preparation LVIII - l-Methyl-4-(5-nitro-2-penta£luoroethyl~ benzyl)-piperazine:
2-Bromomethyl-4-nitro-l-pentafluoroethyl-benzene (2.6 g) was added to N-methylpiperazine (5 ml) and stirred at RT for 3 h. The mixture was filtered and the filtrate was treated with 1-chlorobutane, extracted with 2N HCl (100 ml) . The acidic solution was treated with 5N NaOH (6 ml) then extracted with EtOAc. The organic layer was removed, dried over MgSO4 and concentrated to give the compound as an oil.
The following compounds were prepared similarly to the procedure outlined above:
a) 4- (5-Nitro-2-pentafluoroethyl-benzyl)-morpholine. Preparation LIX - l-Boc-4-(5-nitro~2-penta£luoroethyl- benzyl)-piperazine.
2-Bromomethyl-4-nitro-l-pentafluoroethyl-benzene (2.5 g) was dissolved in CH2Cl2 and added to N-Boc-piperazine (2.5 g) and NaHCO3 (1 g) and stirred at RT overnight. The mixture was diluted with CH2Cl2 (100 ml) , washed with sat'd NH4Cl, dried over MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography (hexane, CH2Cl2:hexane 2:8) to give the compound as a yellow solid.
Preparation LX - (4-Boc-piperazin-l-yl)-(3-nitro-5- trifluoromethyl-phenyl)-methanone:
A mixture of 3-nitro-5-trifluoromethyl-benzoic acid (4.13 g) , 4-Boc-piperazine (2.97 g) , EDC (3.88 g) , HOBt (2.74 g) and DIEA (3.33 ml) in CH2Cl2 (120 ml) was stirred at RT for 3 h. The mixture was diluted with CH2Cl2 (100 ml) , washed with sat'd NH4Cl, dried over MgSO4, filtered and concentrated. The residue was purified by silica gel chromatography (hexane, CH2Cl2:hexane 1:2) to give the compound as a white solid.
Preparation LXI - l-Boc-4-(3-nitro-5-trifluoromethyl- benzyl)-piperazine:
(4-Boc-piperazin-l-yl) - (3-nitro-5-trifluoromethyl-phenyl) - methanone (403 mg) was dissolved in THF (6 ml) and BH3Me2S (300 μl) was added and the reaction was stirred for 3 h at 60 2C and 2 h at RT. The reaction was quenched with MeOH (5 ml) and NaOH (100 mg) and stirred at RT for 1 h. The mixture was concentrated and dissolved in CH2Cl2, washed with sat'd NH4Cl/NaHCO3, dried (MgSO4), filtered and evaporated to give the compound as an oil. M+H 390.3. Preparation LXII - 2-Ethyl-4~aminαmethyl pyridine:
To a solution of 2-ethyl-4-thiopyridylamide (10 g) in MeOH (250 ml) was added Raney 2800 Nickel (5. g, Aldrich) in one portion. The mixture was stirred at RT for 2 days then at 60 2C for 16 h. The mixture was filtered, concentrated to provide the desired compound.
Preparation LXIII - N-Boc-[2-(4-morpholin-4-yl-butyl)- pyrimidin-4-ylmethyl] -amine: N-Boc- (2-chloropyrimidine) -methylamine (663 mg) and 4-
(aminopropyl)morpholine (786 mg) were dissolved in MeOH and concentrated in vacuo. The residue was heated at 100 SC for 15 min, forming a solid, which was dissolved in CH2Cl2/Me0H then concentrated again and heated 15 min more. The solution was concentrated in vacuo and dried under high vacuum, and the resulting solid was triturated with a small amount of IpOH and allowed to settle over a weekend. The solid was filtered, rinsing with a small amount of IpOH, to provide the compound as a white solid.
The following compounds were prepared similarly to the procedure outlined above:
a) (4-Bocaminomethyl-pyrimidin-2-yl) - [2- (1-methyl- pyrrolidin-2-yl)-ethyl]-amine. M+H 336.5; CaIc'd 335.45.
Preparation LXIV - 2-fluoronicotinic acid:
In a flame dried 3-necked round bottom flask equipped with a dropping funnel and thermometer, under N2, THF (250 ml) was added via cannula. LDA (2M in cyclohexane, 54 ml) was added via cannula as the flask was cooled to -78 2C. At -78 2C, 2-fluoropyridine (8.87 ml) was added dropwise over 10 min. The reaction was stirred for 3 h. Condensation was blown off (with N2) a few cubes of solid CO2 and they were added to the mixture. The mixture was warmed to RT once the solution turned yellow, and it was stirred overnight. The reaction was cooled to 0 2C and the pH was adjusted to -2.5 with 5N HCl. The mixture was concentrated in vacuo and extracted with EtOAc. The EtOAc layer was washed with brine, dried over MgSO4, filtered and concentrated to dryness. The resulting solid was taken into a slurry with EtOAc (100 ml) , filtered, washed with cold EtOAc and dried at 50 2C for 1 h to afford 2-fluoronictinic acid. M+H 142.1; CaIc"d 141.0.
Preparation LXV - 4-cyano-2-_nethoxypyridine: Under a stream of N2 and with cooling, Na metal (2.7 g) was added to MeOH (36 ml) with a considerable exotherm. After the Na is dissolved, a solution of 2-chloro-4-cyanopyridine (15 g) in dioxane:MeOH (1:1, 110 ml) was added via dropping funnel over a 10 min period. The reaction was heated to reflux for 3.5 h then cooled at ~10 2C overnight. Solid was filtered off and the solid was washed with MeOH. The filtrate was concentrated to -60 ml and H2O (60 ml) was added to redissolve a precipitate. Upon further concentration, a precipitate formed which was washed with H2O. Further concentration produced additional solids. The solids were combined and dried in vacuo overnight at 35 SC to provide 4-cyano-2-methoxypyridine which was used as is.
Preparation LXVI - (2-methoxypyridin-4-yl)methγlamine: 4-Cyano-2-methoxypyridine (1.7 g) was dissolved in MeOH (50 ml) and cone. HCl (4.96 ml) was added. Pd/C (10%) was added and H2 was added and let stand overnight. The solids were filtered through Celite® and the cake was washed with MeOH
(-250 ml) . Concentration in vacuo produced an oil which was dissolved in MeOH (-20 ml) . Et2O (200 ml) was added and stirred for 1 h. The resulting precipitate was filtered and washed with Et2O to afford (2-methoxypyridin-4- yl)methylamine (HCl salt) as an off-white solid.
Preparation LXVII - 2-(4-Aitiino-phenyl)-2-methyl-propionic acid methyl ester:
2-Methyl-2- (4-nitro-phenyl) -propionic acid methyl ester (2.1 g) was dissolved in THF (70 ml) and AcOH (5 ml) and Zn (10 g) were added. The mixture was stirred for 1 h and filtered through Celite®. The filtrate was rinsed with EtOAc and the organics were evaporated to a residue which was purified on silica gel chromatography (40%EtOAc/hexanes) to provide the desired compound as a yellow oil. M+H 194.
Preparation LXVIII - l-(2-tert-Butyl-phenyl)-4-methyl- piperazine:
2-tert-Butyl-phenylamine and bis- (2-chloro-ethyl) - methylamine were mixed together with K2CO3 (25 g) , NaI (10 g) and diglyme (250 itiL) and heated at 170 2C for 8 h. The reaction mixture was cooled, the solid filtered and solvent evaporated. The residue was diluted with EtOAc, washed with NaHCO3 solution, extracted twice more with EtOAc, washed with brine, dried over Na2SO4 and evaporated to give the compound as a dark solid.
The following compounds were prepared similarly to the procedure outlined above:
a) l-Bromo-2- (2-methyl-allyloxy) -4-nitro-benzene was prepared from methallyl bromide.
Preparation LXIX - 3-(l-Methyl-l,2,3,6-tetrahydro-pyridin-4- yl)-5-trifluoromethyl-phenylamine:
3- (5, 5-Dimethyl-[1,3,2]dioxaborinan-2-yl)-5-trifluoromethyl- phenylamine (8.8 g, 0.032 mol)was added to trifluoro- methanesulfonic acid 1-methyl-l,2,3, 6-tetrahydro-pyridin-4- yl ester (7.91 g, 0.032 mol)and 2N Na2CO3 aqueous solution (25 itiL) was bubbled through N2 for 5 min. Pd(PPh3)4 (3.7 g, 3.2 itimol) was added and the reaction was heated to 80 SC for 16 h. The reaction was cooled to RT and diluted with Et2O (100 itiL) . The mixture was filtered through Celite® and the filtrate was washed with NaHCO3 aqueous solution (25 ml) followed by brine (25 mL) . The organic phase was dried over Na2SO4 and concentrated in vacuo. The desired compound was isolated by passing through silica gel column chromatography (EtOAc, then (2M NH3) in MeOH/EtOAc) to provide a yellow oil.
Preparation LXX - 3#3-Dimethyl-6-nitro-2,3-dihydro- benzotd]isothiasole 1,1-dioxide:
3,3-Dimethyl-2,3-dihydro-benzo[d]isothiazole 1,1-dioxide was added to KNO3 in H2SO4 cooled to 0 2C and stirred for 15 min. The reaction was warmed to RT and stirred overnight. The mix was poured into ice and extracted with EtOAc (3x) , washed with H2O and brine, dried and evaporated to give the compound which was used without further purification.
The following compounds were prepared similarly to the procedure outlined above:
a) 1,1,4, 4-Tetramethyl-6-nitro-l,2,3, 4-tetrahydro- naphthalene
Preparation LXXI - 3-(l-Methyl-l,2,3,4-tetrahydro-pyridin-4- yl)-5-trifluoromethyl-phenylamine:
3- (5, 5-Dimethyl-[1,3,2]dioxaborinan-2-yl) -5-trifluoromethyl- phenylamine (1.2 g) was added to trifluoro-methanesulfonic acid 1-methyl-l,2,3, 6-tetrahydro-pyridin-4-yl ester (1.0 g) , LiCl (500 mg, Aldrich) , PPh3 (300 mg, Aldrich) and 2M Na2CO3 aqueous solution (6 ml) and was bubbled with N2 for 5 min. Pd(PPH3)4 (300 mg, Aldrich) was added and the reaction was heated to 80 2C for 16 h. The reaction was cooled to RT and diluted with Et2O (100 mL) . The mixture was filtered through Celite® and the filtrate was washed with NaHCO3 aqueous solution (25 ml) followed by brine (25 mL) . The organic phase was dried over Na2SO4 and concentrated in vacuo. The desired compound was isolated by silica gel column chromatography (EtOAc 10% (2M NH3) in MeOH/EtOAc) to provide yellow oil. M+H 257.2; CaIc'd 256.1.
Preparation LXXXI - Trifluoromethylsulfonic acid 1-methyl- l,2,3,6-tetrahydro-pyridin-4~yl ester:
In a three-necked round bottom flask equipped with a thermometer and an additional funnel was placed anhydrous
THF (200 mL) and 2M LDA (82.8 mL) . The solution was cooled to -78 2C and a solution of 1-methyl-piperidin-4-one (20 mL) in anhydrous THF (70 mL) was added drop-wise. The reaction was warmed to -10 2C over 30 min and cooled down again to - 78 2C. Tf2NPh (54.32 g) in 200 mL of anhydrous THF was added through the additional funnel over 30 min and anhydrous THF (30 mL) was added to rinse the funnel. The reaction was warmed to RT and the reaction solution was concentrated in vacuo. The residue was dissolved in Et2O purified on neutral Al2O3 column chromatography (Et2O as elutant) . The compound was obtained as orange oil. (20 g)
Preparation LXXIII - 3-(5#5-Dimethyl-[l,3,2]dioxaborinan-2- yl)-5-trifluoromethyl-phenylamine: N2 was bubbled through a solution of 3-bromo-5- trifluoromethyl-phenylamine (2.38 g), 5,5, 5 ' , 5 ' -tetramethyl- [2,2 ' ]bi[ [l,3,2]dioxaborinanyl] (2.24 g, Frontier Scientific) and KOAc (2.92 g) , dppf (165 mg, Aldrich) in anhydrous dioxane (50 ml) for 2 min. PdCl2 (dppf) (243 mg, Aldrich) was added and the reaction was heated to 8O0C for 4 h. After cooling to RT, the mix was diluted with 50 mL of Et2O, filtered through Celite®, and the filtrate was concentrated in vacuo. The residue was dissolved in Et2O (100 mL) , washed with sat. NaHCO3 aqueous solution (50 mL) followed by brine (50 mL) . The organic phase was dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in 3:2 Et2O/Hex (100 mL) , filtered through Celite® and the filtrate was concentrated in vacuo to afford a dark brown semi-solid.
Preparation LXXIV - l-Boc-3-Hydroxymethyl-azetidine:
A solution of l-Boc-azetidine-3-carboxylic acid (1.6 g) and Et3N (2 ml) in anhydrous THF (60 ml) was cooled to 00C. Isopropyl chloroformate (1.3 g) was added via a syringe slowly; forming a white precipitate almost immediately. The reaction was stirred for 1 h at 0 2C and the precipitate was filtered out. The filtrate was cooled to 0 2C again and aqueous NaBH4 solution (900 mg, 5 ml) was added via pipette and stirred for 1 h. The reaction was quenched with NaHCO3 solution (50 mL) and the compound was extracted with EtOAc (200 mL) . The organic phase was washed with brine (50 mL) , dried over Na2SO4 and concentrated in vacuo. The residue was dissolved in EtOAc and passed through a short silica gel pad. Concentrating the filtrate in vacuo provided the compound as a light yellow oil.
Preparation LXXV - l-Boc-3-(3-nitro-5-tri£luoromethyl- phenoxymethyl)-azetidine: A mixture of l-Boc-3-methylsulfonyloxymethyl-azetidine (1.47 g) , 3-nitro-5-trifluoromethyl-phenol (1.15 g) and K2CO3 (1.15 g) in DMF (20 ml) at 80 0C was stirred overnight. The reaction was cooled to RT and diluted with 25 mL of sat. NaHCO3 and 50 mL of EtOAc. The organic phase was separated and washed with brine (25 mL) , dried over Na2SO4 and concentrated in vacuo. The crude compound was purified by column chromatography (50% EtOAc/hex) .
Preparation LXXVI - 2,2-Dimethyl-6-nitro-3,4-dihydro-2H- benzo[1,4]oxazine:
2,2-Dimethyl-6-nitro-4H-benzo[l, 4]oxazin-3-one was added to BH3-THF complex (Aldrich) in THF with ice cooling. The mixture was heated to reflux for 2 h then carefully diluted with 12 mL of MeOH and heated to reflux for an additional 1 h. Concentrated HCl (12 mL) was added and heated to reflux for 1 h. The mixture was concentrated and the resulting solid was suspended in a dilute aqueous solution of NaOH (1 M) and extracted with EtOAc (100 mL x 4) . The organic layers were washed with H2O and dried over MgSO4. Evaporation of solvent gave a yellow solid.
Preparation LXXVII - 2#2#4-Trimethyl-6-nitro-4H- benzo[l,4]oxazin-3-one: 2,2-Dimethyl-6-nitro-4H-benzo[l,4]oxazin-3-one (1.1 g) was mixed with MeI (850 mg, Aldrich), K2CO3 (1.38 g, Aldrich) and DMF (30 ml, Aldrich) at 400C for 48 h. The DMF was removed in vacuo and the residue was diluted with EtOAc (80 ml) . The organic phase was washed with H2O (50 ml) , aqueous Na2SO3 (50 ml) and brine (50 ml) . The resulting solution was dried (MgSO4) and concentrated to provide the compound which was used as is for the next reaction step.
Preparation LXXVIII - 2-Bromo-N-(2-hydroxy-5-nitro-phenyl)- 2-methyl-propionamide:
2-Amino-4-nitro-phenol (3.08 g, Aldrich) was stirred with THF (30 ml, Aldrich) in an ice bath. 2-Bromo-2-methyl- propionyl bromide (2.47 ml, Aldrich) and Et3N (2.0 g, Aldrich) was slowly added via syringe. The mixture was stirred for 45 min then poured into ice. The aqueous phase was extracted by EtOAc (50 mL x 4) . The organic layer was dried and concentrated. The desired compound was crystallized from EtOAc {Chem. Pharm. Bull 1996, 44(1) 103- 114) .
Preparation LXXIX - 2,2-Dimethyl-6-nitro-4H- bexizo[l,4]oxazin-3-one:
2-Bromo-N- (2-hydroxy-5-nitro-phenyl) -2-methyl-propionamide was mixed with K2CO3 in 20 mL of DMF and stirred overnight at 500C. The reaction mixture was poured into ice H20. The precipitate was collected by filtration and washed with H2O. The crude compound was recrystallized from EtOH.
Preparation LXXX -4- [l-(2-Bromo-4-nitro-phenyl)-l-methyl- ethyl]-1-methyl-pyridinium iodide: l-Methyl-4- [1-methyl-l- (4-nitro-phenyl) -ethyl]-pyridinium (8 g) was dissolved in glacial HOAc (10 ml) then diluted with H2SO4 (50 ml), then NBS (3.8 g) was added. After 1 h, additional NBS (1.2 g) was added, 30 min later another 0.5 g of NBS, then 15 min later 200 mg more NBS. After 1 h, the mixture was neutralized with NH4OH (cone.) with ice bath cooling. The neutralized mixture was then concentrated and used as is.
Preparation LXXXI - 4-[l-(2~Bromo-4-nitro-phenyl)-l-methyl- ethyl]-1-methyl-l,2,3,6-tetrahydro-pyridine: 4- [1- (2-Bromo-4-nitro-phenyl) -1-methyl-ethyl] -1-methyl- pyridiniumiodide was mixed with MeOH (400 ml) and CH2Cl2 (200 ml), then treated with NaBH4 (2.5 g) in portions.
After stirring at RT for 2 h, the mixture was extracted with CH2Cl2 (300 mL x 3) . The CH2Cl2 layer was washed with brine, dried over Na2SO4 and concentrated in vacuo, to provide the desired compound. Preparation LXXXIl - l-Methyl-4- [l-methyl-l-(4-nitro- phenyl)-ethyl]-pyridinium iodide:
4- (4-Nitro-benzγl) -pyridine (4.3 g) was mixed with. MeI (4 ml, 9.12 g)/NaOH (5N, 30 ml), Bu4NI (150 mg) and CH2Cl2 (50 ml) and stirred at RT overnight. Additional MeI (2 mL) was added along with 50 mL of NaOH (5N) . 6 h later, more MeI (2 mL) was added. The mixture was stirred at RT over the weekend. The mixture was cooled on ice bath and the base was neutralized by cone. HCl (aq) addition dropwise to pH 7. The compound was used as is.
Preparation LXXXIII - l-Methyl-4-(4-nitro-benzyl)-l,2#3,6- tetrahydro-pyridine: 4- (4-Nitrobenzyl)pyridine (64 g) and TBAI (6 g) were dissolved in CH2Cl2 (500 mL) and the solution was suspended with NaOH (aq. 5N, 450 mL) in a 3L 3-necked round bottom flask. With vigorous stirring, CH3I (213 g) was added and stirred vigorously at RT for 60 h (or until blue color disappears) . The reaction was quenched with dimethylamine (100 mL) and MeOH (300 mL) and stirred for 2 h. NaBH4 (19 g) was added to the mixture in small portions. The reaction mixture was stirred for 30 min at RT, then partitioned between CH2C12/H2O (500 mL/500 mL) . The organic layer was collected and the aqueous layer was washed with CH2Cl2 (300 mL x 3) . The combined organic layers was washed with brine then concentrated in vacuo. The residue was purified on a silica wash-column (7% TEA in EtOAc) . The desired fractions were combined and concentrated under vacuum to give the desired compound as a dark gray solid. (MS: M+l=261) .
Preparation LXXXIV - l-Boc-4-formylpiperidine:
4A Molecular sieves were heated to 100 0C and a vacuum was applied. They were cooled to RT and purged with N2. CH2Cl2 (420 ml) and CH3CN (40 ml), NMO (40 g) and l-Boc-4- hydroxymethylpiperidine (50 g) were added and the mix was stirred for 5 min then cooled to 15 °C. TPAP (4.1 g) is added and an exotherm was observed. The reaction was maintained at RT with external cooling. The reaction was stirred at RT for 3 h, filtered, concentrated, diluted with 50% EtOAc/hexanes and purified on a silica gel plug (50%EtOAc/hexanes) . The eluant fractions were concentrated to afford a yellow oil.
Preparation LXXXV 2-Chloro~4-cyanopyridine:
2-Chloro-4-cyanopyridine was prepared similar to the method described by Daves et al., J. Het. Chem. , 1, 130-32 (1964) .
Preparation LXXXVI 4-(2-tert-Butyl-5-nitro~phenyl)-but-3-en- l-ol:
A mix of 1- (tert-butyl)-2-bromo-4-nitrobenzene (3.652 g) , TEA (5.92 ml), 3-buten-l-ol (5.48 ml), Pd(OAc)2 (32 mg) , Pd(PPh3)4 (327 mg) and toluene (40 ml) was degassed with nitrogen and heated in a sealed vessel for 16 h at 120 0C. The next day, the reaction mixture was cooled to RT, filtered, and concentrated in vacuo. The crude was eluted on a silica gel column with 15% to 22% EtOAc/hexanes gradient system to yield a yellow-brown oil.
Preparation LXXXVII 4-(2-tert-Butyl-5-nitro-phenyl)-but-3- enal:
4-(2-tert-Butyl-5-nitro-phenyl)-but-3-en-l-ol (1.024 g) was dissolved in 10 ml of CH2Cl2 and added dropwise over 5 min to a -78 0C mix of oxalyl chloride (0.645 ml), DMSO (0.583 ml), and 10 ml CH2Cl2. The reaction was stirred at -78 0C for 1 h, then treated with a solution of TEA (1.52 ml) in 7 ml CH2Cl2 and stirred at -78 0C for an additional 25 min, then warmed to -30 0C for 35 min. The reaction was treated with 50 ml of saturated aqueous NH4Cl, diluted with H2O and extracted with EtOAc. The organic layer was brine-washed, dried over Na2SO4, filtered, and concentrated in vacuo to yield a yellow oil which was used as is in Preparation LXXXVIII.
Preparation LXXXVIIl 1-[4-(2-tert-Butyl-5-nitro-phenyl)-but- 3-enyl] -pyrrolidine:
4- (2-tert-Butyl-5-nitro-phenyl)-but-3-enal (895 mg) was dissolved in 40 ml THF, and to the solution was added pyrrolidine (0.317. ml) . To the deep orange solution was added NaBH(OAc)3 (1.151 g) and glacial AcOH (0.207 ml) . The reaction was stirred at RT overnight, then treated with saturated aqueous NaHCO3 and diluted with Et2O and some IN NaOH. The layers were separated, and the organic layer was extracted with aqueous 2N HCl. The acidic aqueous layer was basified to pH>12 with 6 N NaOH, extracted with Et2O, brine- washed, dried over Na2SO4, filtered, and concentrated in vacuo to provide 1-[4- (2-tert-butyl-5-nitro-phenyl) -but-3- enyl]-pyrrolidine as a orange-brown oil.
Preparation LXXXVIX - N-Boc-(2-chloropyrimidin-4-yl)- methylamine:
To 2-chloropyrimidine-4-carbonitrile [2.5 g, prepared by the procedure of Daves et. al. [J. Het. Chem. 1964, 2, 130-132)] in EtOH (250 ml) under N2 was added BoC2O (7.3 g) . After the mixture was briefly placed under high vacuum and flushed with N2, 10% Pd/C (219 mg) was added. H2 was bubbled though the mixture (using balloon pressure with a needle outlet) as it stirred 4.2 h at RT. After filtration through Celite®, addition of 1.0 g additional BoC2O, and concentration, the residue was purified by silica gel chromatography (5:1 -> 4:1 hexanes/EtOAc) to obtain N-Boc- (2-chloropyrimidin-4-yl)- methylamine. Preparation XC - Methanesulfonic acid l-Boc-azetidin-3- ylmethyl ester:
To a solution of (l-Boc-azetidin-3-γl) -methanol (1.06 g, 5.7 mmol) , TEA (1.18 mL, 8.52mmol) in CH2Cl2 at 00C was added MeSO2Cl (0.53 mL, 6.82 mmol) via a syringe. The reaction was warmed to RT over 2 h and stirring was continued at RT for 2 h. The white solid formed was removed by filtration and the filtrate was washed with 25 mL of H2O. The organic phase was dried over Na2SO4, and concentrated in vacuo to afford yellow oil.
Preparation XCI - N-(2-bromo-5-nitrophenyl)acetamide:
2-Bromo-5-nitroaniline (10 g) was dissolved in 500 mL of CH2Cl2, DIEA (6.6 g) was added to the mixture, followed by DMAP (100 mg) . The mixture was cooled to 0 0C in ice bath. Acetyl chloride (4 g in 50 mL CH2Cl2) was added dropwise to the reaction mixture. After the mixture was stirred at RT over 3 h, extracted once with saturated NaHCO3 solution and once with brine, the resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 1:1 EtOAc:Hexane to 100% EtOAc to afford N- (2-bromo-5- nitrophenyDacetamide as a white solid. MS: 258 (M-I) . CaIc'd. for C8H7BrN2O3-259.06.
Preparation XClI - N-(2-bromo-5-nitrophenyl)-N-(2- methylprop-2-enyl)acetamide:
A suspension of 2 g NaH (95% powder) in anhydrous DMF (100 mL) was cooled to -78 0C, N- (2-bromo-5-nitrophenyl)acetamide (7 g) in dry DMF (50 mL) was added to the mixture under N2 atmosphere. After the mixture was warmed to 0 0C, 3-bromo-2- methylpropene (7.3 g in 20 dry DMF) was added to the mixture. The mixture was stirred at RT overnight. The mixture was poured into a container of ice and extracted between saturated NaHCO3 solution and EtOAc. The resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 7:2 hexane:EtOAc to afford the title compound as a yellow gum. MS: 314 (M+l) . Calc'd. for Ci2H13BrN2θ3-313.15.
Preparation XCIII - l~(3#3-dimethyl-6-nitro-2,3-dihydro- indol-1-y1)ethanone:
N- (2-Bromo-5-nitrophenyl)-N-(2-methylprop-2-enyl)acetamide (4.5 g) was dissolved in anhydrous DMF (50 mL) , tetraethyl- ammonium chloride (2.5 g) , sodium formate (1.2 g) , NaOAc (3 g) were added, and the resulting mixture was bubbled with N2 gas for 10 min. Pd(OAc)2 (350 mg) was added and the mixture was heated at 80 0C under N2 atmosphere overnight. After the mixture was concentrated in vacuo, it was partitioned between saturated NaHCO3 solution and EtOAc, the resulting organic layer was, dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 2:1 Hexane:EtOAc to afford the title compound as a yellow gum. MS: 235 (M+l) . Calc'd. for C12H14N2O3-234.25.
Preparation XCIV - 3,3-diπ.ethyl-6-nitroindoline:
1- (3 , 3-Dimethyl-6-nitro-2, 3-dihydro-indol-l-yl)ethanone (1.8 g) was dissolved in EtOH (50 mL) , 12N HCl (50 mL) was added and the resulting mixture was heated at 70 0C overnight. After the mixture was concentrated in vacuo, it was partitioned between saturated NaHCO3 solution and EtOAc, the resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo to afford a yellow solid. MS: 193 (M+l) . Calc'd. for Ci0Hi2N2O2-192.21. Preparation XCV - l-Acetyl-6-amino-3,3-dinιethylindoline l-(3,3-Dimethγl-6-nitro-2,3-dihγdro-indol-l-γl)ethanone (250 mg) was dissolved in MeOH (20 mL) , the mixture was bubbled with H2 for 10 min. 10% Pd/C (50 mg) was added and the mixture was stirred under H2 overnight. The mixture was filtered through Celite® and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 1:1 EtOAcCH2Cl2 to afford the title compound as a white crystalline material. MS: 205 (M+l) . CaIc'd. for C12H16N2O-204.27.
Preparation XCVI - 4-(l,l,2,2,3,3,4,4,4- nonafluorobutyl)phenylamine:
4-Nitro- (1,1,2,2,3,3,4,4,4-nonafluorobutyl)benzene was synthesized by a method analogous to that described by Gregory, W. A. et al. (J. Med. Chem, 1990, 33(9) 2569 - 2578) . The mixture of the above nitro intermediate (1.0 mmol) , iron powder (5.0 mmol) and NH4Cl (0.7 mmol) in EtOH (3 mL) and H2O (3 ml) was stirred for 4 h at 802C. Filtration and concentration gave the crude title compound, which was used without further purification.
Preparation XCVII - 2-bromo-l-tθrt-butyl-4-nitrobenzene:
NBS (125.0 g, 697.5 mmol, 1.5 eq) was slowly added to a solution of TFA:H2SO4 (5:1, 750 mL) and tert-butyl-4- nitrobenzene (100.0 g, 558.0 mmol) at RT. The solution was stirred for 24 h and poured over 5 kg of ice. The resulting suspension was filtered and washed with a 1:1 MeOH:H2O solution (200 mL) and dried in a vacuum oven. MS (ES+) : 258.1, 260.1 (M+H)+. CaIc'd for Ci0H12BrNO2: 257.0.
Preparation XCVIII - 4-(2-tert-butyl-5-nitrophenyl)pyridine:
To a solution of 2-bromo-l-tert-butyl-4-nitrobenzene (8.6 g, 33.3 mmol) and toluene (70 mL) in a 150 mL round bottom flask, 4-pγridγlboronic acid (4.5 g, 36.6 mmol, 1.1 eq) , Pd(PPh3)4 (3.8 g, 3.3 irmol, 0.1 eq) and K2CO3 (13.8 g, 99.9 mmol,3 eq) were added. The solution was stirred for 24 h at 8O0C before cooling to RT. The solution was filtered through a pad of Celite® and purified by silica flash chromatography (30% EtOAc/Hexanes) . This afforded the desired compound as a yellow solid. MS (ES+): 257.2 (M+H)+; (ES-): 255.2 (M-H)". Calc'd for C15H16N2O2: 256.1.
Preparation XCIX - 4-(2-tert-butyl-5-nitrophenyl)-l- itiethylpyridinium:
4- (2-tert-Butyl-5-nitrophenyl)pyridine (2.O g, 7.8 mmol) was added to a round-bottom flask and dissolved in EtOH (10 mL) . CH3I (30 mL) was added to the flask which was placed in a 800C sand bath and heated to reflux. After 6 h, the solution was cooled to RT and the excess CH3I and EtOH were stripped-off under reduced pressure resulting in the desired compound as a light brown solid. MS (ES+) : 271.2 (M+H)+; (ES-): 269.2 (M-H)". CaIc'd for C16H19N2O2 +: 271.1.
Preparation C - 4-tert-butyl-3-(l-methyl-l,2,3,6- tetrahydropyridin-4-yl)aniline:
4-(2-tert-Butyl-5-nitrophenyl) -1-methylpyridinium (2.1 g, 7.8 mmol, Step C) was added to a 100 mL round-bottom flask and dissolved in a 10% H2O/EtOH mixture. To the flask iron dust (1.31 g, 23.4 mmol, 3 eq) and NH4Cl (460 mg, 8.6 mmol, 1.1 eq) were added. The flask was placed in a 1000C sand bath and heated to reflux. After 2 h, the solution was cooled to RT and filtered through a pad of Celite®. The resulting solution was stripped down to a yellow solid and redissolved in MeOH (20 mL, anhydrous) . The solution was cooled to O2C by placing it in an ice bath and slowly adding NaBH4 (450 mg, 11.7 mmol, 1.5 eq) . After addition of the NaBH4, the solution was cooled to RT and stirred for 30 min. The solvent was stripped-off under vacuum and the solid was redissolved in CH2Cl2 and filtered. The solution was concentrated in vacuo to afford an amorphous clear yellow solid. MS (ES+): 245.2 (M+H)+. Calc'd for C16H24N2: 244.2.
Preparation CI - [1-(4-amino-phenyl)-ethyl]carbamic acid tert-butyl ester:
A mixture of 1- (S) -1- (4-nitrophenyl) ethylamine hydrochloride (2 g) , BoC2O (2.6 g) and NaHCO3 (3 g) in Me0H/H20 (1:1, 200 ml) was stirred at RT overnight. The reaction was extracted with EtOAc twice then washed with H20 followed by brine. The organic layer was dried with Na2SO4 and evaporated under reduced pressure to give the protected nitrophenyl ethylamine. Boc-1- (S) -1- (4 nitrophenyl)ethylamine (1 g) was hydrogenated by H2 atmosphere in the presence of Pd/C (200 mg) to give Boc protected aniline (0.8 g) . The intermediate was deprotected with 4N HCl/dioxane to give the title compound as the HCl salt.
Preparation CII - 1-[2-(tert-butyl)-5-aminophenyl]-4- xnethylpiperazine:
A mixture of 2-t-butylaniline (5.4 g) and methylchlorethylamine hydrochloride (7 g) and K2CO3 (5 g) in NaI (2 g) in diglyme (150 m) was heated at 170 2C for 8 h. The reaction was filtered and the filtrate was evaporated under high vacuum. The residue was mixed with EtOAc (200 ml) and H2O (200 ml) and extracted with EtOAc twice. The combined organic layer was washed with brine and dried over Na2SO4 and evaporated to give crude 1-[2- (tert-butylphenyl]- 4-methylpiperazine. The crude 1- [2- (tert-butylphenyl]-4- methylpiperazine (260 mg) was stirred with H2SO4 (3 ml) at 0aC and HNO3 (1.2 ml, 70%) was slowly added to the reaction. The reaction was warmed to RT, stirred for 30 min, poured on ice and basified with K2CO3 slowly. The solution was extracted with EtOAc three times, washed with H2O, followed by brine, dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography to give 1- [2- (tert-butyl)-5-nitrophenyl]-4-methylpiperazine (260 mg) , which was hydrogenated under H2 atmosphere to give 1-[2- (tert-butyl)-5-aminophenyl]-4-methylpiperazine.
The following compounds were prepared similarly to the procedure outlined above:
a) 1- (5-aminophenyl) -4-methylpiperazine
Preparation CIII - 4-(tert-butyl)-2-(4- methylpiperazinyl)phenylamine: A mixture of 1- (tert-butyl) -2-bromo-4-nitrobenzene (3 g) and N-methylpiperazine (8 g) was heated neat at 130 0C for 4 h. The residue was purified by column chromatography to give 1- [4-bromo-5- (tert-butyl) -2-nitrophenyl] -4-methylpiperazine, which was hydrogenated to furnish 4- (tert-butyl)-2- (4- methylpiperazinyl)-phenylamine.
Preparation CIV - {2-[4-(tert-butyl)-2- aminophenoxy]ethyl}dimethylamine:
DEAD (2.6 ml)was added to a mixture of 2-nitro-4-tert- butylphenol (2 g) and N,N-dimethylethanolamine (1.3 g) and Ph3P (4 g) in THF (50 ml) . The reaction was stirred at RT for 1 h, diluted with EtOAc (50 ml) and washed with 1 N HCl twice. The aqueous layer was basified with NaHCO3, extracted with EtOAc twice and washed with H2O and brine. The organic layer was dried over Na2SO4 and evaporated to give {2- [4-
(tert-butyl) -2-nitrophenoxy]ethyl}-dimethylamine. It was hydrogenated under H2 atmosphere to give {2- [4- (tert-butyl)- 2-aminophenoxy]ethyl}-dimethylamine. The following compounds were prepared similarly to the procedure outlined above:
a) [2- (2-aminophenoxy)ethyl]-dimethylamine.
Preparation CV - 2-amino-5/6#7-trihydro-l#2,4-triazolo[3#4- a]isoquinoline:
7-Nitro-2,3,4-trihydroisoquinolin-l-one (500 mg) was heated in POCl3 (10 ml) to reflux for 8 h. The mixture was evaporated, mixed with toluene and evaporated again. The residue was dissolved in THF, H2NNH2 (1 ml) was slowly added to the reaction and stirred for 2 h. The reaction was evaporated, heated with HC(OEt)3 (15 ml) at 1152C for 2 h, extracted with EtOAc and hydrogenated to give 2-amino-5, 6,7- trihydro-1,2,4-triazolo[3,4-a]isoquinoline.
Preparation CVI - tert-butyl 4-[(6-nitro-3#3- dimethylindolinyl)methyl]piperidinecarboxylate:
3,3-Dimethyl-6-nitroindoline (450 mg) was dissolved in 20 πiL of dichloroethane, N-boc-4-formylpiperidine (750 mg) was added to the mixture, followed by 2 g NaHB(OAc)3 and 1 mL of glacial AcOH. The mixture was stirred at RT overnight. Saturated NaHCO3 solution (20 mL) was added to the reaction mixture and stirred for 1 h. The resulting mixture was separated by separation funnel, the organic layer was extracted once with saturated NaHCO3 solution and once with brine. The resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 9 :1 Hexane:EtOAc to afford an orange oil. MS: 290 (M-99) . CaIc'd. for C2iH3iN3O4 - 389.5. Preparation CVII - 3#3-dimethyl-l-piperidin-4-ylmethyl-2#3- dihydro-IH-indol-6-ylamine: tert-Butyl 4-[ (6-nitro-3,3-dimethylindolinyl) - methyl]piperidinecarboxylate (900 mg) was dissolved in 10 mL MeOH, the mixture was bubbled with H2 for 10 min. 10% Pd/C (30 mg) was added and the mixture was stirred under H2 overnight. The mixture was filtered through Celite® and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 1:1 Hexane:EtOAc to afford a colorless oil. MS: 360 (M+l) . CaIc'd. for C2IH33N3O2 - 359.5.
Preparation CVIII - (2-chloro-(3-pyridyl) )-N-(4- phenoxyphenyl)carboxamide: 2-Chloronicotinoyl chloride (9.15 g, 0.052 mol) was added to a stirred solution of 4-phenoxyaniline (10 g, 0.054 mol) and DIEA (10 ml, 0.057 mol) in CH2Cl2 (100 ml) at RT. The mixture was stirred for 48 h before removal of solvent under reduced pressure. The resulting residue was dissolved in EtOAc and washed several times with saturated NaHCO3 aqueous solution and brine, respectively. The organic layer was dried over Na2SO4 and evaporated to leave a solid. This material was re-crystallized from EtOAc/Hexane mixture, followed by filtration and rinsing with Et2O to give the desired compound as a white solid. MS m/z: 325 (M+l); 323 (M-I) .
Preparation CIX - l-(l-methyl(4-piperidyl) )-6-nitroindoline:
6-Nitroindoline (5 g) was dissolved in 200 mL of dichloroethane. N-Methyl-4-piperidone (5 g) was added to the mixture, followed by NaHB(OAc)3 (12 g) and 1 mL of glacial AcOH. The mixture was stirred at RT overnight. A saturated NaHCO3 (200 mL) solution was added to the reaction mixture and stirred for 1 h. The resulting mixture was separated by separation funnel. The organic layer was extracted once with saturated NaHCO3 solution and once with brine. The resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 2:1 EtOAc:MeOH to afford orange oil. MS: 262 (M+l) . Calc'd. for C14H19N3O2 - 261.3.
Preparation CX - l-(l-methyl-4-piperidyl)indoline-6-ylamine: 1- (1-Methyl (4-piperidyl) ) -6-nitroindoline (3 g) was dissolved in 100 mL MeOH and the mixture was bubbled with H2 for 10 min. 10% Pd/C (200 mg) was added and the mixture was stirred under H2 overnight. The mixture was filtered through Celite® and concentrated in vacuo to afford light yellow oil. MS: 232 (M+l) . Calc'd. for C14H21N3 - 231.3.
Preparation CXI - N-(2-bromo-5-nitrophenyl)acetamide:
2-Bromo-5-nitroaniline (10 g) was dissolved in CH2Cl2 (500 mL) , DIEA (6.6 g) was added to the mixture, followed by 100 mg of DMAP. The mixture was cooled to 0 0C in ice bath.
Acetyl chloride (4 g in 50 mL CH2Cl2) was added dropwise to the reaction mixture, which was then stirred at RT over 3 h, and extracted once with saturated NaHCO3 solution and once with brine. The separated organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 1:1 EtOAc:Hexane to 100% EtOAc to afford a white solid. MS: 258 (M-I). Calc'd. for C8H7BrN2O3 - 259.1.
Preparation CXII - N-(2-bromo-5-nitrophenyl)-N-(2- methylprop-2-enyl)acetamide:
A suspension of NaH (2 g) (95% powder) in 100 mL anhydrous
DMF was cooled to -78 0C, and N- (2-bromo-5- nitrophenyl)acetamide (7 g) in 50 mL dry DMF was added to the mixture under N2. After the mixture was warmed to 0°C, 3-bromo-2-methylpropene (7.3 g in 20 dry DMF) was added to the mixture. The mixture was stirred at RT overnight. The mixture was poured into a container of ice and extracted between saturated NaHCO3 solution and EtOAc. The resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 7:2 Hexane:EtOAc to afford a yellow gum. MS: 314 (M+l) . CaIc 'd. for C12H13BrN2O3 - 313.1.
Preparation CXIII - l-(3#3-dimethyl-6-nitro-2,3-dihydro- indol-1-yl)ethanone:
N- (2-Bromo-5-nitrophenyl) -N- (2-methylprop-2-enyl)acetamide (4.5 g) was dissolved in 50 mL anhydrous DMF, 2.5 g tetraethyl-ammonium chloride, 1.2 g sodium formate, 3 g sodium acetate were added, the resulting mixture was bubbled with N2 gas for 10 min. Pd(OAc)2 (350 mg) was added and the mixture was heated at 80 0C under N2 overnight. After the mixture was concentrated in vacuo, it was extracted between saturated NaHCO3 solution and EtOAc, the resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 2:1 Hexane:EtOAc to afford a yellow gum. MS: 235 (M+l) . Calc'd. for C12H14N2O3 - 234.2.
Preparation CXIV - 3#3-dimethyl-6-nitroindoline:
1- (3, 3-Dimethyl-6-nitro-2,3-dihydro-indol-l-yl)ethanone (1.8 g) was dissolved in 50 mL EtOH, 50 mL 12N HCl was added and the resulting mixture was heated at 70 0C overnight. After the mixture was concentrated in vacuo, it was extracted between saturated NaHCO3 solution and EtOAc. The resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo to afford a yellow solid. MS: 193 (M+l) . CaIc'd. for Ci0H12N2O2 - 192.2.
Preparation CXV - 3,3-dimethyl-1-(4-methyl-piperazin-l-yl)- 6-nitro-2,3-aihydro-lH-indole:
3 ,3-Dimethyl-6-nitroindoline (0.8 g) was dissolved in 50 itiL of dichloroethane, N-methyl-4-piperidone (1 g) was added to the mixture, followed by 2.5 g NaHB(OAc)3 and 1 mL of glacial AcOH. The mixture was stirred at RT overnight. Saturated NaHCO3 solution (50 mL) was added to the mixture and stirred for 1 h. The resulting mixture was separated by separation funnel, the organic layer was extracted once with saturated NaHCO3 solution and once with brine, the resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash chromatography on silica gel with 9:1 EtOAc:MeOH to afford an orange oil. MS: 290 (M+l) . Calc'd. for Ci6H23N3O2 - 289.4.
Preparation CXVI - 3,3-dimethyl-l-(l-methyl(4- piperidyl) )indoline-6-ylamine:
3,3-Dimethyl-l- (4-methyl-piperazin-l-yl) -6-nitro-2,3- dihydro-IH-indole (600 mg) was dissolved in 20 mL MeOH, the mixture was bubbled with H2 for 10 min. 10% Pd/C (100 mg) was added and the mixture was stirred under H2. The mixture was filtered through Celite® and concentrated in vacuo to afford an oil. MS: 260 (M+l) . Calc'd. for Ci6H25N3 - 259.4.
Preparation CXVII - 3-(l-methyl-l#2#3#6-tetrahydro-pyridin- 4~yl)-5-nitro-lH-indole:
5-Nitroindole (2.6 g) was dissolved in 100 mL anhydrous MeOH, followed by 5 g N-methyl-4-piperidone and NaOMe (5 g) powder. The mixture was heated to reflux under N2 overnight. The mixture was concentrated in vacuo, and was extracted between saturated NaHCO3 solution and EtOAc. The resulting organic layer was dried over MgSO4, filtered and concentrated in vacuo to afford a yellow solid. This solid was washed with 5 mL EtOAc and 2 mL MeOH to afford a bright yellow solid. MS: 258 (M+l) . Calc'd. for Ci4Hi5N3O2 - 257.29.
Preparation CXVIII - 3-(l-methyl-4-piperidyl)indole-5- ylamine:
3- (1-Methyl-l,2,3, 6-tetrahydro-pyridin-4-yl) -5-nitro-lH- indole (2.7 g) was dissolved in 50 mL MeOH, the mixture was bubbled with H2 for 10 min. 10% Pd/C (150 mg) was added and the mixture and stirred under H2 overnight. The mixture was filtered through Celite® and concentrated in vacuo to afford a yellow oil. MS: 230 (M+l) . Calc'd. for Ci4H19N3 - 229.3.
Preparation CXIX - {3-[3-amino-5-
(trifluoromethyl)phenyl]propynyl}dimethylamine:
A mixture of 3-bromo-5-trifluoromethylaniline (1.4 g, 5.9 mmol) , l-dimethylamino-2-propyne (1.3 mL, 0.76 mmol) , PdCl2(PPh3)2 (0.26 g, 0.29 mmol) and CuI (114 mg, 0.60 mmol) in 10 mL of TEA was heated at 100 0C in a sealed tube for 3 h. The resulting mixture was filtered over Celite®. The filtrate was concentrated, and the residue was purified by prep-HPLC (reverse phase) to give the aniline. MS (ES+) : 243 (M+H)+; (ES-) : 241 (M-H)". CaICd Ci2H13F3N2 - 242.24.
Preparation CXX - {3-[3-amino-5-
(trifluoromethyl)phenyl]propyl}dimethylaxnine:
A mixture of {3- [3-amino-5- (trifluoromethyl)- phenyl]propyl}dimethylamine (7 g, 29 mmol) and Pd(OH)2 (0.5 g)in 250 mL of MeOH was stirred under 50 psi H2. After 2 h, the resulting mixture was filtered over Celite®. The filtrate was concentrated, and the residue was diluted with aq. IN HCl. The aq. layer was washed with Et2O, made basic with aq. 5N NaOH, and extracted with CH2Cl2. The organic solution was dried over Na2SO4 and concentrated to give the titled compound. MS (ES+) : 386 (M+H)+; (ES-) : 384 (M-H)". CaIc'd C18H19ClF3N3O - 385.8.
Preparation CXXI - 4,4,5,5-tetrameth.yl-2-(l-xnethyl(4~ 1,2,5,6-tetrahydropyridyl))-l,3,2-dioxaborolane: To a solution of LiHMDS (25 mL, 25 mmol, 1.0 M in THF) in 35 itiL of THF was added 1-methyl-4-piperidinone (3.0 mL, 25 mmol) at -78 0C. The resulting solution was stirred for 2 h, then Tf2NPh (8.9 g, 25 mmol) was added. The resulting solution was warmed to RT and stirred for 2 h. The mixture was concentrated, and the residue was purified by alumina (neutral) chromatography to give l-methyl-4- (1,2, 5, 6- tetrahydro)pyridyl- (trifluoromethyl) sulfonate. A mixture of above triflate (5.0 g, 20 mmol), bis (pinacolato)diboron (5.6 g, 22 mmol), potassium acetate (6.5 g, 66 mmol), PdCl2dppf (0.44g, 0.6mmol), and (dppf)2 (0.33g, 0.6 mmol) in 60 mL of dioxane was heated at 80 0C for 4 h. The resulting mixture was cooled to RT, diluted with Et2O (150 mL) . The ethereal solution was washed with H2O followed by brine. The organic layer dried over Na2SO4, concentrated, and recrystallized in hexane-Et2O to give the title intermediate.
Preparation CXXII - 5-(l-methyl(4-1,2,5,6- tetrahydropyridyl))-3-(trifluoro-methyl)phenylaπιine:
To a mixture of 4,4,5,5-tetramethyl-2- (l-methyl (4-1,2, 5, 6- tetrahydropyridyl) ) -1, 3,2-dioxaborolane (1.0 g, 4.4 mmol), PdCl2pddf (0.16 g, 0.2 mmol)and K2CO3 (1.8g, 13.2 mmol) and 3-amino-5-bromobenzotrifluoride (0.8g, 3.3 mmol) in DMF (25 mL) was heated at 800C for 16 h. The resulting mixture was diluted with EtOAc, washed with H2O, dried over Na2SO4, and concentrated. The residue was purified by SiO2 chromatography to give the title intermediate. MS (ES+) : 257 (M+H)+. CaIc'd Ci3H15P3N2 - 256.3.
Preparation CXXIII - 4-phenylpiperidine: 4-Cyano-4-phenylpiperidine HCl (10.0 g, 45.0 ramol) was combined with KOH pellets and stirred vigorously under Ar at 1600C for 4 h. The reaction mix was cooled to RT and dissolved into toluene (100 ml) and H2O (100 ml) . After separation of the layers, the aqueous layer was back- extracted two times with toluene. The combined organic layer was dried over Na2SO4, concentrated in vacuo, and dried under high vacuum, yielding a white solid.
Preparation CXXIV - l-methyl-4-phenγlpiperidine: To a stirring mixture at RT of 4-phenylpiperidine (5.24 g, 32.48 mmol) in CH3CN (95 ml) was added a 37% solution of HCHO in H2O (13 ml) . To this mixture was added NaCNBH3 (3.27 g, 51.97 mmol) . AcOH was added dropwise every 10 min over the next h to maintain the reaction pH near 7. The reaction volume was then reduced in vacuo. The reaction mix was diluted with CH2Cl2 and washed with 2N NaOH and then brine. The crude was concentrated in vacuo and eluted through a silica gel column with 10% MeOH/CH2Cl2. The 1- methyl-4-phenylpiperidine was concentrated in vacuo, yielding a clear oil.
Preparation CXXV - 4-(l-methyl-4-piperidyl)phenylamine:
To 1-methyl-4-phenylpiperidine (2.663 g, 15.19 mmol) was added carefully H2SO4 (15.2 ml) . The reaction was cooled in an ice bath and a solution of H2SO4 (1.66 ml) and fuming HNO3 (0.67 ml, 15.95 mmol) was added dropwise over 45 min. The mix was stirred at 00C for 3 h then at RT for 1.5 h before being poured over about 9O g ice and basified with 24 g solid NaOH. The mix was extracted with CH2Cl2. The organic layer was washed with H2O, dried over Na2SO4, and concentrated in vacuo. The crude was eluted on a silica gel column with a MeOH/CH2Cl2 gradient to yield l-methyl-4- (4- nitrophenyl)piperidine which was hydrogenated under H2 to furnish the title compound.
Preparation CXXVI - l-piperidylprop-2-en-l-one:
To a O0C solution of acryloyl chloride (4.576 g, 50.558 mmol) in CH2Cl2 (50 ml) was added dropwise and very carefully piperidine (4.305 g, 50.558 mmol). The reaction flask was vented during the exothermic addition. After the addition was completed, the white slurry was stirred at 00C for 40 min and at RT for 1 h. The reaction was diluted with 70 ml CH2Cl2 and washed first with about 60 ml 2N HCl and then with about 60 ml of a mix of 2N NaOH and brine. The organic layer was dried over Na2SO4. The solution was evaporated by heating in a H2O bath at 600C without vacuum. Once most solvent had been evaporated off, dried the clear oil under high vacuum at RT for 30 min.
Preparation CXXVII - l-(tert-butyl)-2-bromo-4-nitrobenzene: Bromine (17.4 ml) was added dropwise over 40 min to a stirred mixture of 4-tert-butylnitrobenzene (59.5 g, 332 mmol), silver(II) sulfate (56.5 g, 181 mmol), H2SO4 (300 ml), and H2O (33 ml) at RT. The mixture was stirred for a further 3 h and then poured into 0.1 M Na2S2O5/H20 (IL) . The solid was filtered, washed with H2O, Et2O, and CH2Cl2. The filtrate layers were separated. The aqueous fraction was extracted with Et2O. The combined organic layers were combined, dried over Na2SO4, and concentrated in vacuo. The yellow solid was triturated with hexanes to give a pale yellow crystalline solid. Preparation CXXVIII - (2E)-3-[2-(tert-butyl)-5-nitrophenyl]- l-piperidylprop-2-en-l-one: l-(tert-Butyl)-2-bromo-4-nitrobenzene (6.885 g, 26.674 mmol) , l-piperidylprop-2-en-l-one (4.827 g, 34.677 mmol) , and TEA (7.44 ml, 53.35 mmol) were dissolved in toluene (70 ml) . To this solution was added Pd(OAc)2 (60 mg, 0.267 mmol) and Pd(PPh3)4 (617 mg, 0.5335 mmol). The mix was degassed with N2 and heated in a sealed vessel at 120 0C for 15 h. The reaction mixture was cooled to RT, filtered, and concentrated in vacuo. The dark crude oil was eluted through a silica gel column with 15% to 22% EtOAc/hexanes gradient system to yield a viscous, amber-colored oil as the title compound.
Preparation CXXIX - 3-(5-amino-2-tert-butylphenyl)-l- piperidin-1-yl-propenone:
(2E) -3-[2- (tert-Butyl) -5-nitrophenyl] -l-piperidylprop-2-en- 1-one (3.22 g, 10.177 mmol) was dissolved in dioxane (20 ml) and IpOH (40 ml) . To the N2-degassed solution was added Pd/C 10% by weight catalyst (2 g) . The mix was placed in a Parr hydrogenator and stirred for 18 h under 60 psi H2. The reaction was not complete the next day, so the reaction was continued for an additional 2O h with fresh catalyst. The mix was filtered through Celite® and concentrated in vacuo to give a foamy oil.
Preparation CXXX - 4-(tert-butyl)-3-(3- piperidylpropyl)phenylamine:
3- (5-Amino-2-tert-butylphenyl) -1-piperidin-l-yl-propenone (2.312 g, 7.619 mmol) was dissolved in THF (100 ml) at RT. To this solution was added LiAlH4 (434 mg, 11.43 mmol) . After the exothermic reaction stopped, the reaction mixture was heated at reflux at about 800C for 4 h. The reaction mixture was cooled to 00C and treated by dropwise addition of 0.458 ml H2O, 0.730 ml 10% aqueous NaOH, and 1.19 ml H2O, respectively. The mixture was stirred at RT for 1 h. After 40 min about 3 g of Na2SO4 was added. The mixture was filtered through Celite® and concentrated in vacuo. The crude was eluted through silica gel column with a gradient system of 95:5 to 90:10 CH2Cl2/MeOH, to yield a thick, amber-colored oil as the title compound.
The following compounds were prepared similarly to the procedure outlined above:
a) 3- ( (IE)-4-Pyrrolidinylbut-l-enyl)-4- (tert- butyl)phenylamine. b) 4- (tert-Butyl)-3- (3-pyrrolidinylpropyl)phenylamine. c) 4- (tert-Butyl)-3- (3-morpholin-4- ylpropyl)phenylamine. d) 3-[3- (4-methylpiperazinyl)propyl]phenylamine. e) 4-[3- (4-methylpiperazinyl)propyl]phenylamine.
Preparation CXXXI - 3-(3-nitrophenyl)-l-(4- methylpiperazinyl)propan-1-one:
A slurry consisting of CH2Cl2 (15 ml) , 3-nitrocinnamic acid (3.154 g, 16.329 mmol) , 1-methylpiperazine (1.487 g, 14.845 mmol) and EDC (3.557 g, 18.556 mmol) were stirred at RT for 60 h. The reaction was diluted with H2O and EtOAc. The aqueous layer was back-extracted with EtOAc. The combined organic layers were washed with 2N NaOH and then brine, dried over Na2SO4, and concentrated in vacuo. The crude was eluted through a silica gel column with 5% MeOH/CH2Cl2, to yield an off-white solid, mostly trans-olefin compound. Preparation CXXXII - 3-(3-aminophenyl)-l-(4- methylpiperazinyl)propan-1-one:
To a nitrogen-degassed solution of 3- (3-nitrophenyl) -1- (4- methylpiperazinγl)propan-l-one (3.67 g, 13.330 iranol, Step A) in MeOH (50 ml) was added 10% by weight Pd/C (500 mg) . The mix was stirred under H2 atmosphere for 18 h then filtered through Celite® and concentrated in vacuo, yielding a thick amber oil which eventually solidified into a dark pink solid.
The following compounds were prepared similarly to the procedure outlined above: a) 4- [3- (4-methylpiperazinyl) -3-oxopropyl]phenylamine.
Preparation CXXXIII - l-(2-morpholin-4-ylethyl)indol-6- ylamine:
K2CO3 (5.08 g, 36.726 mmol) was added to a slurry of 6- nitroindole (1.985 g, 12.242 mmol), 4- (2-chloroethyl) morpholine. HCl (2.278 g, 12.242 mmol), and CH3CN (100 ml) . The mix was heated to reflux for 18 h, then cooled to RT, filtered, and concentrated in vacuo. The crude was eluted through a silica gel column with a gradient of 3:97 to 5:95 and finally 8:92 MeOH/CH2Cl2, to yield upon drying the desired intermediate which was hydrogenated under conditions previously described.
Preparation CXXXIV - methyl 2-methyl~2-(4- nitrophenyl)propanoate:
To a stirred solution of 2- (4-nitrophenyl)propionic acid (9 g, 46 mmol, 1 eq) in MeOH (300 itiL) was added HCl (4M in
Dioxane, 11.5 mL, 46 mmol, 1 eq) . The mixture was stirred at RT overnight and was quenched with aqueous NaHCO3. The mixture was extracted with EtOAc. The organic layer was dried over MgSO4 and evaporated under reduced pressure and the partial residue (4.34 g, 20.7 iranol, leq) at 00C in THF (100 mL) was added NaH (1.66 g, 41.5 mmol, 2 eq) . Mixture was stirred at RT for Ih and CH3I (2.58 g, 41.5 mmol, 2 eq) was added. Reaction was stirred at RT overnight and was quenched with H2O. Mixture was extracted with EtOAc. The organic layer was dried over MgSO4 and evaporated under reduced pressure and used for the next step without further purification to give title compound.
Preparation CXXXV - 3-methyl-3-(4~nitrophenyl)butan-l-one:
To a stirred solution of methyl 2-methyl-2- (4- nitrophenyl)propionate (5.32 g, 23.8 mmol) in THF (200 mL) at 00C was added a solution of IM BH3 in THF (25.8 mL, 45.8 mmol) . The reaction was stirred at RT overnight and was quenched with MeOH. THF was evaporated under reduced pressure and the residue was diluted in EtOAc and aqueous HCl (IM) was added. The mixture was extracted with EtOAc, the organic layer was dried over MgSO4 and evaporated under reduced pressure. Purification by flash chromatography using 40% EtOAc-hexane gave a yellow solid. To the yellow solid (2.08 g, 10.8 mmol) at 00C in CH2Cl2 was added NMO (1.9 g, 16.1 mmol), molecular sieves 4A and TPAP (76 mg, 0.2 mmol) . The reaction was stirred for Ih and filtered on a silica pad. Solvent was evaporated under reduced pressure, forming the crude aldehyde which was used as is. To a suspension of methoxymethyltriphenylphosphonium chloride (6.4 g, 18.6 mmol) in THF (150 mL) was added a solution of KHMDS 0.5 M in toluene (37 mL, 18.5 mmol) . The mixture was stirred for 30 min and crude aldehyde was added. The reaction was stirred at RT for Ih and quenched with H2O. The mixture was extracted with EtOAc, dried and evaporated under reduced pressure. Et2O was added and a precipitate formed, which was filtered on a silica pad and rinsed with 40% EtOAc-hexane. The solvent was removed and crude material was dissolved in CH2Cl2. A solution of TFA-H2O (1:1, 10 mL) was added and the reaction was stirred for 2 h at RT. Aqueous NaHCO3 was added until pH 7 and the mixture was extracted with CH2Cl2. The organic layer was dried, filtered and evaporated. Crude compound was purified by flash chromatography (40% EtOAc-hexane) to give the title compound as a yellow oil.
Preparation CXXXVI - 4-(l,l-dimethyl-3-morpholin-4- ylpropyl)phenylamine: To a stirred solution of 3-methyl-3- (4-nitrophenyl)butan-l-one (509 mg, 2.4 mmol) and morpholine (0.21 mL, 2.4 mmol) in THF (30 mL) was added NaBH(OAc)3 (0.73 g, 3.4 mmol) . The mixture was stirred at RT overnight and washed with HCl (IM) . CH2Cl2 was added and the layers were separated. The aqueous layer was basified to pH 9 using NaOH IM and extracted with CH2Cl2. The organic layer was dried and evaporated the nitro compound. To a solution of the nitro compound (0.5O g, 1.8 mmol) in THF (40 mL) was added AcOH (1.97 mmol, 34.5 mmol) followed by zinc (9.1 g, 137 mmol) . The mixture was stirred for 1 h, filtered on Celite®, diluted with H2O and aqueous NaHCO3, and the THF layer was evaporated. The residue was extracted with EtOAc, dried and evaporated to give the title compound.
Preparation CXXXVII - 4-{2,2,2-trifluoro-l-[2-(2- methoxy)ethoxy]-1-(trifluoromethyl)ethyl}phenylamine: Diethyl azodicarboxylate (366 mg, 2.1 mmol) was added drop- wise to a solution of 2- (4-aminophenyl)-1, 1, 1,3,3,3- hexafluoropropan-2-ol (520 mg, 2 mmol), 2- (2- methoxyethoxy)ethan-1-ol (240 mg, 2 mmol) and PPh3 (550 mg, 2.1 mmol) in THF (10 mL) . The mixture was stirred for 2 h, then partitioned between EtOAc and aqueous NaHCO3 solution. The organic phase was washed with brine. After concentration in vacuo, the organic residue was purified by flash chromatography on silica to give the compound. MS: 362 (M+l) . CaIc 'a. for C14H17F6NO3 - 361.29.
Preparation CXXXVIII - 2-fluoropyridine-3-carbonyl chloride:
To a solution of 2-fluoropyridine (10 g, 100 mmol) in THF (150 iriL) under -78°C was added an LDA solution (2M in heptane/THF/ethylbenzene, 60 mL) dropwise. The mixture was stirred at -780C for 3 h, then was quenched with a stream of dry CO2. After warming to RT, the mixture was partitioned between EtOAc (100 mL) and H2O (200 mL) . The aqueous layer was acidified to pH between 3-4, and extracted with EtOAc. The organic solution was collected and washed with brine and dried over Na2SO4. After removing the solvent in vacuum, 2- fluoropyridine-3-carboxylic acid was obtained as a brown oil. MS: 140 (M-H) . CaICd. for C6H4FNO2 - 141.10. 2- Fluoropyridine-3-carboxylic acid (7 g) was suspended in SOCl2 (100 mL) . After heating under reflux for 2 h, the mixture became homogeneous. Access SOCl2 was removed in vacuo to afford a brown solid as desired compound.
Preparation CXXXIX - N-(3-Amino-5-chloro-phenyl)-2- dimethylamino-acetamide:
To a solution of 5-chloro-benzene-l, 3-diamine (3 g, 21 mmol) and dimethylamino-acetic acid (2.2 g, 21 mmol) in CH2Cl2 (300 mL) was added EDC (5 g, 25 mmol), HOBt (2.9 g, 21 mmol) , and DIEA (5 mL) . The reaction mixture was stirred at RT for overnight. Solvent was removed in vacuum and the residue was purified through flash chromatography on silica gel (0-8% MeOH in EtOAc) to give the desired compound.
Preparation CXL - 2-amino-4-nitro-benzamide:
To a solution of 2-amino-4-nitro-benzoic acid (9.1 g, 50 mmol) in CH2Cl2 (500 mL) was added EDC (12 gram, 60 mmol) , HOBt (6.8 g, 50 πraiol) , DIEA (12 inL) , and NH3 in MeOH (2M, 40 πiL) . The reaction was stirred at RT for overnight, and a precipitation formed. The solid was isolated via vacuum filtration.
Preparation CXLI - 6-nitro-3H-guina2olin-4-one: 2-Amino-4-nitro-benzamide was suspended in triethyl orthoformate (50 mL) and the mixture was heated to 1400C for 5 h. Excess reagent was removed in vacuum. The residue was washed in hexanes to give the compound as a yellow solid.
Preparation CXLIX - 6-amino-3H-quinazolin-4-one:
Hydrogenation of 6-nitro-3H-quinazolin-4-one (2 g) in EtOH (200 mL) was catalyzed by Pd/c (10%, 200 mg) under a H2 balloon for 1 h. MeOH (200 mL) was added to the mixture. The suspension was filtered through a layer of Celite® and the filtrate was concentrated in vacuum to give the desired compound.
Preparation CXLIII - (2,4-dinitro-phenyl)-acetic acid methyl ester:
To a solution of (2, 4-dinitro-phenyl) -acetic acid (5 g) in MeOH (100 mL) was added concentrated H2SO4 (1 mL) and the resulting solution was heated at reflux for overnight. After removing solvent in vacuum, the residue was partitioned between EtOAc and aqueous NaHCO3 (sat.). The organic solution was concentrated in vacuum to give the desired compound which was used without further purification.
Preparation CXLIV - 6-amino-l#3-dihydro-indol-2-one: An EtOH solution of (2,4-dinitro-phenyl) -acetic acid methyl ester was treated with H2 balloon and catalyzed with Pd/c (10%, 500 mg) at RT. The resulting mixture was filtered through a layer of Celite® and concentrated in vacuum to afford the desired compound.
Preparation CXLVI - 3-Methyl-but-2-enoic acid (6-bromo- pyridin-2-yl)-amide:
To a solution of 2-amino-6-bromopyridine (3.015 g, 0.017 mol) and Et3N (2.40 mL, 0.017 mol) in CH2Cl2 (20.0 mL) , was added 3, 3-dimethylacryloylchloride (1.96 mL, 0.017 mol) under N2 at 0 0C. The mixture was slowly warmed to RT and stirred for 12 h. The reaction was quenched by the addition of H2O (20.0 mL) , the organic layer was separated, dried over Na2SO4 and evaporated to dryness to yield crude compound which was used without purification.
Preparation CXLVI - 3-Methyl-but-2-enoic acid (6-amino- pyridin-2-yl)-amide:
To a solution of 3-methyl-but-2-enoic acid (6-bromo-pyridin- 2-yl) -amide (4.30 g, 0.017 mol) and copper (0.214 g, 3.372 mmol) in IpOH (20.0 mL) , was added NH4OH (20.0 mL) in a sealed vessel under N2. The reaction was sealed and heated to 90 0C for 12 h. The reaction mixture was cooled to RT and EtOAc (50.0 mL) was added. The organic layer was separated, and then the aq layer was washed with EtOAc (50.0 mL) . Combined organic layers were evaporated to dryness, the resulting residue was dissolved in CH2Cl2 (50.0 mL) and washed with H2O (4 x 30 mL) . The organic layer was dried over Na2SO4 and evaporated to dryness to yield crude aminopyridine, which was used without purification.
Preparation CXLVII - 7-Amino-4,4-dimethyl~3,4-dihydro-lH- [1,8]naphthyridin-2-one:
To a mixture of aminopyridine (1.12 g, 5.833 mmol) and AlCl3 (3.11 g, 0.023 mol) was added chlorobenzene (10.0 mL) in a sealed vessel under Ar. The reaction was sealed and heated to 120 0C for 12 h. The reaction mixture was cooled to RT and the mixture was poured over ice/HCl mixture and extracted with EtOAc (3 x 50.0 mL) . The aqueous layer was neutralized via addition of solid NaHCO3 and extracted with EtOAc (5 x 50 mL) . Combined organic layers were dried over Na2SO4 and evaporated to dryness to yield crude compound. Chromatography (Silica gel, CH2Cl2:MeOH, 99:1) yielded pure naphthyridin.
Preparation CXLVHI - 2- [1-(3-Amino-phenyl)-2,2,2-tri£luoro- 1-trifluoromethyl-ethoxymethyl]-pyrrolidine-l-carboxylic acid tert-butyl ester:
To a mixture of 2- (3-amino-phenyl) -1, 1,1, 3,3,3-hexafluoro- propan-2-ol (1.30 g) , 2-hydroxymethyl-pyrrolidine-l- carboxylic acid tert-butyl ester (1.04 g) , PPh3 (2.64 g) and molecular sieves 4 A in THF (100 mL) was added diethyl diazocarboxylate (1.55 mL) slowly. The reaction was stirred at RT for 4h and at reflux for overnight. After filtration to remove solids, the filtrate was concentrated and the residue was taken into Et2O. The organic phase was washed with saturated NaHCO3 and brine. The organic layer was dried over MgSO4 and evaporated to give a crude compound as very viscous brown oil, which was purified by chromatography through silica gel (500 g, 30% to 50% EtOAc in hexanes) to afford 2- [1- (3-amino-phenyl) -2,2,2-trifluoro-l- trifluoromethyl-ethoxymethyl] -pyrrolidine-l-carboxylic acid tert-butyl ester as a light brown oil.
Preparation. CXLIX - Pyrimidine-4-carbaldeh.yde oxixne: 9.14 g (97.11 mmol) of 4-methylpyrimidine was slowly added to a O0C solution of 8.75 g HCl in 40 ml EtOH. To this white suspension was added, over 5 min, 61 ml of a 10-20% by weight solution of ethyl nitrite in EtOH. The reaction was stirred at 0 0C for 10 min and then at RT for 2.5 h. The white salt was filtered and dried under vacuum. The salt was dissolved into 20 ml H2O and very slowly treated with about 200 ml saturated aqueous KHCO3. A white solid precipitated out of the purple solution. The solid was filtered and dried under vacuum to yield the titled compound.
Preparation CL - C-Pyrimidin-4-yl-meth.ylamine dihydrogen chloride: To a solution of 3.549 g (28.82 mmol) pyrimidine-4- carbaldehyde oxime in 200 ml MeOH was added after degassing with Ar, 800 mg of 10% by weight Pd/C. The mix was stirred under H2 for 4 h, then filtered through a Celite® plug. The solution was concentrated under vacuum to a volume of about 50 ml and then treated carefully with 30 ml of 4N HCl in dioxane. The mix was concentrated and dried under vacuum to yield the titled compound as a pink solid.
Preparation CLI - 2~(2#4-Dinitro-phenyl)-3#3,3-tri£luoro-2- trifluoromethyl-propionic acid methyl ester:
A mixture of 7.08 g (38.07 mmol) 2, 4-dinitrofluorobenzene, 2.43 g (41.88 mmol) KF, and 0.58 g (2.21 mmol) 18-crown-6- ether in 37 ml sulfolane was added 4.00 g (19.04 mmol) methyl 2- (trifluoromethyl)-3,3,3-trifluoropropionate dropwise over about 7 h via syringe pump. After the addition was complete, another 2.43 g KF, 0.58 g 18-Crown-6- ether were added and then 4.00 g Methyl 2- (trifluoromethyl) - 3, 3,3-trifluoropropionate were added dropwise over 12 h. The next day, repeated additions using same amounts and setting syringe pump addition over 14 h. The following day, the additions were again repeated, this time using half the amounts as above additions and setting syringe pump addition at 12 h. After addition was completed, the reaction mix was cooled to RT and diluted into Et2O and 0.5N aqueous HCl. The layers were separated, and the organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under vacuum. The crude was eluted on a silica gel column with EtOAc/hexanes gradient, to yield the titled compound, as a yellow solid.
[See Vlasov et al.; J.Org. Chemistry USSR (Engl. Trans.); 15; 1979; 1953-1964) .]
Preparation CLII - 6-Amino-l-hydroxy-3,3-bis- trifluoromethyl-l#3-dihydro-indol-2-one:
To an argon-degassed solution of 5.13 g (13.64 mmol) 2- (2,4- dinitro-phenyl) -3,3,3-trifluoro-2-trifluoromethyl-propionic acid methyl ester in 300 ml EtOH was added 0.5 g of 10% by weight Pd/C. The reaction was stirred under H2 overnight and filtered through Celite®, concentrated down, and dried under vacuum, yielding the titled compound.
Preparation CLIII - 6-Amino-3,3-bis-trifluorαmethyl-l#3- dihydro-indol-2-one: To a solution of 1.245 g (4.151 mmol) 6-amino-1-hydroxy-3,3- bis-trifluoromethyl-1,3-dihydro-indol-2-one in 80 ml THF was added 3.565 ml (62.27 mmol) glacial AcOH and 19 g (290.6 mmol) Zinc dust (100 mesh) . The reaction was stirred 40 min at RT and then 5 h at reflux. The reaction was cooled to RT. The solvent was decanted and concentrated, then dissolved in EtOAc and filtered through Celite®. The EtOAc solution was then washed with saturated aqueous NaHCO3 and brine, dried over Na2SO4, filtered, and concentrated and dried under vacuum, to yield the titled compound, as a yellow solid. Preparation CLIV - N-[3-(2-Amino-ethoxy)-4-pentafluoroethyl- phenyl] -2-chloro-nicotinamide:
To a solution of 500 mg (0.98 mmol) Boc-N- [3- (2-Amino- ethoxy) -4-pentafluoroethyl-phenyl] -2-chloro-nicotinamide in 10 ml CH2Cl2 was added 10 ml TFA and stirred for 2 h. The reaction was concentrated down, treated with 6N aqueous NaOH, and extracted 3 times with CH2Cl2. The combined organic extracts were dried over Na2SO4, filtered, concentrated down, and dried under vacuum, yielding the titled compound.
Preparation CLV - 2-Chloro-N-[3-(2-methanesulfonylamino- ethoxy)-4-pentafluoroethyl-phenyl] -nicotinamide:
To a solution of 381 mg (0.93 mmol) N- [3- (2-amino-ethoxy) -4- pentafluoroethyl-phenyl]-2-chloro-nicotinamide in 10 ml CH2Cl2 at 0 0C was added 0.389 ml Et3N and 0.072 ml (0.93 mmol) methanesulfonylchloride. After 5 min, the reaction was stirred at RT for 30 min. The reaction was diluted with CH2Cl2, washed with brine, dried over Na2SO4, filtered, concentrated, and dried under vacuum, yielding the titled compound as a white foamy solid.
Preparation CLVI - 2-Methyl-2-(4-nitro-phenyl)-propionic acid: To a solution of 2- (4-nitro-phenyl) -propionic acid (50 g,
0.26 mole) in 250 πiL of MeOH was added 6 mL of concentrated HCl. The resulting solution was heated at reflux for 16 h. Then the resultant mixture was diluted with 200 mL of aq. NaHCO3 and 500 mL of EtOAc. The organic layer was separated, dried over Na2SO4, and concentrated. The residue was diluted with 100 mL of THF and added to a suspension of NaH (11.2 g, 0.28 mole, 60% in mineral oil) in 600 mL of THF. To the resulting mixture was added CH3I (18.3 mL, 0.29 mole) in one portion. The resulting mixture was stirred for 48 h at 40 0C, then was diluted with aq. NH4Cl solution and EtOAc. The organic layer was separated, dried over Na2SO4, and concentrated. The residue was used without further purification. To a solution of the residue (54 g, 0.24 mole) in 500 ml of MeOH was added 5N ag. NaOH (144 mL, 0.72 mole) . The mixture was stirred for 16 h at 40 0C. The resulting mixture was concentrated, the residue was diluted with H2O (500 mL) , and acidified with 2N HCl to give a precipitate. The precipitate was filtered and dried to give the titled compound as a yellowish solid. MS: 210 (M+l) , Calc'd for Ci0H12NO4- 210.20.
Preparation CLVII - 2-Methyl-5-[l-methyl-l-(4-nitro-phenyl)- ethγl]-[l,3,4]oxadiazole:
A mixture of 2-methyl-2- (4-nitro-phenyl) -propionic acid (5 g, 24 mmol. ) and a few drops of DMF in SOCl2 was stirred at reflux for 16 h. The resulting solution was concentrated to give corresponding acid chloride as a brown solid. To a mixture of the acid chloride (2.33 g, 10.2 mmol), acetic acid hydrazide (0.91 g, 12.2 mmol.), Et3N (2.86 mL, 20.2 mmol.) in CH2Cl2 (50 mL) was added 2 crystals of DMAP at RT. The mixture was stirred for 16 h and concentrated. A solution of the residue in 50 mL of phosphorous oxychloride was heated at 95°C for 16 h. The mixture was concentrated and diluted with ice-water and EtOAc. The organic layer was washed with saturated aq. NaHCO3 solution twice, dried over Na2SO4, and concentrated. The residue was purified by SiO2 chromatography (hexane: EtOAc=I:1) to give the titled compound as a pale yellow crystal. MS: 248 (M+l), Calc'd for Ci2Hi4N3O3-248.10. Preparation CLVIII - 2-Metlxyl-5-[1-methyl-l-(4-amino- phenyl)-ethyl]-[l#3,4]oxadiazole:
A mixture of 2-methyl-5-[1-methyl-l- (4-nitro-phenγl)-ethyl]- [l,3,4]oxadiazole (1.36 g, 5.5 mmol.) and Pd/C (68 mg) in EtOAc (50 mL) , was stirred under 1 atm of H2 for 16 h. The resultant was filtered over Celite®, and the filtrate was concentrated to give the titled compound as a pale yellow crystalline. MS: 218 (M+l) calc'd for C12H16N3O-218.12.
Preparation CLIX - 4-[1-Methyl-l-(4-nitro-phenyl)-ethyl]- pyrimidine:
To a mixture of 1- (4-nitro-phenyl)-propan-2-one (5.32 g, 29.7 mmol.), triethylbenzylammonium chloride (0.34g, 1.5 mmol.), and 13 mL of aq. 5N KOH solution (65.3 mmol.) in CH2Cl2 was added CH3I (4.06 mL, 65.3 mmol.) . The resulting mixture was stirred at 40 0C, and then diluted with EtOAc and H2O. The organic layer was dried and concentrated. To the residue (1.0 g, 4.8 mmol.) in toluene (30 mL) was added dimethylformamide dimethylacetal (1.27 mL, 9.6 mmol.) . The resulting mixture was heated at reflux for 6 h then concentrated to give l-dimethylamino-4-methyl-4- (4-nitro- phenyl) -pent-1-en-3-one as a yellow solid ( MS 263 (M+l) Calc'd for C14Hi9N2O3-263.13) .
A mixture of l-dimethylamino~4-methyl-4- (4-nitro- phenyl)-pent-1-en-3-one (0.5 g, 1.9 mmol.), formamidine HCl (0.305 g, 3.8 mmol.), and NaOEt (1.29 g, 4.0 mmol) was heated in Smith synthesizer under microwave for 10 min at 150 0C. The resultant mixture was diluted with H2O and EtOAc. The organic layer was dried, and the residue was used without further purification. MS: 244 (M+l) Calc'd for Ci3Hi4N3O2-244.10. Preparation CLX - 5-[l-Methyl-l-(4-nitro-phenyl)-ethyl]-IH- pyrazole:
A mixture of l-dimethylamino-4-methyl-4- (4-nitro-phenγl) - pent-l-en-3-one (0.36 g, 1.4 mmol.) and hydrazine hydrate (1.0 g, 6.25 mmol.) in EtOH was heated at 500C for 3h. The mixture was concentrated, and the residue was diluted with H2O and EtOAc. The organic layer was dried over Na2SO4 and concentrated to give the titled compound as a yellow solid. MS: 232 (M+l) CaIc'd for Ci2H14N3O2 -232.10.
Preparation CLXI - 2-tert-Butyl-5-nitro-phenylamine: Concentrated H2SO4 (1 L) was cooled to -100C with a dry ice IpOH bath in a 2 L 3-neck round bottom flask fitted with a mechanical stirrer and temperature probe. 2-t-Butylaniline (109 g, 730 mmol) was added, giving a clumpy solid. Once the temperature of the mixture was stabilized at -100C, KNO3 (101 g, 1001 mmol) was added portion-wise, as the solid, over 4 h, maintaining the temperature between -20 and -50C. Once all of the KNO3 was added, the reaction was stirred overnight with gradual warming to RT. The reaction was quenched by diluting it with H2O and extracting it 3x with EtOAc. The EtOAc extracts were washed multiple times with saturated NaHCO3 (aq) , until gas evolution ceased, then with brine. The EtOAc extracts were combined, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure giving a black oil. The oil was eluted through a 36 x 7 cm column of silica gel with a 5%; 10%; 15%; 25%; and 50% EtOAc:Hexanes step gradient (2 L each step) giving 2- tert-butyl-5-nitro-phenylamine as a red solid.
Preparation CLXII - 2-Bromo-N-(2-tert-butyl-5-nitro-phenyl)- acetamide:
2-tert-Butyl-5-nitro-phenylamine (70 g, 359 mmol) and a catalytic amount of DMAP were dissolved in THF (1.5 L) under N2. TEA (109 g, 1077 mmol) was added and the solution was cooled to 0 0C. Bromoacetyl bromide (207 g, 1023 mmol) was added and the reaction was gradually warmed to RT with stirring overnight. The reaction was partially concentrated under reduced pressure, treated with H2O and extracted with EtOAc (3x) . The EtOAc extracts were washed with brine, combined, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure giving a black oil. This oil was eluted through a 38 x 7 cm column of silica gel with 95:5:0.5 CH2Cl2:MeOH:NH4OH(aq) eluant giving 2-bromo-N- (2-tert-butyl-5-nitro-phenyl) -acetamide as a brown solid.
Preparation CLXIII - N-(2-tert-Butyl-5-nitro-phenyl)-2- dimethylamino-acetamide: 2-Bromo-N-(2-tert-butyl-5-nitro-phenyl) -acetamide (80 g, 253 mmol) and K2CO3 (70 g, 506 mmol) were combined in a 3-L 3- neck round bottom flask fitted with a mechanical stirrer, N2 inlet, and pressure equalizing addition funnel. THF (1.75 L) was added and the mixture was cooled to 0 0C under N2. DMA (400 mL> of a 2 M solution in THF, 800 mmol) was added to the mixture through the pressure equalizing addition funnel over 30 min. The mixture was gradually warmed to RT with stirring overnight. The reaction was quenched by filtering it under vacuum and then concentrating the filtrate under reduced pressure. The recovered material was eluted through a 36 x 7 cm column of silica gel with 50% EtOAc:Hexanes giving N- (2-tert-butyl-5-nitro-phenyl) -2-dimethylamino- acetamide as a brown solid.
The pyrolidino and morpholino analogs are prepared by substituting the dimethylamine with respectively pyrolidine or morpholine and using the same chemistry as described, a) N- (2-tert-Butyl-5-nitro-phenyl)-2-pyrrolidin-l-yl- acetamide. b) N- (2-tert-Butyl-5-nitro-phenyl) -2-morpholin-4-yl- acetamide.
Preparation CLXIV - N-(5-Amino-2-tert-butyl-phenyl)-2- dimethylamino-acetamide:
N- (2-tert-Butγl-5-nitro-phenγl) -2-dimethγlamino-acetamide (25.8 g, 92 mmol) was dissolved in EtOH (1.4 L) and 1,4- dioxane (200 mL) . The solution was degassed under vacuum with stirring. 10% Pd/C (2.5 g) was added (as a slurry in EtOH) . The mixture was degassed again, then the reaction vessel was charged with H2 gas (balloon) and stirred overnight at RT. The reaction was filtered through Celite® with MeOH and the filtrate was concentrated under reduced pressure. The recovered material was eluted through a 36 x 7 cm column of silica gel with a 97.5:2.5:0.25 and 95:5:0.5 CH2Cl2:MeOH:NH4OH(SCj) step gradient giving N- (5-amino-2-tert- butyl-phenyl) -2-dimethylamino-acetamide as a brown solid.
Preparation CLXV - 5-Chloro-l-methγl-lH-pyrazole-4~ carboxylic acid (4-tert-butyl-phenyl)-amide:
5-Chloro-l-methyl-liϊ-pyrazole-4-carbonyl chloride (1.0 g, 5.6 mmol) was dissolved in CH2Cl2 (100 mL) under N2 and cooled to 0 0C. 4-t-Butylaniline was added and the reaction was stirred with gradual warming to RT overnight. The reaction was quenched with saturated NaHCO3 (aq) and extracted 3 x with fresh CH2Cl2. The CH2Cl2 extracts were washed with brine, combined, dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure giving 5- chloro-l-methyl-lH-pyrazole-4-carboxylic acid (4-tert-butyl- phenyl)-amide as a foamy pink solid.
Preparation CLXVI - l,2-dihydro-3-spiro-l'-cyclopropyl-l.Er- indole:
A solution of 3- (2-bromo-ethyl) -IH-indole (5 g) in anhydrous CH3CN (100 mL) was suspended with oven dried K2CO3 (20 g) and heated to reflux for 10 h. After cooling to RT, the mixture was filtered and the filter cake was washed with EtOH (50 rriL) . The combined filtrate was treated with NaBH4 (300 mg) and stirred for 3 h at RT. Solvents were removed in vacuo and the residue was partitioned between H2O (160 mL) and
EtOAc (60 mL) . The organic layer was extracted with aqueous HCl (0.5N, 30 mL X 2) . The acid layer was basified with NH4OH (aq. Cone.) and extracted with EtOAc. The organic phase was washed with brine and dried over Na2SO4 and concentrated to give the desired compound as a colorless thin oil.
Preparation CLXVII- 6-nitro-l,2-dihydro-3-spiro-l'- cyclopropyl-lH-indole: 1' ,2'-Dihydrospiro(cyclopropane-l,3'-[3H]indole) (1.8 g 12.4 itraiol) was added in dropwise over a period of 20 min to a cooled (-5 to -100C) solution of NaNO3 (1.3 g) in H2SO4 (cone, 30 mL) . After the addition, the reaction was stirred for another 40 min. , then the mixture was poured onto crushed ice (200 g) and the resulting mixture was basified with NH4OH (aq., cone.) with cooling. The basified mixture was extracted with EtOAc twice and the organic layer was washed with brine then dried over Na2SO4. After concentration in vacuo, the compound was isolated as a dark gray solid.
Preparation CLXVIII - Ethyl 6-nitro-l,2-dihydro-3-spiro-l'- cyclopropyl-lH-indole-1-carbamate:
A solution of 6-nitro-l,2-dihydro-3-spiro-l'-cyclopropyl-liϊ- indole (2.7 g) in CH2CL2 (100 mL) was suspended with NaHCO3 (5 g) , and ethyl chloroformate was added dropwise with vigorous stirring. After the addition, the reaction was stirred overnight. The mixture was washed with H2O (100 mL) , then dried over Na2SO4 and concentrated in vacuo. The residue was recrystalized in MeOH to give the title compound as a dark gray crystalline.
Preparation CLXIX - Ethyl 6-amino-l#2-dihydro-3-spiro-l/- cyclopropyl-llϊ-indole-l-carbamate:
Ethyl 6-nitro-l,2-dihydro-3-spiro-l'-cyclopropyl-lfl-indole- 1-carbamate (2.1 g) was dissolved in EtOH (200 πiL) , suspended with Pd/C (10%, 560mg) and equipped with a balloon filled with H2. The hydrogenation was finished in 3 h. The reaction mixture was filtered through a layer of Celite®. The filtrate was concentrated in vacuo to give the desired product as a white solid.
Preparation CLXX - 4- [1-Methyl-l-(4-nitro-phenyl)-ethyl]- 3,6-dihydro-2H-pyridine-l-carboxylic acid ethyl ester: l-Methyl-4- [1-methyl-1- (4-nitro-phenyl) -ethyl] -1, 2,3,6- tetrahydro-pyridine (5.2 g) was dissolved in toluene (100 mL) and ethyl chloroformate (2.4 g) . The mixture was heated at reflux for overnight and cooled to RT. The toluene solution was washed with NaHCO3 (aq. , sat., 100 mL) then brine (100 mL) and dried over Na2SO4. The organic phase was concentrated in vacuo to give the desired compound which was used without purification.
Preparation CLXXI - 4- [1-Methyl-l-(4-amino-phenyl)-ethyl]- 3/6-dihydro-2H-pyridine-l-carboxylic acid ethyl ester:
4- [1-Methyl-l- (4-nitro-phenyl) -ethyl]-3, 6-dihydro-2H- pyridine-1-carboxylic acid ethyl ester was dissolved in EtOH (150 mL) and suspended with Pd/C (10%, Ig) . The reaction flask was equipped with a balloon filled with H2. The hydrogenation was continued for 3 days. The mixture was filtered through a layer of Celite® and concentrated in vacuo to provide the desired compound as a light brown oil. Preparation CLXXII: 3,3-diinethyl-6-nitroindoline 3-Methyl- but-2-enoic acid (3-acetylamino-phenyl)-amide:
3,3-Dimethylacryloyl chloride (3.3 ml, 29.3 mmol) was added to a mixture of 3 '-aminoacetanilide (4.40 g, 29.3 mmol) and Et3N (4.5 ml, 32.2 mmol) in 50 ml of CH2Cl2 and 25 ml of THF at 0 0C under N2. The mixture was stirred at RT overnight, diluted with 100 ml of CH2Cl2, washed with aqueous Na2CO3, then brine, condensed, and purified by flash column chromatography (15 to 30% of EtOAc in CH2Cl2) . The titled compound was obtained as an off-white solid. MS (ES+): 233.1 (M+H)+. CaIc'd for Ci3H15N2O2 - 232.28.
The following compounds were prepared similarly to the procedure outlined above:
a) 3-Methyl-but-2-enoic acid phenylamide. MS(ES+): 176.1 (M+H)+. CaIc'd for Ci1H13NO - 175.23.
Preparation CLXXIII - N-(4#4-Dimeth.yl-2-oxo-l/2,3,4- tetrahydro-quinolin-7-yl)-acetamide:
The mixture of 3,3-dimethyl-6-nitroindoline 3-Methyl-but-2- enoic acid (3-acetylamino-phenyl) -amide (1.05 g, 4.52 mmol) and AlCl3 (5.0 g, 37.5 mmol, Aldrich, 99.99%) in 50 ml of anhydrous chlorobenzene was stirred at 120 0C (oil bath temperature) under N2 overnight, cooled to RT, poured into 10 ml of ice cold HCl, stirred for 30 min, and extracted with EtOAc. The organic portions were combined, washed with brine, dried with Na2SO4, filtered, condensed, and purified by flash column chromatography (1% of MeOH in CH2Cl2) . The titled compound was obtained as an off-white solid. MS (ES+) : 233.2 (M+H)+. Calc'd for Ci3Hi6N2O2 - 232.28.
The following compounds were prepared similarly to the procedure outlined above: a) 4,4-Dimethyl-3,4-dihydro-lH-quinolin-2-one MS(ES+): 175.6 (M+H)+. CaIc'd for Ci1H13NO - 175.23.
Preparation CLXXIV: 7-Amino-4,4-dimethyl-3,4-dihydro-IH- ςpiinolin-2-one:
N- (4,4-Dimethyl-2-oxo-1,2,3,4-tetrahydro-quinolin-7-yl) - acetamide (1.50 g, 6.46 inmol) in 10 ml of HCl (concentrated, 37%) and 30 ml of EtOH was stirred at 75 0C for 4 h. The solvents were removed under reduced pressure. The residue was dissolved in Et0Ac/H20, neutralized with NaHCO3, washed with brine, dried with Na2SO4, filtered, and condensed to give the titled compound as an off-white solid. MS (ES+) : 191.2 (M+H)+. CaICd for C11H14N2O - 190.24.
Preparation CLXXV - 4#4-Diπ.eth.yl-l,2,3,4-tetrahydro- quinolin-7-ylamine:
The mixture of 7-amino-4,4-dimethyl-3, 4-dihydro-l.H-quinolin- 2-one (1.07 g, 5.62 mmol) and borane dimethylsulfide complex (1.60 ml, 16.9 mmol) in 40 ml of anhydrous THF was heated at reflux under N2 for 15 h. The solvents were removed under reduced pressure. The residue was heated at reflux in 20 ml of MeOH for 2 h, then 0.80 g of NaHCO3 was added, and the mixture was heated at reflux for 2 h. The mixture was filtered, condensed, and the residue was purified by flash column chromatography (5 to 10% of EtOAc in CH2Cl2) . The titled compound was obtained as a viscous oil. MS(ES+) : 176.9 (M+H)+. Calc'd for C11H16N - 176.26.
The following compounds were prepared similarly to the procedure outlined above:
a) 4,4-Dimethyl-l,2,3,4-tetrahydroquinoline MS(ES+) : 162.5 (M+H)+. Calc'd for C11H15N - 161.24. Preparation CLXXVI - N-(4,4-Dimethγl-l,2,3,4-tetrahydro- quinolin-7-yl)-2-fluoronicotinamide:
The mixture of 4,4-dimethyl-l,2,3,4-tetrahydro-qταinolin-7- ylamine (0.2Og, 1.13 mmol) , 2-fluoronicotinic acid (0.16g, 1.13 mmol), TBTU (0.36 g, 1.13 mmol), and DIEA (0.24 ml, 1.36 mmol) in 5 ml of DMF was stirred at RT for 3 h, then partitioned between EtOAc and Na2CO3 (aq) . The organic layer was washed with H2O, brine, dried with MgSO4, filtered, condensed, and the residue was purified by flash column chromatography (20 to 30% of EtOAc in CH2Cl2) . The titled compound was obtained as an off-white solid. MS (ES+): 300.1 (M+H)+. Calc'd for C17H18FN3O- 299.34.
The following compounds were prepared similarly to the procedure outlined above:
a) N- (4,4-Dimethyl-2-oxo-l,2,3,4-tetrahydro-quinolin-7-yl)- 2-fluoronicotinamide, as an off-white solid. MS (ES+) : 314.2 (M+H)+. Calc'd for C17H16FN3O2- 313.33. b) N-(l-Ethyl-4,4-dimethyl-l,2,3,4-tetrahydro-quinolin-7- yl) -2-fluoronicotinamide, MS(ES+) : 328.3 (M+H)+. Calc'd for C19H22FN3O - 327.40.
Preparation CLXXVII - 4,4-Dimethyl-7-nitro-l#2/3,4- tetrahydro-quinoline:
To 13 ml of H2SO4 (96%) cooled in a salt ice bath was added dropwise 4,4-dimethyl-1,2, 3,4-tetrahydro-quinoline (5.80 g, 36.0 mmol). The resulting slurry was stirred for 30 min, upon when concomitant addition of HNO3 ( 90%, 1.70 ml, 36.0 mmol) and H2SO4 ( 96%, 7 ml) was started, the addition was finished in 20 min, the mixture was stirred at 0 0C to 15 0C for 2 h, poured into ice, and extracted with EtOAc. The organic portion was washed with brine, condensed, and purified by flash column chromatography (0 to 10% of EtOAc in hexanes) . The titled compound was obtained as a yellow oil. MS (ES+) : 206.9 (M+H)+. Calc'd for C11H14N2O2 - 206.24.
Preparation CLXXVIIl - l-Ethyl-4,4-dimethyl-7-nitro-l,2,3,4- tetrahydroquinoline:
The mixture of 4,4-dimethyl-7-nitro-l,2,3,4-tetrahydro- quinoline (0.48g, 2.33 mmol) , iodoethane (0.21 ml, 2.56 mmol) , and NaH (60%, O.lOg, 2.5 mmol) in 10 ml of DMF was stirred at RT overnight, and partitioned between EtOAc and H2O. The combined organic portions were washed with brine, dried with MgSO4, filtered, and condensed. The crude compound was purified by flash column chromatography (5 to 10% of CH2Cl2 in hexanes) . The titled compound was obtained as a yellow oil. MS (ES+) : 235.3 (M+H)+. Calc'd for C13H18N2O2 - 234.29.
Preparation CLXXIX: l-Ethyl-4,4-dimethyl-l,2/3,4-tetrahydro- quinolin-7-ylamine: The mixture of l-ethyl-4,4-dimethyl-7-nitro-l, 2, 3,4- tetrahydro-quinoline (0.28 g) and Pd/C (0.060 g, 10% wt)in 10 ml of EtOAc was placed under H2 which was provided by a balloon and stirred at RT overnight. Then the mixture was filtered through Celite®, condensed, and the residue was purified by flash column chromatography (2% of EtOAc in CH2Cl2) . The titled compound was obtained as a pink oil. MS(ES+) : 204.8 (M+H)+. Calc'd for C11H16N - 204.31.
Preparation CLXXX - l-(4-Nitro-phenyl)- cyclopropanecarbonitrile:
NaOH (5.0 N, 80ml) was added to a mixture of 4- nitrophenylacetonitrile (10.0 g, 61.7 mmol), 1,2- dibromoethane (8.0 ml, 92.5 mmol), and tetraethylammonium chloride hydrate (10.2 g, 61.7 mmol) in 200 ml of CH2Cl2 at RT. The resulting mixture was stirred at RT for 24 h, diluted with CH2Cl2, and acidified with HCl (10%, aq) . The organic layer was separated, washed with brine, condensed, and the crude was purified by flash column chromatography. The titled compound was obtained as a light yellowish solid.
Preparation CLXXXI - C-[1-(4-Nitro-phenyl)-cyclopropyl]- methylamine:
The mixture of 1- (4-nitro-phenyl) -cyclopropanecarbonitrile (3.O g, 15.9 mmol) and borane THF complex (1.0 M solution in THF, 32 ml, 32 mmol) in 50 ml of anhydrous THF was heated at reflux overnight. The mixture was cooled to RT, quenched with 2.5 ml of 50% AcOH aqueous solution, then partitioned between EtOAc and NaHCO3 (aq) . The combined organic portions were washed with brine, dried with MgSO4, filtered, and condensed. The crude was purified by flash column chromatography (1 to 2% of MeOH in CH2Cl2) . The titled compound was obtained as a light brownish solid. MS (ES+) : 192.9. CaIc'd for C10H12N2O2- 192.2.
Preparation CLXXXII - 2,2,2-Trifluoro-N- [l-(4-nitro-phenyl)- cyclopropylmethyl]-acetamide:
Trifluoroacetic anhydride (5.26 ml, 36.9 mmol) was added to a mixture of C- [1- (4-nitro-phenyl) -cyclopropyl] -methylamine (2.37 g, 12.3 mmol) and triethyl amine (8.6 ml, 61.5 mmol) in 50 ml of CH2Cl2 at RT. The resulting mixture was stirred for 2 h. The volatiles were removed under reduced pressure and the residue was partitioned between EtOAc and aqueous NaHCO3. The organic layer was washed with brine, dired with MgSO4, filtered, and condensed. The crude compound was purified by flash column chromatography (10 to 20% of EtOAc in hexanes) , and the titled compound was obtained as an off- white solid. 25800
A-917 - 199 -
Preparation CLXXXIII - l-(7-Nitro-4-spiro-l'-cyclopropane- 3,4-dihydro-lff-isoquinolin-2-yl)-2,2,2-trifluoroethanone:
A mixture of 2, 2,2-trifluoro-N-1- (4-nitro-phenγl) - eyelopropylinethyl]-acetamide (3.10 g, 10.7 mmol) and paraformaldehyde (0.54 g, 17.2 mmol) was added to a mixture of 12 ml of glacial AcOH and 20 ml of H2SO4 at RT. The resulting mixture was stirred at 40 0C for 12 h, poured into ice-water and extracted with EtOAc. The combined organic portion was washed with NaHCO3 (aq) , H2O, brine, then dried with MgSO4, and condensed. The crude compound was purified by flash column chromatography (10 to 20% of EtOAc in hexanes) , and the titled compound was obtained as a white solid.
Preparation CLXXXIV - 7-Nitro-4-spiro-l/-cyclopropane- 1,2,3,4-tetrahydroisoquinoline:
A mixture of 1- (7-nitro-4-spiro-l ' -cyclopropane-3,4-dihydro- lH-isoquinolin-2-yl) -2,2,2-trifluoroethanone (0.32 g, 1.07 mmol) and K2CO3 (1.50 g, 14.2 mmol) in 7 ml of MeOH and 2 ml of H2O was stirred at RT overnight. The mixture was filtered, and the filtrate was concentrated. The residue was dissolved in EtOAc, washed with NH4Cl (aq) , brine, dried with MgSO4, filtered, and condensed to give the titled compound as a light yellowish solid. MS (ES+): 204.9 (M+H)+. Calc'd for C11H12N2O2 - 204.23.
Preparation CLXXXV - tert-Butyl N-[7-nitro-4-spiro-l'- cyclopropane- 3,4-dihydro-lH-isoquinoline-2-carbamate:
The mixture of 7-nitro-4-spiro-l'-cyclopropane-1,2,3,4- tetrahydroisoquinoline (0.2Og, 0.98 mmol), BOC2O (0.24 g, 1.08 mmol), DMAP( 0.025g, 0.20 mmol), DIEA (0.51 ml, 2.94 mmol) in 10 ml of CH2Cl2 was stirred at RT for 2 h. The solvent was removed, the residue was purified by flash column chromatography (5 to 10% of EtOAc in hexanes) , and the titled compound was obtained as a white solid.
Preparation CLXXXVI: tert-Butyl N-[7-amino-4-spiro-l' - cyclopropane-3,4-dihydro-lH-isoquinoline]carbamate
A mixture of tert-butyl N-[7-nitro-4-spiro-l'-cyclopropane- 3,4-dihydro-2iϊ-isoquinoline-2-carbamate (0.27 g, 0.89 mmol) and Pd/C (0.05 g, 10% wt) in 15 ml of MeOH was placed under H2 which was provided by a balloon and stirred at RT for 1.5 h. The mixture was filtered through CeIite®, and condensed to give the titled compound as a white solid. MS (ES+) : 274.8 (M+H)+. Calc'd for Ci6H22N2O2 - 274.36.
Preparation CLXXXVII - 4- methyl-6-[2-(l-methyl-ppyrrolidin- 2-yl)-ethyl]-pyrimidin -2-ylamine:
To a solution of (S) - (-) -1-methyl-2-pyrrolidine (320 mg, 2.78 mmol) in dry THF (10 mL) at 0 0C was added NaH (167 mg, 4.16 mmol) . After stirred at RT for 1 h, 2-amino-4-chloro- 6-methylpyrimidine (600 mg, 4.16 mmol) in dry THF (10 mL) was added dropwise via the addition funnel. The resulting mixture was heated to reflux under Ar gas for 20 h. The reaction was cooled to RT and quenched with sat. NH4Cl. Solvent was removed. The residue was partitioned between H2O and CHCl3. The organic layer was washed with H2O, brine, dried over MgSO4, and evaporated to dryness. This crude compound was purified in column eluted with CH2Cl2:MeOH = 95%:5% to yield the title compound. MS m/z: 223.2 (M+H) . Calc'd. for C12H20N4 - 222.2.
Preparation CLXXXVIII - (6-bromo-pyridin-2-yl)3-Methyl-but-
2-enoic -amide:
To a solution of 2-amino-6-bromopyridine (4, 3.015 g, 0.017 mol) and Et3N (2.40 mL, 0.017 mol) in CH2Cl2 (20.0 mL) , was added 3,3-dimethylacryloylchloride (1.96 mL, 0.017 mol) under N2 at 0 0C. The reaction mixture was slowly warmed to RT and stirred for 12 h. The reaction was quenched by the addition of H2O (20.0 mL) . The organic layer was separated, dried over Na2SO4 and evaporated to dryness to yield crude compound which was used without purification.
Preparation CLXXXIX - (6-amino-pyridin-2-yl) 3-Methyl-but-2- eπoic -amide:
To a solution of 2-amino-6-bromopyridine (4.30 g, 0.017 mol) and copper (0.214 g, 3.372 mmol) in IPOH (20.0 mL) , was added NH4OH (20.0 mL) in a sealed vessel under N2. The reaction was sealed and heated to 90 0C for 12 h. The mixture was cooled to RT and EtOAc (50.0 mL) was added. The organic layer was separated, and the aq layer was washed with EtOAc (50.0 mL) . The combined organic layers were evaporated to dryness, the resulting residue was dissolved in CH2Cl2 (50.0 mL) and washed with H2O (4 x 30 mL) . The organic layer was dried over Na2SO4 and evaporated to dryness to yield crude compound which was used without purification.
Preparation CXC - 7-Amino-4#4-dimethyl-3,4-dihydro-lH- [1,8]naphthyridin-2-one:
To a mixture of aminopyridine 6 (1.12 g, 5.833 mmol) and AlCl3 (3.11 g, 0.023 mol) was added chlorobenzene (10.0 mL) in a sealed vessel under Ar. The reaction was sealed and heated to 120 °C for 12 h. The reaction mixture was cooled to RT and the mixture was poured over ice/HCl mixture and extracted with EtOAc (3 x 50.0 mL) . The Aq layer was neutralized with solid NaHCO3 and extracted with EtOAc (5 x 50 mL) . The combined organic layers were dried over Na2SO4 and evaporated to dryness to yield crude compound which was purified by chromatography (Silica gel, CH2Cl2:Me0H, 99:1) yielding the title compound. Preparation CXCI - 2-[l-(3-Ainino-phenyl)-2,2,2-trifluoro-l- trifluoromethyl-ethoxymethyl]-pyrrolidine-1-carboxylic acid tert-butyl ester:
To a mixture of 2- (3-amino-phenyl) -1,1, 1,3, 3, 3-hexafluoro- propan-2-ol (1.30 g) , 2-hydroxymethyl-pyrrolidine~l- carboxylic acid tert-butyl ester (1.04 g) , PPh3 (2.64 g) and molecular sieves 4 A in THF (100 mL) was added DEAD (1.55 rriL) slowly. The reaction was stirred at RT for 4 h and at reflux overnight. After filtration to remove solids, the filtrate was concentrated and the residue was taken up into Et2O. The organic phase was washed with saturated NaHCO3 and brine. The organic layer was dried over MgSO4 and evaporated to give a viscous brown oil, which was purified by chromatography through silica gel (500 g, 30% to 50% EtOAc in hexanes) to afford 2- [1- (3-amino-phenyl)-2, 2,2- trifluoro-1-trifluoromethyl-ethoxymethyl]-pyrrolidine-1- carboxylic acid tert-butyl ester as a light brown oil.
Preparation CXCII - N-(3-Amino-5-chloro-phenyl)-2- dimethylamino-acetamide:
To a solution of 5-chloro-benzene-l, 3-diamine (3 g, 21 mmol) and dimethylamino-AcOH (2.2 g, 21 mmol) in CH2Cl2 (300 mL) was added EDC (5 g, 25 mmol), HOBt (2.9 g, 21 mmol), and DIEA (5 mL) . The reaction mixture was stirred at RT overnight. Solvent was removed in vacuo and the residue was purified through flash chromatography on silica gel (0-8% MeOH in EtOAc) to give the desired compound.
General Procedure for the preparation of 2,6- diaminopyridines:
To a solution of 2-amino-6-bromopyridine (1.070 g, 6.061 mmol) in 2,4-dimethylphenol (2.0 mL) was added amine (6.667 mmol) and the reaction mixture was heated to 150 0C for 12 h. The mixture was cooled to RT and aq. HCl (2.0 M, 30 mL) was added. EtOAc (50 inL) was added and the organic layer was separated. The Aq layer was washed with EtOAc (2 x 40 inL) and the combined organic layers were washed with H2O (50 inL) , dried over Na2SO4, concentrated under vacuo to yield crude compound which was used without purification.
The following compounds were prepared similarly to the procedure outlined above:
a) 3,4,5,6-Tetrahydro-2H-[l,21 ]bipyridinyl-6 ' -ylamine: b) 6- (4-Methyl-piperazin-l-yl) -pyridin-2-ylamine:
Preparation CXCIII - 2-Methyl-2-(4-nitrophenyl)propionic acid: To a solution of 2- (4-nitrophenyl)propionic acid (50 g, 0.26 mol) in 250 mL of MeOH was added 6 mL of concentrated HCl. The resulting solution was heated at reflux for 16 h. The reaction was diluted with 200 mL of aq. NaHCO3 and 500 mL of EtOAc. The organic layer was separated, dried over Na2SO4, and concentrated. The residue was diluted with 100 mL of THF and added to a suspension of NaH (11.2 g, 0.28 mol, 60 % in mineral oil) in 600 mL of THF. To the resulting mixture was added CH3I (18.3 mL, 0.29 mol) in one portion. The resulting mixture was stirred for 48 h at 40 0C and diluted with aq. NH4Cl solution and EtOAc. The organic layer was separated, dried over Na2SO4, and concentrated. The residue was used without further purification.
To a solution of the residue (54 g, 0.24 mol) in 500 mL of MeOH was added 5N aq. NaOH solution (144 mL, 0.72 mol) . The mixture was stirred for 16 h at 400C, then, concentrated, and the residue was diluted with H2O (500 mL) . The aq. solution was acidified with 2N HCl to give a precipitate which was filtered and dried to give the titled compound as a yellowish solid. MS : (ES+) 210 (M+H) . Calc ' d for C10Hi2NO4- 210 . 20 .
Preparation CXCIV - 2-Methyl~5-[l-methyl-l~(4-nitro-phenyl)- ethyl]-[1,3,4]oxadiazole:
A mixture of 2-methyl-2- (4-nitro-phenyl) -propionic acid (5 g, 24 mmol) and a few drops DMF in SOCl2 was stirred at reflux for 16 h. The resulting solution was concentrated to give corresponding acid chloride as a brown solid. To a mixture of the acid chloride (2.33 g, 10.2 mmol), acetic acid hydrazide (0.91 g, 12.2 mmol), Et3N (2.86 mL, 20.2 mmol) in CH2Cl2 (50 mL) was added 2 crystals of DMAP at RT. The resulting mixture was stirred for 16 h and concentrated. A solution of the residue in 50 mL of POCl3 was heated at 95 0C for 16 h. The resulting mixture was concentrated and diluted with ice-H2O and EtOAc. The organic layer was washed with saturated aq. NaHCO3 solution twice, dried over Na2SO4, and concentrated. The residue was purified by SiO2 chromatography (hexane: EtOAc=I:!) to give the titled compound as a pale yellow crystalline solid. MS: (ES+) 248 (M+H) . Calc'd for C12Hi4N3O3 - 248.10.
Preparation CXCV - 2-Methyl-5-[1-methyl-1-(4-amino-phenyl)- ethyl]-[l,3,4]oxadiazole: A mixture of 2-methyl-5- [1-methyl-l- (4-nitro-phenyl) -ethyl]- [1,3,4]oxadiazole (1.36 g, 5.5 mmol) and Pd/C (68 mg) in EtOAc (50 mL) was stirred under 1 atm of H2 for 16 h. The resulting slurry was filtered over Celite®, and the filtrate was concentrated to give the titled compound as a pale yellow crystalline solid. MS: (ES+) 218 (M+H). Calc'd for C12Hi6N3O - 218.12. Preparation CXCVI - 4-[1-Methyl-l-(4-nitro-phenyl)-ethyl]- pyrimidine:
To a mixture of 1- (4-nitro-phenyl) -propan-2-one (5.32 g, 29.7 mmol) , triethylbenzylammonium chloride (0.34 g, 1.5 mmol), and 13 mL of aq. 5N KOH solution (65.3 mmol) in CH2Cl2 was added CH3I (4.06 mL, 65.3 mmol) . The resulting mixture was stirred at 40 0C then diluted with EtOAc and H2O. The organic layer was dried and concentrated.
To the residue (1.0 g, 4.8 mmol) in toluene (30 mL) was added dimethylformamide dimethylacetal (1.27 mL, 9.6 mmol) . The resulting mixture was heated at reflux for 6 h, then concentrated to give l-dimethylamino-4-methyl-4- (4- nitro-phenyl) -pent-l-en-3-one as a yellow solid. MS: (ES+) 263 (M+H) . Calc'd for C14H19N2O3-263.13. A mixture of l-dimethylamino-4-methyl-4- (4-nitro- phenyl) -pent-l-en-3-one (0.5 g, 1.9 mmol), formamidine hydrochloride (0.305 g, 3.8 mmol), and NaOEt (1.29 g, 4.0 mmol) was heated in Smith synthesizer under microwave for 10 min at 150 0C. The resultant was diluted with H2O and EtOAc. The organic layer was dried, and the residue was used without further purification. MS: (ES+) 244 (M+H) . Calc'd for C13H14N3O2 - 244.10.
Preparation CXCVII - 5- [1-Methyl-l-(4-nitro-phenyl)-ethyl]- lH-pyrazole:
A mixture of l-dimethylamino-4-methyl-4- (4-nitro-phenyl) - pent-l-en-3-one (0.36 g, 1.4 mmol) and hydrazine hydrate (1.0 g, 6.25 mmol) in EtOH was heated at 50 0C for 3h. The mixture was concentrated, and the residue was diluted with H2O and EtOAc. The organic layer was dried over Na2SO4 and concentrated to give the titled compound as a yellow solid. MS: (ES+) 232 (M+H.) Calc'd for C12H14N3O2 -232.10. Preparation CXCVIII - 2-Methyl~2-(4-nitro-phenyl)-l- pyrrolidin-yl-propan-1-one:
To a round bottom flask charged with 2-methyl-2- (4-nitro- phenyl)-propionic acid, was added 6.5 ml of SOCl2. The mixture was heated to 80a C, with stirring under inert atmosphere for 3.5 h. The mixture was cooled to RT, and then dried in-vacuo. The residue was placed under high vac. After completely dry, the residue was used without further purification. To the residue was added 10 ml of CH2Cl2, along with Et3N and the mixture was cooled to 0 0C on an ice/H20 bath. Pyrrolidine .46 mL (1.25 eq.) was added into the mixture, then stirred to RT under inert atmosphere. After 3 h of stirring, the mixture was quenched with H2O, diluted with CH2Cl2, and transferred to a separatory funnel. The organics were collected, combined, dried over Na2SO4 and filtered. The crude was concentrated in vacuo. After drying, the title compound was produced as an amorphous solid. MS: 263 (M+l) ; calc'd for C14H18N2O3 - 262
Preparation CXCIX - 4-(l,l-Dimethyl-2-pyrrolidin-l-yl-ethyl- phenylamine:
To a 3-neck round bottom flask, charged with 2-Methyl-2- (4- nitro-phenyl) -1-pyrrolidin-yl-propan-l-one was added 66 ml of IM BH3/THF soln, while the mixture was maintained at 0° C on an ice/H2O bath. The mixture was stirred under inert atmosphere overnight. A couple drops of 5N NaOH was added slowly to the reaction mixture for quenching. After stirring an additional 5 min, 22 ml of 5N NaOH was added into the reaction mixture, then stirred vigorously for 3 h. The mixture was diluted with 50 ml of IN NaOH and 100 ml of EtOAc, then transferred into a sep. funnel. The organics were collected and concentrated in vacuo. The residue was dissolved in CH2CL2, then NaHCO3 soln. was added into the mixture the organic extracts were dried over Na2SO4, filtered, then concentrated in vacuo.
To a round bottom flask charged with Pd/C in MeOH under inert atmosphere, was added 1-[2-methyl-2- (4-nitro- phenyl)-propyl] -pyrrolidine in MeOH and H2 was added while stirring vigorously overnight. The mixture was filtered through Celite® and concentrated in vacuo to yield a light yellow oil. MS: 219 (M+l) ; calc'd for C14H22N2.
Preparation CC - l-methyl-l-(4-nitro-phenyl)-ethylamine:
To a round bottom flask charged with 2-methyl-2- (4-nitro- phenyl) -propionic acid (10 g; 0.0440 mole), was added SOCl2 (32 ml ) . The mixture was heated to reflux, until completion of the reaction. After heating, the residual SOCl2 was removed by in vacuo, then placed the residue on high vac. The crude was used without further purification.
To the residue, was added 20 ml toluene and stirred. Then slowly NaN3 (7.14 g,- 0.1099 mole) was added into the mixture, and stirred vigorously under inert atmosphere for 1.5 h. The mixture was poured into 50 ml H2O and transferred into a sep. funnel, with 50 ml EtOAc. The organics were collected, dried, filtered, and concentrated in-vacuo. The residue was dissolved in toluene and heated to 1000C while stirring vigorously under inert atmosphere for 1 h. The solvent was removed in-vacuo, 20% HCl aq was added and the mixture stirred vigorously under reflux conditions at 1000C for 9 h. The mixture was evaporated in- vacuo and to the residue was added 50 ml of 5N NaOH and 80 ml EtOAc, then transferred the mixture to a sep. funnel. The organic layer was collected, dried, filtered, and cone. in-vacuo. The residue was purified on silica-gel column in a solvent gradient of 80% EtOAc/Hexanes to 10% MeOH/ CH2CL2 yielding a brown solid resulted. MS: 181 (M+l); calc'd for C9H12N2O2-180. Preparation CCI - [1-(4-Amino-phenyl)-l-methyl-ethyl] -(2- methylsulfanyl-pyrimidin-4-yl)-amine:
To a Personal Chemistry reaction tube, was added 1-methyl-l- (4-nitro-phenyl)-ethylamine, along with 4-chloro-2- methylsulfanyl-pyrimidine, DIEA (2.0 eq) and t-BuOH (0.6 ml) . The tube was heated by microwave to 1500C for 10 min. After heating, the crude was diluted with CH2CL2 and H2O, then transferred into a sep. funnel. The organics were collected, dried over Na2SO4, then concentrated in vacuo. The crude was used without further purification.
To a round bottom flask charged with PtO2 (12% wt.) in MeOH ( 5 ml), was added crude nitro-intermediate ( .170 g.; 0.0006 mole) . The mixture was stirred vigorously under H2 for 2.5 h. The mixture was filtered through Celite® and concentrated in-vacuo. The desired material was purified by silica-gel chromatography in a solvent gradient of 80% EtOAc/Hexanes to 5% MeOH/CH2CL2. After drying in high vac, the title compound resulted as a light yellow amorphous solid.
Preparation CCII - 2-(2,2,2-Trifluoro-ethoxy)- isonicotinonitrile:
To the suspension of NaH (2.78 g, 0.11 mole) in THF 100 mL) 2,2,2-trifluoroethanol (10 g, 0.1 mol) was added slowly. The mixture was stirred at RT till it turned clear. A solution of 2-chloro-isonicotinonitrile (13.8 g, 0.1 mol) in THF (100 mL) was slowly added and stirred at reflux for 3 h. After filtration and concentration, the crude oily compound was purified through column chromatography providing pure compound as an oil. Preparation CCIII -[2-(2,2,2-Trifluoro-ethoxγ)-pγridin-4- yl]-methylamine hydrogen chloride:
A mixture of 2- (2, 2,2-trifluoro-ethoxy) -isonicotinonitrile (3.90 g, 19.40 mmol) , 12N HC1(8.O iαL) and 10% Pd/C (800 mg) in MeOH (100 ml) was stirred under a balloon of H2 for 7 h. After filtration, the filtrate was concentrated to give compound as a white solid. MS (ES+): 206.9 (M+H)+. Calc'd. for C8H9F3N2O - 206.07.
Preparation CCIV - 2-Bromomethyl-3-nitro-benzoic acid methyl ester:
The mixture of methyl 2-methyl-3-nitro benzoate (5.06 g, 25.9 mmol), NBS (5.54 g, 31.1 mmol), and AIBN (0.43 g, 2.59 mmol) in 100 ml of anhydrous CCl4 was heated at reflux under N2 for 22 h, cooled to RT, diluted with EtOAc, and washed with Na2CO3 (aq) . The organic portion was separated, washed with brine, dried with Na2SO4, filtered, and condensed. The crude material was purified by flash column chromatography to yield pure product, which was used without further purification.
Preparation CCV - 4-Nitro-2# 3-dihydro-isoindol-l-one:
NH3 (2.0 M in MeOH, 50 ml) was slowly added to the solution of 2-bromomethyl-3-nitro-benzoic acid methyl ester (4.46 g, contaminated with a small amount of assumed starting material, 16.3 mmol) in 30 ml of MeOH at RT. The resulting mixture was stirred at RT overnight, to provide the title compound as a white solid. MS (ES+): 179.2 (M+H)+. Calc'd for C8H6N2O3 - 178.14.
Preparation CCVI - 4-Amino-2, 3-dihydro-isoindol-l-one: To the suspension of 4-nitro-2,3-dihydro-isoindol-l-one (2.40 g, 13.5 mmol) in 100 ml of MeOH was added Pd/C (10 wt%, 0.36 g) . The mixture was then placed under H2 from a balloon, stirred at RT for 24 h, filtered through Celite®, and condensed to give the titled compound as a light greenish solid. MS (ES+): 149.1 (M+H)+. Calc'd for C8H8N2O - 148.16.
Preparation CCVII - Pyridin-4-ylmeth.yl-carbamic acid tert- butyl ester:
Boc anhydride (23 g, 105 mmol) was carefully added to a solution of pyridin-4-yl-methylamine (11 g, 102 mmol) and DMAP (0.5 g, 4 mmole) in CH2CL2 (150 mL) . The reaction was extended for 1 hr after the addition. The reaction mixture was concentrated in vacuo and the residue was recrystallized in EtOAc to afford an off white crystal as the desired compound.
Preparation CCVIII - (l-Oxy-pyridin-4-ylmethyl)-carbamic acid tert-butyl ester:
Pyridin-4-ylmethyl-carbamic acid tert-butyl ester (2.1 g, 10 mmol) was dissolved in a one to one mixture of aqueous MeOH (200 mL) with NaHCO3 (5 g, 60 mmol) and Oxone® (12.3 g, 20 mmol) . The mixture was stirred overnight then concentrated in vacuo to remove MeOH. The resulted aqueous mixture was diluted with H2O (150 mL) and filtered. The filter cake was washed with H2O and dried to afford a white solid as the desired compound.
Preparation CCIX - C-(l-0xy-pyridin-4-yl)-methylamine:
Oxy-pyridin-4-ylmethyl) -carbamic acid tert-butyl ester (2.1 g, 9.4 mmol) was dissolved in a 4N HCl in dioxane solution (50 mL) and heated to 50 C for 2 h. After removing solvent in vacuo, a white solid was received as an HCl salt of the desired compound. Preparation CCX - 2-(4-Methoxy-benzylamino)- isonicotinonitrile:
To pyridine (500 πiL) were added 2-chloroisonicotinonitrile (22.0 g, 159 mmole), para-methoxybenzylamine (25 g, 114% Meq.), and NaHCO3 (30 g) . The mixture was heated under reflux overnight. After cooling to RT, the mixture was filtered and the filter cake was rinsed with CH2Cl2. The combined filtrate was concentrated to dryness in vacuum to form a yellow solid. This solid is then recrystalized in EtOAc to give a light yellow crystalline compound and the mother liquor was concentrated and subjected to EtOAc again (repeating three times) to yield the desired compound.
Preparation CCXI - (4-Aminomethyl-pyridin-2-yl)-(4-methoxy- benzyl)-amine:
2- (4-Methoxy-benzylamino) -isonicotinonitrile (12 g, 50 mmole) was dissolved in a mixed solvent of EtOH (800 mL) Et3N (200 mL) and suspended with 2 g of Pd/C (10%) . After removing air with vacuum, the flask was charged with H2 with a balloon. The H2 balloon was refilled every morning and evening. Pd/C was recharged twice (1.3 g each) on days 2 and 3. Reaction was completed on the 4th day and the reaction mixture was filtered through a pad of Celite®. The filter cake was rinsed with MeOH and the combined filtrate was concentrated in vacuo to give the desired compound as a light brown solid.
Preparation CCXII - 4-Aminomethyl-pyridin-2-ylamine:
(4-Aminomethyl-pyridin-2-yl)- (4-methoxy-benzyl) -amine (12 g, 50 mmole) was dissolved in TFA (150 mL) and heated to reflux for 1 h. After cooling, the reaction mixture was concentrated in vacuum and the residue was partitioned between HCl (IN, aq. ) and EtOAc. The aqueous layer was washed with EtOAc then hexanes and concentrated to dryness in vacuum to give an off white solid as a dihydrochloric salt.
Preparation CCXIII - 2-Methylamino-isonicotinonitrile: To a solution of 2-chloroisonicotinonitrile (22.0 g, 159 mmole) in pyridine (500 inL) was added methylamine in THF (2N, 160 mL) , and NaHCO3 (54 g) . The mixture was heated to 120 0C in a sealed vessel for 40 h. After cooled to RT, the mixture was filtered and the filter cake was washed with CH2Cl2. The combined filtrated was concentrated in vacuo to give a yellow solid (21 g) as the desired compound.
Preparation CCXIV - (4-Aminomethyl-pyridin-2-yl)-methyl¬ amine: A suspension of 2-Methylamino-isonicotinonitrile (5.6 g) and Pd/C (10%, 4 g) in EtOH (150 mL) and TEA (40 mL) was placed in a 500 mL Parr Hydrogenation bottle and hydrogenated at or below 60 psi H2 pressure over night. After filtering through a pad of CeIite®, the reaction mixture was concentrated in vacuo to give a yellow oil as the desired compound.
Preparation CCXV - 3-Fluoro-pyridine 1-oxide:
3-Chloroperoxybenzoic acid (70%, 35.0 g, 142 mmol) was added to the solution of 3-fluoropyridine (6.90 g, 71.1 mmol) in 200 ml of CH2Cl2, the mixture was stirred at RT overnight, washed with a small amount of saturated NaHCO3 solution, dried with Na2SO4, filtered, condensed, the crude compound was purified by flash column chromatography (1 to 2% of MeOH in CH2Cl2), the titled compound was obtained as a light yellowish solid. MS (ES+): 114.1 (M+H)+. Calc'd for C5H4FNO - 113.09. Preparation CCXVI - 3-Fluoro-pyridine-2-carbonitrile:
The mixture of 3-fluoro-pyridine 1-oxide (0.99 g, 8.75 mmoX) , trimethylsilyl cyanide (4.80 ml, 35.0 itimol) , and triethyl amine (1.84 ml, 13.2 mmol) in 100 ml of CH3CN was heated at reflux overnight. The solvents were removed, under reduced pressure and the residue was partitioned between EtOAc and saturated NaHCO3. The organic portion was separated, dried with Na2SO4, filtered, condensed, the crude compound as purified by flash column chromatography (10 to 20% of EtOAc in hexanes) . The titled compound was obtained as a light yellowish solid. MS (ES+) : 123.1 (M+H)+. Calc'd for C6H3FN2 - 122.10.
Preparation CCXVII - C-(3-Fluoro-pyridin-2-yl)-iαethylamine: The mixture of 3-fluoro-pyridine-2-carbonitrile (0.81 g, 6.63 mmol) and Pd/C (0.20 g, 10% wt) in 10 ml of MeOH and 2.7 ml of concentrated HCl was placed under H2 which was provided by a balloon and stirred at RT for 4 h, filtered through Celite®, condensed, the residue was purified by flash column chromatography, 0.13 g of the titled compound was obtained as a light yellowish oil. MS(ES+): 127.1 (MH-H)+. Calc'd for C6H7FN2 - 126.13.
Preparation CCXVIII: 5-Bromo-pyridine-2-carbonitrile: The mixture of 2, 5-dibromopyridine (4.74 g, 20.0 mmol), zinc cyanide (1.40 g, 12.0 mmol), zinc dust (0.059 g, 0.90 mmol), and Pd(dppf)Cl2.CH2Cl2 (0.36 g, 0.44 mmol) in 25 ml of DMF was heated at reflux for 5 h, cooled to RT, diluted with H2O, extracted with EtOAc, the organic portion was washed with brine, the solvents were removed, the crude compound was purified by flash column chromatography (5 to 15% of EtOAc in hexanes) , the titled compound was obtained as an off-white solid. Preparation CCXIX - 5-Fluoro-pyridine-2-carbonitrile:
The mixture of 5-bromo-pyridine-2-carbonitrile (0.50 g, 2.73 mmol) , and KF (0.48 g, 8.20 mmol) in 10 ml of 1-methyl-2- pyrrolidinone was stirred at 175 0C for 18 h, cooled to RT, 5 diluted with H2O, extracted with EtOAc, the combined organic portions were washed with H2O, brine, dried with Na2SO4, filtered, condensed, the crude compound was purified by flash column chromatography (5 to 20% of EtOAc in hexanes) . The titled compound was obtained as an off-white solid.
10
Preparation CCXX - C-(5-Fluoro-pyridin-2-yl)-methylamine: The mixture of 5-fluoro-pyridine-2-carbonitrile (0.16 g, 1.27mmol) and Pd/C (0.030 g, 10% wt) in 15 ml of MeOH and 0.50 ml of concentrated HCl was placed under H2 which was
15 provided by a balloon and stirred at RT for 4 h, filtered through Celite®, condensed, the residue was purified by flash column chromatography. The titled compound was obtained as a light yellowish solid. MS(ES+): 127.2 (free base) (M+H)+ . CaIc'd for C6H7FN2 (free base)- 126.13.
•20
Preparation CCXXI - 1H-Pyrrolo[2,3-b]pyridine 7-oxide: To a suspension of lH-pyrrolo[2,3-b]pyridine (10.0 g) and NaHCO3 (45.2 g) in 1:1 MeOH/H2O (1000 mL) was added Oxone® (106 g) in potions during 40 min period. The mixture was
25 stirred at RT for 5 h. The sold was removed by filtration and the filtrate was concentrated to 200 mL in volume. This aqueous phase was extracted with CH2Cl2 (200 mL X 7) to afford lH-pyrrolo[2,3-b]pyridine 7-oxide.
30 Preparation CCXXII - 4-chloro-lH-pyrrolo[2,3-b]pyridine:
To a cooled POCl3 (50 mL) in a dried round bottom flask, IH- pyrrolo[2,3-b]pyridine 7-oxide (5.73 g, step A) was added in potions. The mixture was heated to reflux for 5 h. After cooled down to RT, POCl3 was evaporated under high vacuum under gentle heating (40-50 0C) to obtain black residue. 50 mL of H2O was added slowly and pH was adjusted to 8-9 with Na2CO3 (first with solid, then saturated aqueous solution) . The resulting priticipate was collected by filtration, washed with cold H2O and dried in a vacuum oven (50 0C) to give 4-chloro-lH-pyrrolo[2,3-b]pyridine as tan powder.
Preparation CCXXIII - l-(4-iodo-pyrrolo[2,3-b]pyridin-l-yl)- ethanone: To a suspension of 4-chloro-lH-pyrrolo[2,3-b]pyridine (3.80 g, step B) and NaI (19.15 g) in CH3CN (40 mL) was added acetyl chloride (5.0 mL) slowly. The mixture was heated to reflux for overnight. After cooled to RT, 40 mL of 10% Na2CO3 and 40 mL of 10% NaHSO3 were added. After stirring for 15 min, the mixture was extracted with EtOAc 4 times. The combined organic phases were washed with brine, dried over MgSO4 and concentrated to give a brown residue as the crude compound, which was purified by chromatography through silica gel (220 g, 5 tol5% EtOAc/hexanes to afford l-(4- iodo-pyrrolo[2,3-b]pyridin-l-yl) -ethanone as white solid.
Preparation CCXXIV - l-acetyl-lH-pγrrolo[2,3-b]pyridine-4- carbonitrile:
A mixture of 1- (4-iodo-pyrrolo[2, 3-b]pyridin-l-yl)-ethanone (4.30 g, step C), CuCN (6.841 g) , Pd2dba3 (0.729 g) , and dppf (1.636 g) in 85 mL of dioxane was heated to reflux for 2 h. Solid was removed by filtration through a pad of Celite®. The filtrate was concentrated to give a yellow solid as crude compound, which was purified by chromatography through silica gel (250 g, 5-30%
EtOAc/hexanes, stepwise gradient) to afford 1-acetyl-lH- pyrrolo[2,3-b]pyridine-4-carbonitrile as a white fluffy solid. Preparation CCXXV - l~(4-aminomethyl-pyrrolo[2,3-b]pyridin- 1-yl)-ethanone:
A mixture of l-acetyl-lH-pyrrolo[2,3-b]pyridine-4- carbonitrile (0.872 g, step D), 10% Pd/C (0.882 g) , 20 mL of Et3N, and 80 mL of EtOH was stirred at RT under balloon pressure of H2 for overnight. Solid was removed by filtration through a pad of Celite® and the filtrate was concentrated to yield a cream color residue, which was purified by chromatography through silica gel (70 g, 2 to 5% MeOH/CHCl3 with 1% NH4OH) to afford 1- (4-aminomethyl- pyrrolo[2,3-b]pyridin-l-yl)-ethanone as a white solid.
Preparation CCXXVI - N-(l~acetyl-2#3-dihydro-lH-pyrrolo[2,3- b]pyridin-4-ylmethyl)-acetamide: To a mixture of l-acetyl-lH-pyrrolo[2,3-b]pyridine-4- carbonitrile (0.691 g, example 15, step D), 10% Pd/C (0.702 g) , 5 mL of Et3N, and 20 mL of EtOAc was added acetic anhydride (1.0 mL) . The mixture was stirred at RT under balloon pressure of H2 for overnight. Solid was removed by filtration through a pad of Celite® and the filtrate was concentrated to yield a white residue, which was purified by chromatography through silica gel (150 g, 1 to 5% MeOH/CHCl3 with 1% NH4OH, stepwise gradient) to afford N- (l-acetyl-2,3- dihydro-lH-pyrrolo[2,3-b]pyridin-4-ylmethyl) -acetamide (0.50 g) as white solid.
Preparation CCXXVlI - C-(2/3-dihydro-lH-pyrrolo[2#3- b]pyridin-4-yl)-methylamine hydrogen chloride salt:
A mixture of N- (l-acetyl-2,3-dihydro-lH-pyrrolo[2, 3- b]pyridin-4-ylmethyl) -acetamide (0.50 g, step A), HCl (cone, 3 mL) and EtOH (12 mL) was heated to 70 0C for overnight. Additional 3 mL of cone. HCl was added to the reaction and the heating was continued for 3 more days . Solvent was evaporated to give a white residue as crude C- (2,3-dihydro-lH-pyrrolo[2,3-b]pγridin-4-yl) -methylamine HCl salt, which was used without further purification.
General Procedure for the Preparation of 2-amino-4- methylaminopyridines
Preparation CCXXVIII - 2-aminoisonicotinonitrile:
To a slurry of 2-chloro-4-cyanopyridine (10.00 g, 0.079 mol) and sodiumbicarbonate (19.92 g, 0.237 mol) in amine (0.174 mol) was added pyridine (35.0 mL) and the reaction was heated to 90 0C for 3 h. The reaction was then cooled to RT, diluted with the addition of CH2Cl2 (100 mL) and filtered. The solid was washed with EtOAc. Combined washes were concentrated in vacuo. A mixture of MeOH/hexanes was added and kept in the fridge for 12 h. The crystals that formed were filtered and washed with hexanes.
Preparation CCXXIX - 2-amino-4-methylaminopyridine:
To a mixture of 2-aminoisonicotinonitrile (0.043 mol) and Pd/C (10%, 6.00 g) was added Et3N (40.0 mL) and EtOH (160.0 mL) in a parr bottle and hydrogenated at 50 psi for 12 h. Crude mixture was filtered through CeIite®, concentrated under vacuo and dried under high vacuum to yield compound.
Preparation CCXXX - (2-Pyrrolidin-l-yl-pyridin-4-yl)- xnethylaπiine:
Prepared according to the general procedure with pyrrolidine as the amine.
Preparation CCXXXI - (2-Morpholin-4-yl-pyridin-4-yl)- methylamine:
Prepared according to the general procedure with morpholine as the amine. Preparation CCXXXII - 3#9#9-Triitιethyl-6-nitro-4#9-dihydro- 3H-3-aza-fluorene:
4- [1- (2-Bromo-4-nitro-phenyl) -1-methyl-ethyl]-1-methyl- 1,2,3, 6-tetrahydro-pyridine (9 g) , Pd(OAc)2 (900 mg) , and DIEA (15 πiL) was dissolved in DMF (300 iriL) , and heated to 800C overnight. Solvents were removed in vacuo. The residue was partitioned between CH2Cl2/NaHCO3 (sat, aq.) . The CH2Cl2 layer was washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue was purified via flash chromatography on silica to give the desired compound. (MS: M+H=257) ■
Preparation CCXXXIII - 3,9,9-Trimethyl-2,3,4,4a,9,9a- hexahγdro~lH-3~aza-fluoren-6-ylamine(156) : 3,9,9-Trimethyl-6-nitro-4,9-dihydro-3H-3-aza-fluorene (700 mg) was dissolved in EtOH (20 mL) with aqueous HCl (IN, 5 mL) and suspended with Pd/C (10%, 100 mg) . The flask was capped with a balloon filled with H2. The reaction was completed in 6 h at RT. The reaction mixture was filtered through a layer of Celite® with MeOH. The combined filtrate was concentrated to give desired compound. (MS: M+H=231) .
Preparation CCXXXIV - 2-Chloro-5-nitro-phenol:
A mixture of 2-chloro-4-nitroanisole (10 g, 53.3 mmol) and pyridinium chloride (50 g, 426 mmol) was heated at 200 0C for 3 h. After cooling to RT, the mixture was dissolved in 150 mL of aqueous 2N HCl and 150 mL of EtOAc. The organic phase was separated and was washed with aqueous 2N HCl (2 x 100 mL) . The resulting organic phase was dried over MgSO4 and concentrated in vacuo. The title compound was obtained via chromatography (silica gel, 10:1 hexane/EtOAc) as a yellow solid. Preparation CCXXXV - 3-(5-Amino-2-chloro-plιenoxy-nethyl)- azetidine-1-carboxylic acid tert-butyl ester:
To a solution of 3- (2-chloro-5-nitro-phenoxγmethγl) - azetidine-1-carboxylic acid tert-butyl ester (2.5 g, 7.29 itimol) in 60 πiL of MeOH/H2O (1:1) and 3 mL of acetic acid (J.T. Baker) was added Zn powder (2.3 g, 36.47 mmol, Aldrich) at 0 0C. The reaction mixture was stirred at 0 °C for 2 h then stirred at 10 0C for 2 h. The resulting mixture was filtered through a Celite® pad and the filtrate was concentrated in vacuo. The residue was treated with 60 mL of saturated aqueous NaHCO3 and extracted with EtOAc (3 x 50 mL) . The combined organic layers were washed with brine and dried with MgSO4. The resulting solution was concentrated in vacuo and the title compound was obtained by column chromatography (silica gel, EtOAc) as a yellow solid.
Preparation CCXXXVI: 3~(Benzotriazol-l-yloxy)-6-chloro- pyridazine-4-carboxylic acid (4-tert-butyl-phenyl)-amide:
A mixture of 3, 6-dichloropyridazine-4-carboxylic acid (1.00 g, 5.18 mmol), 4-tert-butylaniline (0.92 ml, 5.60 mmol) ,
TBTU (1.75 g, 5.44 mmol), and DIEA (1.80 ml, 10.4 mmol) in 7.5 ml of anhydrous DMF was stirred at RT under N2 overnight. The mixtrue was diluted with H2O, extracted with EtOAc, and the combined organic portions were washed with brine, dried with Na2SO4, filtered, and condensed. The crude compound was purified by flash column chromatography (hexanes/EtOAc/CH2Cl2, 9:0:1 to 7:2:1), to provide the desired compound as a light yellowish solid. MS (ES+) : 423.0 (M+H)+. CaIc'd for C21H19ClN5O2 - 422.87.
Preparation CCXXXVII - 3-Hydroxyxαethyl-azetidine-l- carboxylic acid benzyl ester:
To a mixture of azetidine-1,3-dicarboxylic acid monobenzyl ester (6.4 g) in THF (200 mL) was added BH3-THF (6 eg, 163 mL, IM solution) dropwise via an addition funnel at -40 C under an N2 atmosphere. The solution was warmed to RT and stirred overnight. To the reaction, 5N NaOH (50 mL) was added and then concentrated under vacuum. The resulting aqueous solution was extracted with Et2O (3 x 100 mL) . The organic layer was dried over Na2SO4 and evaporated to give the title compound which was used without further purification.
Preparation CCXXXVIII - 3-Methanesulfonyloxymethyl- azetidine-1-carboxylic acid benzyl ester:
3-Hydroxymethyl-azetidine-l,3-dicarboxylic acid monobenzyl ester (6.6 g) was dissolved in CH2Cl2 (100 mL) and brought to -15 C. While stirring, TEA was added (3 eq, 9.43 g) followed by methanesulphonic chloride (2.0 eq, 7.69 g) and allowed to come to RT and stirred for 1 h. The resulting organic solution was extracted with water (3 x 100 mL) . The organic layer was dried over Na2SO4 and evaporated to give the desired product as a clear oil which was used without further purification.
Preparation CCXXXIX - 3-Nitro-5-trifluoromethyl-phenol:
A flask containing l-Methoxy-3-nitro-5-trifluoromethyl- benzene (1Og) and hydrochloride pyridine (10 eq, 52.0 g) was heated to 210 C and stirred for 12 h. Once complete, the reaction was cooled and the residue was dissolved in CH2Cl2 and washed twice with water (100 mL) . The organic layer was concentrated under vacuum and then set in the freezer overnight. The resulting crystalline product was filtered off and washed with ether and used as is. Preparation CCXL - 3-(3-Nitro-5-trifluoromethyl- phenoxymethyl)-azetidine-l-carboxylic acid benzyl ester:
A mixture of 3-nitro-5-trifluoromethyl-phenol (750 mg, Step C), K2CO3 (3 eq. , 1.5 g) and 3-hydroxymethyl-azetidine-l- carboxylic acid benzyl ester (1.1 eq. , 1.2 g) in DMF was heated to 80 C for 1 h. The solution was cooled to RT then filtered and concentraced under vacuum. The residue was dissolved in CH2Cl2 and washed with H2O twice, followed by brine. The organic layer was dried over Na2SO4 and evaporated under reduced pressure. The residue was purified by column chromatography using 5% MeOH/CH2Cl2 to provide the desired compound as a colorless solid.
Preparation CCXLI - 3-(3-amino~5-tri£Tuoromethyl- phenoxymethyl)-azetidine-1-carboxylic acid benzyl ester:
To a solution of 3- (3-nitro-5-trifluoromethyl-mg) and NH4Cl (1.1 eq., 80mg) was added iron dust (3 eq. , 220 mg) in a 10% water/EtOH solution. The solution was heated to reflux for 6 h. The solution was cooled, then filtered through a pad of Celite®. The resulting solution was concentrated under vacuum to provide the desired compound as a dark yellow solid and used as is.
Preparation CCXLII - 3-nitro-5-(trifluorαmeth.yl)phenylamine To a solution of 3, 5-dinitrobenzotrifluoride (10 g, 42 mmols, 1 eq.) in 150 mL of EtOH was added 17.6 mL (258.3 mmols, 6.15 eq.) of ammonium sulfide in water (50% by weight, Aldrich) . The reaction was heated to reflux for 16 h during which time it became orange and a yellow precipitate formed. After cooling the volume was reduced to approximately 50 mL. The solid was removed by filtration and the filtrate evaporated to dryness in vacuo. The resulting orange solid was purified by column chromatography eluting with, a step gradient of 20-30% EtOAc:hexane to provide the compound as a yellow/orange solid.
Preparation CCXLIII - N-(3-nitro-5- (trifluoromethyl)phenyl)methanesulfonamide
3-Nitro-5-(trifluoromethyl)phenylamine (2 g, 9.7 mmols, 1 eg) was dissolved in 100 mL of CH2Cl2. The yellow solution was cooled to 0 0C. Et3N (2 mL, 14.55 mmols, 1.5 eq) was added followed by mesyl chloride (0.75 mL, 9.7 mmols, 1 eq) . The reaction was stirred for 2 h at 0 0C and warmed to RT.
Pyridine (0.785 mL, 9.7 mmols, 1 eq) and a catalytic amount of dimethylamine pyridine were added. The reaction was stirred at RT for 16 h. An additional equivalent of mesyl chloride was added and the reaction was heated to reflux for 24 h. After cooling, the solvent was removed in vacuo, and the residue redissolved in CH2Cl2. The solution was washed twice with 2 N HCl and once with brine. After drying over Na2SO4, the solution was filtered and the solvent removed. The resulting solid was triturated briefly with 10% EtOAc:hexane to provide a white solid that was a mixture of sulfonimide and sulfonimide.
The above mixture was dissolve in 20 mL of MeOH that had been saturated with K2CO3. After 30 min the reaction was stripped and the resulting solid portioned between 2 N HCl and CH2Cl2. The CH2C12 was dryed over Na2SO4 and stripped to provide and off-white solid.
Preparation CCXLIV - (3S)-tetrahydro-3-furanyl 3-nitro-5- (trifluoromethyl)phenylcarbamate 3- (S)-Hydroxytetrahydrofuran (4.8 mL, 60.7 mmols, 5 eq) was dissolved in 60 mL of toluene. The solution was cooled to 0 0C and Et3N (5.1 mL, 36.4 mmols, 3 eq) was added. Trichloromethyl chloroformate (3.65 mL, 30.33 mmols, 2.5 eq) was added slowly. The solurion was stirred at 0 0C for 45 min. 3-Amino-5-ntrobenzotrifluoride (2.5 g, 12.13 itmols, 1 eq) was added dropwise in 20 mL of toluene. The reaction was stirred at 0 0C for I h. An additional 5 eq of 3-(S)- hydroxytetrahydrofuran was converted to the chloroformate as described above, and added to the reaction mixture. After an additional h at 0 0C, the reaction was heated to 60 0C for 1 h. The reaction was cooled to RT and concentrated. The residue was dissolved in EtOAc, washed twice with saturated NH4Cl and once with brine. After being dried over Na2SO4 the solution was filtered and the solvent removed in vacuo. The crude product was purified using a Biotage chromatography system eluting with a gradient of 5% to 35% EtOAc:hexane to yield the desired compound.
Preparation CCXLV - N-(2-((3-nitro-5-
(trifluoromethyl)phenyl)oxy)ethyl)-methanesulfonamide
2- ( (3-Nitro-5-(trifluoromethyl)phenyl)oxy)ethylamine (4.05 g, 16.2 mmols, 1 eq) was dissolved in 100 mL of CH2Cl2. The solution was cooled to 0 0C. Pyridine (2.6 mL, 32.4 mmols, 2 eq) was added followed by mesyl chloride (1.25 mL, 16.2 mmols, 1 eq) . The reaction was stirred for 18 h during which time it was warmed slowly to RT. The solvent was removed in vacuo, and the residue dissolved in EtOAc. The resulting solution was washed twice with 2 N HCl, once with water, and 3x with brine. After being dried over Na2SO4 the solution was filtered and concentrated. The crude was purified by silica gel chromatography eluting with 50% to 60% EtOAc:hexane to yield the desired compound.
Preparation CCXLVI - N-(2-( (3-amino-5-
(trifluoromethyl)phenyl)oxy)ethyl)methanesulfonamide
N- (2- ( (3-Nitro-5- (trifluoromethyl)phenyl)oxy)ethyl) - methanesulfonamide (1.7 g, 5.2 mmols, 1 eq) was dissolved in 50 L of MeOH. 10% Pd/C (170 mg, 10 weight %) was added and the reaction sparged with H2. The suspension was stirred for 5 h, then filtered trough Celite. The filtrate was stripped to yield the title compound.
The following compounds were prepared similarly to the procedure outlined above:
a) 3- ( ( ( (2R) -l-acetyl-2-pyrrolidinyl)methyl)oxy) -5-
(trifluoromethyl)phenylamine. b) (3S)-tetrahydro-3-furanyl 3-amino-5-
(trifluoromethyl)phenylcarbamate. c) N- (3-amino-5- (trifluoromethyl)phenyl) -methanesulfonamide
Preparation CCXLVII - (2R)-l-acetyl-2-( ( (3-nitro-5- (trifluoromethyl)phenyl)oxy)methyl)pyrrolidine
(2R) -2- ( ( (3-nitro-5- (trifluoromethyl)phenyl)oxy)methyl) pyrrolidine (3.46 g, 11.9 mmols, 1 eq) was dissolved in 100 mL of CH2Cl2. Et3N (5 mL, 35.7 mmols, 3 eq) was added followed by Ac2O (1.2 mL, 13.1 mmols, 1.1 eq) . The reaction was stirred at RT for 1.5 h. The solvent was removed in vacuo and the residue disolved in EtOAc. The solution was washed once each with saturated NH4Cl, 1 N HCl, and twice with brine. The organic layer was dried over Na2SO4 filtered and concentrated in vacuo. The crude material was purified on a Biotage chromatography system eluting with a gradient of 10% to 75% EtOAc:hexane to yield the title compound. Preparation CCXLVIII - 3-(2-Chloro-5-nitro-phenoxymethyl)- azetidine-1-carboxylic acid tert-butyl ester:
To the mixture of 2-chloro-5-nitro-phenol (1.31 g, 7.54 mmol) and K2CO3 (1.57 g, 11.31 mmol) in 20 iriL of DMF was added 3-methanesulfonyloxymethyl-azetidine-l-carboxylic acid tert-butyl ester (2.0 g, 7.54 mol) . The reaction mixture was stirred at 50 2C for 1 h. After cooling to RT, the reaction mixture was diluted in 100 mL of EtOAc and quenched with 50 mL of water. The organic layer was separated and the aqueous layer was extracted with EtOAc (2 x 50 mL) . The combined organic phases were washed with brine, dried over MgSO4 and concentrated in vacuum. The title compound was obtained via column chromatography (silica gel, 1;1 hexane/EtOAc) as yellow oil with 93% yield.
The following additional preparations for exemplary compounds, intermediates, and starting materials should further assist in the understanding and appreciation of various embodiments, and additional examples (Tables 1-5), of compounds of the present invention.
Example 1
Preparation of 2,2,2-trifluoro-N-[2- (4-nitro-phenyl) -ethyl] - acetamide:
To a solution of 4-nitrophenethylamine hydrochloride (50 g, 0.247 mole), DIEA (128 mL, 0.74 mole, 3 eq.) and CH2Cl2 (500 mL) in a IL round bottom flask equipped with a magnetic stirrer was added (CF3CO)2O (52.5 mL, 0.37 mole, 1.5 eq) dropwise at 5-10 2C (with ice/water bath). After stirring for another 1 h after the addition at RT, the reaction was quenched with water (200 mL) and transferred into a separatory funnel. The organic layer was separated, washed with water and sat. NH4Cl, dried over Na2SO4, filtered, concentrated to give a brown oil. The crude was triturated with water (300 inL) , filtered and dried on vacuum overnight to give the desired 2,2, 2-trifluoro-N- [2- (4-nitro- phenyl) -ethyl]-acetamide as a yellow solid. This can be used for next step without further purification. An analytical sample was obtained through recrystallization from CH3OH/H2O as a yellow solid.
Example 2
Preparation of 2,2,2-trifluoro-l- (7-nitro-3 ,4-dihydro-lH- isoquinolin-2-yl) -ethanone:
To the mixture of 2,2,2-trifluoro-N- [2- (4-nitro- phenyl) -ethyl]-acetamide (65 g, 0.25 mole), paraformaldehyde (42.4 g, 0.375 mole, 1.5 eq.) and HOAc (200 mL) in a IL round bottom flask equipped with a magnetic stirrer and a ice/water bath was added H2SO4 (300 mL) slowly while maintaining reaction temperature under 402C. The resulting mixture was stirred for 2 h at 40 2C, poured into ice, extracted with EtOAc, washed with water, sat. Na2CO3 and sat. NH4Cl, dried over Na2SO4, filtered and concentrated to give the title ethanone compound. This can be used in the next step without further purification. An analytical sample was obtained through silica gel column chromatography with eluant of CH2Cl2:MeOH (9:1) .
Example 3
Preparation of 7-nitro-l,2,3, 4-tetrahydro-isoquinoline:
To a mixture of 2, 2,2-trifluoro-l- (7-nitro-3,4- dihydro-lH-isoquinolin-2-yl) -ethanone (24 g, 0.087 mole), MeOH (300 mL) , CH2Cl2 (50 mL) and H2O (10OmL) in a IL round bottom flask equipped with a magnetic stirrer was added LiOH (24 g) . The reaction was completed after stirring for 10 min at RT. The mixture was concentrated, extracted with CH2Cl2, washed with water, dried over Na2SO4, filtered, concentrated to give the title isoquinoline compound as an off-white solid. MS: (ES+) 179 (M+H) . Calc'd. for C9Hi0N2O2 - 178.07.
Example 4
Preparation of 7-amino-isoquinoline: A mixture of 7-nitro-l,2, 3,4-tetrahydro-isoquinoline (1.5g, 8.38 mmole) and 10% Pd/C (300 mg) in diethylene glycol (5 mL) was reacted in a Smith Synthesizer under microwave radiation at 220 2C for 25 min. The resulting mixture was diluted with MeOH and filtered. The filtrate was concentrated and diluted with CH2Cl2, washed with sat. aq. NH4Cl and dried over Na2SO4. After filtration and concentration, the title compound was isolated through flash chromatography (eluted with CH2Cl2:MeOH 9:1) as an orange solid. MS: (ES+) 145 (M+H). Calc'd. for C9H8N2 - 144.07.
Example 5
Preparation of N4-methyl-quinazoline-4, 6-diamine:
A mixture of methyl- (6-nitro~quinazolin-4-yl) -amine (0.16 g,- see Synthesis of Certain Nitroquinazoline
Derivatives Structurally Related to some Chemotherapeutic Agents, Botros, S., et. al., Egyptian Journal of Pharmaceutical Sciences, 13(1), 11-21, (1972) for a description of preparing the nitro-guinazoline) and Pd/C (10 wt%, 0.032 g) in 10 ml of MeOH was placed under H2 from a balloon and stirred at RT for 3 h, filtered through a pad of Celite®. Removal of the solvents afforded the title compound as an off-white solid. MS (MH+) = 175.3; Calc'd for C9H10N4 - 174.20. Example 6
Preparation of 3-nitro-7, 8-dihydro-5H-[1, 6]naphthyridine-6- carboxylic acid tert-butyl ester:
2M solution of MH3 in MeOH (225 mL, 452.25 mmol) was added to a reaction vessel containing l-methyl-3,5-dinitro- lH-pyridin-2-one (6 g, 30.15 mmol) and 4-oxo-piperidine-l- carboxylic acid tert-butyl ester (6.6 g, 33.15 mmol) . The vessel was then sealed and the reaction was stirred for 24 h at 70 2C. After the resulting mixture was cooled to RT, the solvent was removed to give crude product as yellow solid. After recrystallization in MeOH, the desired title compound was obtained as tan solid. MS (ES+): 280.1 (M+H)+. Calc'd for C13H17N3O4 - 279.12.
Example 7
Preparation of 3-nitro-5, 6,7, 8-tetrahydro- [1, 6] naphthyridine:
To the solution of 3-nitro-7, 8-dihydro-5H-
[1, 6]naphthyridine-6-carboxylic acid tert-butyl ester (6.14 g, 22 mmol) in CH2Cl2 (60 mL) was added TFA (7 mL) . The reaction was stirred for 18h at RT. After evaporation of the solvent, the residue was taken into water and neutralized with saturated NaHCO3 aqueous solution. The solid was filtered and washed with cold water and dried. The solid was recrystallized from CH3CN to give desired title compound as pale white solid. MS (ES+): 180.1 (M+H)+. Calc'd for C8H9N3O2 - 179.07. Example 8
Preparation of [1, 6]naphthyridin-3-ylamine:
3-Nitro-5,6,7,8-tetrahydro-[l, 6]naphthyridine (1 g, 5.6 mmol) , pentanol (2 mL) and Pd/C (300mg) were placed in a microwave reaction vessel and stirred under microwave irradiation at 180 2C for 1 h. After cooling, the mixture was diluted with MeOH and filtered through a pad of Celite. The solvent was removed and the crude was purified by flash column chromatography to give the desired title compound as a yellow solid. MS (ES+) : 146.2 (M+H)+. Calc'd for C8H7N3 - 145.06.
Example 9
4- (2,2, 2-Trifluoro-l-methoxy-l-trifluoromethyl-ethyl) - phenylamine:
A mixture of 2- (4-amino-phenyl)-1, 1, 1, 3, 3, 3- hexafluoro-propan-2-ol (1 eq.), DIAD(I.96 eq.), PPh3 (polymer-bound, 2.36 eq) and MeOH (1.1 eq) in THF (100 mL) was stirred at reflux for 16 h. After filtration and concentration, the crude was purified by flash chromatography (20% EtOAc/CH2Cl2) to give the title compound as a white solid. MS (ES+) : 274 (M+H)+. Calc'd for Ci0H9F6NO- 273.06.
00
A-917 - 230 -
The following Example 10 was prepared utilizing a starting material made by the method described in Example 9.
CaIc ' d
Ex.# Structure MoI . formula Mass M+H
Figure imgf000231_0001
2- (Isoquinolin-7- ylamino)-N- [4- (2, 2, 2- trifluoro-l-methoxy-l- trifluoromethyl-ethyl) -
10 phenyl]-nicotinamide C235H18F6N4O2 520 . 13 521
Example 11
Figure imgf000231_0002
2- (Isoquinolin-7-ylamino) -N- (4-pentafluoroethyl-phenyl)- nicotinamide
To a mixture of 2-fluoro-N- (4-pentafluoroethyl- phenyl) -nicotinamide (112 mg) and 7-aminoisoguinoline (40 mg) in t-BuOH (0.5 inL) was added TFA (94 μL) . The resulting mixture was stirred for 24 h at 90 2C, cooled to RT and purified by flash chromatography (4:1:0.1; MeOH/CH2Cl2/MeOH) to give the title compound as a yellow solid. MS (ES+) : 459 (M+H)+. CaIc'd for C23H15F5N4O- 458.12.
The following Examples 12-25 were prepared utilizing a method similar to that described in Example 11.
CaIc'd
Ex. # Structure MoI. formula Mass M+H
Figure imgf000232_0001
2- (Isoguinolin-7-ylamino) -
N- (4-trifluoromethyl- 12 phenyl) -nicotinamide C22H15F3N4O 408 . 12 409
Figure imgf000232_0002
N- (2-Acetyl-4, 4-dimethyl-
1,2,3,4-tetrahydro- isoquinolin-7-yl) -2-
(isoquinolin-7-ylamino) -
13 nicotinamide C28H27N5O2 465 . 22 466
Figure imgf000233_0001
N- (4-tert-Butyl-phenyl)
2- (isoquinolin-7- ylamino) -nicotinamide C25H24N4O 396 . 20 397
Figure imgf000233_0002
N- (5-tert-Butyl- isoxazol-3-yl)-2- (isoqταinolin-7-ylamino)
C22H21N5O2 nicotinamide 387 . 17 388
Figure imgf000233_0003
N-(2-Acetyl-4,4- dimethyl-1,2,3,4- tetrahydro-isoquinolin-
7-yl) -2- (4-methylamino- guinazolin-6-ylamino)-
C28H29N7O2 495 . 58 496 nicotinamide
Figure imgf000234_0001
N- (4-tert-Butyl-phenyl) 2-(l-oxo-l,3-dihydro- isobenzofuran-4-
C24H23N3O3 401.17 402.1 ylamino)-nicotinamide
Figure imgf000234_0002
2-(l-Oxo-l,3-dihydro- isobenzofuran-4- ylamino) -N- [4- (2,2,2- trifluoro-1-hydroxy-1- trifluoromethyl-ethyl)-
C23H15F6N3O4 511.10 512,
N-
Figure imgf000234_0003
dihydro-lH-indol-6-yl) - 2-(l-oxo-l,3-dihydro- isobenzofuran-4-
C24H22N4O3 414.17 415. ylamino) -nicotinamide
N-
Figure imgf000235_0001
4- tetrahydro-isoquinolin-
7-yl)-2-(l-oxo-l,3- dihydro-isobenzofuran-4- ylamino)-nicotinamide C25H24N4O3 428.18 429.1
Figure imgf000235_0002
N-(l-Acetyl-3,3- dimethyl-2,3-dihydro-lH- indol-6-yl)-2-(1-oxo-
1,3-dihydro- isobenzofuran-4- ylamino)-nicotinamide C26H24N4O4 456.18 457.
Figure imgf000235_0003
2-(2,2-Difluoro- benzo[1,3]dioxol-5- ylamino)-N- (4,4- dimethyl-1,2,3,4- tetrahydro-isoguinolin-
7-yl)-nicotinamide C24H22F2N4O3 452.17 453.
Figure imgf000236_0001
2- (lH-Benzotriazol-5- ylamino) -N- (2-methyl- benzothiazol-5-yl) -
C20Hi5N7OS 401.44 nicotinamide 402.1
Figure imgf000236_0002
2- (IH-I, 2,3- benzotriazol-5-ylamino) -
N- (4, 4-dimethyl-2-oxo-
1,2,3,4- tetrahydroquinolin-7-
C23H21N7O2 427.46 428. yl)nicotinamide 5 025800
A-917 - 236 -
Figure imgf000237_0001
2-(1H- benzo[d] [1,2,3]triazol-
5-ylamino)-N-(5-tert- butylisoxazol-3- C19H19N7O2 377.16 378
25 yl)nicotinamide
Example 26
2-(isoφiinolin-7-ylamino)-benzoic acid ethyl ester:
A mixture of 2-bromo-benzoic acid ethyl ester (458 mg, 2.0 mmol) , 7-aminoisoquinoline (144 mg, 1.0 mmol) , Pd(OAc)2 (11 mg) , BINAP (30 mg) and K2CO3 (414 mg) in 1 mL of toluene in a sealed tube was stirred for 16 h at 105 2C. The reaction mixture was then allowed to cool to RT, diluted with 20 ml of CH2Cl2, filtered through a CeIite® packed funnel and concentrated under reduced pressure. The concentrate was purified by flash column chromatography. The titled compound was obtained as oil. MS (ES+): 293.3 (M+H)+. CaIc'd for C18H15N2O2- 292. Example 27
Figure imgf000238_0001
N- (4-tert-Butyl-phenyl) -2- (isoquinolin-7-ylamino) -benzamide
A mixture of 2- (isoquinolin-7-ylamino)-benzoic acid ethyl ester (155 mg, 0.53 mmole) and LiOH monohydrate (67 mg, 1.6 mmol) in a mix solvent of MeOH (1 mL) , water (1 iriL) and THF (1 mL) was stirred for 14 h at RT. The resulting mixture was concentrated to dryness to the corresponding acid lithium salt as a white solid. The lithium salt obtained was mixed with 4-t-butylaniline (149 mg, 1.0 mmol), TBTU (176 mg, 0.55 mmol) and DIEA (0.04 ml) in 1 ml of DMF and the mixture was stirred at RT for 16 h, then diluted with more CH2Cl2. The organic layer was washed with water, brine, dried with MgSO4, filtered, concentrated and the residue was purified by flash column chromatography (0 to 30% of EtOAc in CH2Cl2) . Upon concentration of the desired fractions, the title compound was obtained as a white solid. MS (ES+): 396.1 (M+H)+. Calc'd for C26H25N3O- 395.20.
The following Examples 28-41 were prepared utilizing a method similar to that described in Examples 11 and 27. CaIc'd
Ex. # Structure MoI. formula Mass M+H
Figure imgf000239_0001
N- (4, 4-Dimethyl-1, 2,3,4- tetrahydro-quinolin-7- yl) -2- (isoquinolin-7- 28 ylamino) -benzamide C27H26N4O 422.52 423
Figure imgf000239_0002
N- (4-tert-Butyl-phenyl) -
3-fluoro-2- (isoquinolin- C25H24FN3O 413.19 414.4
29 7 -ylamino) -benzamide
Figure imgf000239_0003
N- ( 4 , 4-Dimethyl-l , 2,3,4- tetrahydro-quinolin-7- yl) -2- (quinazolin-6- 30 ylamino) -benzamide C26H25N5O 423.21 424.
Figure imgf000240_0001
N- (l-Acetyl-3,3- dimethγl-2 , 3-dihydro-lH- indol-6-yl)-2- (isoquinolin-7-ylamino) - nicotinamide C27H25N5O2 451.52 452.3
Figure imgf000240_0002
N- ( 3 , 3 -Dimethyl- 2 , 3 - dihydro-lH-indol-6-yl) -
2- (isoquinolin-7- ylamino) -nicotinamide C25H23N5O 409.48 410. i
Figure imgf000241_0001
2- (Isoquinolin-7- ylamino) -N- (3-methoxy-5- trif luoromethyl-phenyl) - nicotinamide C23H17F3N4O2 438.13 439.3
Figure imgf000241_0002
N-(4-Chloro-3- trif luoromethyl-phenyl )
2- (isoquinolin-7- ylamino) -nicotinamide C22H14ClF3N4O 442.08 443
Figure imgf000242_0001
N- (4-tert-Butyl-phenyl)- 2- ( [1, 6]naphthyridin-3- ylamino) -nicotinamide C24H23N5O 397.19 398.3
Figure imgf000242_0002
4,4-Dimethyl-7-{ [2-
([1,6] naphthyridin- 3 - ylamino) -pyridine-3- carbonyl] -amino} -3 , 4- dihydro-lH-isoquinoline-
2-carboxylic acid tert- butyl ester C30H22N6O3 524.25 525.:
Figure imgf000243_0001
N- (4 , 4 -Dimethyl -1 ,2,3,4- tetrahydro-isoquinolin-
7-yl)-2-
([1,6] naphthyridin-3 - ylamino) -nicotinamide C25H24N6O 424.2 425.4
Figure imgf000243_0002
2- ( [1, 6 ] Naphthyridin-3 - ylamino) -N- [4- (2, 2, 2- trifluoro-l-hydroxy-1- trifluoromethyl-ethyl) - phenyl] -nicotinamide C23H15F6N5O2 507.11 508.:
Figure imgf000244_0001
2- (isoquinolin-7- ylamino) -N- ( 2 -methyl -
1, 3-benzothiazol-5- yl ) nicotinamide C23H17N5O2S 411.48 412.3
Figure imgf000244_0002
N-(4-chloro-3- methylphenyl ) -2 -
(isoquinolin-7- ylamino) nicotinamide C27H23F5N4O3 508.50 509
Example 41
Figure imgf000244_0003
N- (4, 4-Dimethyl-1,2,3,4-tetrahydro-isoquinolin-7-yl) -2- (isoquinolin-7-ylamino) -nicotinamide
Preparation of 7-[(2-chloro-pyridine-3-carbonyl)-amino]-4,4- di-neth.yl-3,4-dih.ydro-lH-isoquinoline-2-carboxylic acid tert- butyl ester
To a solution of 2-chloronicotinoyl chloride (3.52 g, 20 mmol, 1.0 eq.) and 7-amino-4, 4-dimethyl-3,4-dihydro-lH- isoquinoline-2-carboxylic acid tert-butyl ester (5.52 g, 20 mmol, 1.0 eq.) in CH2Cl2 (100 mL) was added NaHCO3 (6.4 g, 80 mmol, 4.0 eq.) . The mixture was stirred for 1 h at RT, then filtered and concentrated, followed by drying on a vacuum pump for 3 hours. 7- [ (2-Chloro-pyridine-3-carbonyl) -amino]- 4,4-dimethyl-3 ,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester was obtained as a white foamy solid. This title compound was used for next step without further purification.
Preparation of 7-{ [2-(isoquinolin-7-ylamino)-pyridine-3- carbonyl] -amino}-4,4-dimethyl-3,4-dihydro-lH-isoquinoline-2- carboxylic acid tert-butyl ester:
To a mixture of 7- [ (2-chloro-pyridine-3-carbonyl)- amino] -4,4-dimethyl-3,4-dihydro-lH-isoquinoline-2-carboxylic acid tert-butyl ester (20.8 g, 50 mmol, 1.0 eq. ) , 7- aminoisoquinoline (7.2 g, 50 mmol, 1.0 eq. ) , Pd2(dba)3 (915 mg, lmmol,0.02 eq) , 2-dicyclohexylphosphino-2 ' - (N,N- dimethylamino)biphenyl (CAS# 213697-53-1, Strem Chemicals cat no. 15-1145; 785 mg, 2 mmol, 0.04 eq) under N2 in a 250 mL pressure reaction vessel was added 1.0 M LiNTMS2 THF solution (120 mL, 120 mmol, 2.4 eq.). The reaction vessel was sealed with a Teflon screwcap and the mixture was stirred at 70 2C for 17 h. The mixture was then cooled to RT. 100 mL of water was added to the mixture and the mixture was extracted with 500 mL of EtOAc. The organic layer was washed with sat. NH4Cl solution, IM NaHPO4 solution (4x200 mL) then dried over MgSO4. After filtration and concentration, the crude was purified through a silica gel column chromatography, eluting with CH2Cl2/Et0Ac. The desired title compound was obtained as a yellow solid. MS (ES+): 524 (M+H)+. Calc'd for C3IH33N5O3- 523.26
Preparation of N-(4,4-Dimethyl-l#2/3/4-tetrahydro- isoquinolin-7-yl)-2-(isoςpiinolin-7-ylamino)-nicotinamide: To 14.62 g of the compound in the step above (27.95 mmole) in a 2 L RBF was added 4N HCl in EtOAC (500 mL) . The mixture was stirred for 20 h at RT and filtered to collect the product as multi-HCl salt. This solid was dissolved in water (200 mL) and the aqueous layer was extracted with EtOAc. The aqueous layer was acidified to about pH 5 with 2 N NaOH solution. The title compound (as monohydrate and mono HCl salt) was obtained after filtration and drying on vacuum pump for 24 h as a light yellow solid. MS (ES+) : 424 (M+H)+. Calc'd for C26H25N5O- 423.21.
The following examples 42-66 were prepared according to a method similar to that described in Example 41:
CaIc ' d
Ex. # Structure MoI . formula Mass M+H
Figure imgf000247_0001
N- (6-tert-Butyl-pyridin-
3-yl) -2- (isoquinolin-7-
42 ylamino)-nicotinamide C24H23N5O 397 . 19 398
Figure imgf000247_0002
2- (Isoquinolin-7- ylamino)-N-[4-(2,2,2- trifluoro-l-hydroxy-1- trifluoromethyl-ethyl)-
43 phenyl]-nicotinamide C24H16F6N4O2 506 . 12 507
Figure imgf000248_0001
N- (4-Isopropyl-phenyl) -
2- (isoquinolin-7- ylamino) -nicotinamide C24H22N4O 382.18 383
Figure imgf000248_0002
N- (6-Azetidin-l-yl- pyridin-3-yl) -2- (isoquinolin-7-ylamino) nicotinamide C23H20N5O 396.17 397
Figure imgf000248_0003
N- [4- ( 1 , 1 -Dimethyl - propyl ) -phenyl ] - 2 - (isoquinolin-7-ylamino) - nicotinamide C26H26N4O 410.21 411
Figure imgf000249_0001
N- (5-Azetidin-l-yl- pyr idin- 2 -yl ) - 2 - (isoquinolin-7-ylamino) nicotinamide C23H20N6O 396.17 397
Figure imgf000249_0002
2- (Isoquinolin-7- yl amino) -N- ( 3 -methyl- 4 - pentaf luoroethyl- phenyl) -nicotinamide C24H17F5N4O 472.13 473
Figure imgf000249_0003
N- (4-Isopropyl-3-methyl- phenyl) -2- (isoquinolin- 7 -ylamino) -nicotinamide C25H24N4O 396.20 397
Figure imgf000250_0001
N-(3-tert-Butyl- isoxazol-5-γl) -2-
(quinazolin-6-γlamino)- nicotinamide C21H20N6O2 388.16 389
Figure imgf000250_0002
N- (4,4-Dimethyl-1, 2,3,4- tetrahyd.ro-isoquinolin- 7-yl) -2- (quinazolin-6- ylamino) -nicotinamide C25H24N6O 424.20 425
Figure imgf000250_0003
2(R,S)-(4-{[2-
(Isocjuinolin-7-ylamino) - pyridine-3-carbonyl] - amino} -phenyl ) -propionic acid ethyl ester C26H24N4O3 440.18 441
Figure imgf000251_0001
2(R,S)-(4-{[2- (IsoqO.inolin-7-γlamino) - pyridine- 3 -carbonyl] - amino} -phenyl) -propionic acid C24H20N4O3 412.15 413
Figure imgf000251_0002
N- (4,4-Dimethyl-2-oxo- 1,2,3, 4-tetrahydro- quinolin-7-yl) -2- (isoquinolin-7-ylamino) ■ nicotinamide C26H23N5O2 437.50 438.2
Figure imgf000251_0003
2- (isoquinolin-7- ylamino) -N- (3-oxo-3 , 4- dihydro-2H-l,4- benzothiazin-6- yl ) nicotinamide C23Hi7N5O2S 427.49 428.3
Figure imgf000252_0001
N- (4-tert-Butyl-phenyl)
2- (quinazolin-6- ylamino)-nicotinamide C24H23N5O 397.19 398.2
Figure imgf000252_0002
N- ( 4 , 4-Dimethyl-l , 2,3,4- tetrahydro-guinolin-7- yl) -2- (quinazolin-6- ylamino) -nicotinamide C25H24N6O 424.20 425.4
Figure imgf000253_0001
N- (5,5-dimethyl-7-oxo- ,6,7, 8-tetrahydro-l, 8- naphthyridin-2-yl) -2- (isoquinolin-7- ylamino)nicotinamide C25H22N6O2 438.49 439.21
Figure imgf000253_0002
N- (5 , 5-dimethyl-7-oxo- ,6,7, 8-tetrahγdro-l , 8- naphthγridin-2-yl) -2- (quinazolin-6- γlamino) nicotinamide C24H21N7O2 439.49 440.2!
Figure imgf000254_0001
N-(3-chloro-4- methylphenyl) -2- (isoquinolin-7- 60 ylamino)nicotinamide C22H17ClN4O 388.57 389
Figure imgf000254_0002
2- (isoquinolin-7- yl amino) -N- (4- (trif luoroπiethoxy) phenyl 61 ) nicotinamide C22H15F3N4O2 424.38 425.1
Figure imgf000255_0001
2- (isoquinolin-7- ylamino) -N- (3-methyl-4-
(pyrrolidin-1- yl)phenyl)nicotinamide C26H25N5O 423 . 21 424
Figure imgf000255_0002
2- (2-aminoquinazolin-6- ylamino) -N- (3-methyl-4-
(1-methylethyl)phenyl) nicotinamide C24H24N6O 412 . 49 413
Figure imgf000256_0001
2- (2-aminoquinazolin-6- ylamino) -N- (3-chloro-4- methylphenyl) nicotinamide C2IH17N6ClO 404.12 405
Figure imgf000256_0002
2- (2-aminoquinazolin-6- ylamino) -N- (4- chlorophenyl) nicotinamide C20H15N6ClO 390.1 391
Figure imgf000257_0001
2- (2 , 4- diaminoquinazolin-6- ylamino) -N- ( 4-tert- butylphenyl)
66 nicotinamide C25H24N7O 427 . 21 428
The following examples 67 - 72 were prepared according to a method similar to that described in Example 43 and scheme 8. Particularly, the starting materials possessed the nucleophile (NH2) and leaving group (halogen such as Cl) in reverse order, i.e., a chloro-nicotinamide was reacted with an amino- heterocycle to obtain the desired product (scheme 8) .
Figure imgf000257_0002
67 N- (4-tert-Butyl-phenyl) - C25H24N4O 396 .49 2- (isoguinolin-5- ylamino)-nicotinamide 397.1
Figure imgf000258_0001
2- (Isoquinolin-5- ylamino) -N- [3- (1 -methyl - pyrrolidin-2-ylmethoxy)
-5-trifluoromethyl- phenyl] -nicotinamide C28H26F3N5O2 521.24 522.1
Figure imgf000258_0002
N- (4,4-Dimethyl-1,2,3,4- tetrahydro-isoquinolin- 7-yl) -2- (isoquinolin-5- ylamino) -nicotinamide C28H25N5O2 423.52 424.2
Figure imgf000258_0003
C25H23N5O 409.49 N- (3,3-Dimethyl-2,3- dihydro-lH-indol-6-yl) -
2- (isoquinolin-5- ylamino) -nicotinamide 410 .2
Figure imgf000259_0001
N- (3-tert-butylisoxazol- 5-yl) -2- (isoc[uinolin-5- 71 ylamino)nicotinamide C22H2IN5O2 387 . 17 388
Figure imgf000259_0002
N- (4- ( 1 , 1- dimethylethyl ) phenyl ) -2 - (5-quinolinylamino) -3- 72 pyridinecarboxamide C25H24N5O 396 .49 397
Example 73
[2- (7-{ [2- (Isoguinolin-7-ylamino) -pyridine-3-carbonyl] - amino}-4,4-dimethyl-3,4-dihydro-lH-isoquinolin-2-yl) -2-oxo- ethyl]-carbamic acid tert-butyl ester
[2- (7-{ [2- (Isoquinolin-7-ylamino)-pyridine-3- carbonyl]-amino}-4,4-dimethyl-3,4-dihydro-lH-isoquinolin-2- yl) -2-oxo-ethyl]-carbamic acid tert-butyl ester (Example no. 68; 423 mg, 1 mmole) was treated with Boc-glycine (193mg, 1.1 mmole, 1.1 eq) , EDAC (380 mg, 2 mmole, 2 eq) , HOBt (135 mg, 1 mmole, 1.0 eq) , and DIEA (500 mL) in CH2Cl2 (50 mL) . The reaction was stirred over night. The solution was washed with NaHCO3 (Aq., Sat., 50 mL) followed by brine. The CH2Cl2 solution was concentrated in vacuo. The residue was purified via HPLC in reverse phase (eluent: MeCN-H20:5- 95% with 0.1% TFA) to afford the titled compound as a yellow solid. MS: (ES+) 581(M+H). CaIc'd. for C33H36N6O4 - 580.68.
The following example 74 was prepared according to a method similar to that described in Example 73 :
Figure imgf000260_0001
N-[4, 4-Dimethyl-2-
(tetrahydro-furan-2- carbonyl)-1,2,3,4- tetrahydro-isoquinolin-
7-yl] -2- (isoquinolin-7- ylamino) -nicotinamide
74 C3IH31N5O3 521 . 61 522 Example 75
Figure imgf000261_0001
N- [2- (2-Amino-acetyl) -4,4-dimethyl-l,2,3,4-tetrahydro- isoguinolin-7-yl]-2- (isoquinolin-7-ylamino)-nicotinamide
The compound above (Example no.73; 200 mg, 0.34 mmole) was treated with saturated HCl in EtOAc (5OmL) over night at RT. Vacuum filtration of the reaction provided a yellow crystalline solid as the desired titled compound. MS: (ES+) 48KM+H) . Calc'd. for C28H28N6O2 - 480.56.
Example 76
Figure imgf000261_0002
N- (4-tert-Butyl-phenyl) -2- ( [1,7]naphthyridin-2-ylamino) - benzamide
2-Chlorό-[l,7]naphthyridine (100 mg, 0.61 mmol) , 2- amino-N- (4-tert-butyl-phenyl) -benzamide (164 mg, 0.61 mmol), Pd2(dba)3 (6 mg, 0.006 mmol), (2 ' -Dicyclohexylphosphanyl- biphenyl-2-yl) -dimethyl-amine (6 mg, 0.015 mmol), and IM solution of LiN(TMS)2 in THF (1.83 mL) , 1.83 mmol) were added to a reaction vessel. The vessel was sealed and the reaction was stirred at 70 aC for 24h. The mixture was cooled to RT, and solvent was removed under vacuum. The crude was purified by flash column chromatography (gradiant, 0 to 100% EtoAC/Hexane) to give the product as tan solid. MS (ES") : 397.0 (M+H)+. Calc'd for C25H24N4O - 396.20.
The following example 77 was prepared according to a method similar to that described in Example 76:
Figure imgf000262_0001
N- ( 4 , 4 -Dimethyl -
1 , 2 , 3 , 4-tetrahydro- isoquinolin-7-yl ) -2-
( [ 1 , 7 ] naphthyridin-2-
77 ylamino) -benzamide C26H25N5O 423 . 2 424 . 3 The additional examples in Tables 1-5 will further provide assistance in understanding and appreciating various, specific embodiments of the present invention.
Table 1.
Figure imgf000263_0001
78. 2-chlorophenyl H
79. 3-chlorophenyl H
80. 4-chlorophenyl H
81. 3-trifluoromethylphenyl H
82. 4-trifluoromethylphenyl H 83. 3-chloro-4-trifluoromethylphenyl H
84. 3-pentafluoroethylphenyl H
85. 4-pentafluoroethylphenyl H
86. 3-cyclopropylpheny1 H
87. 4-cyclopropylphenyl H 88. 2-methylphenyl H
89. 3-methylpheny H
90. 4-methylpheny1 H
91. 2-(1-methylethyl)phenyl H 92. 3-(1-methylethyl)phenyl H 93. 4- (1-methylethyl)phenyl H
94. 2-methyl-4- (1-methylethyl)phenyl H
95. 3-methyl-4- (1-methylethyl)phenyl H
96. 4- (1-methylethyl)-3-methylpheny1 H
97. 2-t-butylphenyl H 98. 3-1-butylpheny1 H 99 . 4-t-butylphenyl H
100 . 3 - ( l~hydroxy-l , l-di-trifluoromethyl) methylphenyl H
101 . 4- ( l-hydroxy-l , l-di-trifluoromethyl ) methylphenyl H
102 . 3- ( 1 , 1 -dimethyl ) propylphenyl H
Table 1. ( cont . )
Figure imgf000264_0001
# R1 R^_ 103. 4-(l,l-dimethyl)propylphenyl H
104. 2-methoxyphenyl H
105. 3-methoxyphenyl H
106. 4-methoxyphenyl H
107. 4-phenoxyphenyl H 108. 2- (1-methyl)cyclopropylphenyl H
109. 2- ( (pyrrolidinylmethyl)oxy)phenyl H
110. 3- ( (pyrrolidinylmethyl)oxy)phenyl H
111. 4- ( (pyrrolidinylmethyl)oxy)phenyl H
112. 3-(4-piperidinylmethyl)oxy)phenyl H 113. 4-(4-piperidinylmethyl)oxy)phenyl H
114. 3-( (tetrahydrofuranylmethyl)oxy)phenyl H
115. 3-(tetrahydrofuranylmethyl)oxy)-3-CF3phenyl H
116. 3-(4-piperidinylmethyl)phenyl H
117. 3-(4-piperidinylmethyl)phenyl H 118. 3-(glycylamino)phenyl H
119. 4-(glycy1amino)phenyl H
120. 2-chlorophenyl 5-F
121. 3-chlorophenyl 5-F
122. 4-chlorophenyl 5-F 123. 3-trifluoromethylphenyl 5-F
124. 4-trifluoromethylphenyl 5-F
125. 3-chloro-4-trifluoromethylphenyl 5-F 126. 3-pentafluoroethylphenyl 5-F
Table 1. (cont.)
Figure imgf000265_0001
127. 4-pentafluoroethylphenyl 5-F
128 3-cyclopropylphenyl 5-F
129. 4 cyclopropylphenyl 5-F
130. 2 methylphenyl 5-F
131. 3 methylpheny 5-F
132. 4 methylphenyl 5-F
133. 2 (1-methylethyl)phenyl 5-F
134. 3 (1-methylethyl)phenyl 5-F
135. 4 (1-methylethyl)phenyl 5-F
136. 2 methyl-4- (1-methylethyl)phenyl 5-F
137. 3 methyl-4- (1-methylethyl)phenyl 5-F
138. 4 ■ (1-methylethyl) -3-methylphenyl 5-F
139. 2 ■t-butylphenyl 5-F 140 3-t-butylphenyl 5-F
141. 4 t-butylphenyl 5-F
142. 3 (1-hydroxy-l, 1-di-trifluoromethyl)methylphenyl 5-F
143. 4 (1-hydroxy-1,1-di-trifluoromethyl)methylphenyl 5-F
144. 3 (1,1-dimethyl)propylphenyl 5-F
145. 4 (1,1-dimethyl)propylphenyl 5-F
146. 2 ■methoxyphenyl 5-F
147. 3 methoxyphenyl 5-F 148. 4-methoxyphenyl 5-F
149. 2- (1-methyl)eye1opropylphenyl 5-F 150. 2- ( (pyrrolidinylmethyl)oxy)phenyl 5-F 151. 3- ( (pyrrolidinylmethyl)oxy)phenyl 5-F Table 1. (cont.)
Figure imgf000266_0001
# R^ R2
152. 4- ( (pyrrolidinylmethyl)oxy)phenyl 5-F 153. 3- (4-piperidinylmethyl)oxy)phenyl 5-F
154. 4- (4-piperidinylmethyl)oxy)phenyl 5-F
155. 3- ( (tetrahydrofuranylmethyl)oxy)phenyl 5-F
156. 3- (tetrahydrofuranylmethyl)oxy) -3-CF3phenyl 5-F
157. 3- (4-piperidinylmethyl)phenyl 5-F 158. 3- (4-piperidinylmethyl)phenyl 5-F
159. 3- (gIycylamino)phenyl 5-F
160. 4- (gIycylamino)phenyl 5-F
161. 3-pyridyl H
162. 4-pyridyl H 163. 1-isoquinolyl H
164. 3-isoqταinolinyl H
165. 4-isoquinolyl H
166. 5-isoguinolyl H
167. 6-isoquinolyl H 168. 7-isoquinolyl H
169. tetrahydro-7-isoquinolinyl H
170. l-oxo-tetrahydro-7-isoquinolinyl H
171. 2-oxo-tetrahydro-7-isoguinolinyl H
172. 2-quinolinyl H 173. 3-quinolinγl H
174. 4-quinolinyl H
175. 5-quinolinyl H
176. 6-quinolinyl H
Table 1. (cont.)
Figure imgf000267_0001
177. 7-quinolinγl H 178. tetrahydro-7-quinolinyl H
179. 2-oxo-tetrahydro-7-quinolinyl H
180. 5-φiinozalinyl H
181. 6-quinozalinyl H
182. 4-indolyl H 183. 6-indolyl H
184. 2,3-dihydro-6-indolyl H
185. oxo-dihydro-6-indolyl H
186. 5-isoindolyl H
187. 6-isoindolyl H 188. 2-naphthyridinyl H
189. 3-naphthyridinyl H
190. 4-naphthyridinyl H
191. 5-naphthyridinyl H
192. tetrahydro-naphthyridinyl H 193. oxo-tetrahydro-naphthyridinyl H
194. 2-isoxazolyl H
195. 3-pyrazolyl H
196. 5-pyrazolyl H
197. 2-thiazolyl H 198. 3-thiazolyl H
199. 6-indazolγl H
200. 5-indazolyl H
Table 1. (cont.)
Figure imgf000268_0001
201. 6-benzothienyl H 202. 6-benzofuryl H 203. 5-benzothienyl H 204. 5-benzofuryl H 205. 2-benzimidazolyl H 206. 2-benzoxazolyl H 207. 2-benzthiazolyl H 208. 6-benzimidazolyl H 209. 6-benzoxazolyl H 210. 3- (6- (1-methylcyclopropyl)pyridyl H 211. 3- (phenoxy) -6-pyridyl H 212. 4- (phenylcarbonyl)phenyl H 213. 4- (phenylamino)phenyl H 214. 4- (3-1hieny1)phenyl H 215. 4- (pyrazol-3-yl)phenyl H 216. 4-morpholinylmethylphenyl H
Figure imgf000268_0002
217. H
Figure imgf000269_0001
Table 1. (cont.)
Figure imgf000269_0002
220. H 221. 3-isoquinolinγl 5 -F
222. 2-quinolinγl 5-F
223. 3-pγridγl 5-F
224. 4-pγridγl 5-F
225. 3-isoquinolinγl 5-F 226. 4-isoquinolγl 5-F
227. 5-isoquinolγl 5-F
228. 6-isoquinolγl 5-F
229. 7-isoquinolγl 5-F
230. tetrah.γdro-7-isoquinolinγl 5-F 231 . l-oxo-tetrah.γdro-7-isoqτιinolinγl 5-F 232 . 2-oxo-tetrahγdro-7-isoquinolinγl 5-F 233. 2-quinolinyl 5-F
234. 3-quinolinyl 5-F
235. 4-quinolinyl 5-F
236. 5-quinolinyl 5-F
237. 6-quinolinyl 5-F
Table 1. (cont.)
Figure imgf000270_0001
238. 7-quinolinyl 5-F
239. tetrahydro-7-quinolinyl 5-F
240. 2-oxo-tetrahydro-7-quinolinyl 5-F
241. 5-quinozalinyl 5-F
242. 6-quinozalinyl 5-F 243. 4-indolyl 5-F
244. 6-indolyl 5-F
245. 2,3-dihydro-6-indolyl 5-F
246. oxo-dihydro-6-indolyl 5-F
247. 5-isoindolyl 5-F 248. 6-isoindolyl 5-F
249. 2-naphthyridinyl 5-F
250. 3-naphthyridinyl 5-F
251. 4-naphthyridinyl 5-F
252. 5-naphthyridinyl 5-F 253. tetrahydro-naphthyridinyl 5-F
254. oxo-tetrahydro-naphthyridinyl 5-F
255. 2-isoxazolyl 5-F
256. 3-pyrazolyl 5-F
257. 5-pyrazolyl 5-F 258. 2-thiazolyl 5-F
259. 3-thiazolγl 5-F
260. 6-indazolyl 5-F
261. 5-indazolyl 5-F
262. 6-benzothienyl 5-F
Table 1. (cont . )
Figure imgf000271_0001
263. 6-benzofuryl 5-F
264. 5-benzothienyl 5-F
265. 5-benzofuryl 5-F
266. 2-benzoxazolyl 5-F
267. 2-benzthiazolyl 5-F
268. 6-benzimidazolyl 5-F
269. 6-benzoxazolyl 5-F
270. 3- (6- (1-methylcyclopropyl)pyridyl 5-F
271. 3- (phenoxy) -6-pyridyl 5-F
272. 4-(phenylcarbonyl)phenyl 5-F
273. 4- (phenylamino)phenyl 5-F
274. 4- (3-1hieny1)phenyl 5-F
275. 4- (pyrazol-3-yl)phenyl 5-F
276. 4-morpholinylmethylphenyl 5-F
Figure imgf000271_0002
277 . 5-F
Figure imgf000272_0001
Table 2a.
Figure imgf000272_0002
# R^
280. 2 chlorophenyl H
281. 3 ch.lorophen.yl H
282. 4 chlorophenyl H
283. 3 trifluoromethylphenyl H
284. 4 trifluoromethylpheny1 H
285. 3 pentafluoroethylphenyl H
286. 4 pentafluoroethylphenyl H
287. 3 eye1opropylpheny1 H
288. 4 eye1opropylpheny1 H
289. 2 methylphenyl H
290. 3 ■methylpheny H
291. 4 ■methylphenyl H
292. 2 ■ (1-methylethyl)phenyl H
293. 3 ■ (1-methylethyl)phenyl H
294. 4 ■ (1-methylethyl)phenyl H
295. 2 methyl-4- (1-methylethyl)phenyl H
296. 3 ■methyl-4- (1-methylethyl)phenyl H
297. 4- (1-methylethyl) -3-methylphenyl H 298. 2-t-butylphenyl H
299. 3-t-butylphenyl H
300. 4-t-butylphenyl H
301. 3-(l-hydroxy-l,l-di-trifluoromethyl)methylphenyl H
302. 4- (1-hydroxy-l,l-di-trifluoromethyl)methylphenyl H
303. 3- (1,1-dimethyl)propylphenyl H
304. 4- (1,1-dimethyl)propylphenyl H
Table 2a. (cont.)
Figure imgf000273_0001
#
305. 2-methoxyphenyl H
306. 3-methoxyphenyl H
307. 4-methoxyphenyl H
308. 4-phenoxyphenyl H
309. 2- (1-methyl)cyclopropylphenyl H
310. 2- ( (pyrrolidinylmethyl)oxy)phenyl H
311. 3- ( (pyrrolidinylmethyl)oxy)phenyl H
312. 4- ( (pyrrolidinylmethyl)oxy)phenyl H
313. 3- (4-piperidinylmethyl)oxy)phenyl H
314. 4- (4-piperidinylmethyl)oxy)phenyl H
315. 3- ( (tetrahydrofuranylmethyl)oxy)phenyl H
316. 3- (tetrahydrofuranylmethyl)oxy)-3-CF3phenyl H
317. 3- (4-piperidinylmethyl)phenyl H
318. 3- (4-piperidinylmethyl)phenyl H
319. 3- (glycylamino)phenyl H
320. 4- (glycylamino)phenyl H
Figure imgf000274_0001
Table 2a. (cont.)
Figure imgf000274_0002
324. 2 -chlorophenyl 5-F
325. 3 -chlorophenyl 5-P
326. 4 -chloroplieny1 5-F 327 -trifluoromethylphenyl 5-F 328 -trifluoromethylphenyl 5-F 329. -pentafluoroethylphenyl 5-F
330. 4 -pentafluoroethylphenyl 5-F
331. 3 -cyclopropylphenyl 5-F
332. 4 -eye1opropylphenyl 5-F
333. 2 -methylpϊieny1 5-F
334. 3 -methylpheny 5-F
335. 4 -methylphenyl 5-F
336. 2 -(1-methylethyl)phenyl 5-F 337. 3- (1-methylethyl)phenyl 5-F
338. 4- (1-methylethyl)phenyl 5-F
339. 2-methyl-4-(1-methylethyl)phenyl 5-F
340. 3-methyl-4-(1-methylethyl)phenyl 5-F 341. 4- (1-methylethyl) -3-methylphenyl 5-F
342. 2-t-butylphenyl 5-F
343. 3-t-butylphenyl 5-F
344. 4-t-butylphenyl 5-F
345. 3-(l-hydroxy-l,l-di-trifluoromethyl)methylphenyl 5-F Table 2a. (cont.)
Figure imgf000275_0001
# R1 R2 346. 4- (1-hydroxy-l, 1-di-trifluoromethyl)methylphenyl 5-F
347. 3- (1,1-dimethyl)propylphenyl 5-F
348. 4- (1,1-dimethyl)propylphenyl 5-F
349. 2-methoxyphenyl 5-F
350. 3-methoxypheny1 5-F 351. 4-methoxyphenyl ' 5-F
352. 2-(l-methyl)cyclopropylphenyl 5-F
353. 2- ( (pyrrolidinylmethyl)oxy)phenyl 5-F
354. 3- ( (pyrrolidinylmethyl) oxy)phenyl 5-F
355. 4- ( (pyrrolidinylmethyl)oxy)phenyl 5-F 356. 3- (4-piperidinylmethyl)oxy)phenyl 5-F
357. 3- ( (tetrahydrofuranylmethyl)oxy)phenyl 5-F
358. 3- (tetrahydrofuranylmethyl) oxy) -3-CF3phenyl 5-F
359. 3- (4-piperidinylmethyl)phenyl 5-F
360. 3- (glycylamino)phenyl 5-F 361. 4- (glycylamino)phenyl 5-F 362. 3-pyridyl H
363. 4-pγridyl H
364. 1-isoquinolyl H
365. 3-isoquinolinyl H
366. 4-isoquinolyl H
367. 5-isoquinolyl H
368. 6-isoquinolyl H
Table 2a . (coxit . )
Figure imgf000276_0001
369. 7-isoquinolyl H
370. tetrahydro-7-isoquinolinyl H
371. l-oxo-tetrahydro-7-isoquinolinyl H
372. 2-oxo-tetrahydro-7-isoquinolinyl H
373. 2-quinolinyl H
374. 3-quinolinyl H
375. 4-quinolinyl H
376. 5-quinolinyl H
377. 6-quinolinyl H
378. 7-quinolinyl H
379. tetrahydro-7-quinolinyl H
380. 2-oxo-tetrahydro-7-quinolinyl H
381. 5-quinozalinyl H
382. 6-quinozalinyl H
383. 4-indolyl H
384. 6-indolyl H 385. 2,3-dihγdro-6-indolγl H
386. oxo-dihydro-6-indolyl H
387. 5-isoindolγl H
388. 6-isoindolγl H
389. 2-naphthyridinyl H
390. 3-naphthyridinyl H
391. 4-naphthyridinyl H
392. 5-naphthyridinyl H
Table 2a . (cont . )
Figure imgf000277_0001
#
393. tetrahydro-naphthyridinyl H
394. oxo-tetrahydro-naphthyridinyl H
395. 2-isoxazolyl H
396. 3-pyrazolyl H
397. 5-pyrazolyl H
398. 2-thiazolyl H
399. 3-thiazolyl H
400. 6-indazolyl H
401. 5-indazolyl H
402. 3- (6- (1-methylcyclopropyl)pyridyl H
403. 6-benzofuryl H
404. 5-benzothienyl H
405. 5-benzofuryl H
406. 2-benzimidazolyl H
407. 2-benzoxazolyl H
408. 2-benzthiazolyl H
409. 6-benzimidazolyl H 410. 6-benzoxazolyl H
411. 6-benzthiazolyl H
412. 3- (phenoxy) -6-pyridyl H
413. 4- (phenylcarbony1)phenyl H 414. 4- (phenylamino)phenyl H
415. 4- (3-thienyl)phenyl H
416. 4- (pyrazol-3-yl)phenyl H
417. 4-morpholinylπιethylphenyl H
Table 2a. (cont.)
Figure imgf000278_0001
421. 3-isoquinolinyl 5-F
422. 2-quinolinyl 5-F
423. 3-pyridyl 5-F
424. 4-pyridyl 5-F
425. 3-isoquinolinyl 5-F 426. 4-isoquinolyl 5-F
427. 5-isoquinolyl 5-F
428. 6-isoquinolyl 5-F
429. 7-isoguinolyl 5-F
430. tetrahydro-7-isoquinolinyl 5-F
431. 1-oxo-tetrahydro-7-isoquinolinyl 5-F
432. 2-oxo-tetrahydro-7-isoquinolinyl 5-F
433. 2-guinolinyl 5-F
Table 2a. (cont.)
Figure imgf000279_0001
434. 3-guinolinyl 5-F
435. 4-quinolinyl 5-F
436. 5-guinolinyl 5-F
437. 6-quinolinyl 5-F
438. 7-quinolinyl 5-F
439. tetrahydro-7-quinolinyl 5-F
440. 2-oxo-tetrahydro-7-quinolinyl 5-F
441. 5-quinozalinyl 5-F
442. 6-quinozalinyl 5-F
443. 4-indolyl 5-F
444. 6-indolyl 5-F
445. 2,3-dihydro-6-indolyl 5-F
446. oxo-dihydro-6-indolyl 5-F
447. 5-isoindolyl 5-F
448. 6-isoindolyl 5-F
449. 2-naphthyridinyl 5-F
450. 3-naphthyridinyl 5-F 451. 4-naphthyridinyl 5-F
452. 5-naphthyridinyl 5-F
453. tetrahydro-naphthyridinyl 5-F
454. oxo-tetrahydro-naphthyridinyl 5-F
455. 2-isoxazolyl 5-F
456. 3-pyrazolyl 5-F
457. 5-pyrazolyl 5-F
458. 2-thiazolyl 5-F
Table 2a. (cont.)
Figure imgf000280_0001
#
459. 3-thiazolyl 5-F
460. 6-indazolyl 5-F
461. 5-indazolyl 5-F
462. 3- (6- (l-methylcyclopropyl)pyridyl 5-F
463. 6-benzofuryl 5-F
464. 5-benzothienyl 5-F
465. 5-benzofuryl 5-F
466. 2-benzoxazolyl 5-F
467. 2-benzthiazolyl 5-F
468. 6-benzimidazolyl 5-F
469. 6-benzoxazolyl 5-F
470. 6-benzthiazolyl 5-F
471. 3- (phenoxy)-6-pyridyl 5-F
472. 4- (phenylcarbonyl)phenyl 5-F
473. 4- (phenylamino)phenyl 5-F
474. 4- (3-1hieny1)phenyl 5-F
475. 4- (pyrazol-3-yl)phenyl 5-F 476. 4-morpholinylmethylphenyl H
Figure imgf000281_0001
477. 2-chlorophenyl H
478. 3-chlorophenyl H 479. 4-chlorophenyl H
480. 3-trifluoromethylphenyl H
481. 4-trifluoromethylphenyl H
482. 3-chloro-4-trifluoromethylphenyl H
483. 3-pentafluoroethylphenyl H 484. 4-pentafluoroethylphenyl H
485. 3-eye1opropylpheny1 H
486. 4-cyclopropylphenyl H
487. 2-methylphenyl H
488. 3-methylpheny H 489. 4-methylphenyl H
490. 2- (1-methylethyl)phenyl H
491. 3- (1-methylethyl)phenyl H
492. 4- (1-methylethyl)phenyl H
493. 2-methyl-4- (1-methylethyl)phenyl H 494. 3-methyl-4- (1-methylethyl)phenyl H
495. 4- (1-methylethyl) -3-methylpheny1 H
496. 2-t-butylphenyl H
497. 3-t-butylphenyl H
498. 4-t-butylphenyl H 499. 3- (1-hydroxy-1, 1-di-trifluoromethyl)methylpheny1 H 500. 4-(l-hydroxy-l,l-di-trifluoromethyl)methylphenyl H
501. 3- (1, 1-dimethyl)propylphenyl H
Table 2b. (cont.)
Figure imgf000282_0001
502. 4- (1, 1-dimethyl)propylphenyl H 503. 2-methoxyphenyl H 504. 3-methoxyphenyl H 505. 4-methoxyphenyl H 506. 4-phenoxyphenyl H 507. 2- (1-methyl)cyclopropylphenyl H 508. 2- ( (pyrrolidinylmethyl)oxy)phenyl H 509. 3- ( (pyrrolidinylmethyl) oxy)phenyl H 510. 4- ( (pyrrolidinylmethyl)oxy)phenyl H 511. 3- (4-piperidinylmethyl)oxy)phenyl H 512. 4- (4-piperidinylmethyl)oxy)phenyl H 513. 3- ( (tetrahydrofuranylmethyl)oxy)phenyl H 514. 3- (tetrahydrofuranylmethyl)oxy) -3-CF3phenyl H 515. 3- (4-piperidinylmethyl)phenyl H 516. 3- (6- (1-methylcyclopropyl)pyridyl H 517. 3- (glycylamino)phenyl H 518. 4- (glycylamino)phenyl H 519. 3-pyridyl H 520. 4-pyridyl H 521. 1-isoquinolyl H 522. 3-isoquinolinyl H 523. 4-isoquinoIyI H 524. 5-isoquinolyl H 525. 6-isoquinolyl H
526. 7-isoquinolyl H
Table 2b. (cont . )
Figure imgf000283_0001
527. tetrahydro-7-isoqu.inolinyl H
528. l-oxo-tetrahydro-7-isoquinolinyl H 529. 2-oxo-tetrahydro-7-isoquinolinyl H
530. 2-quinolinyl H
531. 3-guinolinyl H
532. 4-quinolinyl H
533. 5-guinolinyl H 534. 6-quinolinyl H
535. 7-quinolinyl H
536. tetrahydro-7-guinolinyl H
537. 2-oxo-tetrahydro-7-quinolinyl H
538. 5-quinozalinyl H 539. 6-quinozalinyl H
540. 4-indolyl H
541. 6-indolyl H
542. 2,3-dihydro-6-indolyl H
543. oxo-dihydro-6-indolyl H 544. 5-isoindolyl H
545. 6-isoindolyl H
546. 2-naphthyridinyl H
547. 3-naphthyridinyl H
548. 4-naphthyridiny1 H 549. 5-naphthyridinyl H 550. tetrahydro-naphthyridinyl H
551. oxo-tetrahydro-naphthyridinyl H
Table 2b. (cont.)
Figure imgf000284_0001
552 . 2-isoxazolyl H
553 . 3-pyrazolyl H
554 . 5-pyrazolyl H
Figure imgf000284_0002
Table 3 .
Figure imgf000285_0001
# R1 R2
560. 2-chlorophenyl H
561. 3-chlorophenyl H
562. 4-chlorophenyl H 563. 3-trifluoromethylphenyl H
564. 4-trifluoromethylphenyl H
565. 3-chloro-4-trifluoromethylpb.eri.yl H
566. 3-pentafluoroethylphenyl H
567. 4-pentafluoroethylphenyl H 568. 3-cyclopropylphenyl H
569. 4-cyclopropylphenyl H
570. 2-methylphenyl H
571. 3-methylpheny H
572. 4-methylphenyl H 573. 2- (1-methylethyl)phenyl H
574. 3- (1-methylethyl)phenyl H
575. 4- (1-methylethyl)phenyl H
576. 2-methyl-4-(1-methylethyl)phenyl H
577. 3-methyl-4-(1-methylethyl)phenyl H 578. 4- (1-methylethyl) -3-methylphenyl H
579. 2-t-butylphenyl H
580. 3-t-butylphenyl H
581. 4-t-butylphenyl H
582. 3-(l-hydroxy-l,l-di-trifluoromethyl)methylphenyl H 583. 4- (l-hydroxy-l,l-di-trifluoromethyl)methylphenyl H 584. 3- (1,1-dimethyl)propylphenyl H
Table 3. (cont.)
Figure imgf000286_0001
585. 4- (1,1-dimethyl)propylphenyl H 586. 2-methoxyphenyl H 587. 3-methoxyphenyl H 588. 4-methoxyphenyl H 589. 4-phenoxyphenyl H 590. 2- (1-methyl)cyclopropylphenyl H 591. 2- ( (pyrrolidinylmethyl)oxy)phenyl H 592. 3- ( (pyrrolidinylmethyl)oxy)phenyl H 593. 4- ( (pyrrolidinylmethyl)oxy)phenyl H 594. 3- (4-piperidinylmethyl)oxy)phenyl H 595. 4- (4-piperidinylmethyl)oxy)phenyl H 596. 3- ( (tetrahydrofuranylmethyl)oxy)phenyl H 597. 3- (tetrahydrofuranylmethyl)oxy) -3-CF3phenyl H 598. 3- (4-piperidinylmethyl)phenyl H 599. 3- (6- (1-methylcyclopropyl)pyridyl H 600. 3- (glycylamino)phenyl H 601. 4- (glycylamino)phenyl H 602. 3-pyridyl H 603. 4-pyridyl H 604. 1-isoquinolyl H 605. 3-isoqu.inolinyl H 606. 4-isoquinolyl H 607. 5-isoquinolyl H 608. 6-isoquinolyl H
609. 7-isoquinolyl H
Table 3. (cont.)
Figure imgf000287_0001
610. tetrahydro-7-isoquinolinyl H
611. l-oxo-tetrahydro-7-isoquinolinyl H 612. 2-oxo-tetrahydro~7-isoquinolinyl H
613. 2-qumolxnyl H
614. 3-quinolinyl H
615. 4-quinolinyl H
616. 5-quinolinyl H
617. 6-quinolinyl H
618. 7-quinolinyl H
619. tetrahydro-7-quinolinyl H
620. 2-oxo-tetrahydro-7-quinolinyl H
621. 5-quinozalinyl H
622. 6-quinozalinyl H
623. 4-indolyl H
624. 6-indolyl H
625. 2, 3-dihydro-6-indolyl H
626. oxo-dihydro-6-indolyl H
627. 5-isoindolyl H
628. 6-isoindolyl H
629. 2-naphthyridinyl H
630. 3-naphthyridinyl H
631. 4-naphthyridinyl H 632. 5-naphthyridinyl H 633. tetrahydro-naphthyridinyl H
634. oxo-tetrahydro-naphthyridinyl H
Table 3. (cont.)
Figure imgf000288_0001
635 . 2-isoxazolyl H
636 . 3-pyrazolyl H
637 . 5-pyrazolyl H
Figure imgf000288_0002
642, H Table 4.
Figure imgf000289_0001
#
643. 3-pyridyl H
644. 4-pyridyl H
645. 1-isoquinolyl H 646. 3-isoquinolinyl H
647. 4-isoquinolyl H
648. 5-isoquinolyl H
649. 6-isoquinolyl H
650. 7-isoquinolyl H 651. tetrahydro-7-isoquinolinyl H
652. l-oxo-tetrahydro-7-isoquinolinyl H
653. 2-oxo-tetrahydro-7-isoguinolinyl H
654. 2-quinolinyl H
655. 3-quinolinyl H 656. 4-quinolinyl H
657. 5-quinolinyl H
658. 6-quinolinyl H
659. 7-guinolinyl H
660. tetrahydro-7-quinolinyl H 661. 2-oxo-tetrahydro-7-guinolinyl H
662. 5-quinozalinyl H
663. 6-quinozalinyl H
664. 4-indolyl H
665. 6-indolyl H 666. 2,3-dihydro-6-indolyl H
667. oxo-dihydro-6-indolyl H
Table 4. (cont.)
Figure imgf000290_0001
# JL
668. 5-isoindolyl H 669. 6-isoindolyl H 670. 2-naphthyridinyl H 671. 3-naphthyridinyl H 672. 4-naphthyridinyl H 673. 5-naphthyridinyl H 674. tetrahydro-naphthyridinyl H 675. oxo-tetrahydro-naphthyridinyl H 676. 2-isoxazolyl H 677. 3-pyrazolyl H 678. 5-pyrazolyl H
Figure imgf000290_0002
682. H Table 4. (cont . )
Figure imgf000291_0001
683. H H
684. 6-indazolyl H
685. 5-indazolyl H
686. 3- (6- (l-methγlcγclopropyl)pyridγl H
687. 6-benzofurγl H
688. 5-benzothienyl H
689. 5-benzofuryl H
690. 6-benzthiazolyl H
691. 2-benzimidazolγl H
692. 2-benzoxazolyl H
693. 2-benzthiazolγl H
694. 6-benzimidazolγl H
695. 6-benzoxazolyl H
Figure imgf000291_0002
697 , H Table 4. (cont.)
Figure imgf000292_0001
698. H
Figure imgf000292_0002
702. H
Figure imgf000293_0001
Table 4. (cont.)
Figure imgf000293_0002
705 H
Figure imgf000293_0003
707. 3-pyridyl 5-F 708. 4-pyridyl 5-F 709. 1-isoquinoIyI 5-F 710. 3-isoquinolinyl 5-F 711. 4-isoquinolyl 5-F 712. 5-isoguinolyl 5-F 713. 6-isoquinolyl 5-F 714. 7-isoquinolyl 5-F 715. tetrahydro-7-isoquinolinyl 5-F 716. l-oxo-tetrahγdro-7-isoquinolinγl 5-F
717. 2-oxo-tetrahydro-7-isoquinolinyl 5-F
718. 2-quinolinyl 5-F
719. 3-quinolinyl 5-F
Table 4. (cont.)
Figure imgf000294_0001
#
720. 4-quinolinyl 5-F 721. 5-guinolinyl 5-F
722. 6-guinolinyl 5-F
723. 7-quinolinyl 5-F
724. tetrahydro-7-quinolinyl 5-F
725. 2-oxo-tetrahydro-7-quinolinyl 5-F 726. 5-quinozalinyl 5-F
727. 6-guinozalinyl 5-F
728. 4-indolyl 5-F
729. 6-indolyl 5-F
730. 2,3-dihydro-6-indolyl 5-F 731. oxo-dihydro-6-indolyl 5-F
732. 5-isoindolyl 5-F
733. 6-isoindolyl 5-F
734. 2-naphthyridinyl 5-F
735. 3-naphthyridinyl 5-F 736. 4-naphthyridinyl 5-F
737. 5-naphthyridinyl 5-F
738. tetrahydro-naphthyridinyl 5-F
739. oxo-tetrahydro-naphthyridinyl 5-F
740. 2-isoxazolyl 5-F 741. 3-pyrazolγl 5-F
742. 5-pγrazolγl 5-F
Table 4. (cont . )
Figure imgf000295_0001
748. 6-indazolyl 5-F
749. 5-indazolyl 5-F
750. 3- (6- (l-methylcyclopropyl)pyridyl 5-F
751. 6-benzofuryl 5-F 752. 5-benzothienγl 5-F
753. 5-benzofurγl 5-F
754. 6-benzthiazolyl 5-F
Table 4. (cont.)
Figure imgf000296_0001
756. 5-F
Figure imgf000296_0002
757 5-F
Figure imgf000296_0003
759 5-F
Figure imgf000297_0001
Table 4. (cont.)
Figure imgf000297_0002
# R"
Figure imgf000297_0003
764. 5-F
Figure imgf000298_0001
Figure imgf000298_0002
# R" 766. 3-pyridγl H
767. 3- (6- (l-methylcγclopropyl)pyridyl H
768. 1-isoquinolyl H
769. 3-isoquinolinyl H
770. 4-isoquinolyl H 771. 5-isoquinolyl H
772. 6-isoquinolyl H
773. 7-isoquinolyl H
774. tetrahydro-7-isoquinolinyl H
775. l-oxo-tetrahydro-7-isoquinolinyl H 776. 2-oxo-tetrahydro-7-isoquinolinyl H
777. 2-quinolinyl H
778. 3-quinolinyl H
779. 4-quinolinyl H
780. 5-quinolinyl H 781. 6-guinolinyl H
782. 7-quinolinyl H
783. tetrahydro-7-guinolinyl H
784. 2-oxo-tetrahydro-7-quinolinyl H 785. 5-quinozalinyl H
786. 6-quinozalinyl H
787. 4-indolyl H
788. 6-indolyl H 789. 2, 3-dihydro-6-indolyl H
790. oxo-dihydro-6-indolyl H
Table 5. (cont.)
Figure imgf000299_0001
791. 5-isoindolyl H
792. 6-isoindolyl H
793. 2-naphthyridinyl H 794. 3-naphthyridinyl H
795. 4-naphthyridinyl H
796. 5-naphthyridinyl H
797. tetrahydro-naphthyridinyl H
798. oxo-tetrahydro-naphthyridinyl H 799. 2-isoxazolyl H
800. 3-pyrazolyl H
801. 5-pyrazolyl H
Figure imgf000299_0002
803. H
Figure imgf000300_0001
Table 5. (cont.)
Figure imgf000300_0002
807. 6-indazolyl H 808. 5-indazolyl H 809. 3- (6-chloro)pγridyl H 810. 6-benzofuryl H 811. 3- (6-trifluoromethyl)pyridyl H 812. 5-benzofuryl H 813. 6-benzthiazolyl H 814. 2-benzimidazolyl H 815. 2-benzoxazolyl H 816. 2-benzthiazolyl H 817. 6-benzimidazolyl H 818. 6-benzoxazolyl H
Figure imgf000300_0003
819. H
Figure imgf000301_0001
Table 5. (cont.)
Figure imgf000301_0002
821. H
Figure imgf000301_0003
Figure imgf000302_0001
Table 5. (cont.)
Figure imgf000302_0002
828, H
Figure imgf000302_0003
830. 3-pyridyl 5-F 831. 3- (6- (1-methylcyclopropyl)pyridyl 5-F 832. 1-isoquinolyl 5-F 833. 3-isoquinolinyl 5-F 834, 4-isoquinolyl 5-F 835. 5-isoquinolyl 5-F 836, 6-isoguinolyl 5-F 837, 7-isoquinolyl 5-F 838, tetrahydro-7-isoquinolinyl 5-F 839. l-oxo-tetrahγdro-7-isoquinolinyl 5-F
840. 2-oxo-tetrahγdro-7-isoquinolinγl 5-F
841. 2-quinolinγl 5-F
842. 3-quinolinyl 5-F
Table 5. (cont . )
Figure imgf000303_0001
#
843 . 4-quinolinyl 5-F 844 . 5-quinolinγl 5-F
845. 6-quinolinγl 5-F
846. 7-quinolinγl 5-F
847. tetrahydro-7-quinolinyl 5-F
848. 2-oxo-tetrahydro-7-quinolinyl 5-F 849. 5-quinozalinyl 5-F
850. 6-quinozalinγl 5-F
851. 4-indolyl 5-F
852. 6-indolyl 5-F
853. 2,3-dihγdro-6-indolyl 5-F 854. oxo-dihydro-6-indolyl 5-F
855. 5-isoindolγl 5-F
856. 6-isoindolyl 5-F
857. 2-naphthyridinyl 5-F
858. 3-naphthyridinyl 5-F 859. 4-naphthyridinyl 5-F
860. 5-naphthyridinyl 5-F
861. tetrahydro-naphthyridinyl 5-F
862. oxo-tetrahydro-naphthyridinyl 5-F
863. 2-isoxazolyl 5-F 864. 3-pyrozolyl 5-F
865. 5-pγrazolγl 5-F
Table 5. (cont.)
Figure imgf000304_0001
870.
871. 6-indazolyl 5-F
872. 5-indazolyl 5-F
873. 3- (6- (1 -methyl cyclopropyDpyr idyl 5-F
874. 6-benzofuryl 5-F 875. 5-benzothienyl 5-F
876. 5-benzofurγl 5-F
877. 6-benzthiazolyl 5-F
Table 5. (cont.)
Figure imgf000305_0001
879 5-F
Figure imgf000305_0002
880 5-F
Figure imgf000305_0003
882 5-F
Figure imgf000306_0001
Table 5. (cont.)
Figure imgf000306_0002
887, 5-F
Figure imgf000306_0003
888, 5-F Table 5. (cont.)
Figure imgf000307_0001
# RA R"
889. '2-chlorophenγl H 890. 3-chlorophenγl H
891. 4-chlorophenyl H
892. 3-trifluoromethylphenyl H
893. 4-trifluoromethylphenyl H
894. 3-pentafluoroethylphenyl H 895. 4-pentafluoroethylphenyl H
896. 3-cyclopropylphenyl H
897. 4-cyclopropylphenyl H
898. 2-methylphenyl H
899. 3-methylpheny H 900. 4-methylphenyl H
901. 2- (1-methylethyl)phenyl H
902. 3- (1-methylethyl)phenyl H
903. 4- (1-methylethyl)phenyl H
904. 2-methyl-4-(l-methylethyl)phenyl H 905. 3-methyl-4- (1-methylethyl)phenyl H
906. 4- (l-methylethyl)-3-methylphenyl H
907. 2-t-butylphenyl H
908. 3-t-butylphenyl H
909. 4-t-butylphenyl H 910. 3-(l-hydroxy-l,l-di-trifluoromethyl)methylphenyl H
911. 4- (l-hydroxy-l,l-di-trifluoromethyl)methylphenyl H
912. 3- (1,1-dimethyl)propylphenyl H Table 5. (cont . )
Figure imgf000308_0001
913 . 4- ( 1 , 1- dimethyl ) propylphenyl H 914 . 2 -me t hoxypheny 1 H 915 . 3 -methoxyphenyl H 916 . 4 -methoxyphenyl H
917. 4-phenoxyphenyl H
918. 2- (1-methyl)cyclopropylphenyl H 919. 2- ( (pyrrolldinylmethyDoxy)phenyl H
920. 3- ( (pyrrolidinylmethyl)oxy)phenyl H
921. 4- ( (pyrrolidinylmethyl) oxy)phenyl H
922. 3- (4-piperidinylmethyl)oxy)phenyl H 923. 4- (4-piperidinylmethyl)oxy)phenyl H 924. 3- (1-piperizinyl)phenyl H
925. 4- (1-piperizinyl)phenyl H
926. 3- (4-piperidinylmethyl)phenyl H
927. 3- (4-piperidinylmethyl)phenyl H
928. 3- (glycylamino)phenyl H 929. 4- (glycy1amino)phenyl H
930. 2-chlorophenyl 5-F
931. 3-chloropheny1 5-F 932. 4-chloropheny1 5-F
933. 3-trifluoromethylphenyl 5-F 934. 4-trifluoromethylphenyl 5-F
935. 3-pentafluoroethylphenyl 5-F
936. 4-pentafluoroethylphenyl 5-F
937. 3-eye1opropylphenyl 5-F Table 5. (cont.)
Figure imgf000309_0001
938. 4-cyclopropylphenyl 5-F 939. 2-methylpheny1 5-F 940. 3-methylpheny 5-F 941. 4-methylpheny1 5-F 942. 2- (1-methylethyl)phenyl 5-F 943. 3- (1-methylethyl)phenyl 5-F 944. 4- (1-methylethyl)phenyl 5-F 945. 2-methyl-4- (1-methylethyl)phenyl 5-F 946. 3-methyl-4- (1-methylethyl)phenyl 5-F 947. 4- (1-methylethyl) -3-methylphenyl 5-F 948. 2-t-butylphenyl 5-F 949. 3-t-butylphenyl 5-F 950. 4-t-butylphenyl 5-F 951. 3- (1-hydroxy-1, l-di-trifluoromethyl)methylphenyl5-F 952. 4- (1-hydroxy-l, l-di-trifluoromethyl)methylphenyl5-F 953. 3- (1, 1-dimethyl)propylpheny1 5-F 954. 4- (1, 1-dimethyl)propylphenyl 5-F 955. 2-methoxyphenyl 5-F 956. 3-methoxyphenyl 5-F 957. 4-methoxyphenyl 5-F 958. 2- (1-methyl) cyclopropylphenyl 5-F 959. 2- ( (pyrrolidinylmethyl) oxy)phenyl 5-F 960. 3- ( (pyrrolidinylmethyl) oxy)phenyl 5-F 961. 4- ( (pyrrolidinylmethyl)oxy)phenyl 5-F Table 5. (cont.)
Figure imgf000310_0001
962. 3- (4-piperidinylmethyl) oxy)phenyl 5-F
963. 4- (4-piperidinylmethyl)oxy)phenyl 5-F
964. 3- (1-piperizinyl)phenyl 5-F
965. 4- (1-piperizinyl)phenyl 5-F
966. 3- (4-piperidinylmethyl)phenyl 5-F
967. 3- (4-piperidinylmethyl)phenyl 5-F
968. 3- (gIycy1amino)phenyl 5-F
969. 4- (glycylamino)phenyl 5-F
Although the pharmacological properties of the compounds of Formulas I and II vary with structural change, in general, activity possessed by compounds of Formulas I and II may be demonstrated in vivo. The pharmacological properties of the compounds of this invention may be confirmed by a number of pharmacological in vitro assays. The exemplified pharmacological assays which follow have been carried out with the compounds according to the invention and their salts. Compounds of the present invention showed inhibition of KDR at doses less than 50 μm. BIOLOGICAL EVALUATION
HUVEC Proliferation Assay
Human Umbilical Vein Endothelial cells are purchased from Clonetics, Inc., as cryopreserved cells harvested from a pool of donors. These cells, at passage 1, are thawed and expanded in EBM-2 complete medium, until passage 2 or 3. The cells are trypsinized, washed in DMEM + 10% FBS + antibiotics, and spun at 1000 rpm for 10 min. Prior to centrifugation of the cells, a small amount is collected for a cell count. After centrifugation, the medium is discarded, and the cells are resuspended in the appropriate volume of DMEM + 10% FBS + antibiotics to achieve a concentration of 3xlO5 cells/mL. Another cell count is performed to confirm the cell concentration. The cells are diluted to 3xlO4 cells/mL in DMEM + 10% FBS + antibiotics, and 100 μL of cells are added to a 96-well plate. The cells are incubated at 37 2C for 22 h.
Prior to the completion of the incubation period, compound dilutions are prepared. Five-point, five-fold serial dilutions are prepared in DMSO, at concentrations 400-fold greater than the final concentrations desired. 2.5 μL of each compound dilution are diluted further in a total of 1 mL DMEM + 10% FBS + antibiotics (40Ox dilution) . Medium containing 0.25% DMSO is also prepared for the 0 μM compound sample. At the 22-hour timepoint, the medium is removed from the cells, and 100 μL of each compound dilution is added. The cells are incubated at 37 aC for 2-3 h.
During the compound pre-incubation period, the growth factors are diluted to the appropriate concentrations. Solutions of DMEM + 10% FBS + antibiotics, containing either VEGF or bFGF at the following concentrations: 50, 10, 2, 0.4, 0.08, and 0 ng/mL are prepared. For the compound- treated cells, solutions of VEGF at 550 ng/mL or bFGF at 220 ng/mL for 50 ng/mL or 20 ng/mL final concentrations, respectively, are prepared since 10 μL of each will be added to the cells (110 μL final volume) . At the appropriate time after adding the compounds, the growth factors are added. VEGF is added to one set of plates, while bFGF is added to another set of plates. For the growth factor control curves, the media on wells B4-G6 of plates 1 and 2 are replaced with media containing VEGF or bFGF at the varying concentrations (50 - 0 ng/mL) . The cells are incubated at 370C for an additional 72 h.
At the completion of the 72 h incubation period, the medium is removed, and the cells are washed twice with PBS. After the second wash with PBS, the plates are tapped gently to remove excess PBS, and the cells are placed at -70 2C for at least 30 min. The cells are thawed and analyzed using the CyQuant fluorescent dye (Molecular Probes C-7026) , following the manufacturer's recommendations. The plates are read on a Victor/Wallac 1420 workstation at 485 nm/530 nm (excitation/emission) . Raw data are collected and analyzed using a 4-parameter fit equation in XLFit. IC50 values are then determined.
The compounds of examples 10-16, 22-25, 27-77, 103, 114, 138, 210, 217-220, 638, 639, 690, 694, 696, 697, 773, 800, 805, 809, 811, 819, 820 inhibited VEGF-stimulated HUVEC proliferation at a level below 1.OuM.
Angiogenesis Model
To determine the effects of the present compounds on angiogenesis in vivo, selective compounds are tested in the rat corneal neovascularization micropocket model or the angiogenesis assay of Passaniti, Lab. Invest., 67, 519-28 (1992) . Rat Corneal Neovascularization Micropocket Model
In Life Aspects: Female Sprague Dawley rats weighing approximately 250 g were randomized into one of five treatment groups. Pretreatment with the vehicle or compound was administered orally, 24 h prior to surgery and continued once a day for seven additional days. On the day of surgery, the rats were temporarily anesthetized in an Isofluorane gas chamber (delivering 2.5 liters/min oxygen + 5% Isofluorane) . An othoscope was then placed inside the mouth of the animal to visualize the vocal cords. A tip- blunted wire was advanced in between the vocal cords and used as a guide for the placement of an endotracheal Teflon tube (Small Parts Inc. TFE-standard Wall R-SWTT-18) . A volume-controlled ventilator (Harvard Apparatus, Inc. Model 683) was connected to the endotracheal tube to deliver a mixture of oxygen and 3% Isofluorane. Upon achieving deep anesthesia, the whiskers were cut short and the eye areas and eyes gently washed with Betadine soap and rinsed with sterile saline. The corneas were irrigated with one to two drops of Proparacaine HCl ophthalmic topical anesthetic solution (0.5%) (Bausch and Lomb Pharmaceuticals, Tampa FL) . The rat was then positioned under the dissecting microscope and the corneal surface brought into focus. A vertical incision was made on the midline of the cornea using a diamond blade knife. A pocket was created by using fine scissors to separate the connective tissue layers of the stroma, tunneling towards the limbus of the eye. The distance between the apex of the pocket and the limbus was approximately 1.5 mm. After the pocket had been made, the soaked nitrocellulose disk filter (Gelman Sciences, Ann Arbor MI.) was inserted under the lip of the pocket. This surgical procedure was performed on both eyes. rHu-bFGF soaked disks were placed into the right eye, and the rHu- VEGF soaked disks were placed into the left eye. Vehicle soaked disks were placed in both eyes. The disk was pushed into position at the desired distance from the liπibal vessels. Ophthalmic antibiotic ointment was applied to the eye to prevent drying and infection. After seven days, the rats were euthanized by CO2 asphyxiation, and the eyes enucleated. The retinal hemisphere of the eye was windowed to facilitate fixation, and the eye placed into formalin overnight.
Post Mortem Aspects: After twenty-four hours in fixative, the corneal region of interest was dissected out from the eye, using fine forceps and a razorblade. The retinal hemisphere was trimmed off and the lens extracted and discarded. The corneal dome was bisected and the superfluous cornea trimmed off. The iris, conjunctiva and associated limbal glands were then carefully teased away. Final cuts were made to generate a square 3x3 mm containing the disk, the limbus, and the entire zone of neovascularization.
Gross Image Recording: The corneal specimens were digitally photographed using a Sony CatsEye DKC5000 camera (A.G. Heinz, Irvine CA) mounted on a Nikon SMZ-U stereo microscope (A.G. Heinz) . The corneas were submerged in distilled water and photographed via trans-illumination at approximately 5.0 diameters magnification.
Image analysis: Numerical endpoints were generated using digital micrographs collected from the whole mount corneas after trimming and were used for image analysis on the Metamorph image analysis system (Universal Imaging Corporation, West Chester PA) . Three measurements were taken: Disk placement distance from the limbus, number of vessels intersecting a 2.0 mm perpendicular line at the midpoint of the disk placement distance, and percent blood vessel area of the diffusion determined by thresholding.
General Formulations:
0.1% BSA in PBS vehicle: 0.025 g of BSA was added to 25.0 ml of sterile IX phosphate buffered saline, gently shaken until fully dissolved, and filtered at 0.2 μm. Individual 1.0 ml samples were aliquoted into 25 single use vials, and stored at -20 2C until use. For the rHu-bFGF disks, a vial of this 0.1% BSA solution was allowed to thaw at room temperature. Once thawed, 10 μl of a 100 mM stock solution of DTT was added to the 1 ml BSA vial to yield a final concentration of 1 mM DTT in 0.1% BSA.
rHu-VEGF Dilutions:
Prior to the disk implant surgery, 23.8 μl of the 0.1% BSA vehicle above was added to a 10 μg rHu-VEGF lyophilized vial yielding a final concentration of 10 μM.
rHu-bFGF: Stock concentration of 180 ng/μl:
R&D rHu- bFGF: Added 139 μl of the appropriate vehicle above to the 25 μg vial lyophilized vial. 13.3 μl of the [180 ng/μl] stock vial and added 26.6 μl of vehicle to yield a final concentration of 3.75 μM concentration.
Nitro-cellulose disk preparation: The tip of a 20-gauge needle was cut off square and beveled with emery paper to create a punch. This tip was then used to cut out =0.5mm diameter disks from a nitrocellulose filter paper sheet (Gelman Sciences) . Prepared disks were then placed into Eppendorf microfuge tubes containing solutions of either 0.1% BSA in PBS vehicle, 10 μM rHu-VEGF (R&D Systems, Minneapolis, MN), or 3.75 μM rHu-bFGF (R&D Systems, Minneapolis, MN) and allowed to soak for 45-60 min before use. Each nitrocellulose filter disk absorbs approximately 0.1 μl of solution.
In the rat micropocket assay, compounds of the present invention will inhibit angiogenesis at a dose of less than 50 mg/kg/day.
Tumor model
A431 cells (ATCC) are expanded in culture, harvested and injected subcutaneously into 5-8 week old female nude mice (CDl nu/nu, Charles River Labs) (n=5-15) . Subsequent administration of compound by oral gavage (10 - 200 mpk/dose) begins anywhere from day 0 to day 29 post tumor cell challenge and generally continues either once or twice a day for the duration of the experiment. Progression of tumor growth is followed by three dimensional caliper measurements and recorded as a function of time. Initial statistical analysis is done by repeated measures analysis of variance (RMANOVA) , followed by Scheffe post hoc testing for multiple comparisons. Vehicle alone (Ora-Plus, pH 2.0) is the negative control. Compounds of the present invention are active at doses less than 150 mpk.
Rat Adjuvant Arthritis Model:
The rat adjuvant arthritis model (Pearson, Proc. Soc. Exp. Biol. 91, 95-101 (1956)) is used to test the anti- arthritic activity of compounds of the formula 1, or salts thereof. Adjuvant Arthritis can be treated using two different dosing schedules: either (i) starting time of immunization with adjuvant (prophylactic dosing) ,- or from day 15 when the arthritic response is already established (therapeutic dosing) . Preferably a therapeutic dosing schedule is used.
Rat Carrageenan-induced Analgesia Test
The rat carrageenan analgesia test was performed with materials, reagents and procedures essentially as described by Hargreaves, et al., (Pain, 32, 77 (1988)) . Male Sprague- Dawley rats were treated as previously described for the Carrageenan Foot Pad Edema test. Three hours after the injection of the carrageenan, the rats were placed in a special plexiglass container with a transparent floor having a high intensity lamp as a radiant heat source, positionable under the floor. After an initial twenty minute period, thermal stimulation was begun on either the injected foot or on the contralateral uninjected foot. A photoelectric cell turned off the lamp and timer when light was interrupted by paw withdrawal. The time until the rat withdraws its foot was then measured. The withdrawal latency in seconds was determined for the control and drug-treated groups, and percent inhibition of the hyperalgesic foot withdrawal determined.
Formulations Also embraced within this invention is a class of pharmaceutical compositions and medicaments comprising active compounds of Formula I, or Formula II, in association with one or more non-toxic, pharmaceutically-acceptable carriers and/or diluents and/or adjuvants (collectively referred to herein as "carrier" materials) and, if desired, other active ingredients. The term "pharmaceutical composition" as used herein, is intended to be synonymous with the term "medicament", for purposes of preparation, administration and/or use, as is readily appreciated by those of ordinary skill in the art. The compositions which comprise the active compounds, may be administered by any suitable route, preferably in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compositions may, for example, be administered orally, mucosally, topically, rectally, pulmonarily such as by inhalation spray, or parentally including intravascularly, intravenously, intraperitoneally, subcutaneousIy, intramuscularly intrasternally and infusion techniques, in dosage unit formulations containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles.
The pharmaceutically active compounds of this invention can be processed in accordance with conventional methods of pharmacy to produce medicinal agents for administration to patients, including humans and other mammals .
For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. The pharmaceutical composition or medicament is preferably made in the form of a dosage unit containing a particular amount of the active ingredient. Examples of such dosage units are tablets or capsules. For example, these may contain an amount of active ingredient from about 1 to 2000 mg, preferably from about 1 to 500 mg or 5 to 1000 mg. A suitable daily dose for a human or other mammal may vary widely depending on the condition of the patient and other factors, but, once again, can be determined using routine methods.
The amount of compounds which are administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, gender and medical condition of the subject, the type of disease, the severity of the disease, the route and frequency of administration, and the particular compound employed. Thus, the dosage regimen may vary widely, but can be determined routinely using standard methods. A daily dose of about 0.01 to 500 mg/kg, preferably between about 0.1 and about 50 mg/kg, and more preferably about 0.1 and about 20 mg/kg body weight may be appropriate. The daily dose can be administered in one to four doses per day.
For therapeutic purposes, the active compounds of this invention are ordinarily combined with one or more adjuvants appropriate to the indicated route of administration. If administered per dose, the compounds may be admixed with suitable excipients, including lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinylpyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropylmethyl cellulose.
In the case of psoriasis and other skin conditions, it may be preferable to apply a topical preparation of compounds of this invention to the affected area two to four times a day.
Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin (e.g., liniments, lotions, ointments, creams, or pastes) and drops suitable for administration to the eye, ear, or nose. A suitable topical dose of active ingredient of a compound of the invention is 0.1 mg to 150 mg administered one to four, preferably one or two times daily. For topical administration, the active ingredient may comprise from 0.001% to 10% w/w, e.g., from 1% to 2% by weight of the formulation, although it may comprise as much as 10% w/w, but preferably not more than 5% w/w, and more preferably from 0.1% to 1% of the formulation.
When formulated in an ointment, the active ingredients may be employed with either paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base. If desired, the aqueous phase of the cream base may include, for example at least 30% w/w of a polyhydric alcohol such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol and mixtures thereof. The topical formulation may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include DMSO and related analogs.
Compounds of the invention can also be administered to a subject by a transdermal device. Preferably transdermal administration will be accomplished using a patch either of the reservoir and porous membrane type or of a solid matrix variety. In either case, the active agent is delivered continuously from the reservoir or microcapsules through a membrane into the active agent permeable adhesive, which is in contact with the skin or mucosa of the recipient. If the active agent is absorbed through the skin, a controlled and predetermined flow of the active agent is administered to the recipient. In the case of microcapsules, the encapsulating agent may also function as the membrane.
The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While the phase may comprise merely an emulsifier, it may comprise a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabilizer. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabilizer(s) make-up the so-called emulsifying wax, and the wax together with the oil and fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations. Emulsifiers and emulsion stabilizers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, glyceryl distearate alone or with a wax, or other materials well known in the art. The choice of suitable oils or fats for the formulation is based on achieving the desired cosmetic properties, since the solubility of the active compound in most oils likely to be used in pharmaceutical emulsion formulations is very low. Thus, the cream should preferably be a non-greasy, non-staining and washable product with suitable consistency to avoid leakage from tubes or other containers. Straight or branched chain, mono- or dibasic alkyl esters such as di-isoadipate, isocetyl stearate, propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl oleate, isopropyl palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain esters may be used. These may be used alone or in combination depending on the properties required. Alternatively, high melting point lipids such as white soft paraffin and/or liquid paraffin or other mineral oils can be used.
Formulations suitable for topical administration to the eye also include eye drops wherein the active ingredients are dissolved or suspended in suitable carrier, especially an aqueous solvent for the active ingredients. The active ingredients are preferably present in such formulations in a concentration of 0.5 to 20%, advantageously 0.5 to 10% and particularly about 1.5% w/w. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules using one or more of the carriers or diluents mentioned for use in the formulations for oral administration or by using other suitable dispersing or wetting agents and suspending agents. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth gum, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art. The active ingredient may also be administered by injection as a composition with suitable carriers including saline, dextrose, or water, or with cyclodextrin (ie. Captisol) , cosolvent solubilization (ie. propylene glycol) or micellar solubilization (ie. Tween 80) .
The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1, 3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables. For pulmonary administration, the pharmaceutical composition may be administered in the form of an aerosol or with an inhaler including dry powder aerosol.
Suppositories for rectal administration of the composition can be prepared by mixing the pharmaceutically active ingredients (including compounds of Formula I, also commonly referred to as "drug") with one or more suitable non-irritating excipients such as cocoa butter and polyethylene glycols that are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.
The pharmaceutical compositions may be subjected to conventional pharmaceutical operations such as sterilization and/or may contain conventional adjuvants, such as preservatives, stabilizers, wetting agents, emulsifiers, buffers etc. Tablets and pills can additionally be prepared with enteric coatings. Such compositions may also comprise adjuvants, such as wetting, sweetening, flavoring, and perfuming agents. The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.
All mentioned references, patents, applications and publications, are hereby incorporated by reference in their entirety, as if here written.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula I
Figure imgf000324_0001
or a pharmaceutically acceptable derivative thereof, wherein R is a 9- or 10-membered heterocyclyl ring containing at least one nitrogen or oxygen atom, said ring selected from 7-isoquinolinyl, 2-methyl-3-oxo-2, 3- dihydroindazol-6-yl, [1, 6] -naphthydrin-3-yl, [1,7]- naphthydrin-2-yl, l-oxo-2, 3-dihydrobenzofuran-4-yl, 3-oxo- 2,3-dihydrobenzofuran-5-yl, dihydro-benzodioxinyl, 6- quinazolinyl, 2-amino-6-quinazolinyl, 4-methylamino-6- quinazolinyl, 2,4-diamino-6-quinazolinyl, 3-oxo-3, 4-dihydro- 1,4-benzoxazin-6-yl, 2,2-difluoro-l, 3-benzodioxol-5-yl and 2,2,3,3-tetrafluoro-2, 3-dihydro-l,4-benzodioxin-6-yl, each of which is optionally substituted with one or more substitutions selected from halo, haloalkyl, C1-6 alkyl, C2_8 alkenyl, C2_8 alkynyl, N-dimethylamino-C^g-alkyl, N- dimethylamino-Cj.g-alkoxy, amino, alkyl-carbonylamino, morpholino-sulfonyl, amino-sulfonyl, oxazolyl, pyrrolyl, morpholinyl, carboxyl, cyano, and acetyl; wherein R1 is selected from unsubstituted or substituted phenyl, 5-6 membered heteroaryl,
9-10 membered bicyclic heterocyclyl and 11-14 membered tricyclic heterocyclyl, wherein substituted R1 is substituted with one or more substituents selected from halo, optionally substituted Ci-6-alkyl, optionally substituted C3-6- cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-Ci_C4-alkylenyl, Ci_2-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-Ci-Cβ-alkyl, optionally substituted 4-6 membered heterocyclyl-C2-C4- alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-Cχ-4-alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted 4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl-Ci_4- alkylcarbonyl, optionally substituted 4-6 membered heterocyclylcarbonyl-Ci-4-alkyl, optionally substituted 4-6 membered heterocyclyl-Ci_4-alkylcarbonylamino, optionally substituted 4-6 membered heterocyclyl- oxycarbonylamino, Ci_2-haloalkyl, Ci-4-aminoalkyl, optionally substituted Ci-4-aminoalkylcarbonyl, nitro, amino, Ci-3-alkylsulfonylamino, hydroxy, cyano, aminosulfonyl, C^-alkylsulfonyl, Ci_2- alkylsulfonylamino, C1_2-alkylsulfonylamino-Ci-4-alkoxy, halosulfonyl, Cχ-4-alkylcarbonyl, amino-Ci-4- alkylcarbonyl, C1-3-alkylamino-Ci-4-alkylcarbonyl, Ci_3- alkylamino-Ci_4-alkylcarbonylamino, Ci-4-alkoxycarbonyl- Ci_4-alkyl, Ci_3-alkylamino-Ci_3-alkyl, Ci-3-alkylamino-Ci_ 3-alkoxy, Cx-s-alkylamino-Ci-s-alkoxy-Ci-s-alkoxy, Ci_4- alkoxycarbonyl , Ci_4-alkoxycarbonylamino-Ci-4-alkyl , C1-. 3-alkylsulf onylamino-Ci_3-alkoxy# Ci_4-hydroxyalkyl ,
Figure imgf000325_0001
and Ci-4-alkoxy; and wherein Re and Rf are independently selected from H and Ci_2- haloalkyl; and wherein R7 is selected from H, Ci_3-alkyl, optionally substituted phenyl, optionally substituted phenyl-Ci_3- alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-Ci-Ca-alkyl, C3.-3- alkoxy-Cχ-2-alkyl and Ci-a-alkoxy-Cx-s-alkoxy-Ci-B-alkyl; and wherein R2 is selected from H, halo, haloalkyl and C1-6 alkyl.
2. The compound of claim 1 wherein R is 7- isoquinolinyl.
3. The compound of claim 1 wherein R is 2-methyl-3- oxo-2, 3-dihydroindazol-6-yl.
4. The compound of claim 1 wherein R is [1,6]- naphthydrin-3-yl.
5. The compound of claim 1 wherein R is [1,7]- naphthydrin-2-yl.
6. The compound of claim 1 wherein R is selected from l-oxo-2, 3-dihydrobenzofuran-4-yl and 3-oxo-2,3- dihydrobenzofuran-5-yl.
7. The compound of claim 1 wherein R is dihydro- benzodioxinyl.
8. The compound of claim 1 wherein R is 2-amino-6- quinazolinyl.
9. The compound of claim 1 wherein R is 4-methylamino- 6-quinazolinyl.
10. The compound of claim 1 wherein R is 2,4-diamino- 6-quinazolinyl.
11. The compound of claim 1 wherein R is selected from 3-oxo-3,4-dihydro-l,4-benzoxazin-6-yl, 2, 2-difluoro-l,3- benzodioxol-5-yl and 2, 2,3,3-tetrafluoro-2,3-dihydro-l,4- benzodioxin-6-yl.
12. The compound of claim 1 wherein R is 6- guinazolinyl.
13. The compound of claim 1 wherein R1 is selected from phenyl, 3-isoxazolyl, 3-pyrazolyl, 2-thiazolyl, 1,3,4- thiadiazol-2-yl, thienyl, 3-pyridyl, pyrimidinyl, pyridazinyl, 1, 2-dihydroquinolyl, 1,2,3,4- tetrahydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 2-oxo- 1,2,3,4-tetrahydroquinolyl, 2-oxo-l,2, 3,4- tetrahydroquinolyl, 1-oxo-l,2,3,4-tetrahydro-isoquinolyl, 1' ,2'-dihydro-spiro[cyclopropane-1,3 '- [3H]indol] -6'-yl, isoquinolyl, quinolyl, indol-6-yl, 6-isoindolyl, 3,4- dihydro-2H-benzo[l,4]oxazin-6-yl, 3-oxo-3,4-dihydro-2H- benzo[l, 4]oxazin-6-yl, 2,3-dihydro-lH-indol-6-yl, naphthyridinyl, 2-oxo-3,4-dihydro-lH- [1,8]naphthyridin-7-yl, 3,4-dihydro- [1, 8]naphthyridinyl, 1,2,3, 4-tetrahydro- [1, 8]naphthyridinyl, quinozalinyl, 2-oxo-chromen-7-yl, benzo[d]isothiazolyl, 3,4-dihydro-quinazolinyl, 2,3,4,4a,9,9a-hexahydro-lH-3-aza-fluorenyl, 5,6,7-trihydro- 1,2,4-triazolo[3, 4-a] isoquinolyl, 5, 6-dihydro- [1,2,4]triazolo[3,4-a]isoquinolin-9-yl, indazol-6-yl, 2,1,3- benzothiadiazolyl, benzodioxanyl, benzothienyl, 2,3-dihydro- benzofuran-6-yl, benzofuranyl, benzimidazolyl, dihydro- benzimidazolyl, benzoxazolyl and 5-benzthiazol-5-yl, where R1 is unsubstituted or substituted with one or more substituents selected from bromo, chloro, fluoro, iodo, nitro, amino, cyano, Boc-aminoethyl, hydroxy, fluorosulfonyl, methylsulfonyl, aminosulfonyl, 4- methylpiperazinylsulfonyl, cyclohexyl, phenyl, phenylmethyl, 4-pyridylmethyl, 4-morpholinylmethyl, l-methylpiperazin-4- ylmethyl, l-methylpiperazin-4-ylpropyl, morpholinylpropyl, piperidin-1-ylmethyl, l-methylpiperidin-4-ylmethyl, 2- methyl-2-(l-methylpiperidin-4-yl)ethyl, 2-methyl-2- (4- pyrimidinyl)ethyl, 2-methyl-2- (5-methyloxadiazol-2-yl)ethyl, 2-methyl-2- (pyrazol-5-yl)ethyl, 2-methyl-2- (1- ethoxycarbonyl-1,2,3, 6-tetrahydropyridin-4-yl) ethyl, morpholinylethyl, 1- (4-morpholinyl) -2, 2-dimethylpropyl, 1- (4-morpholinyl) -2,2-dimethylethyl, piperidin-4-ylethyl, 1- Boc-piperidin-4-ylethyl, piperidin-1-ylethyl, 1-Boc- piperidin-4-ylethyl, piperidin-4-ylmethyl, 1-Boc-piperidin- 4-ylmethyl, piperidin-4-ylpropyl, l-Boc-piperidin-4- ylpropyl, piperidin-1-ylpropyl, pyrrolidin-1-ylpropyl, pyrrolidin-2-ylpropyl, l-Boc-pyrrolidin-2-ylpropyl, 1-
(pyrrolidin-1-yl) -2-methylpropyl, pyrrolidin-1-ylmethyl, pyrrolidin-2-ylmethyl, l-Boc-pyrrolidin-2-ylmethyl, pyrrolidinylpropenyl, pyrrolidinylbutenyl, methylcarbonyl, Boc, piperidin-1-ylmethylcarbonyl, pyrrolidin-1-yl-carbonyl, 4-pyridylcarbonyl, 4-methylpiperazin-l-ylcarbonylethyl, CH3O-C(=0) -CH2-, methoxycarbonyl, aminomethylcarbonyl, dimethylaminomethylcarbonyl, methylsulfonylamino, dimethylaminomethylcarbonylamino, l-pyrrolidinyl-CH2-C(=0) - NH-, 4-morpholinyl-CH2-C(=0)-NH-, 3-tetrahydrofuryl-O-C (=0) - NH-, cyclohexyl-NCCHs)-, (4-pyrimidinyl)amino, (2- methylthio-4-pyrimidinyl)amino, 3-ethoxycarbonyl-2-methyl- fur-5-yl, 4-methylpiperazin-l-yl, 4-methyl-l-piperidyl, 1- Boc-4-piperidyl, piperidin-4-yl, l-methylpiperidin-4-yl, 1- methyl- (1,2,3, 6-tetrahydropyridyl) , imidazolyl, morpholinyl, 4-trifluoromethγl-1-piperidinyl, hydroxybutyl, methyl, gem- dimethyl, ethyl, propyl, isopropyl, butyl, tert-butyl, sec- butyl, trifluoromethyl, pentafluoroethyl, nonafluorobutyl, dimethylaminopropyl, 1, 1-di(trifluoromethyl)-1- hydroxymethyl, 1,1-di (trifluoromethyl) -1-
(piperidinylethoxy)methyl, 1, 1-di(trifluoromethyl)-1- (pyrrolidin-2-ylmethoxy)methyl, 1, 1-di (trifluoromethyl) -1- (methoxyethoxyethoxy)methyl, 1-hydroxyethyl, 2-hydroxyethyl, trifluoromethoxy, 1-aminoethyl, 2-aminoethyl, 1-(N- isopropylamino)ethyl, 2- (N-isopropylamino)ethyl, 3- tetrahydrofuryloxy, dimethylaminoethoxy, 4-chlorophenoxy, phenyloxy, azetidin-3-ylmethoxy, l-Boc-azetidin-3-ylmethoxy, 3-tetrahydrofurylmethoxy, pyrrolidin-2-ylmethoxy, 1- methylcarbonyl-pyrrolidin-2-ylmethoxy, l-Boc-pyrrolidin-2- ylmethoxy, pyrrolidin-1-ylmethoxy, l-methyl-pyrrolidin-2- ylmethoxy, l-isopropyl-pyrrolidin-2-ylmethoxy, 1-Boc- piperdin-4-ylmethoxy, (1-pyrrolidinyl)ethoxy, piperdin-4- ylmethoxy, piperdin-3-ylmethoxy, l-methylpiperdin-4-yloxy, methylsulfonylaminoethoxy, isopropoxy, methoxy and ethoxy.
14. The compound of claim 1 wherein R1 is selected from phenyl, 1,2, 3,4-tetrahydroisoquinol-7-yl, 2,3-dihydro- lH-indol-6-yl, 1,2,3,4-tetrahydro-[1,8]naphthyridinyl, 1' , 2 ' -dihydro-spiro[cyclopropane-1,3 ' - [3H]indol-6' -yl, tetrahydroquinolin-7-yl, 3-isoxazolyl, 3-pyrazolyl, 1,3,4- thiadiazol-2-yl, 3-pyridyl, 2-oxo-l,2, 3, 4-tetrahydroquinol- 7-yl, 2-oxo-tetrahydroquinolin-7-yl, 1-oxo-l,2,3,4- tetrahydro-isoquinol-7-yl, indol-6-yl, 3, 4-dihydro-2H- benzo[l,4]oxazin-6-yl, 3-oxo-3, 4-dihydro-2H- benzo[l,4]oxazin-6-yl, 2-oxo-3, 4-dihydro-lH-
[1, 8]naphthyridin-7-yl, 2-oxo-chromen-7-yl, 5,6-dihydro- [1,2, 4]triazolo[3,4-a]isoguinolin-9-yl, indazol-6-yl, 2,1,3- benzothiadiazolyl, 2,3-dihydro-benzofur-6-yl, and 5- benzthiazol-5-yl, wherein R1 is unsubstituted or substituted with one or more substituents selected from chloro, fluoro, acetyl, oxo, methylsulfonyl, 2-methyl-2- (1-methylpiperidin- 4-yl)ethyl, piperidine-ethoxy-ditrifluoromethyl-methyl-, 1- methylpiperidin-4-yl, l-methylpiperidin-4-yl-methyl, 1- methylpiperidin-4-yl-propyl, pyrrolidin-1-yl-carbonyl, methylsulfonylamino, dimethylaminomethylcarbonylamino, 1- pyrrolidinyl-CH2-C(=0) - NH-, N-methyl-pyrrolidinyl-CHs-O-, N-isopropyl-pyrrolidinyl-C^-O-, N-pyrrolidinyl-CH2CH20-, pyrrolidinyl-propyl, morpholine-propyl, N-methyl-piperazine, piperazine-methyl, 4N-methylsulfonyl-piperazine-methyl, tetrafluoroethyl-O-, 4-morpholinyl-CH2-C(=0) -NH-, N-Boc- methyl C(O)-, amino-CH2-C(0) -, 3-tetrahydrofuryl-C(=0) -, 3- tetrahydrofuryl-0-C(=0)-NH-, 3-tetrahydrofuryl-CH2-0-, N,N- dimethylamino-CH2-C(0)-, N,N-dimethylamino-CH2-C(O)NH-, N,N- dimethylamino-CH2CH2CH2-, hydroxyethylamino, methyleye1opropyl, methyl, gem-dimethyl, ethyl, tert-butyl, t-butoxycarbonyl, propyl, isopropyl, methoxy, piperidinemethyl, 1,1-dimethyl-propyl, azetidinyl, trifluoromethyl, pentafluoroethyl, 1, 1-di (trifluoromethyl) - 1-hydroxymethyl, 1-hydroxy-l,1-di (trifluoromethyl) methyl,
1, 1-di (trifluoromethyl) -1- (pyrrolidin-2-ylmethoxy)methyl, 3- tetrahydrofuryloxy, l-methylcarbonyl-pyrrolidin-2-ylmethoxy, l-methyl-pyrrolidin-2-ylmethoxy, 2-hydroxy-3-pyrrolidin- propoxy, 1, 1-dimethylethylacetyl, 1, 1-dimethylacetic acid, and methylsulfonylaminoethoxy.
15. The compound of claim 1 wherein R1 is substituted with one or more substituents selected from methyl, ethyl, isopropyl, t-butyl, 2-methyl-2- (1-ethoxycarbonyl-l,2,3, 6- tetrahydropyridin-4-yl)ethyl, 1- (4-morpholinyl)-2,2- dimethylethyl, pyrrolidin-1-yl-carbonyl, CH3O-C(=0) -CH2-, methylsulfonylamino, dimethylaminomethylcarbonylamino, 1- pyrrolidinyl-CH2-C(=0)-NH-, 4-morpholinyl-CH2-C(=0)-NH-, 3- tetrahydrofuryl-0-C(=0)-NH-, I,1-di (trifluoromethyl) -1- (pyrrolidin-2-ylmethoxy)methyl, 3-tetrahydrofuryloxy, 1- methylcarbonyl-pyrrolidin-2-ylmethoxy, and methylsulfonylaminoethoxy.
16. The compound of claim 1 wherein R1 is phenyl substituted with one or more substituents selected from methyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, methoxy, hydroxyl, phenyl, chloro, ethyl-2-propanoyl, 2- methyl-2- (l-methylpiperidin-4-yl) ethyl, methylsulfonylamino, dimethylaminomethylcarbonylamino, piperazine-methyl, 4- methylsulfonyl-1-piperazine-methyl, l-pyrrolidinyl-CH2- C(=O)-NH-, 1-methyl-pyrrolidinyl-CHz-O-, 1-isopropyl- pyrrolidinyl-CH2-0-, l-acetyl-pyrrolidinyl-CH2-0-,2-hydroxy- 3-pyrrolidinyl-propoxy, 4-morpholinyl-CH2-C (=0) -NH-, 1- pyrrolidinyl-CH2CH20-, pyrrolidinyl-propyl, piperidinyl- propyl, 1-methyl-l,2,3, 6-tetrahydro-4-pyridinyl, 1- pyrrolidinyl-1-butenyl, 3, 3-dimethylamino-l-propynyl, 4- methyl-1-piperazinyl, piperazinyl, 4-methyl-l-piperazinyl- methyl, morpholino-propyl, l-N-methyl-piperidinyl-CH2-, 1- piperidinyl-propyl, hydroxyethylamino, 3-tetrahydrofuryl-O- CC=O)-NH-, 3-tetrahydrofuryl-CH20-, trifluoromethyl, pentafluoroethyl, tetrafluoroethoxyl, 1,1- di(trifluoromethyl) -1-hydroxymethyl, 1,1- di (trifluoromethyl) -1- (pyrrolidin-2-ylmethoxy)methyl, 3- tetrahydrofuryloxy, l-methylcarbonyl-pyrrolidin-2-ylmethoxy, 1-methyl-pyrrolindin-2-ylmethoxy, piperidinyl-amino, N,N- dimethyl-glycyl-amino, isopropyl-piperidinyl-methoxyl, isopropyl-piperazinyl, benzoxyl, 4-N-methyl-piperazinyl- propyl, 4-N-propyl-piperazinyl, methylsulfonyl, methylsulfonylaminoethoxy.
17. The compound of claim 16 wherein R is 7- isoquinolinyl.
18. The compound of claim 1 wherein R1 is 4,4-dimethy1- 1,2,3,4-tetrahydro-lH-quinolin-7-yl.
19. The compound of claim 1 wherein R1 is 4, 4-dimethyl- 3,4-dihydro-2-oxo-lH- [1,8]naphthyridinyl.
20. The compound of claim 1 wherein R1 is 3,3-dimethyl- 2, 3-dihydro-lH-indol-6-yl, optionally substituted with a substituent selected from pyrrolidin-1-yl-carbonyl, pyrrolidin-1-yl-methyl, 1-methyl-4-piperidinyl, 1-methyl-4- piperidinyl-methyl, 1-4-piperidinyl, tetrahydro-2- furanylcarbonyl, acetyl, N,N-dimethylglycyl, methylcarbonyl, and methylsulfonyl.
21. The compound of claim 1 wherein R1 is 4, 4-dimethyl- 1,2,3, 4-tetrahydro-lH-isoguinolin-7-yl.
22. The compound of claim 1 wherein R1 is 4,4- dimethyl-1,2,3,4-tetrahydro-2-oxo-lH-isoquinolin-7-yl.
23. The compound of claim 1 wherein R2 is selected from H, fluoro, chloro, bromo, iodo, trifluoromethyl, methyl, ethyl, isopropyl and t-butyl.
24. The compound of claim 1 or a pharmaceutically acceptable derivative thereof selected from: 2- ( (2-amino-6-quinazolinyl)amino) -N- (3-methyl-4- (1- methylethyl)phenyl) -3-pyridinecarboxamide; N- (4,4-dimethyl-l,2,3, 4-tetrahydro-7-quinolinyl) -2- (6- guinazolinylamino) -3-pyridinecarboxamide;
N- (4, 4-dimethyl-2-oxo-1,2,3,4-tetrahydro-7-quinolinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (5- (1, 1-dimethylethyl)-3-isoxazolyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N-(l-acetyl-3,3-dimethyl-2,3-dihydro-lH-indol-6-yl)-2-(7- isoquinolinylamino) -3-pyridinecarboxamide; N- (4, 4-dimethyl-1, 2,3,4-tetrahydro-7-isoquinolinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; 5-fluoro-2- (7-isoquinolinylamino) -N- (3-methyl-4- ti¬ methylethyl)phenyl) -3-pyridinecarboxamide; N-(4,4-dimethyl-l,2,3,4-tetrahydro-7-quinolinyl)-2-(7- isoquinolinylamino) -3-pyridinecarboxamide; N- (3, 3-dimethyl-2,3-dihydro-lH-indol-6-yl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (2-glycyl-4,4-dimethyl-l,2,3, 4-tetrahydro-7- isoquinolinyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide;
2- (7-isoguinolinylamino) -N- (3-methyl-4- (1- methylethyl)phenyl) -3-pyridinecarboxamide;
N- (3, 3-dimethyl-l- ( (2S) -tetrahydro-2-furanylcarbonyl) -2, 3- dihydro-lH-indol-6-yl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide;
N- (4- (1,1-dimethylethyl)phenyl) -2- (6-quinazolinylamino) -3- pyridinecarboxamide;
N- (4, 4-dimethyl-l,2,3,4-tetrahydro-7-isoquinolinyl) -2- (6- quinazolinylamino) -3-pyridinecarboxamide; N- (5, 5-dimethyl-7-oxo-5, 6, 7, 8-tetrahydro-l, 8-naphthyridin-2- yl) -2- (7-isoquinolinylamino) -3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (2,2,2-trifluoro-l-hydroxy-l-
(trifluoromethyl) ethyl)phenyl) -3-pyridinecarboxamide; N- (4, 4-dimethyl-2- ( (2R) -tetrahydro-2-furanylcarbonyl) -
1,2,3, 4-tetrahydro-7-isoquinolinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; N- (5- (l,l-dimethylethyl)-3-isoxazolyl)-2-(6- quinazolinylamino) -3-pyridinecarboxamide; N- (5,5-dimethyl-7-oxo-5, 6,7, 8-tetrahydro-l, 8-naphthyridin-2- yl) -2- (6-quinazolinylamino) -3-pyridinecarboxamide; N- (4- (1,1-dimethylethyl)phenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (4,4-dimethyl-l,2,3,4-tetrahydro-7-isoquinolinyl)-2- (5- isoquinolinylamino)-3-pyridinecarboxamide; N- (2-acetγl-4,4-dimethyl-1,2,3,4-tetrahydro-7- isoquinolinyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3-methyl-4-
(pentafluoroethyl)phenyl) -3-pyridinecarboxamide; N- (5- (1, 1-dimethylethyl)-3-isoxazolyl) -2- (5- isoquinolinylamino) -3-pyridinecarboxamide;
N- (4- (1, 1-dimethylpropyl)phenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3- (methyloxy) -5-
(trifluoromethyl)phenyl) -3-pyridinecarboxamide; N-(4,4-dimethyl-l,2,3,4-tetrahydro-7-isoquinolinyl)-2- (1,6- naphthyridin-3-ylamino) -3-pyridinecarboxamide; N- (6- (1, 1-dimethylethyl)-3-pyridinyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide; N- (4- (1,1-dimethylethyl)phenyl) -2- (5-isoquinolinylamino) -3- pyridinecarboxamide;
2- ( (l-oxo-2,3-dihydro-lH-isoindol-4-yl)amino) -N- (4- (2,2,2- trifluoro-1- (methyloxy) -1-
(trifluoromethyl)ethyl)phenyl) -3-pyridinecarboxamide; N- (6- (1-methylcyclopropyl) -3-pyridinyl) -2- ( (l-oxo-2,3- dihydro-lH-isoindol-4-yl)amino) -3-pyridinecarboxamide; 2- (IH-I, 2,3-benzotriazol-5-ylamino) -N- (5- (1, 1- dimethylethyl) -3-isoxazolyl) -3-pyridinecarboxamide; 2- ( (l-oxo-2,3-dihydro-lH-isoindol-4-yl)amino) -N- (4-
(pentafluoroethyl)-3- (1-piperazinylmethyl)phenyl) -3- pyridinecarboxamide;
2- (7-isoquinolinylamino) -N- (4- (pentafluoroethyl)phenyl) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (2,2,2-trifluoro-1-
(methyloxy)-1- (trifluoromethyl) ethyl)phenyl) -3- pyridinecarboxamide; 2- (lH-indazol-6-ylamino) -N- (6- (1-methylcyclopropyl) -3- pyridinyl) -3-pyridinecarboxamide;
N- (4- (1,1-dimethylethyl)phenyl)-2- {1, 6-naphthyridin-3- ylamino) -3-pyridinecarboxamide;
2- (7-isoquinolinylamino) -N- (2-methyl-1,3-benzothiazol-5-yl)
3-pyridinecarboxamide; N- (4-chloro-3- (trifluoromethyl)phenyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (trifluoromethyl)phenyl) -3- pyridinecarboxamide;
2- (1, 6-naphthyridin-3-ylamino)-N- (4- (2,2,2-trifluoro-l- hydroxy-l- (trifluoromethyl)ethyl)phenyl) -3- pyridinecarboxamide; 1, 1-dimethylethyl 4, 4-dimethyl-7- ( ( (2- (1, 6-naphthyridin-3- ylamino) -3-pyridinyl)carbonyl)amino) -3, 4-dihydro-
2 (IH) -isoquinolinecarboxylate; 2-( (l-oxo-2,3-dihydro-lH-isoindol-4-yl)amino) -N- (3-
((1,1,2,2-tetrafluoroethyl)oxy)phenyl)benzamide; N- (3-( (4- (methylsulfonyl)-1-piperazinyl)methyl) -4-
(pentafluoroethyl)phenyl) -2- ( (l-oxo-2,3-dihydro-lH- isoindol-4-yl)amino) -3-pyridinecarboxamide; N- (4,4-dimethyl-l,2,3,4-tetrahydro-7-isoquinolinyl)-2- ( (1- oxo-1,3-dihydro-2-benzofuran-4-yl)amino) -3- pyridinecarboxamide;
N- (3- (1, 1-dimethylethyl)phenyl) -2- ( (l-oxo-2, 3-dihydro-lH- isoindol-4-yl)amino) -3-pyridinecarboxamide; N- (4- (1, 1-dimethylethyl)phenyl) -2- ( (2-methyl-3-oxo-2, 3- dihydro-lH-indazol-6-yl)amino) -3-pyridinecarboxamide; 2-( (2,2-difluoro-l,3-benzodioxol-5-yl)amino)-N-(4,4- dimethyl-1,2,3,4-tetrahydro-7-isoguinolinyl) -3- pyridinecarboxamide; 2- ( (2,4-diamino-6-quinazolinyl)amino)-N- (4- (1, 1- dimethylethyl)phenyl) -3-pyridinecarboxamide; 2- ( (l-oxo-2,3-dihydro-lH-isoindol-4-yl)amino) -N- (6-
(trifluoromethyl) -3-pyridinyl) -3-pyridinecarboxamide; N- (6-chloro-3-pγridinγl)-2- ( (l-oxo-2,3-dihydro-lH-isoindol-
4-yl)amino) -3-pyridinecarboxamide; N- (2-acetyl-4,4-dimethyl-l,2,3,4-tetrahydro-7- isoquinolinyl)-2- ( (4- (methylamino)-6- quinazolinyl)amino) -3-pyridinecarboxamide; 2- (4- (1, 1-dimethylethyl)phenyl) -4- (lH-indazol-6-ylamino) -
1, 2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one; 2-(5-isoquinolinylamino)-N-(3-( ( ( (2S)-l-methyl-2- pyrrolidinyl)methyl)oxy)-5- (trifluoromethyl)phenyl)-3- pyridinecarboxamide; N-(l-acetyl-3,3-dimethyl-2,3-dihydro-lH-indol-6-yl)-2-( (1- oxo-1,3-dihydro-2-benzofuran-4-yl)amino) -3- pyridinecarboxamide;
N- (4-(phenyloxy)phenyl) -2- ( (4-
(trifluoromethyl)phenyl)amino) -3-pyridinecarboxamide; N- (3,3-dimethyl-2,3-dihydro-lH-indol-6-yl) -2- ( (1-oxo-l,3- dihydro-2-benzofuran-4-yl)amino) -3- pyridinecarboxamide;
2- ( (1-oxo-l,3-dihydro-2-benzofuran-5-yl)amino) -N- (4-
(pentafluoroethyl)phenyl) -3-pyridinecarboxamide; N- (4- (1, 1-dimethylethyl)phenyl) -2- ( (1-oxo-l,3-dihydro-2- benzofuran-4-yl)amino) -3-pyridinecarboxamide 2- ( (1-oxo-l,3-dihydro-2-benzofuran-4-yl)amino) -N- (4- (2,2, 2- trifluoro-1-hydroxy-1- (trifluoromethyl)ethyl)phenyl) -
3-pyridinecarboxamide; N-(3,3-dimethyl-2,3-dihydro-lH-indol-6-yl)-2-(5- isoquinolinylamino) -3-pyridinecarboxamide; 2- ( (3-oxo-l,3-dihydro-2-benzofuran-5-yl)amino) -N- (4-
(pentafluoroethyl)phenyl) -3-pyridinecarboxamide; N- (6- (1-azetidinyl) -3-pyridinyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (5- (1-azetidinyl) -2-pyridinyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (5- (1, 1-dimethylethyl) -3-isoxazolyl)-2-((2,2,3,3- tetrafluoro-2,3-dihydro-l, 4-benzodioxin-6-yl)amino) -3- pyridinecarboxamide; N- (4- (1,1-dimethylethyl)phenyl) -2- ( (2,2, 3, 3-tetrafluoro-2,3- dihydro-1,4-benzodioxin-6-yl)amino) -3- pyridinecarboxamide;
N- (4,4-dimethyl-2-oxo-l, 2,3,4-tetrahydro-7-quinolinyl) -2- ((2,2,3,3-tetrafluoro-2,3-dihydro-l, 4-benzodioxin-6- yl)amino) -3-pyridinecarboxamide;
2- (7-isoquinolinylamino)-N- (3- ( ( (2R) -tetrahydro-2- furanylmethyl)oxy) -5- (trifluoromethyl)phenyl) -3- pyridinecarboxamide;
N- (5, 5-dimethyl-7-oxo-5, 6,7, 8-tetrahydro-l, 8-naphthyridin-2- yl)-2-( (3-oxo-3,4-dihydro-2H-l,4-benzoxazin-6- yl)amino) -3-pyridinecarboxamide;
N- (5- (1, 1-dimethylethyl) -3-isoxazolyl) -2- ( (3-oxo-3,4- dihydro-2H-l,4-benzoxazin-6-yl)amino) -3- pyridinecarboxamide; , ethyl (2S) -2- (4- ( ( (2- (7-isoquinolinylamino)-3- pyridinyl)carbonyl)amino)phenyl)propanoate; (2S) -2- (4- ( ( (2- (7-isoquinolinylamino) -3- pyridinyl)carbonyl)amino)phenyl)propanoic acid; 2- (7-isoquinolinylamino)-N- (3-oxo-3, 4-dihydro-2H-l,4- benzothiazin-6-yl) -3-pyridinecarboxamide; and
N- (4- (1, 1-dimethylethyl)phenyl) -2- (5-quinolinylamino) -3- pyridinecarboxamide.
25. A pharmaceutically acceptable salt form of the compound of claim 24, wherein the salt is selected from a benzenesulfonate salt, an ethanesulfonate salt, an ethanedisulfonate salt, a methanesulfonate salt, a p- toluenesulfonate salt, a phosphate salt, a hydrobromide salt, a nitrate salt, a hydrochloride salt, a citrate salt, a medronate salt, a tosylate salt, a maleate salt, a fumarate salt, a napsylate salt, a pamoate salt, a salicylate salt and a stearate salt.
26. The compound of claim 1 selected from:
N- (4,4-dimethyl-2-oxo-l,2,3,4-tetrahydro-7-quinolinyl)-2- (7- isoquinolinylamino)-3-pyridinecarboxamide; N- (4,4-dimethyl-l, 2,3,4-tetrahydro-7-q^inolinyl) -2- (7- isoquinolinylamino)benzamide; N- (5- (1,1-dimethylethyl) -3-isoxazolyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3-methyl-4- (1- pyrrolidinyl)phenyl) -3-pyridinecarboxamide; N- (l-acetyl-3,3-dimethyl-2,3-dihydro-lH-indol-6-yl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide;
N- (4, 4-dimethyl-1,2,3, 4-tetrahydro-7-isoquinolinyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide; 5-fluoro-2- (7-isoquinolinylamino) -N- (3-methyl-4- (1- methylethyl)phenyl)-3-pyridinecarboxamide; N- (4,4-dimethyl-l, 2,3,4-tetrahydro-7-quinolinyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide; N- (3, 3-dimethyl-2,3-dihydro-lH-indol-6-yl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide; N- (2-glycyl-4, 4-dimethyl-l,2,3, 4-tetrahydro-7- isoquinolinyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (3, 3-dimethyl-l- ( (2S) -tetrahydro-2-furanylcarbonyl) -2,3- dihydro-lH-indol-6-yl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (5, 5-dimethyl-7-oxo-5, 6,7, 8-tetrahydro-l, 8-naphthyridin-2- yl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (4- (1, 1-dimethylethyl)phenyl) -2- (7- isoquinolinylamino)benzamide; 2- (7-isoquinolinylamino) -N- (4- (2,2,2-trifluoro-1-hydroxy-1- (trifluoromethyl)ethyl)phenyl) -3- pyridinecarboxamide; N- (4,4-dimethyl-2- ( (2R) -tetrahydro-2-furanylcarbonyl)-
1,2,3,4-tetrahydro-7-isoquinolinyl)-2- (7- isoquinolinylamino) -3-pyridinecarboxamide;
N- (4- (1,1-dimethylethyl)phenyl) -2- (7-isoguinolinylamino) -3- pyridinecarboxamide; N- (2-acetyl-4,4-dimethyl-1,2,3,4-tetrahydro-7- isoquinolinyl) -2- (7-isoc[uinolinylamino) -3- pyridinecarboxamide;
2- (7-isoquinolinylamino) -N- (3-methyl-4-
(pentafluoroethyl)phenyl) -3-pyridinecarboxamide,- N- (4- (1, 1-dimethylethyl)phenyl) -3-fluoro-2- (7- isoquinolinylamino)benzamide; 2- (7-isoquinolinylamino) -N- (4- (1-methylethyl)phenyl)-3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3-methyl-4- (1- methylethyl)phenyl) -3-pyridinecarboxamide;
N- (4- (1,1-dimethylpropyl)phenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide;
2- (7-isoquinolinylamino) -N- (3- (methyloxy)-5-
(trifluoromethyl)phenyl) -3-pyridinecarboxamide; N- (3-chloro-4-methylphenyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; N- (6- (1, 1-dimethylethyl) -3-pyridinyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (pentafluoroethyl)phenyl) -3- pyridinecarboxamide;
2- (7-isόquinolinylamino) -N- (4- (2,2,2-trifluoro-l- (methyloxy) -1- (trifluoromethyl)ethyl)phenyl)-3- pyridinecarboxamide; 2- (7-isoquinolinylamino)-N- (2-methyl-1,3-benzothiazol-5-yl) -
3-pyridinecarboxamide; N- (4-chloro-3- (trifluoromethyl)phenyl) -2- (7- isoquinolinylamino) -3-pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (4- (trifluoromethyl)phenyl) -3- pyridinecarboxamide;
N- (6- (1-azetidinyl)-3-pyridinyl)-2- (7-isoquinolinylamino) -3- pyridinecarboxamide;
N- (5- (1-azetidinyl) -2-pyridinyl) -2- (7-isoquinolinylamino) -3- pyridinecarboxamide; 2- (7-isoquinolinylamino) -N- (3- ( ( (2R) -tetrahydro-2- furanylmethyl)oxy)-5- (trifluoromethyl)phenyl)-3- pyridinecarboxamide; ethyl (2S) -2- (4- ( ( (2- (7-isoquinolinylamino) -3- pyridinyl)carbonyl)amino)phenyl)propanoate; (2S)-2- (4- ( ( (2- (7-isoquinolinylamino)-3- pyridinyl)carbonyl)amino)phenyl)propanoic acid; (2R) -2- (4- ( ( (2- (7-isoquinolinylamino) -3- pyridinyl)carbonyl)amino)phenyl)propanoic acid; 2- (7-isoquinolinylamino) -N- (3-oxo-3, 4-dihydro-2H-l, 4- benzothiazin-6-yl) -3-pyridinecarboxamide;
2- (7-isoquinolinylamino) -N- (4- ( (trifluoromethyl) oxy)phenyl)• 3-pyridinecarboxamide; and
N- (3-chloro-4- (trifluoromethyl)phenyl) -2- (7- isoquinolinylamino)-3-pyridinecarboxamide, wherein said compound is one of a hydrochloride, a sulfate, a sulfonate and a phosphate salt.
27. A pharmaceutically acceptable salt form of the compound of claim 1, wherein the salt is selected from a benzenesulfonate salt, an ethanesulfonate salt, an ethanedisulfonate salt, a methanesulfonate salt, a p- toluenesulfonate salt, a phosphate salt, a hydrobromide salt, a nitrate salt, a hydrochloride salt, a citrate salt, a medronate salt, a tosylate salt, a maleate salt, a fumarate salt, a napsylate salt, a pamoate salt, a salicylate salt and a stearate salt.
28. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound as in any of claims 1-27.
29. A method of treating cancer in a subject, said method comprising administering to the subject an effective amount of a compound of any of claims 1-27.
30. The method of claim 29 wherein administering the an effective amount of the compound to the subject comprises administering the compound in combination with one or more compounds selected from antineoplastic agents, anti- angiogenic agents, chemotherapeutic agents and peptidal cancer therapy agents.
31. The method of claim 30 wherein the antineoplastic agents are selected from antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, kinase inhibitors, miscellaneous agents and combinations thereof.
32. A method of treating angiogenesis in a subject, said method comprising administering to the subject an effective amount of a compound of any of claims 1-27.
33. A method of treating VEGFR-related disorders in a subject, said method comprising administering to the subject an effective amount of a compound of any of claims 1-27.
34. A method of treating at least one proliferation- related disorder in a subject, said method comprising administering to the subject an effective amount of a compound of any of claim 1-27.
35. The method of claim 34 wherein the disorder is inflammation or an inflammation-related disorder.
36. A method of reducing blood flow in a tumor in a subject, said method comprising administering to the subject an effective amount of a compound of any of claims 1-27.
37. A method of reducing tumor size in a subject, said method comprising administering to the subject an effective amount of a compound of any of claims 1-27.
38. A method of treating diabetic retinopathy in a subject, said method comprising administering to the subject an effective amount of a compound of any of claims 1-27.
39. A compound defined by Formula II
Figure imgf000342_0001
II or a pharmaceutically acceptable derivative thereof, wherein R is selected from 7-isoquinolinyl, 2-methyl-3-oxo- 2, 3-dihydroindazol-6-yl, [1,6] -naphthydrin-3-yl, [1, 7] -naphthydrin-2-yl, oxo-2,3-dihydrobenzofuranyl, dihydro-benzodioxinyl, 6-quinazolinyl, 2-amino-6- quinazolinyl, 4-methylamino-6-quinazolinyl, 2,4- diamino-6-quinazolinyl, 3-oxo-3,4-dihydro-l,4- benzoxazin-6-yl, 2,2-difluoro-1,3-benzodioxol-5-yl and 2,2,3,3-tetrafluoro-2,3-dihydro-l, 4-benzodioxin- 6-γl, each of which is optionally substituted with one or more substitutions selected from halo, haloakyl, C1-6 alkyl, C2_s alkenyl, C2.8 alkynyl, N- dimethylamino-C^-alkyl, N-dimethylamino-C^-alkoxy, amino, carbonylamino, morpholino-sulfonyl, amino- sulfonyl, oxazolyl, pyrrolyl, morpholinyl, carboxyl, cyano, and acetyl; wherein R1 is selected from unsubstituted or substituted
1,2-dihydroquinolyl, 1,2,3,4-tetrahydroquinolyl, 1,2,3,4-tetrahydro-isoquinolyl, 2-oxo-l,2, 3 ,4- tetrahydroquinolyl, 2-oxo-l,2,3,4-tetrahydroquinolyl, 1-oxo- 1, 2,3, 4-tetrahydro-isoguinolyl, isoquinolyl, quinolyl, indol-6-yl, 6-isoindolyl, 3, 4-dihydro-2H-benzo[l,4]oxazin-6- yl, 3-oxo-3,4-dihydro-2H-benzo[l,4]oxazin-6-yl, 2,3-dihydro- IH-indol-6-yl, naphthyridinyl, 2-oxo-3,4-dihydro-lH-
[1,8]naphthyridin-7-yl, 3,4-dihydro- [1,8]naphthyridinyl, 1,2,3,4-tetrahydro- [1, 8]naphthyridinyl, quinozalinyl, wherein substituted R1 is substituted with one or more substituents selected from halo, optionally substituted Ci_6-alkyl, optionally substituted C3_6- cycloalkyl, optionally substituted phenyl, optionally substituted phenyl-Ci_C4-alkylenyl, Ci-2-haloalkoxy, optionally substituted phenyloxy, optionally substituted 4-6 membered heterocyclyl-Ci-Cβ-alkyl, optionally substituted 4-6 membered heterocyclyl-C2-C4- alkenyl, optionally substituted 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyloxy, optionally substituted 4-6 membered heterocyclyl-Ci_4-alkoxy, optionally substituted 4-6 membered heterocyclylsulfonyl, optionally substituted
4-6 membered heterocyclylamino, optionally substituted 4-6 membered heterocyclylcarbonyl, optionally substituted 4-6 membered heterocyclyl-Ci_4- alkylcarbonyl, optionally substituted 4-6 membered heterocyclylcarbonyl-Cχ-4-alkyl , optionally substituted 4-6 membered heterocyclyl-C1_4-alkylcarbonylamino , optionally substituted 4-6 membered heterocyclyl- oxyc arbonyl amino , Ci-2-haloalkyl , Ci-4-aminoalkyl , optionally substituted Ci-4-aminoalkylcarbonyl , nitro , amino, Ci_3-alkylsulfonylamino, hydroxy, cyano, aminosulfonyl , Ci_2-alkylsulfonyl , Ci_2- alkylsulfonylamino, Ci-2-alkylsulf onylamino-Ci-4-alkoxy, halosulf onyl , Ci_4-alkylcarbonyl , amino-Ci-4- alkylcarbonyl , C1-3-alkylamino-C1-4-alkylcarbonyl , Cχ_3- alkylamino-Ci-4-alkylcarbonylamino , Ci-4-alkoxycarbonyl- Ci_4-alkyl , Ci-3-alkylamino-C;i._3-alkyl , Ci-s-alkylamino-Ci- 3-alkoxy, Ci^-alkylamino-Ci-s-alkoxy-Ci-s-alkoxy, C1-4- alkoxycarbonyl , C1_4-alkoxycarbonylamino-Ci-4-alkyl , Ci_ s-alkylsulfonylamino-Cx-a-alkoxy, Ci-4-hydroxyalkyl ,
Figure imgf000344_0001
and Cχ-4-alkoxy; and wherein Re and Rf are independently selected from H and Ci_2- haloalkyl; wherein R7 is selected from H, Ci_3-alkyl, optionally substituted phenyl, optionally substituted phenyl-Cχ-3- alkyl, 4-6 membered heterocyclyl, optionally substituted 4-6 membered heterocyclyl-Ci_C3-alkyl, Ci_3- alkoxy-Ci-2-alkyl and Ci_3-alkoxy-Ci_3-alkoxy-Ci-3-alkyl; and wherein R2 is selected from H, halo, haloalkyl and C1-6 alkyl.
40. A pharmaceutically acceptable salt form of the compound of claim 39, wherein the salt is selected from a benzenesulfonate salt, an ethanesulfonate salt, an ethanedisulfonate salt, a methanesulfonate salt, a p- toluenesulfonate salt, a phosphate salt, a hydrobromide salt, a nitrate salt, a hydrochloride salt, a citrate salt, a medronate salt, a tosylate salt, a maleate salt, a fumarate salt, a napsylate salt, a pamoate salt, a salicylate salt and a stearate salt.
41. A pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of claim 39.
42. A method of treating cancer in a subject, said method comprising administering to the subject an effective amount of a compound of claim 39.
43. The method of claim 42 wherein administering the an effective amount of the compound to the subj.ect comprises administering the compound in combination with one or more compounds selected from antineoplastic agents, anti- angiogenic agents, chemotherapeutic agents and peptidal cancer therapy agents.
44. The method of claim 43 wherein the antineoplastic agents are selected from antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, kinase inhibitors, miscellaneous agents and combinations thereof.
45. A method of treating angiogenesis in a subject, said method comprising administering to the subject an effective amount of a compound of claim 39.
46. A method of treating VEGFR-related disorders in a subject, said method comprising administering to the subject an effective amount of a compound of claim 39.
47. A method of treating at least one proliferation- related disorder in a subject, said method comprising administering to the subject an effective amount of a compound of claim 39.
48. The method of claim 47 wherein the disorder is inflammation or an inflammation-related disorder.
49. A method of reducing blood flow in a tumor in a subject, said method comprising administering to the subject an effective amount of a compound of claim 39.
50. A method of reducing tumor size in a subject, said method comprising administering to the subject an effective amount of a compound of claim 39.
51. A method of treating diabetic retinopathy in a subject, said method comprising administering to the subject an effective amount of a compound of claim 39.
PCT/US2005/025800 2004-07-22 2005-07-20 Substituted aryl-amine derivatives and methods of use WO2006012374A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2007522715A JP2008507539A (en) 2004-07-22 2005-07-20 Substituted aryl-amine derivatives and methods of use
MX2007000672A MX2007000672A (en) 2004-07-22 2005-07-20 Substituted aryl-amine derivatives and methods of use.
EP05791799A EP1773817B1 (en) 2004-07-22 2005-07-20 Substituted aryl-amine derivatives and methods of use
CA2571627A CA2571627C (en) 2004-07-22 2005-07-20 Substituted aryl-amine derivatives and methods of use
AT05791799T ATE440834T1 (en) 2004-07-22 2005-07-20 SUBSTITUTED ARYLAMIN DERIVATIVES AND METHODS OF USE
AU2005267161A AU2005267161B2 (en) 2004-07-22 2005-07-20 Substituted aryl-amine derivatives and methods of use
DE602005016261T DE602005016261D1 (en) 2004-07-22 2005-07-20 SUBSTITUTED ARYLAMINE DERIVATIVES AND METHOD OF USE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59054404P 2004-07-22 2004-07-22
US60/590,544 2004-07-22
US11/185,556 2005-07-19
US11/185,556 US7507748B2 (en) 2004-07-22 2005-07-19 Substituted aryl-amine derivatives and methods of use

Publications (1)

Publication Number Publication Date
WO2006012374A1 true WO2006012374A1 (en) 2006-02-02

Family

ID=35355478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/025800 WO2006012374A1 (en) 2004-07-22 2005-07-20 Substituted aryl-amine derivatives and methods of use

Country Status (10)

Country Link
US (2) US7507748B2 (en)
EP (1) EP1773817B1 (en)
JP (1) JP2008507539A (en)
AT (1) ATE440834T1 (en)
AU (1) AU2005267161B2 (en)
CA (1) CA2571627C (en)
DE (1) DE602005016261D1 (en)
ES (1) ES2331318T3 (en)
MX (1) MX2007000672A (en)
WO (1) WO2006012374A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
WO2013015657A3 (en) * 2011-07-27 2013-06-13 보령제약 주식회사 Novel compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same
WO2013167495A1 (en) 2012-05-09 2013-11-14 Bayer Pharma Aktiengesellschaft Bicyclically substituted uracils and the use thereof
US8586571B2 (en) 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN107245075A (en) * 2017-08-04 2017-10-13 西安交通大学 Simultaneously [3,4 d] pyrimidines and its salt and the application of 2,4,6 3 substituted pyridines

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507748B2 (en) * 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
WO2006026348A1 (en) * 2004-08-25 2006-03-09 The University Of Chicago Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma
JP2013543480A (en) * 2010-10-18 2013-12-05 ラクオリア創薬株式会社 Arylamide derivatives as TTX-S blockers
US9029553B2 (en) * 2011-02-14 2015-05-12 Council Of Scientific & Industrial Research 2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof
JP2014517847A (en) * 2011-05-24 2014-07-24 ザ ウィスター インスティテュート Compositions and methods for modulating the activity of Epstein-Barr nuclear antigen 1
WO2014058744A2 (en) 2012-10-09 2014-04-17 California Institute Of Technology In vivo and in vitro olefin cyclopropanation catalyzed by heme enzymes
WO2014058729A1 (en) * 2012-10-09 2014-04-17 California Institute Of Technology In vivo and in vitro carbene insertion and nitrene transfer reactions catalyzed by heme enzymes
KR101652577B1 (en) * 2013-04-19 2016-08-30 영남대학교 산학협력단 Amidopyridinol derivative or a pharmaceutically acceptable salt thereof and pharmaceutical composition for treating or preventing angiogenesis-related disease comprising the same
US9399762B2 (en) 2014-02-18 2016-07-26 California Institute Of Technology Methods and systems for sulfimidation or sulfoximidation of organic molecules
MX2017011269A (en) 2015-03-06 2018-01-12 Pharmakea Inc Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof.
JP6800872B2 (en) 2015-03-06 2020-12-16 ファーマケア，インク． Lysyl oxidase-like 2 inhibitor and its use
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
CN105837452B (en) * 2016-04-05 2019-01-29 田志高 2- methyl-5-nitro phenol production process
KR102615565B1 (en) 2016-09-07 2023-12-18 파마케아, 인크. Uses of Lysyl Oxidase-Like 2 Inhibitors
JP7079772B2 (en) 2016-09-07 2022-06-02 ファーマケア，インク． Crystal form and production method of lysyl oxidase-like 2 inhibitor
KR20200130834A (en) 2018-03-09 2020-11-20 리커리엄 아이피 홀딩스, 엘엘씨 Substituted 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
AR117169A1 (en) 2018-11-28 2021-07-14 Bayer Ag (TIO) PYRIDAZINE AMIDES AS FUNGICIDE COMPOUNDS
MX2022003873A (en) * 2019-10-01 2022-06-02 Goldfinch Bio Inc Substituted 1, 6-naphthyridine inhibitors of cdk5.
CN115697059A (en) 2020-05-27 2023-02-03 拜耳公司 Active compound combinations
CN111909053B (en) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 Diarylamine unit-based amide derivative and preparation method and application thereof
JP2022104792A (en) * 2020-12-29 2022-07-11 ヒュサイオン カンパニー リミテッド Piperlongumine-based compound and immunoregulator comprising the same
CN116354937A (en) * 2021-12-27 2023-06-30 江苏恩华药业股份有限公司 Pyridine (pyrimidine) amine derivative and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085715A2 (en) * 2000-05-09 2001-11-15 Novartis Ag Aza- and polyazanthranyl amides and their use as medicaments
WO2004005279A2 (en) * 2002-07-09 2004-01-15 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
WO2004007481A2 (en) * 2002-07-17 2004-01-22 Amgen Inc. Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders
WO2005000232A2 (en) * 2003-06-16 2005-01-06 Guoqing Paul Chen Six membered amino-amide derivatives as angiogenesis inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532358A (en) 1994-10-12 1996-07-02 Boehringer Ingelheim Pharmaceuticals, Inc. Method for preparing alkyl-5,11-dihydro-6h-dipyrido[3,2-B:2',3'-E] [1,4] diazepin-6-ones
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
AUPO395396A0 (en) 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US20020111495A1 (en) 1997-04-04 2002-08-15 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
ID22781A (en) 1997-04-04 1999-12-09 Pfizer Prod Inc Nicotynamide derivatives
US6140351A (en) 1997-12-19 2000-10-31 Berlex Laboratories, Inc. Ortho-anthranilamide derivatives as anti-coagulants
RU2226529C2 (en) 1997-12-19 2004-04-10 Шеринг Акциенгезельшафт Derivatives of ortho-antranilamide as anti-coagulating agents, pharmaceutical composition and method for treatment
NZ516258A (en) 1999-06-07 2004-02-27 Immunex Corp Tek antagonists
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
WO2001046110A2 (en) 1999-12-23 2001-06-28 The University Of Georgia Research Foundation, Inc. Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
AU2001231143A1 (en) 2000-01-27 2001-08-07 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1259595B1 (en) 2000-02-25 2007-04-04 Immunex Corporation Integrin antagonists
AU4890301A (en) 2000-04-17 2001-10-30 Dong Wha Pharmaceutical Industrial Co., Ltd. 6-methylnicotinamide derivatives as antiviral agents
DE10023484A1 (en) 2000-05-09 2001-11-22 Schering Ag New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
HU230302B1 (en) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds and pharmaceutical compositions containing them
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085715A2 (en) * 2000-05-09 2001-11-15 Novartis Ag Aza- and polyazanthranyl amides and their use as medicaments
WO2004005279A2 (en) * 2002-07-09 2004-01-15 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
WO2004007481A2 (en) * 2002-07-17 2004-01-22 Amgen Inc. Substituted amine derivatives and methods of use in the treatment of angiogenesis relates disorders
WO2005000232A2 (en) * 2003-06-16 2005-01-06 Guoqing Paul Chen Six membered amino-amide derivatives as angiogenesis inhibitors

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9487509B2 (en) 2007-10-18 2016-11-08 Takeda Pharmaceutical Company Limited Heterocyclic compound
US8586571B2 (en) 2007-10-18 2013-11-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
US9227955B2 (en) 2011-07-27 2016-01-05 Boryung Pharmaceutical Co., Ltd. Compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same
CN103827089A (en) * 2011-07-27 2014-05-28 保宁制药株式会社 Novel compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same
KR101412794B1 (en) 2011-07-27 2014-07-01 보령제약 주식회사 New compound, the preparation thereof and the pharmaceutical composition comprising the same for anti-angiogenic drug
WO2013015657A3 (en) * 2011-07-27 2013-06-13 보령제약 주식회사 Novel compound having angiogenesis inhibitory activity, method for preparing same, and pharmaceutical composition comprising same
US9481672B2 (en) 2012-05-09 2016-11-01 Bayer Pharma Aktiengesellschaft Bicyclically substituted uracils and the use thereof
EP3045456A1 (en) 2012-05-09 2016-07-20 Bayer Pharma Aktiengesellschaft Bicyclic substituted uracils and their use
WO2013167495A1 (en) 2012-05-09 2013-11-14 Bayer Pharma Aktiengesellschaft Bicyclically substituted uracils and the use thereof
US9949977B2 (en) 2012-05-09 2018-04-24 Bayer Pharma Aktiengesellschaft Bicyclically substituted uracils and the use thereof
US9949978B2 (en) 2012-05-09 2018-04-24 Bayer Pharma Aktiengesellschaft Bicyclically substituted uracils and the use thereof
US10300062B2 (en) 2012-05-09 2019-05-28 Bayer Pharma Aktiengesellschaft Bicyclically substituted uracils and the use thereof
CN107245075A (en) * 2017-08-04 2017-10-13 西安交通大学 Simultaneously [3,4 d] pyrimidines and its salt and the application of 2,4,6 3 substituted pyridines
CN107245075B (en) * 2017-08-04 2020-03-17 西安交通大学 2,4, 6-trisubstituted pyrido [3,4-d ] pyrimidine compound and salt and application thereof

Also Published As

Publication number Publication date
US20060040966A1 (en) 2006-02-23
EP1773817B1 (en) 2009-08-26
US8247430B2 (en) 2012-08-21
EP1773817A1 (en) 2007-04-18
AU2005267161B2 (en) 2009-02-12
ATE440834T1 (en) 2009-09-15
JP2008507539A (en) 2008-03-13
US20090143355A1 (en) 2009-06-04
ES2331318T3 (en) 2009-12-29
CA2571627A1 (en) 2006-02-02
MX2007000672A (en) 2007-03-08
CA2571627C (en) 2010-02-16
DE602005016261D1 (en) 2009-10-08
AU2005267161A1 (en) 2006-02-02
US7507748B2 (en) 2009-03-24

Similar Documents

Publication Publication Date Title
CA2571627C (en) Substituted aryl-amine derivatives and methods of use
EP1971604B1 (en) Pyrrolo-pyridine derivatives for the treatment of cancer diseases
EP1537084B1 (en) Substituted 2-alkylamine nicotinic amide derivatives and use there of
EP1562933B1 (en) Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders
EP2118088B1 (en) Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
CA2434178C (en) Substituted amine derivatives and methods of use
US8017601B2 (en) Bis-aryl kinase inhibitors and method
US7687522B2 (en) Substituted pyridines and pyrimidines and their use in treatment of cancer
US20030134836A1 (en) Substituted arylamine derivatives and methods of use
CA2489166A1 (en) Substituted anthranilic amide derivatives and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2571627

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005267161

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000672

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2007522715

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2005267161

Country of ref document: AU

Date of ref document: 20050720

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2005791799

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005267161

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2005791799

Country of ref document: EP